pci 32765 profile

ibrutinib: a Btk protein inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	24821094
CHEMBL ID	1873475
CHEBI ID	76612
SCHEMBL ID	201859
MeSH ID	M0549477

Synonym
HY-10997
(r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
NCGC00187912-01
NCGC00187912-02
EX-5960
pci 32765
936563-96-1
PCI-32765 ,
ibrutinib
pci32765
ibrutinib (jan/usan)
imbruvica (tn)
D10223
pci-32765 (ibrutinib)
cra 032765
cra-032765
2-propen-1-one, 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-
jnj 02
1x70osd4vx ,
unii-1x70osd4vx
hsdb 8260
ibrutinib [usan:inn]
imbruvica
1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one
CHEMBL1873475
bdbm50357312
chebi:76612 ,
pci-32765-00
pc-32765
1-{(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one
ibrutinibum
NCGC00187912-03
1-{(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one
ibrutinib [orange book]
ibrutinib [mi]
ibrutinib [vandf]
ibrutinib [who-dd]
ibrutinib [inn]
ibrutinib [jan]
ibrutinib [usan]
ibrutinib (pci-32765)
gtpl6912
1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
(r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one
1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
XYFPWWZEPKGCCK-GOSISDBHSA-N
AKOS022185476
smr004701213
MLS006010041
SCHEMBL201859
1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one
AC-26942
DB09053
1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
A1-01649
1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
J-523872
mfcd20261150
EX-A066
NCGC00187912-12
SW218096-2
imbruvica; pci-32765
DTXSID60893450 ,
Q5984881
(r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
(r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
EN300-97039
AMY27873
nsc-800769
nsc800769
ibrutinib, free base
BI164531
ibrutinib- bio-x
dtxcid601323465
l01xe27
1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
Z1302446275

Excerpt	Reference	Relevance
" The most frequent adverse events (any grade) were diarrhea (70%), infusion-related reaction (45%), and peripheral sensory neuropathy (44%)."	( Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Andritsos, LA; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Hall, N; Heerema, NA; Jaglowski, SM; James, DF; Johnson, AJ; Jones, JA; Lozanski, G; Maddocks, KJ; Munneke, B; Nagar, V; Neuenburg, JK; Ruppert, AS; Smucker, K; Stefanos, M; West, JS; Woyach, JA, 2015)	0.42
" Discontinuation of ibrutinib is rarely due to adverse events related to the drug."	( The clinical safety of ibrutinib in chronic lymphocytic leukemia. Molica, S, 2015)	0.42
"Ibrutinib is associated with bleeding-related adverse events of grade ≤ 2 in severity, and infrequently with grade ≥ 3 events."	( Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Cullinane, AM; Farooqui, MZ; Herman, SE; Holland, SM; Lipsky, AH; Lozier, JN; Marti, G; Martyr, S; Nghiem, K; Niemann, CU; Saba, N; Soto, S; Sun, C; Tian, X; Uzel, G; Valdez, J; Wiestner, A, 2015)	0.42
" The most common (≥ 20% patients) adverse events were neutropenia, anemia, nasopharyngitis, increased bilirubin, and rash."	( Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y, 2016)	0.43
" We report a serious side effect of ibrutinib potentially attributable to interaction with the moderate CYP3A4 inhibitor verapamil."	( Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016)	0.43
"This is the first description of a serious side effect of ibrutinib likely due to an interaction with the CYP3A4 inhibitor verapamil."	( Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016)	0.43
" A total of 8/16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31."	( Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Choi, I; Fukuhara, N; Hatake, K; Ishikawa, T; Kinoshita, T; Kitano, T; Maruyama, D; Matsuno, Y; Nagai, H; Nishikawa, T; Nishikori, M; Shibayama, H; Takahara, S; Tobinai, K; Uchida, T, 2016)	0.43
" Safety was consistent with prior experience for each drug, with infusion reactions the most prevalent adverse event."	( Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Brooks, HD; Burke, JM; Fanning, S; Farber, CM; Greenwald, DR; Klein, L; Kolibaba, KS; Mahadevan, D; Miskin, HP; Schreeder, MT; Sharman, JP; Sportelli, P; Weiss, MS, 2017)	0.46
" With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase."	( Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Kaur, V; Swami, A, 2017)	0.46
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas."	( Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)	0.51
"This is a retrospective observational study done at a tertiary care facility, to evaluate adverse events in patients with B-cell malignancies on treatment with ibrutinib between 2014 and 2018."	( Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)	0.51
"We found 10 patients with unique adverse events related to ibrutinib."	( Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)	0.51
"We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators."	( Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J, 2018)	0.48
" The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%])."	( Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019)	0.51
" Here side effects of ibrutinib have been summarized and important considerations in the management of these adverse events have been reviewed."	( Management of adverse effects/toxicity of ibrutinib. Paydas, S, 2019)	0.51
" Emerging real-world-data shows similar response and survival, but higher discontinuation rates due to adverse events (AEs)."	( Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Angelopoulou, M; Bitsani, C; Dimou, M; Iliakis, T; Kalyva, S; Koudouna, A; Kyrtsonis, MC; Panayiotidis, P; Papaioannou, P; Pardalis, V; Tsaftaridis, P; Vassilakopoulos, TP, 2019)	0.51
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."	( Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)	0.51
"There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL)."	( Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2019)	0.51
" The most frequent treatment-emergent adverse events (AEs) in patients with FL and DLBCL, respectively, were diarrhea (16 [59%]; 16 [47%]), fatigue (12 [44%]; 16 [47%]), nausea (9 [33%]; 12 [35%]), peripheral edema (7 [26%]; 13 [38%]), decreased appetite (8 [30%]; 11 [32%]), neutropenia (6 [22%]; 11 [32%]), and vomiting (5 [19%]; 12 [35%])."	( Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Goy, A; Guan, S; Herrera, AF; Hill, JS; Kwei, K; Liu, EA; Mehta, A; Pagel, JM; Phillips, T; Ramchandren, R; Svoboda, J, 2020)	0.56
" Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time."	( Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dai, S; Dean, JP; Devereux, S; Ghia, P; Grosicki, S; Hillmen, P; Kipps, TJ; Lal, I; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Simpson, D; Tedeschi, A, 2020)	0.56
" Outcomes assessed included overall response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), and adverse events."	( Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J, 2019)	0.51
"To characterize cutaneous eruptions arising from ibrutinib and highlight overlap with epidermal growth factor receptor (EGFR) inhibitor-induced dermatologic adverse events."	( Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. Davids, M; Dewan, AK; LaCasce, AS; LeBoeuf, NR; Singer, S; Tan, SY; Treon, SP, 2023)	0.91
" We observed that these reactions can be successfully managed using approaches for EGFR inhibitor-induced cutaneous adverse events."	( Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. Davids, M; Dewan, AK; LaCasce, AS; LeBoeuf, NR; Singer, S; Tan, SY; Treon, SP, 2023)	0.91
" The purpose of this study was to describe treatment patterns, adverse events (AEs), and economic burden among treated patients with CLL."	( Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study. Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2020)	0.56
"6 % patients experienced ≥ grade 3 adverse events and serious adverse events."	( Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. Fang, H; Feng, Y; Hou, K; Huang, L; Jia, Y; Shao, S; Yu, Z, 2020)	0.56
" Patient characteristics, ibrutinib use and adverse drug reactions (ADRs) were collected from medical records."	( Patterns of use and safety of ibrutinib in real-life practice. Allouchery, M; Delaunay, P; Delwail, V; Guidez, S; Lafay-Chebassier, C; Pérault-Pochat, MC; Salvo, F; Tomowiak, C, 2021)	0.62
" Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%)."	( Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H, 2021)	0.62
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)."	( Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021)	0.62
"Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons."	( Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Abramson, JS; Bartlett, NL; Booth, AM; Brander, DM; Brown, JR; Byrd, JC; Coutre, S; Ding, W; Erba, H; Kuzma, CS; Larson, RA; Little, RF; Litzow, M; Mandrekar, SJ; Nattam, S; Owen, C; Ruppert, AS; Smith, SE; Stone, RM; Woyach, JA, 2021)	0.62
"The occurrence of adverse events was revealed as a major cause of ibrutinib failure in the real-world."	( Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Baek, DW; Cho, HJ; Kim, J; Lee, JM; Moon, JH; Sohn, SK, 2021)	0.62
" While 176 adverse events (AEs) were reported in 74 (54."	( Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data Akay, OM; Akdeniz, A; Akpınar, S; Aydoğdu, İ; Baştürk, A; Batur, DS; Berber, İ; Çekdemir, D; Çetin, G; Davulcu, EA; Demircioğlu, S; Deveci, B; Dinçyürek, HD; Doğu, MH; Durusoy, SS; Ertop, Ş; Ferhanoğlu, B; Güneş, AK; Gürkan, E; İlhan, G; Kaya, E; Kızıklı, A; Kurtoğlu, E; Mehtap, Ö; Okan, V; Okay, M; Özcan, MA; Özcan, Ö; Özet, G; Özkocamaz, V; Pepedil Tanrıkulu, F; Sahip, B; Saydam, G; Sayınalp, N; Seyhanlı, A; Sönmez, M; Terzi, H; Tombak, A; Turgut, B; Uçar, MA; Ümit, EG; Ünal, A; Yavaşoğlu, İ; Yıldırım, R; Yılmaz, M, 2021)	0.62
"This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes."	( Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data Akay, OM; Akdeniz, A; Akpınar, S; Aydoğdu, İ; Baştürk, A; Batur, DS; Berber, İ; Çekdemir, D; Çetin, G; Davulcu, EA; Demircioğlu, S; Deveci, B; Dinçyürek, HD; Doğu, MH; Durusoy, SS; Ertop, Ş; Ferhanoğlu, B; Güneş, AK; Gürkan, E; İlhan, G; Kaya, E; Kızıklı, A; Kurtoğlu, E; Mehtap, Ö; Okan, V; Okay, M; Özcan, MA; Özcan, Ö; Özet, G; Özkocamaz, V; Pepedil Tanrıkulu, F; Sahip, B; Saydam, G; Sayınalp, N; Seyhanlı, A; Sönmez, M; Terzi, H; Tombak, A; Turgut, B; Uçar, MA; Ümit, EG; Ünal, A; Yavaşoğlu, İ; Yıldırım, R; Yılmaz, M, 2021)	0.62
" The most common grade 3 adverse events were rash/pruritis/dermatitis (19%), diarrhea (11%), hyperglycemia (11%), and hypertension (11%)."	( Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Batlevi, CL; De Frank, S; Drullinsky, P; Gerecitano, JF; Hamilton, A; Hamlin, PA; Horwitz, SM; Kumar, A; Matasar, MJ; Michaud, L; Moskowitz, A; Moskowitz, CH; Nakajima, R; Nichols, C; Rademaker, J; Salles, G; Schöder, H; Seshan, V; Stewart, CM; Straus, D; Tsui, DWY; Whiting, K; Younes, A; Zelenetz, AD, 2022)	0.72
"Adverse events were generally mild, but one case of fatal suspected unexpected serious adverse reaction occurred."	( Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. Akber, M; Aleman, S; Bergman, P; Blennow, O; Blixt, L; Bogdanovic, G; Buggert, M; Chen, MS; Chen, P; Friman, G; Gomez, AC; Hansson, L; Hober, S; Lindgren, G; Ljunggren, HG; Ljungman, P; Loré, K; Mielke, S; Muschiol, S; Nilsson, P; Nordlander, A; Norlin, AC; Nowak, P; Österborg, A; Smith, CIE; Söderdahl, G; Thalme, A; Valentini, D; Vesterbacka, J; Wahren-Borgström, E; Wullimann, D, 2021)	0.62
"The results showed that the mRNA BNT162b2 vaccine was safe in immunocompromised patients."	( Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. Akber, M; Aleman, S; Bergman, P; Blennow, O; Blixt, L; Bogdanovic, G; Buggert, M; Chen, MS; Chen, P; Friman, G; Gomez, AC; Hansson, L; Hober, S; Lindgren, G; Ljunggren, HG; Ljungman, P; Loré, K; Mielke, S; Muschiol, S; Nilsson, P; Nordlander, A; Norlin, AC; Nowak, P; Österborg, A; Smith, CIE; Söderdahl, G; Thalme, A; Valentini, D; Vesterbacka, J; Wahren-Borgström, E; Wullimann, D, 2021)	0.62
"The increasing indications and addition of newer agents to clinical practice and emergence of BTK inhibitor-related cardiac adverse events have complicated the management decisions for utilization of this class of therapy."	( Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Awan, FT; Christensen, BW; Zaha, VG, 2022)	0.72
"The newer BTK inhibitor acalabrutinib represents a new standard of care in front-line chronic lymphocytic leukemia (CLL) given the results of the ELEVATE-RR trial demonstrating comparable efficacy and a more favorable toxicity profile especially with regard to cardiac adverse events as compared to ibrutinib."	( Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Awan, FT; Christensen, BW; Zaha, VG, 2022)	0.72
" Common nonhematologic adverse events were fatigue (56%), nausea (53%), anorexia (41%), and diarrhea (41%) and were mostly low grade."	( Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA, 2022)	0.72
" Adverse events occurred in 74."	( Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. Akizuki, R; Fujino, A; Nomura, F; Omi, A; Tsujioka, S, 2022)	0.72
" Toxic effects of the combination of ibrutinib and cetuximab have been reported in a patient with metastatic CRC."	( Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia. Araz, M; Artaç, M; Çeneli, Ö; Karaağaç, M; Karakurt Eryilmaz, M; Korkmaz, M, 2022)	0.72
" The meta-analysis performed on adverse events (AEs) demonstrated that single-agent ibrutinib had a high risk of bleeding, nausea, and diarrhea."	( Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis. Akbari, V; Farrokhi, P; Heidari, Z; Javeri, M; Matin, PH; Moghaddas, A; Roufarshbaf, M; Sadeghi, E, 2022)	0.72
" We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors."	( Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Dong, R; Lin, N; Tan, B; Yan, Y; Zeng, X, 2022)	0.72
"Ibrutinib, a first-class Bruton tyrosine kinase inhibitor, is known to be associated with adverse bleeding events and has been recently approved for the treatment of relapse Waldenström macroglobulinemia (WM)."	( Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider. Bauters, A; Butelet, A; Chauvet, P; de Charette, M; Dupont, A; Jeanpierre, E; Nudel, M; Poulain, S; Srour, M; Susen, S, 2022)	0.72
" The secondary outcome was the occurrence of major adverse cardiac events (MACE), defined as atrial fibrillation, heart failure, symptomatic ventricular arrhythmias, and sudden death of probable or definite ibrutinib association after CMR."	( Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity. Addison, D; Awan, FT; Bhat, S; Bonsu, JM; Buck, B; Byrd, JC; Carter, R; Chum, AP; Gambril, J; Guha, A; Haddad, D; Kittai, AS; Kola-Kehinde, O; Mann, J; Nawaz, H; Patel, M; Raman, SV; Rogers, KA; Ruz, P; Sanchez, R; Simonetti, OP; Wallace, G; Wei, L; Wiczer, T; Woyach, JA; Yildiz, V, 2023)	0.91
" Cardiovascular magnetic resonance measures were highest in those with suspected toxic effects (P = ."	( Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity. Addison, D; Awan, FT; Bhat, S; Bonsu, JM; Buck, B; Byrd, JC; Carter, R; Chum, AP; Gambril, J; Guha, A; Haddad, D; Kittai, AS; Kola-Kehinde, O; Mann, J; Nawaz, H; Patel, M; Raman, SV; Rogers, KA; Ruz, P; Sanchez, R; Simonetti, OP; Wallace, G; Wei, L; Wiczer, T; Woyach, JA; Yildiz, V, 2023)	0.91
" Baseline hypertension was not associated with major adverse cardiovascular events in ibrutinib-treated patients nor with event-free or overall survival."	( Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Burger, JA; Durand, JB; Ferrajoli, A; George, B; Gordon, MJ; Jain, N; Jones, JE; Keating, M; Peterson, C; Wierda, WG, 2023)	0.91
" Other than chronic kidney disease, baseline cardiovascular disease did not affect ibrutinib-related hypertension nor was hypertension associated with major adverse cardiovascular events or survival."	( Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Burger, JA; Durand, JB; Ferrajoli, A; George, B; Gordon, MJ; Jain, N; Jones, JE; Keating, M; Peterson, C; Wierda, WG, 2023)	0.91
"ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia."	( Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Bajwa, N; Brown, JR; Byrd, JC; Chanan-Khan, A; de Borja, M; Furman, RR; Ghia, P; Higgins, K; John, E; Jurczak, W; Kater, AP; Mato, A; Miranda, P; Munir, T; O'Brien, S; Seymour, JF; Stilgenbauer, S; Woyach, JA, 2023)	0.91
"Ibrutinib is reported effective in the management of refractory/relapsed primary central nervous system lymphoma but it has adverse effects."	( Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis. Huang, C; Liu, Q; Qiao, L, 2023)	0.91

Excerpt	Reference	Relevance
" We developed a population pharmacokinetic (PK) model for ibrutinib in patients."	( Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015)	0.42
" The analytical method was applied to support a pharmacokinetic study of simultaneous estimation of lenalidomide, ibrutinib, and its active metabolite PCI-45227 in Wistar rat."	( Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. Govindarajulu, B; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S, 2015)	0.42
" When corrected for repeated dosing, pharmacokinetic parameters in healthy participants and patients were comparable."	( The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Byrd, JC; Chauhan, V; de Jong, J; Hellemans, P; James, D; Jiao, J; Loury, DJ; Mannaert, E; Murphy, J; O'Brien, S; Skee, D; Sukbuntherng, J, 2015)	0.42
" Finally, the assay was used for a pharmacokinetic study of plasma levels in treated FVB mice."	( Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Beijnen, JH; Rood, JJM; Schellens, JHM; Schinkel, AH; Sparidans, RW; van Hoppe, S, 2016)	0.43
" In-vivo pharmacokinetic studies in rats showed that optimized SNEDDS I1 controlled the absorption of IBR compared with IBR suspension."	( Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. Ezzeldin, E; Iqbal, M; Shakeel, F, 2016)	0.43
"Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions."	( Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling. De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J, 2016)	0.43
" Here, we review the available literature on the pharmacokinetic and pharmacodynamic properties of these novel agents to guide the reader in the appropriate use of ibrutinib, idelalisib, and venetoclax."	( Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. Hill, BT; Waldron, M; Winter, A, 2017)	0.46
" To elucidate on-target and pharmacodynamic effects of acalabrutinib, we evaluated several laboratory endpoints, including proteomic changes, chemokine modulation and impact on cell migration."	( Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Ayres, ML; Balakrishnan, K; Cheung, JP; Gandhi, V; Gay, J; Ivan, C; Keating, MJ; Lamothe, B; Marszalek, JR; Morse, J; Nelson, M; Patel, VK; Wierda, WG, 2018)	0.48
" Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab."	( Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Avigdor, A; Bartlett, N; Cramer, P; de Jong, J; De Nicolao, G; Demirkan, F; Dilhuydy, MS; Fraser, G; Ganguly, S; Goy, A; Howes, A; Lavezzi, SM; Loscertales, J; Mahler, M; Neyens, M; Poggesi, I; Rule, S; Salman, M; Samoilova, O, 2019)	0.51
"A new series of Proteolysis Targeting Chimeras (PROTACs) targeting Bruton's Tyrosine Kinase (BTK) was synthesized, with the goal of improving the pharmacokinetic properties of our previously reported PROTAC, MT802."	( Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Buhimschi, AD; Crews, CM; Hines, J; Jaime-Figueroa, S; Toure, M, 2020)	0.56
" The aim of this work is to develop a population pharmacokinetic model for ibrutinib and its dihydrodiol metabolite to quantify pharmacokinetic inter- and intra-individual variability, to evaluate the impact of several covariates on ibrutinib pharmacokinetic parameters, and to examine the relationship between exposure and clinical outcome."	( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)	0.56
" Pharmacokinetic blood samples were taken from months 1 to 12 after inclusion."	( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)	0.56
"A total of 89 patients and 1501 plasma concentrations were included in the pharmacokinetic analysis."	( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)	0.56
"We present the first population pharmacokinetic model describing ibrutinib and dihydrodiol-ibrutinib concentrations simultaneously."	( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)	0.56
"In our present experiment, the aim of this paper was to develop and fully validate an accurate and simple ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay for simultaneous quantification of acalabrutinib, ibrutinib, and their metabolites (ACP-5862 and PCI-45227) in beagle dog plasma and to survey the pharmacokinetic study of all analytes in beagle dogs."	( Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study. Jiang, Z; Lin, G; Shi, L; Wang, Y; Zhang, Y, 2020)	0.56
"A population pharmacokinetic modeling approach was applied to 39 healthy subjects."	( Population Pharmacokinetics of Ibrutinib in Healthy Adults. Al-Ghazawi, M; Najib, N; Najib, O; Saleh, MI; Salem, I, 2021)	0.62
" The pharmacokinetic and pharmacodynamic data of acalabrutinib were also discussed."	( Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Li, J; Miao, Y; Xu, W, 2021)	0.62
" We hypothesized that the oral bioavailability of ibrutinib is limited by CYP3A isoform-mediated metabolism, and that this pathway can be inhibited to improve the pharmacokinetic properties of ibrutinib."	( Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Baker, SD; Byrd, JC; Eisenmann, ED; Fu, Q; Garrison, DA; Jin, Y; Muhowski, EM; Sparreboom, A; Uddin, ME; Weber, RH; Woyach, J, 2021)	0.62
"The population pharmacokinetic (PK) and exposure-response (E-R) analyses for the safety of ibrutinib for the treatment of chronic graft-versus-host disease (cGVHD) is presented."	( Population Pharmacokinetic and Exposure-Safety Analyses of Ibrutinib for the Treatment of Chronic Graft-Versus-Host Disease. Atluri, H; Iwaki, Y; Mita, S; Ogawa, T, 2023)	0.91

Excerpt	Reference	Relevance
" We investigated the efficacy of the histone deacetylase (HDAC) inhibitor vorinostat combined with one of several B-cell receptor (BCR) signaling inhibitors on MCL cell death and the underlying mechanisms, using MCL cell lines."	( The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T, 2015)	0.42
" We here compare bortezomib with carfilzomib and LU-102 in MM and MCL in vitro with regard to their effects on pIκB/NF-κB signaling and their cytotoxic activity in combination with ibrutinib."	( The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H, 2015)	0.42
" Anti-CD20 antibodies have improved response and progression-free survival (PFS) when combined with chemotherapy."	( Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Andritsos, LA; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Hall, N; Heerema, NA; Jaglowski, SM; James, DF; Johnson, AJ; Jones, JA; Lozanski, G; Maddocks, KJ; Munneke, B; Nagar, V; Neuenburg, JK; Ruppert, AS; Smucker, K; Stefanos, M; West, JS; Woyach, JA, 2015)	0.42
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma."	( Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016)	0.43
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."	( Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)	0.43
" Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vorinostat, the Bruton's tyrosine kinase inhibitor ibrutinib, the anti-CD20 monoclonal antibody rituximab, and the mTOR inhibitor everolimus in a diffuse large B cell lymphoma model."	( Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E, 2016)	0.43
" Ublituximab in combination with ibrutinib resulted in rapid and high response rates."	( Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Brooks, HD; Burke, JM; Fanning, S; Farber, CM; Greenwald, DR; Klein, L; Kolibaba, KS; Mahadevan, D; Miskin, HP; Schreeder, MT; Sharman, JP; Sportelli, P; Weiss, MS, 2017)	0.46
" We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients."	( A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Courtien, AI; Devlin, SM; Drullinsky, P; Gerecitano, J; Kumar, A; Matasar, MJ; McCall, SJ; Miller, ST; Moskowitz, CH; Noy, A; Palomba, ML; Portlock, CS; Sauter, CS; Schoder, H; Straus, DJ; Younes, A; Zelenetz, AD, 2018)	0.48
" The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily."	( Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L, 2019)	0.51
" The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases."	( Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019)	0.51
" The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma."	( Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Alvarez, J; Avivi, I; Balasubramanian, S; Ben-Yehuda, D; Bosch, F; Brody, J; Buglio, D; Caballero Barrigón, MD; Carpio, C; Ceulemans, R; Cordoba, R; de Jong, J; Demirkan, F; Ferhanoglu, B; Fourneau, N; Hellmann, A; Hodkinson, BP; Horowitz, NA; Jurczak, W; Kuss, B; Lopez-Guillermo, A; Ma, DDF; Marlton, P; Nagler, A; Ozcan, M; Schaffer, M; Streit, M; Wang, SS; Wrobel, T; Yağci, M; Younes, A, 2019)	0.51
"Ibrutinib alone or in combination with cytarabine or azacitidine demonstrated an acceptable safety profile."	( Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS, 2019)	0.51
"We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies."	( A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020)	0.56
"Ibrutinib combined with bortezomib and dexamethasone elicited clinical responses."	( A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020)	0.56
" This study assessed the in vitro and in vivo functionality of CAR T cells transduced to express the anti-CD19 CAR of liso-cel in combination with ibrutinib or acalabrutinib."	( Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. Baturevych, A; Clouser, CR; Hause, RJ; Johnstone, TG; Jones, JC; Krejsa, CM; Ponce, R; Ports, MO; Qin, JS; Ragan, SP; Salmon, RA, 2020)	0.56
" High-dose chemotherapy regimens such as DA-EPOCH should be administered to young patients in combination with rituximab."	( Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma. Chen, Z; Li, Y; Tian, C, 2020)	0.56
" However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity."	( Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. Fancher, KM; Pappacena, JJ, 2020)	0.56
" These variants were subsequently combined with replacement of the cysteine 481 residue to which irreversible inhibitors, such as ibrutinib, acalabrutinib and zanubrutinib, bind."	( BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L, 2021)	0.62
" He was placed on intravenous immunoglobulin (IVIg) in combination with ibrutinib."	( [Intravenous immunoglobulin in combination with ibrutinib for the treatment of IgM-type M protein associated peripheral neuropathy complicated with chronic lymphocytic leukemia]. Kawano, K; Kawano, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Uchida, H, 2021)	0.62
" The highest tested dose of ibrutinib, 560 mg once daily, was combined with a fixed dose of pembrolizumab 200 mg every 3 weeks for the phase 2 portion."	( A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Carballido, E; Imanirad, I; Kim, DW; Kim, RD; Martinez, M; Mehta, R; Schell, MJ; Strosberg, J; Tan, E; Yu, J; Zhou, JM, 2021)	0.62
" Herein, we investigated the effects of the two drugs on UDP-glucuronosyltransferase (UGT) activities to evaluate their potential risk for drug-drug interactions (DDIs) via UGT inhibition."	( Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase. Cao, J; Fan, X; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y; Yan, M, 2021)	0.62
" We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients."	( Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Aymerich, M; Beà, S; Campo, E; Casanova, M; Cortés-Romera, M; de la Cruz, F; de la Fuente, A; García Sanz, R; Giné, E; González Barca, E; González-López, TJ; Jiménez Ubieto, A; López Jimenez, J; López-Guillermo, A; Marín-Niebla, A; Martín García-Sancho, A; Medina Herrera, A; Muntañola, A; Nadeu, F; Rodríguez, S; Rotger, A; Setoain, X; Terol, MJ, 2022)	0.72
" In conclusion ibrutinib in combination with rituximab is an active second-line treatment option for patients with relapsed or refractory AIHA/PRCA and underlying CLL."	( Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias. Belyakova, V; Biderman, B; Dmitrieva, E; Kaplanov, K; Kislova, M; Klitochenko, T; Konstantinova, T; Makarovskaya, P; Matveeva, I; Mayorova, O; Morozov, D; Nikitin, E; Obukhova, T; Poddubnaya, I; Ptushkin, V; Samoilova, O; Shipaeva, A; Shirokova, M; Sudarikov, A; Suvorova, A; Sveshnikova, J; Vyscub, G, 2023)	0.91
" The current intention of the research was to enhance solubility followed by oral bioavailability of IBR using the hot melt extrusion (HME) technique by formulating drug-drug cocrystals (DDCs)."	( In Silico Screening as a Tool to Prepare Drug-Drug Cocrystals of Ibrutinib-Ketoconazole: a Strategy to Enhance Their Solubility Profiles and Oral Bioavailability. Bangera, PD; Kara, DD; Mehta, CH; Rathnanand, M; Tanvi, K, 2023)	0.91

Excerpt	Reference	Relevance
" Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL."	( Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Bojnik, E; Buggy, JJ; Byrd, JC; Chang, BY; Davis, ME; Dubovsky, JA; Efremov, DG; Gobessi, S; Goettl, VM; Harrington, BK; Johnson, AJ; Laurenti, L; MacMurray, J; Ruppert, AS; Smith, LL; Smucker, KA; Stefanovski, MR; Towns, WH; Woyach, JA, 2014)	0.4
" The fasting state was characterized by a 67 % relative bioavailability compared with the meal conditions used in the trials and administration after a high-fat meal."	( Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015)	0.42
" Ibrutinib is an orally bioavailable and highly specific BTK inhibitor that was recently approved for treatment of patients with recurrent CLL and mantle cell lymphoma (MCL)."	( Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Lynn Wang, Y; Smith, SM; Zhang, SQ; Zhang, SY, 2015)	0.42
" The present study was designed to investigate the absolute bioavailability (F) of ibrutinib in the fasting and fed state and assess the effect of grapefruit juice (GFJ) on the systemic exposure of ibrutinib in order to determine the fraction escaping the gut (Fg ) and the fraction escaping hepatic extraction (Fh ) in the fed state."	( Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. de Jong, J; de Vries, R; de Zwart, L; Hellemans, P; Jiao, J; Mannaert, E; Murphy, J; Skee, D; Smit, JW; Snoeys, J; Sukbuntherng, J; Vliegen, M, 2016)	0.43
" Orally bioavailable inhibitors of spleen tyrosine kinase, Bruton's tyrosine kinase, or PI3Kδ, induce high rates of durable responses."	( The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Wiestner, A, 2015)	0.42
" In the in vivo studies 18 demonstrated a good bioavailability (30%) and significantly suppressed the tumor growth in MV4-11 cell inoculated xenograft model (50 mg/kg) without exhibiting obvious toxicity."	( Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. Chen, C; Hu, C; Li, X; Liu, J; Liu, Q; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Wu, H; Wu, J; Yu, K; Zhang, S; Zhao, Z; Zou, F, 2015)	0.42
"These results indicated the potential of developed SNEDDS as an alternative drug delivery system for IBR to enhance its bioavailability and anticancer efficacy."	( Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. Ezzeldin, E; Iqbal, M; Shakeel, F, 2016)	0.43
" In addition, the new ProTide strategy was shown to enhance oral bioavailability of the corresponding monoester phosphoramidate."	( Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma. Aldrich, CC; Dawadi, S; Demosthenous, C; Gupta, M; Han, J; Okon, A; Wagner, CR, 2017)	0.46
" Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia."	( Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018)	0.48
" However, IBR is insoluble at neutral pH and can dissolve only at low pH: thus, commercial IBR products present poor bioavailability and weakened in vivo antitumor activity."	( Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility. Deng, Y; Hu, L; Lai, C; Li, C; Liu, M; Liu, X; Lu, M; Luo, X; Qiu, Q; Song, Y; Zhang, H; Zheng, H, 2018)	0.48
" Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor (BTKi) and forms an irreversible covalent bound to BTK at the Cysteine-481 residue."	( Management of adverse effects/toxicity of ibrutinib. Paydas, S, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first-pass metabolism by cytochrome P450 (CYP) 3A4."	( Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction. Backman, JT; Elonen, E; Neuvonen, M; Neuvonen, PJ; Niemi, M; Olkkola, AM; Tapaninen, T; Tornio, A, 2020)	0.56
" Moreover, the biosafety of the ternary formulation was the same as that of IBR while the in vitro performance advantage of the ternary formulation was converted into higher bioavailability in vivo experiments."	( Microcrystalline cellulose as an effective crystal growth inhibitor for the ternary Ibrutinib formulation. Gan, N; Li, H; Peng, X; Suo, Z; Tang, P; Wei, X; Zhang, M; Zhao, L, 2020)	0.56
" KIN-8194 demonstrated excellent bioavailability and pharmacokinetic parameters, with good tolerance in rodent models at pharmacologically achievable and active doses."	( The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Anderson, KC; Buhrlage, SJ; Cameron, M; Castillo, JJ; Che, J; Chen, JG; Demos, MG; Gray, NS; Guerrera, ML; Hunter, ZR; Kofides, A; Liu, X; Meid, K; Munshi, M; Munshi, NC; Patterson, CJ; Tan, L; Treon, SP; Tsakmaklis, N; Wang, J; Xu, L; Yang, G, 2021)	0.62
" Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported."	( Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Brullo, C; Russo, E; Spallarossa, A; Tasso, B; Villa, C, 2021)	0.62
" However, ibrutinib has very low oral bioavailability that contributes to significant variability in systemic exposure between patients, and this has the potential to affect both efficacy and toxicity."	( Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Baker, SD; Byrd, JC; Eisenmann, ED; Fu, Q; Garrison, DA; Jin, Y; Muhowski, EM; Sparreboom, A; Uddin, ME; Weber, RH; Woyach, J, 2021)	0.62
" However, conducting the rational discovery of orally bioavailable BTK-PROTACs presents significant challenges."	( Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma. Che, J; Dong, X; Huang, W; Jin, Y; Kan, W; Li, C; Li, J; Luo, X; Pang, A; Wang, H; Wu, M; Wu, Y; Xu, Y; Zeng, S; Zhang, J; Zhou, Y; Zhuang, W, 2022)	0.72
" During its clinical development, a stable isotopologue of ibrutinib was required for the assessment of the drug's absolute oral bioavailability via intravenous microdosing."	( Carbon-13 labeling of ibrutinib for human microdosing. Gong, Y; Salter, R, 2023)	0.91
" The bioavailability of IBR was largely improved, and enhanced sensitivity of glioma to IBR was achieved due to inhibition effect of HCQ on IBR-induced pro-survival autophagy."	( Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma. Du, Y; Gao, H; Lei, L; Li, Y; Tong, F; Wang, X; Xia, X; Yang, Z, 2023)	0.91
" In this study, we investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK inhibitor in the pathogenesis of Graves' orbitopathy (GO) in in vitro model."	( Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy. Chae, MK; Jang, SY; Kikkawa, DO; Ko, J; Park, HY; Yoon, JS, 2022)	0.72
" The oral bioavailability of IBR was improved 22."	( Core Shell Lipid-Polymer Hybrid Nanoparticles for Oral Bioavailability Enhancement of Ibrutinib via Lymphatic Uptake. Desai, A; Kansara, V; Patel, M; Vyas, B, 2023)	0.91
" IBR has an extremely low oral bioavailability due to the activity of the CYP3A4 enzyme."	( In Silico Screening as a Tool to Prepare Drug-Drug Cocrystals of Ibrutinib-Ketoconazole: a Strategy to Enhance Their Solubility Profiles and Oral Bioavailability. Bangera, PD; Kara, DD; Mehta, CH; Rathnanand, M; Tanvi, K, 2023)	0.91
" High gastric pH reduces the bioavailability of some Bruton tyrosine kinase inhibitors."	( Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia. McGeachie, M; Mulligan, S; Opat, S; Puig, A; Salvaris, R, 2023)	0.91

Excerpt	Relevance	Reference
" However, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition."	( Ibrutinib and novel BTK inhibitors in clinical development. Akinleye, A; Chen, Y; Liu, D; Mukhi, N; Song, Y, 2013)	0.39
" Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo."	( Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP, 2015)	0.42
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs."	( A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. Kim, SS; Lee, CS; Rattu, MA, 2016)	0.43
"Ibrutinib administered in fasted condition reduces exposure to approximately 60 % as compared with dosing in proximity to food-intake, regardless of timing/type of meal."	( The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Byrd, JC; Chauhan, V; de Jong, J; Hellemans, P; James, D; Jiao, J; Loury, DJ; Mannaert, E; Murphy, J; O'Brien, S; Skee, D; Sukbuntherng, J, 2015)	0.42
" Cohort 1 (n = 3) consisted of two phases, a single-dose (140 and 280 mg) phase and a multiple-dose (420 mg) phase of ibrutinib; cohort 2 (n = 6) included multiple doses of ibrutinib 560 mg; and cohort 3 (n = 6) included only patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) dosed at ibrutinib 420 mg."	( Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y, 2016)	0.43
" Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already observed in ibrutinib-treated patients."	( Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Norman, P, 2016)	0.43
" Patients with rapidly progressing disease received an accelerated dosing schedule (to 400 mg per day by week 3)."	( Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Barr, PM; Byrd, JC; Cheson, BD; Choi, M; Chyla, B; Coutre, S; Davids, MS; Furman, RR; Humerickhouse, RA; Jones, JA; Lamanna, N; Mato, AR; Potluri, J; Salem, AH; Verdugo, M; Wierda, WG; Woyach, J; Zhou, L, 2018)	0.48
" There was no inducibility difference after chronic dosing with washout."	( Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib. Jones, DL; Tuomi, JM; Xenocostas, A, 2018)	0.48
" The additive and synergistic inhibition of this combination additionally supports a therapeutic strategy involving lower dosing of each drug to reduce potential side effects."	( Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib. Curtis, A; Rajan, S; Rueter, J; Shopland, L; Zhang, R, 2018)	0.48
"This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations."	( A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J, 2018)	0.48
" These findings suggest deterioration of the humoral immune system is associated with progressive CLL and altering the dosing of IgRT to achieve higher than conventional IgG target levels may have therapeutic activity."	( Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia. Huang, J; Lazarus, A; Norris, P; Shi, Y; Spaner, DE; Venema, R; Wang, G, 2018)	0.48
" To test this postulate, a pilot study (NCT02801578) was designed to systematically reduce ibrutinib dosing within the same patient with CLL over the course of three 28-day cycles."	( A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Bose, P; Chen, LS; Cruz, ND; Feng, S; Gandhi, V; Huang, X; Jain, N; Jiang, Y; Keating, MJ; Kroll, MH; Qiao, W; Thompson, PA; Wierda, WG; Wu, Q, 2018)	0.48
"As oral targeted agents, such as ibrutinib, become more widely used, understanding the impact of suboptimal dosing on overall survival (OS) and progression-free survival (PFS) outside of clinical trials is imperative."	( Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Baloga, E; Baran, AM; Barr, PM; Casulo, C; Friedberg, JW; Helber, M; Moore, J; Reagan, P; Williams, AM; Zent, CS, 2019)	0.51
" Additionally, debate exists regarding the recommended dosing strategy for ibrutinib for this indication with disease remission demonstrated at 560 mg and 420 mg."	( Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report. Arnall, JR; Hartsell, L; Janes, A; Larck, C; Park, S, 2019)	0.51
" Submaximal ibrutinib dosing will have to be further systematically evaluated."	( Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. Banerji, V; Brown, K; Bucher, O; Dawe, DE; Dhaliwal, DH; Geirnaert, M; Hibbert, I; Johnston, JB; Uminski, K, 2019)	0.51
" A link between the dosing compartment and the dihydrodiol-ibrutinib central compartment was added to assess for high first-pass hepatic metabolism."	( Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L, 2020)	0.56
" Ibrutinib is currently not available in a liquid oral dosage form."	( Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. Arnall, JR; DiSogra, KY; Janes, A; Moore, DC; Park, SI; Tran, T, 2021)	0.62
"The model can be used to simulate clinical trials or various dosing scenarios."	( Population Pharmacokinetics of Ibrutinib in Healthy Adults. Al-Ghazawi, M; Najib, N; Najib, O; Saleh, MI; Salem, I, 2021)	0.62
" We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily)."	( Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME, 2022)	0.72
" Ruxolitinib dosing was based on a previous phase I trial."	( Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial. Gallagher, J; Luo, Y; Shi, Y; Spaner, DE; Tsui, H; Wang, G, 2021)	0.62
" Ibrutinib dosing was held (≥7 days) for 79 patients and reduced for 31 patients because of AEs; these AEs resolved or improved in 85% (67 of 79) and 90% (28 of 31) of patients, respectively."	( Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Bairey, O; Barr, PM; Burger, JA; Coutre, SE; Dearden, C; Ghia, P; Grosicki, S; Hillmen, P; Hsu, E; Kipps, TJ; Li, JY; McCarthy, H; Moreno, C; Offner, F; Owen, C; Robak, T; Szoke, A; Tedeschi, A; Zhou, C, 2022)	0.72
" The impact of this reduced dosing is unclear with regards to outcomes."	( Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more. Tohidi-Esfahani, I; Trotman, J, 2023)	0.91
" The optimal dosing schedule for mitigating this adverse effect is currently under discussion."	( Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models. Friberg, LE; Ibrahim, EIK; Karlsson, MO, 2023)	0.91

Role	Description
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrazolopyrimidine
aromatic amine	An amino compound in which the amino group is linked directly to an aromatic system.
aromatic ether	Any ether in which the oxygen is attached to at least one aryl substituent.
acrylamides	An enamide which is acrylamide or a derivative of acrylamide obtained by replacement of one or more of its hydrogens.
N-acylpiperidine
tertiary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Acute myeloid leukemia	0	9

Protein Targets (326)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	0.1000	20.8793	79.4328	AID588456
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	18.5569	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	6.4468	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	11.2202	0.0052	7.8098	29.0929	AID588855
EWS/FLI fusion protein	Homo sapiens (human)	Potency	23.1592	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	0.8972	0.0001	8.4406	100.0000	AID720579; AID720580
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	0.0013	0.0000	5.0182	79.2586	AID686947; AID686948
Interferon beta	Homo sapiens (human)	Potency	18.5569	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Testosterone 17-beta-dehydrogenase 3	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0028	0.0001	0.0015	0.0040	AID1241390; AID1241391
Tyrosine-protein kinase JAK2	Homo sapiens (human)	GI50	5.0345	0.0240	2.8125	9.0230	AID1499236; AID1499237
Tyrosine-protein kinase JAK2	Homo sapiens (human)	IC50 (µMol)	5.5000	0.0001	0.3722	10.0000	AID1650543; AID1714844
Solute carrier family 22 member 3	Homo sapiens (human)	IC50 (µMol)	7.9000	0.0900	3.7277	9.5000	AID1745861
Epidermal growth factor receptor	Homo sapiens (human)	GI50	2.0493	0.0003	0.6494	3.5000	AID1481308; AID1481309; AID1481310; AID1481353; AID1499230; AID1499231; AID1499233
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	0.0402	0.0000	0.5369	10.0000	AID1375525; AID1458976; AID1458977; AID1458978; AID1469890; AID1488737; AID1549564; AID1587023; AID1591631; AID1615345; AID1615387; AID1638787; AID1638788; AID1656256; AID1673827; AID1673834; AID1714838; AID1718992; AID1718993; AID1720509; AID1738568; AID1781999; AID1822764; AID1822769; AID1871765; AID1880138; AID1889499; AID629929
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50 (µMol)	0.0104	0.0001	0.5453	10.0000	AID1375530; AID1412710; AID1488738; AID1549565; AID1615366; AID1714839; AID1720526; AID1871766
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	50.0095	0.0001	1.7740	10.0000	AID1615366; AID1725079
Tyrosine-protein kinase Lck	Homo sapiens (human)	IC50 (µMol)	0.0180	0.0002	1.3173	10.0000	AID1615373; AID1714871
Tyrosine-protein kinase Fyn	Homo sapiens (human)	IC50 (µMol)	0.0960	0.0002	1.6789	8.6800	AID1714870
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	IC50 (µMol)	3.2725	0.0006	0.5676	5.5450	AID1375535; AID1714866
Tyrosine-protein kinase Yes	Homo sapiens (human)	IC50 (µMol)	0.0065	0.0004	0.5740	8.9000	AID1714869
Tyrosine-protein kinase Lyn	Homo sapiens (human)	IC50 (µMol)	0.2000	0.0002	0.5594	5.2000	AID1714872; AID631101
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	IC50 (µMol)	0.0262	0.0001	0.3484	3.5970	AID1375529; AID1714856; AID671744
Tyrosine-protein kinase HCK	Homo sapiens (human)	IC50 (µMol)	0.0095	0.0001	1.2226	7.7000	AID1714868; AID1718985
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	12.9945	0.0001	1.7536	10.0000	AID1399798; AID1615387; AID1615388; AID1725081
Platelet-derived growth factor receptor beta	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0006	0.8007	8.5000	AID1375533
Tyrosine-protein kinase Fgr	Homo sapiens (human)	IC50 (µMol)	0.0021	0.0007	1.1659	8.5000	AID1615371; AID1714863
Cytochrome P450 2C8	Homo sapiens (human)	IC50 (µMol)	3.9595	0.0008	1.8848	7.9000	AID1399794; AID1615366
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	50.0384	0.0000	2.0151	10.0000	AID1615388; AID1725077
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	6.0643	0.0000	2.8005	10.0000	AID1399797; AID1615374; AID1725080
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	IC50 (µMol)	0.0768	0.0002	0.5335	10.0000	AID1587020; AID1714873; AID1718984; AID1718986; AID1738571
Cytochrome P450 2B6	Homo sapiens (human)	IC50 (µMol)	5.6005	0.0011	3.4186	10.0000	AID1399795; AID1615387
Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)	GI50	0.0040	0.0040	0.0040	0.0040	AID1499232
Tyrosine-protein kinase JAK1	Homo sapiens (human)	GI50	8.9270	0.0953	3.2734	8.9270	AID1499235
Tyrosine-protein kinase JAK1	Homo sapiens (human)	IC50 (µMol)	5.5000	0.0003	0.2378	7.3000	AID1650542; AID1714843
G1/S-specific cyclin-E1	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0010	1.0404	10.0000	AID1587597
Cyclin-dependent kinase 2	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0004	1.0444	10.0000	AID1587597
Ephrin type-A receptor 2	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0008	0.0436	0.2626	AID1375534
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	17.5256	0.0000	2.3983	10.0000	AID1399796; AID1615388; AID1725078
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.4653	9.7000	AID1714855
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	GI50	0.1200	0.0000	0.6457	9.3000	AID1267792
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	IC50 (µMol)	0.5365	0.0001	0.3275	9.5480	AID1375531; AID1714867
Tyrosine-protein kinase CSK	Homo sapiens (human)	IC50 (µMol)	0.0023	0.0013	1.3352	5.1800	AID1714850
Tyrosine-protein kinase Tec	Homo sapiens (human)	IC50 (µMol)	0.0092	0.0005	0.0631	0.4720	AID1375526; AID1465439; AID1465442; AID1615365; AID1615389; AID1720522; AID1871761; AID1880136; AID1889498
Tyrosine-protein kinase TXK	Homo sapiens (human)	IC50 (µMol)	0.0025	0.0003	0.0821	0.4720	AID1375527; AID1615374; AID1720525; AID1871763
Tyrosine-protein kinase FRK	Homo sapiens (human)	IC50 (µMol)	0.0541	0.0013	0.5514	2.3000	AID1615372; AID1714864
Tyrosine-protein kinase SYK	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0001	0.8260	10.0000	AID1714877
Tyrosine-protein kinase Blk	Homo sapiens (human)	IC50 (µMol)	0.0004	0.0001	0.4357	5.4700	AID1375523; AID1615367; AID1714837; AID1720538; AID1738570; AID1871768; AID671742
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	GI50	0.0090	0.0090	0.0090	0.0090	AID1499234
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	IC50 (µMol)	0.0020	0.0004	0.2336	2.6650	AID1375532; AID1469888; AID1488736; AID1615368; AID1673830; AID1714833; AID1720523; AID1781997; AID1871764; AID671743
Tyrosine-protein kinase JAK3	Homo sapiens (human)	IC50 (µMol)	0.0411	0.0001	0.4193	7.9200	AID1397229; AID1401308; AID1469889; AID1549567; AID1615341; AID1650544; AID1654023; AID1714842; AID1720528; AID1871769
Tyrosine-protein kinase BTK	Homo sapiens (human)	IC50 (µMol)	0.1466	0.0001	0.2557	7.6000	AID1155511; AID1155512; AID1241390; AID1241391; AID1245614; AID1304228; AID1304229; AID1324656; AID1334877; AID1337175; AID1375479; AID1375480; AID1387234; AID1387235; AID1391148; AID1397230; AID1398718; AID1399782; AID1399788; AID1399789; AID1401307; AID1412699; AID1417607; AID1417608; AID1418272; AID1418273; AID1418276; AID1424595; AID1426139; AID1465438; AID1465441; AID1468772; AID1468826; AID1469887; AID1484553; AID1530075; AID1549553; AID1553406; AID1558403; AID1560795; AID1560796; AID1560797; AID1560882; AID1563020; AID1563025; AID1574152; AID1587021; AID1587022; AID1591625; AID1615343; AID1615363; AID1623549; AID1650541; AID1650930; AID1650931; AID1656236; AID1656238; AID1656239; AID1656330; AID1656331; AID1673828; AID1673837; AID1673923; AID1673924; AID1709139; AID1714774; AID1718990; AID1720521; AID1725071; AID1738555; AID1738572; AID1741721; AID1781996; AID1822762; AID1822767; AID1830229; AID1830230; AID1830231; AID1830232; AID1830233; AID1851504; AID1853204; AID1869073; AID1869074; AID1869075; AID1869076; AID1869077; AID1871760; AID1875918; AID1880135; AID1880547; AID1889496; AID1894182; AID1894183; AID1897142; AID631100; AID671741; AID719893
Tyrosine-protein kinase BTK	Homo sapiens (human)	Ki	0.2149	0.0032	0.0703	0.4250	AID1469894; AID1656244
Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)	IC50 (µMol)	0.0471	0.0010	0.3090	5.6500	AID1375528; AID1412711; AID1615364; AID1615388; AID1714835; AID1720524; AID1738569; AID1781998; AID1822763; AID1822768; AID1871762; AID1880137; AID1889497
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	4.4000	0.0009	1.9014	10.0000	AID1417599; AID1725082
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	1.1000	0.0021	1.8407	10.0000	AID1399793
Protein-tyrosine kinase 6	Homo sapiens (human)	IC50 (µMol)	0.0180	0.0053	0.5770	2.3000	AID1615369
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	IC50 (µMol)	0.0066	0.0001	0.1736	2.5900	AID1375524; AID1549566; AID1615370; AID1656257; AID1673832; AID1720527; AID1871767
Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0001	0.1861	1.2600	AID1714854
Sigma intracellular receptor 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.0000	0.0143	1.3756	7.5000	AID1650543
Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)	IC50 (µMol)	0.0780	0.0780	0.0780	0.0780	AID1714834
Peroxiredoxin-like 2A	Homo sapiens (human)	IC50 (µMol)	0.9000	0.9000	0.9000	0.9000	AID1337177
Platelet glycoprotein VI	Homo sapiens (human)	IC50 (µMol)	0.1200	0.0020	1.5588	4.0000	AID1692287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bone morphogenetic protein receptor type-1B	Homo sapiens (human)	Kd	30.0000	0.0009	1.1413	3.7000	AID1424922
Cell division cycle 7-related protein kinase	Homo sapiens (human)	Kd	30.0000	0.5110	0.5110	0.5110	AID1424936
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Kd	30.0000	0.0008	1.5144	9.0000	AID1425121
ATP-dependent RNA helicase DDX3X	Homo sapiens (human)	Kd	30.0000	0.4350	0.4350	0.4350	AID1424975
Pyridoxal kinase	Homo sapiens (human)	Kd	30.0000	0.2860	5.0765	16.4040	AID1425106
Citron Rho-interacting kinase	Homo sapiens (human)	Kd	30.0000	0.0330	3.0646	48.8760	AID1424954
Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Kd	30.0000	0.0028	1.4744	8.7000	AID1424953
Aurora kinase A	Homo sapiens (human)	Kd	30.0000	0.0001	0.7342	9.3000	AID1424917
Cyclin-G-associated kinase	Homo sapiens (human)	Kd	30.0000	0.0003	0.9086	28.6510	AID1425009
Ephrin type-B receptor 6	Homo sapiens (human)	Kd	30.0000	0.0000	1.0768	9.0000	AID1424995
Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)	Kd	30.0000	0.0260	1.3140	2.6020	AID1424896
Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	Kd	0.0570	0.0020	1.6212	11.4330	AID1425155
Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)	Kd	30.0000	0.0940	1.3910	3.5070	AID1424926
Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0170	0.3610	0.7050	AID1425097
Putative nucleoside diphosphate kinase	Homo sapiens (human)	Kd	30.0000	0.8620	0.8620	0.8620	AID1425092
Rho-associated protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0002	2.7105	56.0660	AID1425158
Serine/threonine-protein kinase ULK1	Homo sapiens (human)	Kd	30.0000	0.0008	1.8410	23.2730	AID1425208
Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)	Kd	30.0000	0.0057	2.0095	12.2010	AID1424997
Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)	Kd	30.0000	0.0170	1.9737	29.9570	AID1425162
U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)	Kd	30.0000	1.3820	1.3820	1.3820	AID1425174
Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)	Kd	30.0000	0.0120	1.6396	7.2000	AID1425161
Serine/threonine-protein kinase 16	Homo sapiens (human)	Kd	30.0000	0.0017	1.2483	9.9690	AID1425179
Serine/threonine-protein kinase 10	Homo sapiens (human)	Kd	30.0000	0.0000	2.9234	57.4530	AID1425177
Serine/threonine-protein kinase D3	Homo sapiens (human)	Kd	30.0000	0.0089	2.2738	23.3410	AID1425137
Structural maintenance of chromosomes protein 2	Homo sapiens (human)	Kd	30.0000	0.2090	0.6575	1.1060	AID1425173
Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)	Kd	30.0000	0.1700	1.5781	8.0000	AID1425050
Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)	Kd	30.0000	0.0082	2.3645	62.7720	AID1425054
Serine/threonine-protein kinase LATS1	Homo sapiens (human)	Kd	1.8840	0.0140	1.8393	10.7330	AID1425033
Serine/threonine-protein kinase PAK 4	Homo sapiens (human)	Kd	30.0000	0.0027	2.5694	30.3710	AID1425100
Tyrosine-protein kinase ABL1	Homo sapiens (human)	Kd	1.6940	0.0000	1.0411	13.4530	AID1424890
Epidermal growth factor receptor	Homo sapiens (human)	EC50 (µMol)	0.0595	0.0020	0.9902	7.9300	AID1720530; AID1880140
Epidermal growth factor receptor	Homo sapiens (human)	Kd	0.0179	0.0001	1.3514	20.8270	AID1424983; AID1560826; AID1878118
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	Kd	0.0010	0.0008	1.2931	5.1000	AID1560827; AID1878102
High affinity nerve growth factor receptor	Homo sapiens (human)	Kd	30.0000	0.0020	1.3484	9.2000	AID1425094
Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)	Kd	30.0000	0.1840	0.1840	0.1840	AID1425011
ADP/ATP translocase 2	Homo sapiens (human)	Kd	30.0000	0.4510	0.4510	0.4510	AID1425169
Protein kinase C beta type	Homo sapiens (human)	Kd	30.0000	0.0013	2.7081	26.3240	AID1425130
Insulin receptor	Homo sapiens (human)	Kd	30.0000	0.0017	1.0823	7.9060	AID1425026
Tyrosine-protein kinase Lck	Homo sapiens (human)	Kd	0.1030	0.0002	1.1174	24.2210	AID1425034
Tyrosine-protein kinase Fyn	Homo sapiens (human)	Kd	0.3050	0.0008	1.4238	8.4000	AID1425008
Cyclin-dependent kinase 1	Homo sapiens (human)	Kd	30.0000	0.2880	1.4952	3.0490	AID1424937
Glycogen phosphorylase, liver form	Homo sapiens (human)	Kd	30.0000	2.1210	2.1210	2.1210	AID1425146
Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)	Kd	30.0000	0.0048	1.0986	7.4000	AID1425003
Adenine phosphoribosyltransferase	Homo sapiens (human)	Kd	30.0000	0.0290	0.0290	0.0290	AID1424914
Tyrosine-protein kinase Yes	Homo sapiens (human)	Kd	0.0270	0.0003	1.3708	17.1520	AID1425212
Tyrosine-protein kinase Lyn	Homo sapiens (human)	Kd	0.1480	0.0006	1.0485	5.7000	AID1425037
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	Kd	18.0500	0.0007	0.8642	27.5420	AID1425154
Insulin-like growth factor 1 receptor	Homo sapiens (human)	Kd	30.0000	0.0010	1.9211	19.2170	AID1425022
Signal recognition particle receptor subunit alpha	Homo sapiens (human)	Kd	30.0000	0.0080	0.0080	0.0080	AID1425176
Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.2020	0.2020	0.2020	AID1424969
Hepatocyte growth factor receptor	Homo sapiens (human)	Kd	30.0000	0.0002	1.6297	8.5000	AID1425076
Tyrosine-protein kinase HCK	Homo sapiens (human)	Kd	0.0420	0.0003	2.0343	15.9930	AID1425017
Platelet-derived growth factor receptor beta	Homo sapiens (human)	Kd	30.0000	0.0001	1.0050	11.1070	AID1425104
Serine/threonine-protein kinase A-Raf	Homo sapiens (human)	Kd	30.0000	0.0470	9.6832	33.6550	AID1424915
Glycogen phosphorylase, brain form	Homo sapiens (human)	Kd	30.0000	3.5690	3.5690	3.5690	AID1425145
Breakpoint cluster region protein	Homo sapiens (human)	Kd	1.4590	0.0030	1.2196	17.3640	AID1424919
Serine/threonine-protein kinase pim-1	Homo sapiens (human)	Kd	30.0000	0.0010	1.1393	19.3160	AID1425111
Fibroblast growth factor receptor 1	Homo sapiens (human)	Kd	30.0000	0.0003	1.5581	6.2000	AID1425004
DNA topoisomerase 2-alpha	Homo sapiens (human)	Kd	30.0000	0.0640	0.2750	0.4860	AID1425202
Cyclin-dependent kinase 4	Homo sapiens (human)	Kd	30.0000	0.0033	1.6050	8.6000	AID1424946
ADP/ATP translocase 3	Homo sapiens (human)	Kd	30.0000	0.0060	0.2505	0.4950	AID1425170
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	Kd	0.0970	0.0002	1.5077	9.6000	AID1425175
cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)	Kd	30.0000	0.0520	1.7535	3.4550	AID1425128
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	Kd	30.0000	0.0002	1.6258	26.0180	AID1424924
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)	Kd	30.0000	0.0001	2.0569	9.5000	AID1425110
Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)	Kd	30.0000	0.0040	6.7556	88.9030	AID1425093
Tyrosine-protein kinase Fer	Homo sapiens (human)	Kd	30.0000	0.0014	1.3604	8.8000	AID1425002
Protein kinase C alpha type	Homo sapiens (human)	Kd	30.0000	0.0003	1.7922	21.3520	AID1425129
cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)	Kd	30.0000	0.0039	2.9479	23.2450	AID1425123
General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)	Kd	30.0000	0.0020	1.6906	12.0220	AID1424996
Casein kinase II subunit alpha'	Homo sapiens (human)	Kd	30.0000	0.0010	2.5309	28.8720	AID1424968
Ras-related protein Rab-6A	Homo sapiens (human)	Kd	30.0000	0.0330	0.0330	0.0330	AID1425150
Ephrin type-A receptor 1	Homo sapiens (human)	Kd	30.0000	0.0041	1.8000	9.8000	AID1424987
Multifunctional protein ADE2	Homo sapiens (human)	Kd	30.0000	5.4810	5.4810	5.4810	AID1425098
Nucleoside diphosphate kinase B	Homo sapiens (human)	Kd	30.0000	0.1420	0.1420	0.1420	AID1425091
cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)	Kd	30.0000	0.0020	8.5577	49.2780	AID1425125
cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)	Kd	30.0000	0.0130	0.7408	4.1000	AID1425124
Ferrochelatase, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.2430	6.4343	67.9140	AID1425001
Ribosomal protein S6 kinase beta-1	Homo sapiens (human)	Kd	30.0000	0.0013	1.1805	4.8000	AID1425164
Tyrosine-protein kinase JAK1	Homo sapiens (human)	Kd	30.0000	0.0016	1.2166	7.8000	AID1425030
Cyclin-dependent kinase 2	Homo sapiens (human)	Kd	30.0000	0.0070	1.5179	10.4870	AID1424944
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	Kd	30.0000	0.1700	5.5791	22.4940	AID1424908
Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)	Kd	30.0000	4.1030	4.1030	4.1030	AID1424977
Mitogen-activated protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.4300	5.2743	9.8000	AID1425061
MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)	Kd	30.0000	0.0030	3.9689	58.2400	AID1425069
Deoxycytidine kinase	Homo sapiens (human)	Kd	30.0000	0.0120	1.0875	2.1630	AID1424970
Mitogen-activated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0001	2.7441	7.3000	AID1425056
Ephrin type-A receptor 2	Homo sapiens (human)	Kd	30.0000	0.0009	1.0752	8.1980	AID1424988
Ephrin type-B receptor 2	Homo sapiens (human)	Kd	30.0000	0.0004	3.1536	53.1980	AID1424992
Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)	Kd	30.0000	0.0009	1.5575	8.7000	AID1425207
Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)	Kd	30.0000	0.0030	0.0030	0.0030	AID1425107
Wee1-like protein kinase	Homo sapiens (human)	Kd	30.0000	0.0014	3.5389	65.1580	AID1425210
Heme oxygenase 2	Homo sapiens (human)	Kd	30.0000	0.1190	0.1190	0.1190	AID1425018
DnaJ homolog subfamily A member 1	Homo sapiens (human)	Kd	30.0000	0.9620	0.9620	0.9620	AID1424980
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0006	1.0621	4.4000	AID1424910
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0021	1.6196	8.7000	AID1424911
Dual specificity protein kinase TTK	Homo sapiens (human)	Kd	30.0000	0.0065	1.6269	8.5000	AID1425205
DNA replication licensing factor MCM4	Homo sapiens (human)	Kd	30.0000	0.6290	0.6290	0.6290	AID1425072
Myosin-10	Homo sapiens (human)	Kd	30.0000	0.2290	0.4935	0.7580	AID1425079
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0039	1.6429	9.6000	AID1425039
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	Kd	1.5780	0.0002	0.9559	9.9000	AID1425006
Bone morphogenetic protein receptor type-1A	Homo sapiens (human)	Kd	30.0000	0.0600	1.5010	7.0000	AID1424921
Activin receptor type-1B	Homo sapiens (human)	Kd	30.0000	0.0040	1.5110	15.2580	AID1424901
TGF-beta receptor type-1	Homo sapiens (human)	Kd	30.0000	0.0050	2.2785	9.6000	AID1425196
TGF-beta receptor type-2	Homo sapiens (human)	Kd	30.0000	0.0800	1.8351	6.9000	AID1425197
Tyrosine-protein kinase CSK	Homo sapiens (human)	Kd	0.3990	0.0010	3.4578	39.5530	AID1424960
Glycine--tRNA ligase	Homo sapiens (human)	Kd	30.0000	0.0400	0.0400	0.0400	AID1425010
Protein kinase C iota type	Homo sapiens (human)	Kd	30.0000	0.0260	9.3316	51.0180	AID1425133
Exosome RNA helicase MTR4	Homo sapiens (human)	Kd	30.0000	2.6070	2.6070	2.6070	AID1425168
Tyrosine-protein kinase Tec	Homo sapiens (human)	Kd	0.0092	0.0010	1.0095	8.7000	AID1425193; AID1560824; AID1878121
Tyrosine-protein kinase TXK	Homo sapiens (human)	Kd	0.0006	0.0006	1.9196	6.0000	AID1878122
Tyrosine-protein kinase ABL2	Homo sapiens (human)	Kd	0.9190	0.0002	1.1249	14.9240	AID1424891
Tyrosine-protein kinase FRK	Homo sapiens (human)	Kd	0.5890	0.0003	1.2424	10.8370	AID1425007
G protein-coupled receptor kinase 6	Homo sapiens (human)	Kd	30.0000	1.1890	1.4020	1.6150	AID1425012
Tyrosine-protein kinase SYK	Homo sapiens (human)	Kd	30.0000	0.0070	2.0052	9.2260	AID1425188
26S proteasome regulatory subunit 6B	Homo sapiens (human)	Kd	30.0000	0.0050	0.0050	0.0050	AID1425141
Mitogen-activated protein kinase 8	Homo sapiens (human)	Kd	30.0000	0.0110	2.0965	26.0590	AID1425063
Mitogen-activated protein kinase 9	Homo sapiens (human)	Kd	30.0000	0.0020	1.4596	8.1000	AID1425064
Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0050	2.0462	6.6000	AID1425040
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)	Kd	30.0000	0.2080	3.6125	7.0170	AID1425113
Casein kinase I isoform delta	Homo sapiens (human)	Kd	30.0000	0.0150	2.2270	18.3960	AID1424962
MAP kinase-activated protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0003	2.0274	14.7420	AID1425065
Elongation factor Tu, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.4640	0.4640	0.4640	AID1425206
Choline-phosphate cytidylyltransferase A	Homo sapiens (human)	Kd	30.0000	0.0410	0.0410	0.0410	AID1425103
Casein kinase I isoform epsilon	Homo sapiens (human)	Kd	30.0000	0.0130	1.4086	12.4090	AID1424963
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)	Kd	30.0000	1.6890	1.6890	1.6890	AID1424894
Dual specificity protein kinase CLK1	Homo sapiens (human)	Kd	30.0000	0.0020	1.8791	29.8810	AID1424955
Dual specificity protein kinase CLK2	Homo sapiens (human)	Kd	30.0000	0.0070	1.1384	6.5000	AID1424956
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	Kd	30.0000	0.0060	2.4754	22.5430	AID1425013
Glycogen synthase kinase-3 beta	Homo sapiens (human)	Kd	30.0000	0.0070	1.0057	6.1680	AID1425014
Cyclin-dependent kinase 7	Homo sapiens (human)	Kd	30.0000	0.0025	1.6783	7.7000	AID1424949
Cyclin-dependent kinase 9	Homo sapiens (human)	Kd	30.0000	0.0010	1.6166	9.9010	AID1424950
Ras-related protein Rab-27A	Homo sapiens (human)	Kd	30.0000	4.4930	4.4930	4.4930	AID1425149
Tyrosine-protein kinase Blk	Homo sapiens (human)	Kd	0.0006	0.0002	0.8228	7.9000	AID1878115
Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)	Kd	30.0000	0.0061	1.5252	8.5000	AID1425027
Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)	Kd	30.0000	0.0170	2.8896	37.6050	AID1425160
Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)	Kd	0.0015	0.0014	1.5489	7.4000	AID1560823; AID1878116
cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)	Kd	30.0000	0.0072	1.3066	5.8000	AID1425139
Serine/threonine-protein kinase Nek2	Homo sapiens (human)	Kd	30.0000	0.1100	1.5649	6.5000	AID1425086
Serine/threonine-protein kinase Nek3	Homo sapiens (human)	Kd	30.0000	0.1700	5.9368	38.0880	AID1425087
Tyrosine-protein kinase JAK3	Homo sapiens (human)	Kd	0.0290	0.0002	1.0688	8.7000	AID1560829; AID1878120
Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)	Kd	30.0000	0.0034	2.3943	6.5000	AID1425043
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Kd	30.0000	0.0001	0.5711	5.0000	AID1425120
LIM domain kinase 1	Homo sapiens (human)	Kd	21.0890	0.0260	1.7840	21.0890	AID1425035
LIM domain kinase 2	Homo sapiens (human)	Kd	30.0000	0.0570	4.9717	52.0560	AID1425036
Mitogen-activated protein kinase 10	Homo sapiens (human)	Kd	30.0000	0.0010	1.6354	5.9000	AID1425057
Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)	Kd	30.0000	3.3160	3.3160	3.3160	AID1425211
5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)	Kd	30.0000	0.0060	1.4681	10.2120	AID1425126
Ephrin type-B receptor 3	Homo sapiens (human)	Kd	30.0000	0.0069	2.1713	6.4100	AID1424993
Ephrin type-A receptor 5	Homo sapiens (human)	Kd	30.0000	0.0002	1.2100	5.9000	AID1424990
Ephrin type-B receptor 4	Homo sapiens (human)	Kd	30.0000	0.0003	2.1678	26.3990	AID1424994
Ephrin type-A receptor 4	Homo sapiens (human)	Kd	30.0000	0.0012	3.1525	43.9420	AID1424989
Adenylate kinase 2, mitochondrial	Homo sapiens (human)	Kd	30.0000	1.0360	1.0360	1.0360	AID1424909
Adenosine kinase	Homo sapiens (human)	Kd	30.0000	0.0130	1.8368	3.4930	AID1424907
Ras-related protein Rab-10	Homo sapiens (human)	Kd	30.0000	1.3480	1.3480	1.3480	AID1425148
Actin-related protein 3	Homo sapiens (human)	Kd	30.0000	0.0360	2.7735	5.5110	AID1424899
Actin-related protein 2	Homo sapiens (human)	Kd	30.0000	0.0040	0.0040	0.0040	AID1424898
GTP-binding nuclear protein Ran	Homo sapiens (human)	Kd	30.0000	0.7590	0.7590	0.7590	AID1425153
Casein kinase I isoform gamma-2	Homo sapiens (human)	Kd	30.0000	0.0460	1.4506	6.6000	AID1424965
Cyclin-dependent kinase 3	Homo sapiens (human)	Kd	30.0000	0.0080	3.0602	63.6140	AID1424945
Cyclin-dependent kinase 6	Homo sapiens (human)	Kd	30.0000	0.0320	1.2007	3.3560	AID1424948
Cyclin-dependent-like kinase 5	Homo sapiens (human)	Kd	30.0000	0.0430	1.3757	8.3000	AID1424947
Cyclin-dependent kinase 16	Homo sapiens (human)	Kd	30.0000	0.0011	1.5855	10.0000	AID1424941
Cyclin-dependent kinase 17	Homo sapiens (human)	Kd	30.0000	0.0010	0.8233	5.6000	AID1424942
ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)	Kd	30.0000	0.9830	0.9830	0.9830	AID1425108
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	Kd	30.0000	0.0002	1.1386	8.7730	AID1425038
DNA topoisomerase 2-beta	Homo sapiens (human)	Kd	30.0000	0.1480	1.2270	2.5970	AID1425203
Protein kinase C theta type	Homo sapiens (human)	Kd	30.0000	0.0007	1.6140	7.2000	AID1425134
Activin receptor type-1	Homo sapiens (human)	Kd	30.0000	0.0040	1.4853	16.1210	AID1424900
Macrophage-stimulating protein receptor	Homo sapiens (human)	Kd	30.0000	0.0030	2.0718	8.4000	AID1425078
Focal adhesion kinase 1	Homo sapiens (human)	Kd	30.0000	0.0005	1.2255	13.0390	AID1425142
Protein kinase C delta type	Homo sapiens (human)	Kd	30.0000	0.0002	1.1261	9.2060	AID1425131
Tyrosine-protein kinase BTK	Homo sapiens (human)	EC50 (µMol)	0.0058	0.0058	0.2020	0.4750	AID1880139
Tyrosine-protein kinase BTK	Homo sapiens (human)	Kd	0.0042	0.0006	1.5299	10.1530	AID1424925; AID1560822; AID1878117
Activated CDC42 kinase 1	Homo sapiens (human)	Kd	30.0000	0.0020	1.7138	9.6000	AID1425201
Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)	Kd	30.0000	0.0002	1.6314	71.4840	AID1424972
Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)	Kd	0.0600	0.0130	0.8600	5.6000	AID1560825; AID1878119
Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0031	1.4681	14.0430	AID1425052
Tyrosine-protein kinase Mer	Homo sapiens (human)	Kd	30.0000	0.0003	1.7055	6.8000	AID1425075
Serine/threonine-protein kinase 4	Homo sapiens (human)	Kd	30.0000	0.0002	1.7120	25.9020	AID1425185
5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)	Kd	30.0000	0.0037	1.8913	15.3890	AID1425122
Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)	Kd	0.2430	0.0002	2.6590	65.6770	AID1425042
Mitogen-activated protein kinase 7	Homo sapiens (human)	Kd	30.0000	0.0420	2.0073	9.9000	AID1425062
Serine/threonine-protein kinase PAK 2	Homo sapiens (human)	Kd	30.0000	0.0031	2.3045	6.0000	AID1425099
Serine/threonine-protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.0002	1.8602	17.5260	AID1425182
Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)	Kd	30.0000	0.0970	2.5995	12.4730	AID1425044
Integrin-linked protein kinase	Homo sapiens (human)	Kd	30.0000	0.0200	0.4603	1.3290	AID1425024
Rho-associated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0003	1.7555	13.4620	AID1425157
Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)	Kd	30.0000	0.0018	1.0064	11.2690	AID1425200
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)	Kd	30.0000	0.0005	1.0209	7.8000	AID1424929
Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)	Kd	30.0000	0.0003	1.5044	20.3010	AID1424928
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	Kd	30.0000	0.0001	2.1016	40.2910	AID1424981
Activin receptor type-2B	Homo sapiens (human)	Kd	30.0000	0.0076	2.7328	9.9000	AID1424902
Bone morphogenetic protein receptor type-2	Homo sapiens (human)	Kd	30.0000	0.0190	2.5917	14.3770	AID1424923
Protein-tyrosine kinase 6	Homo sapiens (human)	Kd	0.0310	0.0043	1.7430	9.0000	AID1425144
cGMP-dependent protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0016	0.7072	3.8000	AID1425138
Cyclin-dependent kinase 13	Homo sapiens (human)	Kd	30.0000	0.0009	1.2571	4.5180	AID1424940
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)	Kd	30.0000	0.0051	1.1093	8.3000	AID1425023
Protein-tyrosine kinase 2-beta	Homo sapiens (human)	Kd	30.0000	0.0011	1.9450	30.4140	AID1425143
Maternal embryonic leucine zipper kinase	Homo sapiens (human)	Kd	30.0000	0.0049	2.2835	29.9330	AID1425074
Structural maintenance of chromosomes protein 1A	Homo sapiens (human)	Kd	30.0000	0.3650	0.3650	0.3650	AID1425172
Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)	Kd	30.0000	0.0030	0.0030	0.0030	AID1424952
Serine/threonine-protein kinase 38	Homo sapiens (human)	Kd	30.0000	0.0560	1.5651	9.4000	AID1425183
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	Kd	0.0017	0.0009	1.2548	7.0000	AID1560828; AID1878104
Ephrin type-A receptor 7	Homo sapiens (human)	Kd	30.0000	0.0025	1.4445	6.5000	AID1424991
Delta(24)-sterol reductase	Homo sapiens (human)	Kd	30.0000	0.4320	0.4320	0.4320	AID1424978
Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	Kd	30.0000	0.0280	2.5286	22.7260	AID1425159
Myosin light chain kinase, smooth muscle	Homo sapiens (human)	Kd	30.0000	0.0030	1.2088	7.9000	AID1425081
Mitogen-activated protein kinase 11	Homo sapiens (human)	Kd	30.0000	0.0001	0.4610	3.7430	AID1425058
Serine/threonine-protein kinase STK11	Homo sapiens (human)	Kd	30.0000	0.0030	0.9949	5.9000	AID1425178
Serine/threonine-protein kinase N1	Homo sapiens (human)	Kd	30.0000	0.0013	3.1729	49.8130	AID1425117
Serine/threonine-protein kinase N2	Homo sapiens (human)	Kd	30.0000	0.0018	1.7527	9.9000	AID1425118
Mitogen-activated protein kinase 14	Homo sapiens (human)	Kd	30.0000	0.0000	0.5036	8.5000	AID1425059
Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)	Kd	30.0000	0.0300	1.9215	5.4600	AID1424930
Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)	Kd	30.0000	0.0110	1.5639	17.9840	AID1425045
MAP kinase-activated protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.0020	0.0170	0.0260	AID1425066
Discoidin domain-containing receptor 2	Homo sapiens (human)	Kd	30.0000	0.0030	1.9888	42.2800	AID1424973
AP2-associated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0012	1.3707	13.7110	AID1424889
Myosin light chain kinase 3	Homo sapiens (human)	Kd	30.0000	0.0020	1.6184	10.4240	AID1425082
Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)	Kd	30.0000	2.5660	2.5660	2.5660	AID1425019
Rab-like protein 3	Homo sapiens (human)	Kd	30.0000	4.8300	4.8300	4.8300	AID1425151
Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)	Kd	30.0000	0.0570	4.5547	14.0200	AID1424933
Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)	Kd	30.0000	0.0370	1.9625	9.5000	AID1424935
Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)	Kd	30.0000	0.0780	1.6997	3.9570	AID1424892
Serine/threonine-protein kinase ULK3	Homo sapiens (human)	Kd	30.0000	0.0012	1.3350	9.9000	AID1425209
Uncharacterized protein FLJ45252	Homo sapiens (human)	Kd	30.0000	0.0030	1.2292	9.3110	AID1425147
Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)	Kd	30.0000	1.9160	3.0730	4.1470	AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)	Kd	30.0000	0.1160	0.7604	1.5000	AID1424998
Serine/threonine-protein kinase MARK2	Homo sapiens (human)	Kd	30.0000	0.0001	1.8425	11.1030	AID1425068
ATP-dependent RNA helicase DHX30	Homo sapiens (human)	Kd	30.0000	0.0060	0.0060	0.0060	AID1424979
Serine/threonine-protein kinase TAO1	Homo sapiens (human)	Kd	30.0000	0.0004	2.1612	18.7570	AID1425189
STE20-related kinase adapter protein alpha	Homo sapiens (human)	Kd	30.0000	0.3160	1.7208	3.6720	AID1425186
AarF domain-containing protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0230	3.1137	22.7470	AID1424904
Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0051	1.6413	15.4350	AID1425053
MAP kinase-activated protein kinase 5	Homo sapiens (human)	Kd	30.0000	0.0080	1.1241	3.1180	AID1425067
Misshapen-like kinase 1	Homo sapiens (human)	Kd	30.0000	0.0010	1.1425	8.9000	AID1425077
Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0940	5.1673	65.3020	AID1424905
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)	Kd	30.0000	0.0030	2.7522	8.8000	AID1425115
Mitogen-activated protein kinase 15	Homo sapiens (human)	Kd	30.0000	0.0049	0.6880	4.5000	AID1425060
Serine/threonine-protein kinase Nek9	Homo sapiens (human)	Kd	30.0000	0.0160	2.7428	19.6170	AID1425089
Serine/threonine-protein kinase Nek7	Homo sapiens (human)	Kd	30.0000	0.0030	3.6719	8.7000	AID1425088
ATP-dependent RNA helicase DDX1	Homo sapiens (human)	Kd	30.0000	0.0860	0.0860	0.0860	AID1424974
Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)	Kd	30.0000	0.0010	0.9378	5.5000	AID1425051
Aurora kinase B	Homo sapiens (human)	Kd	30.0000	0.0020	1.0614	22.8520	AID1424918
MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)	Kd	30.0000	0.0054	1.1029	4.9000	AID1425070
Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)	Kd	30.0000	0.0010	1.9148	6.8000	AID1424927
Serine/threonine-protein kinase Nek1	Homo sapiens (human)	Kd	30.0000	0.1700	2.4294	8.3000	AID1425085
PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	1.0670	1.0670	1.0670	AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0000	3.2331	52.8470	AID1424931
EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)	Kd	30.0000	0.3110	1.9519	3.8400	AID1425204
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)	Kd	30.0000	0.0440	0.9285	2.9000	AID1425116
Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)	Kd	30.0000	0.0700	6.5647	50.5360	AID1425049
Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0060	1.5331	9.9000	AID1425047
Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)	Kd	30.0000	0.0580	1.9224	4.8360	AID1424984
Nucleolar GTP-binding protein 1	Homo sapiens (human)	Kd	30.0000	0.0090	4.1035	8.1980	AID1425016
Serine/threonine-protein kinase D2	Homo sapiens (human)	Kd	30.0000	0.0081	2.3723	25.0190	AID1425136
NUAK family SNF1-like kinase 2	Homo sapiens (human)	Kd	30.0000	0.0001	0.6774	4.6000	AID1425095
RNA cytidine acetyltransferase	Homo sapiens (human)	Kd	30.0000	1.2400	1.2400	1.2400	AID1425083
Serine/threonine-protein kinase SIK2	Homo sapiens (human)	Kd	30.0000	0.0011	1.8165	41.7950	AID1425166
STE20-like serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0000	3.8573	99.2320	AID1425171
Serine/threonine-protein kinase TAO3	Homo sapiens (human)	Kd	30.0000	0.0002	2.7131	14.1960	AID1425191
dCTP pyrophosphatase 1	Homo sapiens (human)	Kd	30.0000	0.5730	1.7403	3.0540	AID1424971
Dual specificity protein kinase CLK4	Homo sapiens (human)	Kd	30.0000	0.0020	1.4122	8.3000	AID1424958
Casein kinase I isoform gamma-1	Homo sapiens (human)	Kd	30.0000	0.0530	2.0622	5.7000	AID1424964
Serine/threonine-protein kinase PAK 6	Homo sapiens (human)	Kd	30.0000	0.0004	1.9194	9.7000	AID1425101
Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)	Kd	30.0000	0.0030	0.0045	0.0060	AID1425000
BMP-2-inducible protein kinase	Homo sapiens (human)	Kd	30.0000	0.0022	2.4097	56.0320	AID1424920
Obg-like ATPase 1	Homo sapiens (human)	Kd	30.0000	0.0030	0.0050	0.0070	AID1425096
Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)	Kd	30.0000	0.0017	3.4719	34.1450	AID1425029
Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)	Kd	1.7050	0.0023	1.7034	13.6380	AID1425213
Cyclin-dependent kinase 12	Homo sapiens (human)	Kd	30.0000	0.0320	1.8032	5.6350	AID1424939
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)	Kd	30.0000	3.9200	3.9200	3.9200	AID1425084
Serine/threonine-protein kinase 26	Homo sapiens (human)	Kd	30.0000	0.0074	1.7380	8.3000	AID1425181
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0070	0.0070	0.0070	AID1425187
Serine/threonine-protein kinase NLK	Homo sapiens (human)	Kd	30.0000	0.0060	1.0226	4.4000	AID1425090
5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)	Kd	30.0000	0.0050	1.1581	9.1280	AID1425127
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	Kd	30.0000	0.0009	1.7674	49.6010	AID1425192
Septin-9	Homo sapiens (human)	Kd	30.0000	0.0100	0.2430	0.6350	AID1425165
Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)	Kd	30.0000	0.0040	2.4153	23.7620	AID1425163
TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)	Kd	30.0000	0.0047	1.3935	10.0000	AID1425199
Serine/threonine-protein kinase TAO2	Homo sapiens (human)	Kd	30.0000	0.0100	2.0176	12.9420	AID1425190
Serine/threonine-protein kinase ICK	Homo sapiens (human)	Kd	30.0000	0.0007	1.4717	9.3000	AID1425021
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0025	1.7646	6.2000	AID1424912
Serine/threonine-protein kinase SIK3	Homo sapiens (human)	Kd	30.0000	0.0005	1.5086	10.3180	AID1425167
Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0024	1.3298	6.9000	AID1425046
Thyroid hormone receptor-associated protein 3	Homo sapiens (human)	Kd	30.0000	2.7460	2.7460	2.7460	AID1425198
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)	Kd	30.0000	0.0280	1.8129	9.5000	AID1424982
Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)	Kd	30.0000	0.0005	1.9494	50.2140	AID1425055
Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)	Kd	0.0850	0.0110	1.4797	6.7000	AID1425156
Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)	Kd	30.0000	0.0340	3.6252	50.0050	AID1424934
Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)	Kd	30.0000	0.0070	1.7137	25.5810	AID1425028
Serine/threonine-protein kinase 24	Homo sapiens (human)	Kd	30.0000	0.0065	0.8920	4.0840	AID1425180
Casein kinase I isoform gamma-3	Homo sapiens (human)	Kd	30.0000	0.0970	2.3978	8.7000	AID1424966
Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)	Kd	30.0000	0.0390	2.3970	8.4000	AID1425048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 3A4	Homo sapiens (human)	INH	11.0000	1.7000	2.8500	4.0000	AID1418290
Cytochrome P450 2C8	Homo sapiens (human)	INH	7.9000	7.9000	7.9000	7.9000	AID1418289
Cytochrome P450 2C9	Homo sapiens (human)	INH	8.5000	4.4000	7.0000	9.1000	AID1418285
Cytochrome P450 2C19	Homo sapiens (human)	INH	19.0000	7.0000	7.0000	7.0000	AID1418288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2582)

Process	via Protein(s)	Taxonomy
positive regulation of gene expression	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cartilage condensation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovarian cumulus expansion	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
eye development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
chondrocyte development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
inflammatory response	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
central nervous system neuron differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
proteoglycan biosynthetic process	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of bone mineralization	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP signaling pathway	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retinal ganglion cell axon guidance	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of chondrocyte differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovulation cycle	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retina development in camera-type eye	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
endochondral bone morphogenesis	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of cartilage development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to BMP stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
negative regulation of chondrocyte proliferation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dorsal/ventral pattern formation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein phosphorylation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to growth factor stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of cell population proliferation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of nuclear cell cycle DNA replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell cycle phase transition	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell division	Cell division cycle 7-related protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
double-strand break repair via break-induced replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
signal transduction	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
trophoblast giant cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
translational initiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
chromosome segregation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
response to virus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA secondary structure unwinding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of gene expression	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
Wnt signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of translation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of cell growth	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of cell growth	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of protein-containing complex assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein autophosphorylation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of type I interferon production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
DNA duplex unwinding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of interferon-alpha production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of interferon-beta production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
stress granule assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of toll-like receptor 7 signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of toll-like receptor 8 signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
intracellular signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translation in response to endoplasmic reticulum stress	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosolic ribosome assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of viral genome replication	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
innate immune response	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translational initiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
lipid homeostasis	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to arsenic-containing substance	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to osmotic stress	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
intrinsic apoptotic signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to virus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein acetylation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein K63-linked ubiquitination	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein localization to cytoplasmic stress granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of gene expression	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
gamete generation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cell differentiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
pyridoxal 5'-phosphate salvage	Pyridoxal kinase	Homo sapiens (human)
pyridoxal metabolic process	Pyridoxal kinase	Homo sapiens (human)
pyridoxamine metabolic process	Pyridoxal kinase	Homo sapiens (human)
mitotic cell cycle	Citron Rho-interacting kinase	Homo sapiens (human)
mitotic cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
positive regulation of cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
negative regulation of hippo signaling	Citron Rho-interacting kinase	Homo sapiens (human)
generation of neurons	Citron Rho-interacting kinase	Homo sapiens (human)
neuron apoptotic process	Citron Rho-interacting kinase	Homo sapiens (human)
DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
inner cell mass cell proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA replication	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA repair	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin remodeling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus organization	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of cell population proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
signal transduction in response to DNA damage	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2/M transition checkpoint	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
positive regulation of cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of mitotic nuclear division	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of mitotic centrosome separation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of G0 to G1 transition	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to mechanical stimulus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to caffeine	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replicative senescence	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process involved in development	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of DNA biosynthetic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
response to wounding	Aurora kinase A	Homo sapiens (human)
liver regeneration	Aurora kinase A	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
chromatin remodeling	Aurora kinase A	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
apoptotic process	Aurora kinase A	Homo sapiens (human)
spindle organization	Aurora kinase A	Homo sapiens (human)
spindle assembly involved in female meiosis I	Aurora kinase A	Homo sapiens (human)
mitotic centrosome separation	Aurora kinase A	Homo sapiens (human)
anterior/posterior axis specification	Aurora kinase A	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
negative regulation of gene expression	Aurora kinase A	Homo sapiens (human)
peptidyl-serine phosphorylation	Aurora kinase A	Homo sapiens (human)
regulation of protein stability	Aurora kinase A	Homo sapiens (human)
negative regulation of protein binding	Aurora kinase A	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
negative regulation of apoptotic process	Aurora kinase A	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic nuclear division	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
regulation of centrosome cycle	Aurora kinase A	Homo sapiens (human)
protein autophosphorylation	Aurora kinase A	Homo sapiens (human)
cell division	Aurora kinase A	Homo sapiens (human)
centrosome localization	Aurora kinase A	Homo sapiens (human)
cilium disassembly	Aurora kinase A	Homo sapiens (human)
protein localization to centrosome	Aurora kinase A	Homo sapiens (human)
positive regulation of mitochondrial fission	Aurora kinase A	Homo sapiens (human)
positive regulation of oocyte maturation	Aurora kinase A	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Aurora kinase A	Homo sapiens (human)
neuron projection extension	Aurora kinase A	Homo sapiens (human)
mitotic spindle organization	Aurora kinase A	Homo sapiens (human)
regulation of cytokinesis	Aurora kinase A	Homo sapiens (human)
receptor-mediated endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
endoplasmic reticulum organization	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi organization	Cyclin-G-associated kinase	Homo sapiens (human)
negative regulation of neuron projection development	Cyclin-G-associated kinase	Homo sapiens (human)
synaptic vesicle uncoating	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular transport	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat disassembly	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-dependent endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to plasma membrane	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi to lysosome transport	Cyclin-G-associated kinase	Homo sapiens (human)
regulation of clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
protein phosphorylation	Ephrin type-B receptor 6	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 6	Homo sapiens (human)
axon guidance	Ephrin type-B receptor 6	Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidase	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
lipid homeostasis	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
toll-like receptor 2 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
adaptive immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of T-helper 1 type immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
apoptotic process	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
inflammatory response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
JNK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytokine-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein ubiquitination	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of chemokine production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interferon-alpha production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interferon-beta production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of type II interferon production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-12 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-2 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-6 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
immature T cell proliferation in thymus	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of immature T cell proliferation in thymus	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
defense response to bacterium	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of apoptotic process	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to exogenous dsRNA	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
innate immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of T-helper 1 cell differentiation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of JNK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
defense response to Gram-positive bacterium	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
T cell receptor signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein homooligomerization	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
stress-activated MAPK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of macrophage cytokine production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
ERK1 and ERK2 cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-1	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-12	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-18	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to lipoteichoic acid	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to peptidoglycan	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to muramyl dipeptide	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
xenophagy	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein K63-linked ubiquitination	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of xenophagy	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
chromatin remodeling	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
apoptotic process	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
chromosome segregation	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
regulation of sister chromatid cohesion	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
cell division	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
regulation of chromosome segregation	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
positive regulation of maintenance of mitotic sister chromatid cohesion, centromeric	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
meiotic sister chromatid cohesion, centromeric	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
mitochondrion organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial genome maintenance	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial fission	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
neural tube closure	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
apoptotic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrion organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
inner mitochondrial membrane organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
visual perception	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
axonal transport of mitochondrion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-17 production	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cristae formation	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTP metabolic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
protein complex oligomerization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cellular senescence	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane tubulation	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTP biosynthetic process	Putative nucleoside diphosphate kinase	Homo sapiens (human)
UTP biosynthetic process	Putative nucleoside diphosphate kinase	Homo sapiens (human)
CTP biosynthetic process	Putative nucleoside diphosphate kinase	Homo sapiens (human)
regulation of apoptotic process	Putative nucleoside diphosphate kinase	Homo sapiens (human)
positive regulation of platelet aggregation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of platelet activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to antibiotic	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
microglial cell activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
chromatin remodeling	Tyrosine-protein kinase JAK2	Homo sapiens (human)
transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mesoderm development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell-substrate adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to amine	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
erythrocyte differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
axon regeneration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of insulin secretion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-17 production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of natural killer cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to hydroperoxide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
symbiont-induced defense-related programmed cell death	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to tumor necrosis factor	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-embryonic hemopoiesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to interleukin-3	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-5-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
collagen-activated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-3-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of protein import into nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of Janus kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of DNA binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-translational protein modification	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MHC class II biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of inflammatory response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of NK T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type II interferon-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mammary gland epithelium development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of leukocyte proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to interleukin-12	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-35-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to dexamethasone stimulus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to virus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of epithelial cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of signaling receptor activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
epithelial to mesenchymal transition	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
response to ischemia	Rho-associated protein kinase 2	Homo sapiens (human)
aortic valve morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 2	Homo sapiens (human)
canonical NF-kappaB signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of endothelial cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of angiogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell adhesion	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
cortical actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of nervous system process	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of circadian rhythm	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of MAPK cascade	Rho-associated protein kinase 2	Homo sapiens (human)
modulation by host of viral process	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of nitric oxide biosynthetic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of keratinocyte differentiation	Rho-associated protein kinase 2	Homo sapiens (human)
rhythmic process	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of focal adhesion assembly	Rho-associated protein kinase 2	Homo sapiens (human)
mRNA destabilization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of biomineral tissue development	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to testosterone stimulus	Rho-associated protein kinase 2	Homo sapiens (human)
response to transforming growth factor beta	Rho-associated protein kinase 2	Homo sapiens (human)
protein localization to plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
blood vessel diameter maintenance	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of angiotensin-activated signaling pathway	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of protein localization to lysosome	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cellular response to hypoxia	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid-beta formation	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein localization to early endosome	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of endothelial barrier	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to acetylcholine	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue replacement	Rho-associated protein kinase 2	Homo sapiens (human)
response to angiotensin	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of cell polarity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell motility	Rho-associated protein kinase 2	Homo sapiens (human)
actomyosin structure organization	Rho-associated protein kinase 2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
mitotic cytokinesis	Rho-associated protein kinase 2	Homo sapiens (human)
embryonic morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
Rho protein signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein localization	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of cell population proliferation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection regeneration	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection development	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cellular response to nutrient levels	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
response to starvation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of protein lipidation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon extension	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
reticulophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
piecemeal microautophagy of the nucleus	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of collateral sprouting	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endothelial cell proliferation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mRNA catabolic process	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of RNA splicing	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to unfolded protein	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
peptidyl-serine autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-mediated unfolded protein response	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of JUN kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to hydrogen peroxide	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to glucose stimulus	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein response	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
insulin metabolic process	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
peptidyl-serine trans-autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
negative regulation of cytokine production	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
chromatin remodeling	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein phosphorylation	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
inflammatory response	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
axon guidance	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
intracellular signal transduction	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
post-translational protein modification	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
regulation of postsynapse organization	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cis assembly of pre-catalytic spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
mRNA splicing, via spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
osteoblast differentiation	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
negative regulation of cytokine production	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
chromatin remodeling	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein phosphorylation	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
inflammatory response	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
intracellular signal transduction	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
post-translational protein modification	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 16	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Serine/threonine-protein kinase 16	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 10	Homo sapiens (human)
lymphocyte aggregation	Serine/threonine-protein kinase 10	Homo sapiens (human)
regulation of lymphocyte migration	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Serine/threonine-protein kinase D3	Homo sapiens (human)
sphingolipid biosynthetic process	Serine/threonine-protein kinase D3	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase D3	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Serine/threonine-protein kinase D3	Homo sapiens (human)
mitotic chromosome condensation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
meiotic chromosome condensation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
meiotic chromosome segregation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cell division	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
kinetochore organization	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
positive regulation of chromosome segregation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
positive regulation of chromosome separation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
positive regulation of chromosome condensation	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
signal transduction	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
cellular response to stress	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
microvillus assembly	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of cell migration	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of ARF protein signal transduction	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of hippo signaling	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
negative regulation of apoptotic process	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of GTPase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
regulation of JNK cascade	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of keratinocyte migration	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of focal adhesion assembly	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
positive regulation of focal adhesion disassembly	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
regulation of MAPK cascade	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
neuron projection morphogenesis	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
sister chromatid segregation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
inner cell mass cell fate commitment	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
inner cell mass cellular morphogenesis	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
hormone-mediated signaling pathway	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathway	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
keratinocyte differentiation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of actin filament polymerization	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of intracellular estrogen receptor signaling pathway	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
hippo signaling	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of protein-containing complex assembly	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
cytoplasmic sequestering of protein	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
cell division	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
mammary gland epithelial cell differentiation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
negative regulation of protein localization to nucleus	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic process	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
positive regulation of apoptotic process	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of organ growth	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
regulation of cell growth	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytoskeleton organization	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cell migration	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
positive regulation of angiogenesis	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
dendritic spine development	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cellular response to organic cyclic compound	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cell-cell adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of phospholipase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neural tube closure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B-1 B cell homeostasis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell proliferation involved in immune response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transitional one stage B cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mismatch repair	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of DNA-templated transcription	Tyrosine-protein kinase ABL1	Homo sapiens (human)
autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA damage response	Tyrosine-protein kinase ABL1	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
associative learning	Tyrosine-protein kinase ABL1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to xenobiotic stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
post-embryonic development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of autophagy	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cerebellum morphogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
microspike assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of BMP signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of axon extension	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of microtubule polymerization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of Cdc42 protein signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of interleukin-2 production	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of osteoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to oxidative stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to endoplasmic reticulum stress	Tyrosine-protein kinase ABL1	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein modification process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
signal transduction in response to DNA damage	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endothelial cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of vasoconstriction	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of mitotic cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase ABL1	Homo sapiens (human)
alpha-beta T cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of fibroblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
spleen development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
thymus development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuromuscular process controlling balance	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of oxidoreductase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuron apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
myoblast proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of stress fiber assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
establishment of localization in cell	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell cycle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrial depolarization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of focal adhesion assembly	Tyrosine-protein kinase ABL1	Homo sapiens (human)
Bergmann glial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cardiac muscle cell proliferation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuroepithelial cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA conformation change	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
response to epinephrine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of protein serine/threonine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cell-cell adhesion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of dendrite development	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of hematopoietic stem cell differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of extracellular matrix organization	Tyrosine-protein kinase ABL1	Homo sapiens (human)
podocyte apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cellular response to dopamine	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of establishment of T cell polarity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DN4 thymocyte differentiation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-end	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of microtubule binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of modification of synaptic structure	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of blood vessel branching	Tyrosine-protein kinase ABL1	Homo sapiens (human)
activation of protein kinase C activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
regulation of cell motility	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Tyrosine-protein kinase ABL1	Homo sapiens (human)
positive regulation of T cell migration	Tyrosine-protein kinase ABL1	Homo sapiens (human)
negative regulation of cellular senescence	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
heart development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
motor neuron axon guidance	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
Schwann cell development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell growth	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of microtubule-based process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
intracellular signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
wound healing	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelination	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAP kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of translation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of angiogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell adhesion	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase I	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
oligodendrocyte differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
semaphorin-plexin signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein targeting to membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAPK cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of apoptotic process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
multicellular organism development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuron differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to amyloid-beta	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	High affinity nerve growth factor receptor	Homo sapiens (human)
protein phosphorylation	High affinity nerve growth factor receptor	Homo sapiens (human)
axon guidance	High affinity nerve growth factor receptor	Homo sapiens (human)
learning or memory	High affinity nerve growth factor receptor	Homo sapiens (human)
circadian rhythm	High affinity nerve growth factor receptor	Homo sapiens (human)
negative regulation of cell population proliferation	High affinity nerve growth factor receptor	Homo sapiens (human)
response to xenobiotic stimulus	High affinity nerve growth factor receptor	Homo sapiens (human)
programmed cell death involved in cell development	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of neuron projection development	High affinity nerve growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	High affinity nerve growth factor receptor	Homo sapiens (human)
olfactory nerve development	High affinity nerve growth factor receptor	Homo sapiens (human)
B cell differentiation	High affinity nerve growth factor receptor	Homo sapiens (human)
response to nutrient levels	High affinity nerve growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	High affinity nerve growth factor receptor	Homo sapiens (human)
nerve growth factor signaling pathway	High affinity nerve growth factor receptor	Homo sapiens (human)
mechanoreceptor differentiation	High affinity nerve growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of programmed cell death	High affinity nerve growth factor receptor	Homo sapiens (human)
negative regulation of neuron apoptotic process	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of GTPase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of Ras protein signal transduction	High affinity nerve growth factor receptor	Homo sapiens (human)
protein autophosphorylation	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin TRK receptor signaling pathway	High affinity nerve growth factor receptor	Homo sapiens (human)
ephrin receptor signaling pathway	High affinity nerve growth factor receptor	Homo sapiens (human)
sympathetic nervous system development	High affinity nerve growth factor receptor	Homo sapiens (human)
response to axon injury	High affinity nerve growth factor receptor	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	High affinity nerve growth factor receptor	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
neuron apoptotic process	High affinity nerve growth factor receptor	Homo sapiens (human)
response to hydrostatic pressure	High affinity nerve growth factor receptor	Homo sapiens (human)
response to electrical stimulus	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of synapse assembly	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	High affinity nerve growth factor receptor	Homo sapiens (human)
Sertoli cell development	High affinity nerve growth factor receptor	Homo sapiens (human)
axonogenesis involved in innervation	High affinity nerve growth factor receptor	Homo sapiens (human)
behavioral response to formalin induced pain	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	High affinity nerve growth factor receptor	Homo sapiens (human)
cellular response to nicotine	High affinity nerve growth factor receptor	Homo sapiens (human)
cellular response to nerve growth factor stimulus	High affinity nerve growth factor receptor	Homo sapiens (human)
multicellular organism development	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	High affinity nerve growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	High affinity nerve growth factor receptor	Homo sapiens (human)
signal transduction	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
negative regulation of adenylate cyclase activity	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
response to nutrient	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cell population proliferation	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of cell population proliferation	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of cell migration	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of superoxide anion generation	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of urine volume	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosis	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
negative regulation of synaptic transmission	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cell division	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
regulation of calcium ion transport	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
positive regulation of neural precursor cell proliferation	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
chromosome segregation	ADP/ATP translocase 2	Homo sapiens (human)
positive regulation of cell population proliferation	ADP/ATP translocase 2	Homo sapiens (human)
adenine transport	ADP/ATP translocase 2	Homo sapiens (human)
B cell differentiation	ADP/ATP translocase 2	Homo sapiens (human)
erythrocyte differentiation	ADP/ATP translocase 2	Homo sapiens (human)
regulation of mitochondrial membrane permeability	ADP/ATP translocase 2	Homo sapiens (human)
adenine nucleotide transport	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial ADP transmembrane transport	ADP/ATP translocase 2	Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	ADP/ATP translocase 2	Homo sapiens (human)
positive regulation of mitophagy	ADP/ATP translocase 2	Homo sapiens (human)
proton transmembrane transport	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial ATP transmembrane transport	ADP/ATP translocase 2	Homo sapiens (human)
cellular response to leukemia inhibitory factor	ADP/ATP translocase 2	Homo sapiens (human)
adaptive thermogenesis	ADP/ATP translocase 2	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
adaptive immune response	Protein kinase C beta type	Homo sapiens (human)
chromatin remodeling	Protein kinase C beta type	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Protein kinase C beta type	Homo sapiens (human)
protein phosphorylation	Protein kinase C beta type	Homo sapiens (human)
calcium ion transport	Protein kinase C beta type	Homo sapiens (human)
intracellular calcium ion homeostasis	Protein kinase C beta type	Homo sapiens (human)
apoptotic process	Protein kinase C beta type	Homo sapiens (human)
mitotic nuclear membrane disassembly	Protein kinase C beta type	Homo sapiens (human)
signal transduction	Protein kinase C beta type	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
response to xenobiotic stimulus	Protein kinase C beta type	Homo sapiens (human)
response to glucose	Protein kinase C beta type	Homo sapiens (human)
regulation of glucose transmembrane transport	Protein kinase C beta type	Homo sapiens (human)
negative regulation of glucose transmembrane transport	Protein kinase C beta type	Homo sapiens (human)
regulation of dopamine secretion	Protein kinase C beta type	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Protein kinase C beta type	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
positive regulation of insulin secretion	Protein kinase C beta type	Homo sapiens (human)
response to vitamin D	Protein kinase C beta type	Homo sapiens (human)
regulation of growth	Protein kinase C beta type	Homo sapiens (human)
B cell activation	Protein kinase C beta type	Homo sapiens (human)
positive regulation of odontogenesis of dentin-containing tooth	Protein kinase C beta type	Homo sapiens (human)
lipoprotein transport	Protein kinase C beta type	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Protein kinase C beta type	Homo sapiens (human)
post-translational protein modification	Protein kinase C beta type	Homo sapiens (human)
response to ethanol	Protein kinase C beta type	Homo sapiens (human)
positive regulation of angiogenesis	Protein kinase C beta type	Homo sapiens (human)
positive regulation of DNA-templated transcription	Protein kinase C beta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
B cell receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
positive regulation of B cell receptor signaling pathway	Protein kinase C beta type	Homo sapiens (human)
cellular response to carbohydrate stimulus	Protein kinase C beta type	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Protein kinase C beta type	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	Protein kinase C beta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C beta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C beta type	Homo sapiens (human)
positive regulation of MAP kinase activity	Insulin receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Insulin receptor	Homo sapiens (human)
positive regulation of receptor internalization	Insulin receptor	Homo sapiens (human)
heart morphogenesis	Insulin receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Insulin receptor	Homo sapiens (human)
protein phosphorylation	Insulin receptor	Homo sapiens (human)
receptor-mediated endocytosis	Insulin receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Insulin receptor	Homo sapiens (human)
learning	Insulin receptor	Homo sapiens (human)
memory	Insulin receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Insulin receptor	Homo sapiens (human)
insulin receptor signaling pathway	Insulin receptor	Homo sapiens (human)
epidermis development	Insulin receptor	Homo sapiens (human)
male gonad development	Insulin receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Insulin receptor	Homo sapiens (human)
male sex determination	Insulin receptor	Homo sapiens (human)
adrenal gland development	Insulin receptor	Homo sapiens (human)
positive regulation of cell migration	Insulin receptor	Homo sapiens (human)
exocrine pancreas development	Insulin receptor	Homo sapiens (human)
receptor internalization	Insulin receptor	Homo sapiens (human)
activation of protein kinase activity	Insulin receptor	Homo sapiens (human)
activation of protein kinase B activity	Insulin receptor	Homo sapiens (human)
cellular response to insulin stimulus	Insulin receptor	Homo sapiens (human)
glucose homeostasis	Insulin receptor	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Insulin receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Insulin receptor	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Insulin receptor	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	Insulin receptor	Homo sapiens (human)
positive regulation of glycolytic process	Insulin receptor	Homo sapiens (human)
positive regulation of mitotic nuclear division	Insulin receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Insulin receptor	Homo sapiens (human)
regulation of embryonic development	Insulin receptor	Homo sapiens (human)
positive regulation of glucose import	Insulin receptor	Homo sapiens (human)
symbiont entry into host cell	Insulin receptor	Homo sapiens (human)
protein autophosphorylation	Insulin receptor	Homo sapiens (human)
positive regulation of developmental growth	Insulin receptor	Homo sapiens (human)
positive regulation of meiotic cell cycle	Insulin receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Insulin receptor	Homo sapiens (human)
positive regulation of respiratory burst	Insulin receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Insulin receptor	Homo sapiens (human)
dendritic spine maintenance	Insulin receptor	Homo sapiens (human)
amyloid-beta clearance	Insulin receptor	Homo sapiens (human)
transport across blood-brain barrier	Insulin receptor	Homo sapiens (human)
neuron projection maintenance	Insulin receptor	Homo sapiens (human)
regulation of female gonad development	Insulin receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Insulin receptor	Homo sapiens (human)
multicellular organism development	Insulin receptor	Homo sapiens (human)
positive regulation of kinase activity	Insulin receptor	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Lck	Homo sapiens (human)
intracellular zinc ion homeostasis	Tyrosine-protein kinase Lck	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase Lck	Homo sapiens (human)
response to xenobiotic stimulus	Tyrosine-protein kinase Lck	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Lck	Homo sapiens (human)
hemopoiesis	Tyrosine-protein kinase Lck	Homo sapiens (human)
platelet activation	Tyrosine-protein kinase Lck	Homo sapiens (human)
T cell differentiation	Tyrosine-protein kinase Lck	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Lck	Homo sapiens (human)
positive regulation of heterotypic cell-cell adhesion	Tyrosine-protein kinase Lck	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Lck	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Tyrosine-protein kinase Lck	Homo sapiens (human)
Fc-gamma receptor signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
positive regulation of T cell receptor signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
positive regulation of T cell activation	Tyrosine-protein kinase Lck	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Lck	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Tyrosine-protein kinase Lck	Homo sapiens (human)
regulation of lymphocyte activation	Tyrosine-protein kinase Lck	Homo sapiens (human)
positive regulation of leukocyte cell-cell adhesion	Tyrosine-protein kinase Lck	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Lck	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase Lck	Homo sapiens (human)
response to singlet oxygen	Tyrosine-protein kinase Fyn	Homo sapiens (human)
neuron migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
heart process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
calcium ion transport	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
axon guidance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
learning	Tyrosine-protein kinase Fyn	Homo sapiens (human)
feeding behavior	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase Fyn	Homo sapiens (human)
gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
forebrain development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to ethanol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite morphogenesis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein targeting to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to L-glutamate	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to glycine	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of calcium ion import across plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
microtubule cytoskeleton organization	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 1	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 1	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
apoptotic process	Cyclin-dependent kinase 1	Homo sapiens (human)
DNA damage response	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic nuclear membrane disassembly	Cyclin-dependent kinase 1	Homo sapiens (human)
centrosome cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
pronuclear fusion	Cyclin-dependent kinase 1	Homo sapiens (human)
response to xenobiotic stimulus	Cyclin-dependent kinase 1	Homo sapiens (human)
response to toxic substance	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of gene expression	Cyclin-dependent kinase 1	Homo sapiens (human)
negative regulation of gene expression	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of Schwann cell differentiation	Cyclin-dependent kinase 1	Homo sapiens (human)
response to amine	Cyclin-dependent kinase 1	Homo sapiens (human)
response to activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cell migration	Cyclin-dependent kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Cyclin-dependent kinase 1	Homo sapiens (human)
chromosome condensation	Cyclin-dependent kinase 1	Homo sapiens (human)
epithelial cell differentiation	Cyclin-dependent kinase 1	Homo sapiens (human)
animal organ regeneration	Cyclin-dependent kinase 1	Homo sapiens (human)
protein localization to kinetochore	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of protein import into nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of circadian rhythm	Cyclin-dependent kinase 1	Homo sapiens (human)
negative regulation of apoptotic process	Cyclin-dependent kinase 1	Homo sapiens (human)
response to ethanol	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of embryonic development	Cyclin-dependent kinase 1	Homo sapiens (human)
response to cadmium ion	Cyclin-dependent kinase 1	Homo sapiens (human)
response to copper ion	Cyclin-dependent kinase 1	Homo sapiens (human)
symbiont entry into host cell	Cyclin-dependent kinase 1	Homo sapiens (human)
fibroblast proliferation	Cyclin-dependent kinase 1	Homo sapiens (human)
rhythmic process	Cyclin-dependent kinase 1	Homo sapiens (human)
response to axon injury	Cyclin-dependent kinase 1	Homo sapiens (human)
cell division	Cyclin-dependent kinase 1	Homo sapiens (human)
ventricular cardiac muscle cell development	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of mitotic sister chromatid segregation	Cyclin-dependent kinase 1	Homo sapiens (human)
protein-containing complex assembly	Cyclin-dependent kinase 1	Homo sapiens (human)
cellular response to hydrogen peroxide	Cyclin-dependent kinase 1	Homo sapiens (human)
ERK1 and ERK2 cascade	Cyclin-dependent kinase 1	Homo sapiens (human)
cellular response to organic cyclic compound	Cyclin-dependent kinase 1	Homo sapiens (human)
Golgi disassembly	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochore	Cyclin-dependent kinase 1	Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosis	Cyclin-dependent kinase 1	Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transport	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Cyclin-dependent kinase 1	Homo sapiens (human)
protein deubiquitination	Cyclin-dependent kinase 1	Homo sapiens (human)
glycogen metabolic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
response to bacterium	Glycogen phosphorylase, liver form	Homo sapiens (human)
glucose homeostasis	Glycogen phosphorylase, liver form	Homo sapiens (human)
necroptotic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
glycogen catabolic process	Glycogen phosphorylase, liver form	Homo sapiens (human)
microtubule bundle formation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
centrosome cycle	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of cell adhesion	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
positive regulation of microtubule polymerization	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of cell population proliferation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of mast cell degranulation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of cell differentiation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
positive regulation of myeloid cell differentiation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
positive regulation of monocyte differentiation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
myoblast proliferation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cardiac muscle cell proliferation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of vesicle-mediated transport	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cellular response to vitamin D	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
regulation of cell motility	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
chemotaxis	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cell adhesion	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
positive regulation of macrophage chemotaxis	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of macrophage proliferation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
response to ischemia	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
inflammatory response	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
signal transduction	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
axon guidance	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cell population proliferation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
regulation of cell shape	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cytokine-mediated signaling pathway	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
olfactory bulb development	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
forebrain neuron differentiation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
hemopoiesis	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
monocyte differentiation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
macrophage differentiation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
osteoclast differentiation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
ruffle organization	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of chemokine production	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
regulation of actin cytoskeleton organization	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulus	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
macrophage colony-stimulating factor signaling pathway	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
negative regulation of apoptotic process	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation by host of viral process	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
innate immune response	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
regulation of bone resorption	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cell-cell junction maintenance	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
protein autophosphorylation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of protein tyrosine kinase activity	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
microglial cell proliferation	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cellular response to cytokine stimulus	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
regulation of macrophage migration	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of cell motility	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of cell migration	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
regulation of MAPK cascade	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
positive regulation of kinase activity	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
multicellular organism development	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
purine ribonucleoside salvage	Adenine phosphoribosyltransferase	Homo sapiens (human)
grooming behavior	Adenine phosphoribosyltransferase	Homo sapiens (human)
GMP salvage	Adenine phosphoribosyltransferase	Homo sapiens (human)
IMP salvage	Adenine phosphoribosyltransferase	Homo sapiens (human)
AMP salvage	Adenine phosphoribosyltransferase	Homo sapiens (human)
adenine salvage	Adenine phosphoribosyltransferase	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Yes	Homo sapiens (human)
regulation of glucose transmembrane transport	Tyrosine-protein kinase Yes	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Yes	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein modification process	Tyrosine-protein kinase Yes	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Yes	Homo sapiens (human)
regulation of vascular permeability	Tyrosine-protein kinase Yes	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase Yes	Homo sapiens (human)
ephrin receptor signaling pathway	Tyrosine-protein kinase Yes	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Yes	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Yes	Homo sapiens (human)
cellular response to retinoic acid	Tyrosine-protein kinase Yes	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase Yes	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Yes	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Yes	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Yes	Homo sapiens (human)
DNA damage checkpoint signaling	Tyrosine-protein kinase Lyn	Homo sapiens (human)
B cell homeostasis	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of cytokine production	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of protein phosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of protein phosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of protein phosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Fc receptor mediated stimulatory signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
tolerance induction to self antigen	Tyrosine-protein kinase Lyn	Homo sapiens (human)
histamine secretion by mast cell	Tyrosine-protein kinase Lyn	Homo sapiens (human)
platelet degranulation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of myeloid leukocyte differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
immune response-regulating cell surface receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Fc receptor mediated inhibitory signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of B cell apoptotic process	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
DNA damage response	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to sterol depletion	Tyrosine-protein kinase Lyn	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of cell population proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to xenobiotic stimulus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to toxic substance	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to hormone	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to carbohydrate	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase Lyn	Homo sapiens (human)
oligodendrocyte development	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to organic cyclic compound	Tyrosine-protein kinase Lyn	Homo sapiens (human)
fatty acid transport	Tyrosine-protein kinase Lyn	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
erythrocyte differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
eosinophil differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of B cell proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to insulin	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of mast cell activation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of toll-like receptor 4 signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cellular response to heat	Tyrosine-protein kinase Lyn	Homo sapiens (human)
interleukin-5-mediated signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Lyn	Homo sapiens (human)
C-X-C chemokine receptor CXCR4 signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to amino acid	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of mast cell degranulation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of MAP kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of erythrocyte differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ephrin receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
response to axon injury	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of immune response	Tyrosine-protein kinase Lyn	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of B cell receptor signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of glial cell proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathway	Tyrosine-protein kinase Lyn	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of oligodendrocyte progenitor proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of mast cell proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of mast cell proliferation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cellular response to retinoic acid	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of monocyte chemotaxis	Tyrosine-protein kinase Lyn	Homo sapiens (human)
regulation of platelet aggregation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
dendritic cell differentiation	Tyrosine-protein kinase Lyn	Homo sapiens (human)
negative regulation of intracellular signal transduction	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process	Tyrosine-protein kinase Lyn	Homo sapiens (human)
positive regulation of dendritic cell apoptotic process	Tyrosine-protein kinase Lyn	Homo sapiens (human)
neuron projection development	Tyrosine-protein kinase Lyn	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Lyn	Homo sapiens (human)
MAPK cascade	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
ureteric bud development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
neural crest cell migration	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
embryonic epithelial tube formation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
protein phosphorylation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
neuron cell-cell adhesion	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
signal transduction	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
axon guidance	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
posterior midgut development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
response to xenobiotic stimulus	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of gene expression	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of neuron projection development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of neuron maturation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
regulation of cell adhesion	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of cell migration	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
membrane protein proteolysis	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
ureter maturation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
glial cell-derived neurotrophic factor receptor signaling pathway	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
neuron maturation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of MAPK cascade	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of cell size	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of DNA-templated transcription	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
response to pain	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
enteric nervous system development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
regulation of axonogenesis	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
retina development in camera-type eye	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
innervation	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
Peyer's patch morphogenesis	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
cellular response to retinoic acid	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of metanephric glomerulus development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
lymphocyte migration into lymphoid organs	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
GDF15-GFRAL signaling pathway	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway in absence of ligand	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
positive regulation of kinase activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
multicellular organism development	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cardiac atrium development	Insulin-like growth factor 1 receptor	Homo sapiens (human)
immune response	Insulin-like growth factor 1 receptor	Homo sapiens (human)
signal transduction	Insulin-like growth factor 1 receptor	Homo sapiens (human)
axonogenesis	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor signaling pathway	Insulin-like growth factor 1 receptor	Homo sapiens (human)
negative regulation of muscle cell apoptotic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cerebellum development	Insulin-like growth factor 1 receptor	Homo sapiens (human)
hippocampus development	Insulin-like growth factor 1 receptor	Homo sapiens (human)
establishment of cell polarity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of cell migration	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of cytokinesis	Insulin-like growth factor 1 receptor	Homo sapiens (human)
response to vitamin E	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of osteoblast proliferation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to zinc ion starvation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
response to nicotine	Insulin-like growth factor 1 receptor	Homo sapiens (human)
negative regulation of apoptotic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Insulin-like growth factor 1 receptor	Homo sapiens (human)
response to alkaloid	Insulin-like growth factor 1 receptor	Homo sapiens (human)
negative regulation of MAPK cascade	Insulin-like growth factor 1 receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Insulin-like growth factor 1 receptor	Homo sapiens (human)
estrous cycle	Insulin-like growth factor 1 receptor	Homo sapiens (human)
transcytosis	Insulin-like growth factor 1 receptor	Homo sapiens (human)
response to ethanol	Insulin-like growth factor 1 receptor	Homo sapiens (human)
regulation of JNK cascade	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein autophosphorylation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of axon regeneration	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of DNA metabolic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to progesterone stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of steroid hormone biosynthetic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular senescence	Insulin-like growth factor 1 receptor	Homo sapiens (human)
dendritic spine maintenance	Insulin-like growth factor 1 receptor	Homo sapiens (human)
amyloid-beta clearance	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Insulin-like growth factor 1 receptor	Homo sapiens (human)
response to L-glutamate	Insulin-like growth factor 1 receptor	Homo sapiens (human)
negative regulation of hepatocyte apoptotic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to aldosterone	Insulin-like growth factor 1 receptor	Homo sapiens (human)
negative regulation of cholangiocyte apoptotic process	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to angiotensin	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to amyloid-beta	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
multicellular organism development	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of kinase activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cellular response to glucose stimulus	Insulin-like growth factor 1 receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Insulin-like growth factor 1 receptor	Homo sapiens (human)
cotranslational protein targeting to membrane	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
intracellular protein transport	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
protein targeting to ER	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome c	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
response to glucagon	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
cellular respiration	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
proton transmembrane transport	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
endothelial cell morphogenesis	Hepatocyte growth factor receptor	Homo sapiens (human)
signal transduction	Hepatocyte growth factor receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of autophagy	Hepatocyte growth factor receptor	Homo sapiens (human)
positive regulation of microtubule polymerization	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of Rho protein signal transduction	Hepatocyte growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Hepatocyte growth factor receptor	Homo sapiens (human)
hepatocyte growth factor receptor signaling pathway	Hepatocyte growth factor receptor	Homo sapiens (human)
branching morphogenesis of an epithelial tube	Hepatocyte growth factor receptor	Homo sapiens (human)
positive chemotaxis	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of stress fiber assembly	Hepatocyte growth factor receptor	Homo sapiens (human)
excitatory postsynaptic potential	Hepatocyte growth factor receptor	Homo sapiens (human)
establishment of skin barrier	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Hepatocyte growth factor receptor	Homo sapiens (human)
semaphorin-plexin signaling pathway	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell death	Hepatocyte growth factor receptor	Homo sapiens (human)
negative regulation of guanyl-nucleotide exchange factor activity	Hepatocyte growth factor receptor	Homo sapiens (human)
positive regulation of endothelial cell chemotaxis	Hepatocyte growth factor receptor	Homo sapiens (human)
liver development	Hepatocyte growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Hepatocyte growth factor receptor	Homo sapiens (human)
phagocytosis	Hepatocyte growth factor receptor	Homo sapiens (human)
multicellular organism development	Hepatocyte growth factor receptor	Homo sapiens (human)
neuron differentiation	Hepatocyte growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Hepatocyte growth factor receptor	Homo sapiens (human)
cell migration	Hepatocyte growth factor receptor	Homo sapiens (human)
pancreas development	Hepatocyte growth factor receptor	Homo sapiens (human)
nervous system development	Hepatocyte growth factor receptor	Homo sapiens (human)
leukocyte migration involved in immune response	Tyrosine-protein kinase HCK	Homo sapiens (human)
innate immune response-activating signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase HCK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase HCK	Homo sapiens (human)
inflammatory response	Tyrosine-protein kinase HCK	Homo sapiens (human)
cell adhesion	Tyrosine-protein kinase HCK	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
mesoderm development	Tyrosine-protein kinase HCK	Homo sapiens (human)
positive regulation of cell population proliferation	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase HCK	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase HCK	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
positive regulation of actin filament polymerization	Tyrosine-protein kinase HCK	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of actin cytoskeleton organization	Tyrosine-protein kinase HCK	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase HCK	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase HCK	Homo sapiens (human)
negative regulation of apoptotic process	Tyrosine-protein kinase HCK	Homo sapiens (human)
leukocyte degranulation	Tyrosine-protein kinase HCK	Homo sapiens (human)
respiratory burst after phagocytosis	Tyrosine-protein kinase HCK	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of inflammatory response	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of phagocytosis	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Tyrosine-protein kinase HCK	Homo sapiens (human)
type II interferon-mediated signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
regulation of podosome assembly	Tyrosine-protein kinase HCK	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase HCK	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase HCK	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase HCK	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
signal transduction	Platelet-derived growth factor receptor beta	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of cell population proliferation	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of phospholipase C activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Platelet-derived growth factor receptor beta	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of cell migration	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
regulation of actin cytoskeleton organization	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cell migration involved in vasculogenesis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
aorta morphogenesis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of MAP kinase activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of mitotic nuclear division	Platelet-derived growth factor receptor beta	Homo sapiens (human)
phosphatidylinositol metabolic process	Platelet-derived growth factor receptor beta	Homo sapiens (human)
protein autophosphorylation	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of chemotaxis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cardiac myofibril assembly	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cell chemotaxis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cell migration involved in coronary angiogenesis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
retina vasculature development in camera-type eye	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Platelet-derived growth factor receptor beta	Homo sapiens (human)
smooth muscle cell chemotaxis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
metanephric glomerular mesangial cell proliferation involved in metanephros development	Platelet-derived growth factor receptor beta	Homo sapiens (human)
metanephric glomerular capillary formation	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of calcium ion import	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of kinase activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
angiogenesis	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Platelet-derived growth factor receptor beta	Homo sapiens (human)
multicellular organism development	Platelet-derived growth factor receptor beta	Homo sapiens (human)
positive regulation of cytokine production	Tyrosine-protein kinase Fgr	Homo sapiens (human)
immune response-regulating cell surface receptor signaling pathway	Tyrosine-protein kinase Fgr	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase Fgr	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase Fgr	Homo sapiens (human)
response to virus	Tyrosine-protein kinase Fgr	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
bone mineralization	Tyrosine-protein kinase Fgr	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase Fgr	Homo sapiens (human)
negative regulation of natural killer cell activation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Fgr	Homo sapiens (human)
positive regulation of mast cell degranulation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
regulation of innate immune response	Tyrosine-protein kinase Fgr	Homo sapiens (human)
regulation of protein kinase activity	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
skeletal system morphogenesis	Tyrosine-protein kinase Fgr	Homo sapiens (human)
regulation of phagocytosis	Tyrosine-protein kinase Fgr	Homo sapiens (human)
defense response to Gram-positive bacterium	Tyrosine-protein kinase Fgr	Homo sapiens (human)
myoblast proliferation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase Fgr	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Fgr	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Fgr	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Fgr	Homo sapiens (human)
regulation of TOR signaling	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic process	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
protein modification process	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
MAPK cascade	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 2C8	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 2C8	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C8	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C8	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C8	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
glycogen catabolic process	Glycogen phosphorylase, brain form	Homo sapiens (human)
negative regulation of cellular extravasation	Breakpoint cluster region protein	Homo sapiens (human)
renal system process	Breakpoint cluster region protein	Homo sapiens (human)
protein phosphorylation	Breakpoint cluster region protein	Homo sapiens (human)
phagocytosis	Breakpoint cluster region protein	Homo sapiens (human)
signal transduction	Breakpoint cluster region protein	Homo sapiens (human)
small GTPase-mediated signal transduction	Breakpoint cluster region protein	Homo sapiens (human)
brain development	Breakpoint cluster region protein	Homo sapiens (human)
actin cytoskeleton organization	Breakpoint cluster region protein	Homo sapiens (human)
keratinocyte differentiation	Breakpoint cluster region protein	Homo sapiens (human)
regulation of Rho protein signal transduction	Breakpoint cluster region protein	Homo sapiens (human)
inner ear morphogenesis	Breakpoint cluster region protein	Homo sapiens (human)
regulation of vascular permeability	Breakpoint cluster region protein	Homo sapiens (human)
neutrophil degranulation	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of neutrophil degranulation	Breakpoint cluster region protein	Homo sapiens (human)
focal adhesion assembly	Breakpoint cluster region protein	Homo sapiens (human)
homeostasis of number of cells	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of inflammatory response	Breakpoint cluster region protein	Homo sapiens (human)
positive regulation of phagocytosis	Breakpoint cluster region protein	Homo sapiens (human)
modulation of chemical synaptic transmission	Breakpoint cluster region protein	Homo sapiens (human)
neuromuscular process controlling balance	Breakpoint cluster region protein	Homo sapiens (human)
regulation of small GTPase mediated signal transduction	Breakpoint cluster region protein	Homo sapiens (human)
regulation of cell cycle	Breakpoint cluster region protein	Homo sapiens (human)
definitive hemopoiesis	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of respiratory burst	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of blood vessel remodeling	Breakpoint cluster region protein	Homo sapiens (human)
intracellular protein transmembrane transport	Breakpoint cluster region protein	Homo sapiens (human)
cellular response to lipopolysaccharide	Breakpoint cluster region protein	Homo sapiens (human)
activation of GTPase activity	Breakpoint cluster region protein	Homo sapiens (human)
macrophage migration	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of macrophage migration	Breakpoint cluster region protein	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Breakpoint cluster region protein	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
regulation of transmembrane transporter activity	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
negative regulation of innate immune response	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
protein stabilization	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
vitamin D receptor signaling pathway	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
cellular response to type II interferon	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
regulation of hematopoietic stem cell proliferation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of TORC1 signaling	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of cardioblast proliferation	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
cellular detoxification	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
positive regulation of cell population proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
fibroblast growth factor receptor signaling pathway	Fibroblast growth factor receptor 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Fibroblast growth factor receptor 1	Homo sapiens (human)
MAPK cascade	Fibroblast growth factor receptor 1	Homo sapiens (human)
skeletal system development	Fibroblast growth factor receptor 1	Homo sapiens (human)
angiogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
ureteric bud development	Fibroblast growth factor receptor 1	Homo sapiens (human)
in utero embryonic development	Fibroblast growth factor receptor 1	Homo sapiens (human)
organ induction	Fibroblast growth factor receptor 1	Homo sapiens (human)
neuron migration	Fibroblast growth factor receptor 1	Homo sapiens (human)
epithelial to mesenchymal transition	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of mesenchymal cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
chondrocyte differentiation	Fibroblast growth factor receptor 1	Homo sapiens (human)
protein phosphorylation	Fibroblast growth factor receptor 1	Homo sapiens (human)
sensory perception of sound	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of cell population proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
fibroblast growth factor receptor signaling pathway	Fibroblast growth factor receptor 1	Homo sapiens (human)
mesenchymal cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
gene expression	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of phospholipase activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of phospholipase C activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
regulation of phosphate transport	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Fibroblast growth factor receptor 1	Homo sapiens (human)
cell migration	Fibroblast growth factor receptor 1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Fibroblast growth factor receptor 1	Homo sapiens (human)
ventricular zone neuroblast division	Fibroblast growth factor receptor 1	Homo sapiens (human)
cell projection assembly	Fibroblast growth factor receptor 1	Homo sapiens (human)
embryonic limb morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
midbrain development	Fibroblast growth factor receptor 1	Homo sapiens (human)
neuron projection development	Fibroblast growth factor receptor 1	Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development	Fibroblast growth factor receptor 1	Homo sapiens (human)
inner ear morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
outer ear morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
middle ear morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
chordate embryonic development	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of MAP kinase activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of MAPK cascade	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Fibroblast growth factor receptor 1	Homo sapiens (human)
cellular response to fibroblast growth factor stimulus	Fibroblast growth factor receptor 1	Homo sapiens (human)
regulation of cell differentiation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of neuron differentiation	Fibroblast growth factor receptor 1	Homo sapiens (human)
protein autophosphorylation	Fibroblast growth factor receptor 1	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Fibroblast growth factor receptor 1	Homo sapiens (human)
paraxial mesoderm development	Fibroblast growth factor receptor 1	Homo sapiens (human)
regulation of lateral mesodermal cell fate specification	Fibroblast growth factor receptor 1	Homo sapiens (human)
cell maturation	Fibroblast growth factor receptor 1	Homo sapiens (human)
skeletal system morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
stem cell differentiation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Fibroblast growth factor receptor 1	Homo sapiens (human)
calcium ion homeostasis	Fibroblast growth factor receptor 1	Homo sapiens (human)
cardiac muscle cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
auditory receptor cell development	Fibroblast growth factor receptor 1	Homo sapiens (human)
branching involved in salivary gland morphogenesis	Fibroblast growth factor receptor 1	Homo sapiens (human)
lung-associated mesenchyme development	Fibroblast growth factor receptor 1	Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling	Fibroblast growth factor receptor 1	Homo sapiens (human)
vitamin D3 metabolic process	Fibroblast growth factor receptor 1	Homo sapiens (human)
diphosphate metabolic process	Fibroblast growth factor receptor 1	Homo sapiens (human)
cementum mineralization	Fibroblast growth factor receptor 1	Homo sapiens (human)
stem cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway	Fibroblast growth factor receptor 1	Homo sapiens (human)
negative regulation of fibroblast growth factor production	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replication	Fibroblast growth factor receptor 1	Homo sapiens (human)
response to sodium phosphate	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of stem cell proliferation	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of parathyroid hormone secretion	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of endothelial cell chemotaxis	Fibroblast growth factor receptor 1	Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligand	Fibroblast growth factor receptor 1	Homo sapiens (human)
multicellular organism development	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of cell differentiation	Fibroblast growth factor receptor 1	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Fibroblast growth factor receptor 1	Homo sapiens (human)
positive regulation of kinase activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
hematopoietic progenitor cell differentiation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topological change	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA ligation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA damage response	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
female meiotic nuclear division	DNA topoisomerase 2-alpha	Homo sapiens (human)
apoptotic chromosome condensation	DNA topoisomerase 2-alpha	Homo sapiens (human)
embryonic cleavage	DNA topoisomerase 2-alpha	Homo sapiens (human)
regulation of circadian rhythm	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of apoptotic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	DNA topoisomerase 2-alpha	Homo sapiens (human)
rhythmic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
negative regulation of DNA duplex unwinding	DNA topoisomerase 2-alpha	Homo sapiens (human)
resolution of meiotic recombination intermediates	DNA topoisomerase 2-alpha	Homo sapiens (human)
sister chromatid segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
response to xenobiotic stimulus	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
positive regulation of fibroblast proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
cell division	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of transcription initiation by RNA polymerase II	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of type B pancreatic cell proliferation	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to lipopolysaccharide	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to interleukin-4	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristate	Cyclin-dependent kinase 4	Homo sapiens (human)
cellular response to ionomycin	Cyclin-dependent kinase 4	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 4	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 4	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 4	Homo sapiens (human)
apoptotic process	ADP/ATP translocase 3	Homo sapiens (human)
mitochondrial ADP transmembrane transport	ADP/ATP translocase 3	Homo sapiens (human)
mitochondrial ATP transmembrane transport	ADP/ATP translocase 3	Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	ADP/ATP translocase 3	Homo sapiens (human)
GMP biosynthetic process	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
GTP biosynthetic process	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
circadian rhythm	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
lymphocyte proliferation	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
cellular response to interleukin-4	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
'de novo' XMP biosynthetic process	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
primary ovarian follicle growth	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of cytokine production	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
signal transduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
signal complex assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
integrin-mediated signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
spermatogenesis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
learning or memory	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to xenobiotic stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to mechanical stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to acidic pH	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of gene expression	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of epithelial cell migration	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of epithelial cell migration	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of glucose metabolic process	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of protein processing	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
skeletal muscle cell proliferation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
macroautophagy	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of cell-cell adhesion	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
platelet activation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
forebrain development	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
T cell costimulation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein destabilization	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to nutrient levels	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to insulin stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of intracellular estrogen receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of integrin activation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of toll-like receptor 3 signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
adherens junction organization	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of dephosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of hippo signaling	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
intracellular signal transduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
entry of bacterium into host cell	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
osteoclast development	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ERBB2 signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
angiotensin-activated signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
odontogenesis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of apoptotic process	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of apoptotic process	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of vascular permeability	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
stress fiber assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
transcytosis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of bone resorption	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
bone resorption	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of Notch signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of bone resorption	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of Ras protein signal transduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein autophosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
neurotrophin TRK receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ephrin receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
focal adhesion assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
oogenesis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
progesterone receptor signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
leukocyte migration	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of small GTPase mediated signal transduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of protein transport	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to mineralocorticoid	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
myoblast proliferation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to electrical stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of focal adhesion assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of telomerase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
uterus development	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
branching involved in mammary gland duct morphogenesis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of cell projection assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
intestinal epithelial cell development	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to hydrogen peroxide	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
response to interleukin-1	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to lipopolysaccharide	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to peptide hormone stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to progesterone stimulus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to fatty acid	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to hypoxia	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to fluid shear stress	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of podosome assembly	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
DNA biosynthetic process	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cell-cell adhesion	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of protein localization to nucleus	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of TORC1 signaling	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cellular response to prolactin	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of male germ cell proliferation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of ovarian follicle development	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of lamellipodium morphogenesis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of early endosome to late endosome transport	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of anoikis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of caveolin-mediated endocytosis	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cell differentiation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cell adhesion	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
innate immune response	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein phosphorylation	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
symbiont entry into host cell	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
regulation of protein phosphorylation	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
intracellular signal transduction	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
negative regulation of cAMP/PKA signal transduction	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activity	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
MAPK cascade	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
myeloid progenitor cell differentiation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
visual learning	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
animal organ morphogenesis	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of gene expression	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
negative regulation of fibroblast migration	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of glucose transmembrane transport	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
synaptic vesicle exocytosis	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
thyroid gland development	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
T cell differentiation in thymus	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
somatic stem cell population maintenance	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
regulation of cell population proliferation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
stress fiber assembly	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
CD4-positive, alpha-beta T cell differentiation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
CD4-positive or CD8-positive, alpha-beta T cell lineage commitment	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
response to peptide hormone	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
negative regulation of neuron apoptotic process	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
regulation of T cell differentiation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
thymus development	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of axon regeneration	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of axonogenesis	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
T cell receptor signaling pathway	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of stress fiber assembly	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
response to cAMP	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
long-term synaptic potentiation	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
head morphogenesis	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
face development	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
ERK1 and ERK2 cascade	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cellular response to calcium ion	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cellular response to xenobiotic stimulus	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
endothelial cell apoptotic process	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
establishment of protein localization to membrane	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
negative regulation of synaptic vesicle exocytosis	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
glycogen metabolic process	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
glycogen biosynthetic process	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
glycogen catabolic process	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
generation of precursor metabolites and energy	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
protein phosphorylation	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
positive regulation of glycogen catabolic process	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
quinone catabolic process	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
microtubule cytoskeleton organization	Tyrosine-protein kinase Fer	Homo sapiens (human)
regulation of protein phosphorylation	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fer	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase Fer	Homo sapiens (human)
germ cell development	Tyrosine-protein kinase Fer	Homo sapiens (human)
positive regulation of cell population proliferation	Tyrosine-protein kinase Fer	Homo sapiens (human)
insulin receptor signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
regulation of lamellipodium assembly	Tyrosine-protein kinase Fer	Homo sapiens (human)
regulation of fibroblast migration	Tyrosine-protein kinase Fer	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fer	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein kinase Fer	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase Fer	Homo sapiens (human)
positive regulation of actin filament polymerization	Tyrosine-protein kinase Fer	Homo sapiens (human)
response to lipopolysaccharide	Tyrosine-protein kinase Fer	Homo sapiens (human)
negative regulation of mast cell activation involved in immune response	Tyrosine-protein kinase Fer	Homo sapiens (human)
adherens junction assembly	Tyrosine-protein kinase Fer	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Tyrosine-protein kinase Fer	Homo sapiens (human)
cellular response to reactive oxygen species	Tyrosine-protein kinase Fer	Homo sapiens (human)
extracellular matrix-cell signaling	Tyrosine-protein kinase Fer	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Fer	Homo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulus	Tyrosine-protein kinase Fer	Homo sapiens (human)
response to platelet-derived growth factor	Tyrosine-protein kinase Fer	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
Kit signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
regulation of epidermal growth factor receptor signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
cell-cell adhesion mediated by cadherin	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase Fer	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
diapedesis	Tyrosine-protein kinase Fer	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tyrosine-protein kinase Fer	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase Fer	Homo sapiens (human)
Sertoli cell development	Tyrosine-protein kinase Fer	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Tyrosine-protein kinase Fer	Homo sapiens (human)
seminiferous tubule development	Tyrosine-protein kinase Fer	Homo sapiens (human)
adherens junction disassembly	Tyrosine-protein kinase Fer	Homo sapiens (human)
cell adhesion	Tyrosine-protein kinase Fer	Homo sapiens (human)
chemotaxis	Tyrosine-protein kinase Fer	Homo sapiens (human)
angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Protein kinase C alpha type	Homo sapiens (human)
desmosome assembly	Protein kinase C alpha type	Homo sapiens (human)
chromatin remodeling	Protein kinase C alpha type	Homo sapiens (human)
protein phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
mitotic nuclear membrane disassembly	Protein kinase C alpha type	Homo sapiens (human)
cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C alpha type	Homo sapiens (human)
regulation of mRNA stability	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
post-translational protein modification	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of macrophage differentiation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of bone resorption	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of mitotic cell cycle	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Protein kinase C alpha type	Homo sapiens (human)
response to interleukin-1	Protein kinase C alpha type	Homo sapiens (human)
regulation of platelet aggregation	Protein kinase C alpha type	Homo sapiens (human)
apoptotic signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiotensin-activated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of dense core granule biogenesis	Protein kinase C alpha type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of insulin secretion	Protein kinase C alpha type	Homo sapiens (human)
mesoderm formation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
neural tube closure	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of heart rate	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mRNA processing	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein export from nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of macroautophagy	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytokine-mediated signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of insulin secretion	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of interleukin-2 production	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to heat	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mitochondrial protein catabolic process	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of osteoblast differentiation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of gluconeogenesis	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of smoothened signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of protein export from nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
sperm capacitation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of calcium-mediated signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cell cycle	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac muscle contraction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of proteasomal protein catabolic process	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to cold	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of protein processing	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to glucose stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to parathyroid hormone stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to glucagon stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to epinephrine stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac conduction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphate	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein localization to lipid droplet	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of bicellular tight junction assembly	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
response to hypoxia	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
in utero embryonic development	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription-coupled nucleotide-excision repair	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
nucleotide-excision repair	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
regulation of transcription by RNA polymerase II	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription elongation by RNA polymerase I	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription by RNA polymerase II	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
apoptotic process	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
response to oxidative stress	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
chromosome segregation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
determination of adult lifespan	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
UV protection	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
post-embryonic development	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
spinal cord development	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
extracellular matrix organization	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
bone mineralization	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
central nervous system myelin formation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
DNA duplex unwinding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
multicellular organism growth	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
hair cell differentiation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
embryonic cleavage	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
erythrocyte maturation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
embryonic organ development	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
hair follicle maturation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
hematopoietic stem cell differentiation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
hematopoietic stem cell proliferation	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
positive regulation of mitotic recombination	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha'	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha'	Homo sapiens (human)
spermatogenesis	Casein kinase II subunit alpha'	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
cerebral cortex development	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha'	Homo sapiens (human)
liver regeneration	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of mitophagy	Casein kinase II subunit alpha'	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Casein kinase II subunit alpha'	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha'	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha'	Homo sapiens (human)
peptidyl-cysteine methylation	Ras-related protein Rab-6A	Homo sapiens (human)
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	Ras-related protein Rab-6A	Homo sapiens (human)
antigen processing and presentation	Ras-related protein Rab-6A	Homo sapiens (human)
neuron projection development	Ras-related protein Rab-6A	Homo sapiens (human)
protein localization to Golgi apparatus	Ras-related protein Rab-6A	Homo sapiens (human)
early endosome to Golgi transport	Ras-related protein Rab-6A	Homo sapiens (human)
minus-end-directed organelle transport along microtubule	Ras-related protein Rab-6A	Homo sapiens (human)
protein localization to Golgi membrane	Ras-related protein Rab-6A	Homo sapiens (human)
intracellular protein transport	Ras-related protein Rab-6A	Homo sapiens (human)
intra-Golgi vesicle-mediated transport	Ras-related protein Rab-6A	Homo sapiens (human)
retrograde transport, endosome to Golgi	Ras-related protein Rab-6A	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Ephrin type-A receptor 1	Homo sapiens (human)
negative regulation of protein kinase activity	Ephrin type-A receptor 1	Homo sapiens (human)
cell surface receptor signaling pathway	Ephrin type-A receptor 1	Homo sapiens (human)
positive regulation of cell population proliferation	Ephrin type-A receptor 1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Ephrin type-A receptor 1	Homo sapiens (human)
positive regulation of cell migration	Ephrin type-A receptor 1	Homo sapiens (human)
negative regulation of cell migration	Ephrin type-A receptor 1	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Ephrin type-A receptor 1	Homo sapiens (human)
regulation of GTPase activity	Ephrin type-A receptor 1	Homo sapiens (human)
positive regulation of angiogenesis	Ephrin type-A receptor 1	Homo sapiens (human)
protein autophosphorylation	Ephrin type-A receptor 1	Homo sapiens (human)
positive regulation of stress fiber assembly	Ephrin type-A receptor 1	Homo sapiens (human)
activation of GTPase activity	Ephrin type-A receptor 1	Homo sapiens (human)
positive regulation of kinase activity	Ephrin type-A receptor 1	Homo sapiens (human)
multicellular organism development	Ephrin type-A receptor 1	Homo sapiens (human)
angiogenesis	Ephrin type-A receptor 1	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-A receptor 1	Homo sapiens (human)
endocardial cushion development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of cell adhesion	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
signal transduction	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
peripheral nervous system development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
heart development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of signal transduction	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of gene expression	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
Schwann cell differentiation	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
Schwann cell development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
cranial nerve development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
wound healing	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
myelination	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of neuron apoptotic process	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of secretion	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
neuron apoptotic process	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of cardiac muscle tissue development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascade	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
motor neuron apoptotic process	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of motor neuron apoptotic process	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
negative regulation of apoptotic process	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
neurogenesis	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
positive regulation of kinase activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
multicellular organism development	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
GMP biosynthetic process	Multifunctional protein ADE2	Homo sapiens (human)
'de novo' IMP biosynthetic process	Multifunctional protein ADE2	Homo sapiens (human)
purine nucleobase biosynthetic process	Multifunctional protein ADE2	Homo sapiens (human)
'de novo' AMP biosynthetic process	Multifunctional protein ADE2	Homo sapiens (human)
'de novo' XMP biosynthetic process	Multifunctional protein ADE2	Homo sapiens (human)
GTP biosynthetic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
UTP biosynthetic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
CTP biosynthetic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
cell adhesion	Nucleoside diphosphate kinase B	Homo sapiens (human)
integrin-mediated signaling pathway	Nucleoside diphosphate kinase B	Homo sapiens (human)
nucleoside triphosphate biosynthetic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
negative regulation of apoptotic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Nucleoside diphosphate kinase B	Homo sapiens (human)
regulation of epidermis development	Nucleoside diphosphate kinase B	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nucleoside diphosphate kinase B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nucleoside diphosphate kinase B	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Nucleoside diphosphate kinase B	Homo sapiens (human)
regulation of apoptotic process	Nucleoside diphosphate kinase B	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
spermatogenesis	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
male gonad development	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
neural tube closure	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
signal transduction	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
negative regulation of smoothened signaling pathway	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
regulation of protein processing	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
generation of precursor metabolites and energy	Ferrochelatase, mitochondrial	Homo sapiens (human)
heme biosynthetic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
heme A biosynthetic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
heme B biosynthetic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
cholesterol metabolic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to xenobiotic stimulus	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to light stimulus	Ferrochelatase, mitochondrial	Homo sapiens (human)
detection of UV	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to lead ion	Ferrochelatase, mitochondrial	Homo sapiens (human)
regulation of eIF2 alpha phosphorylation by heme	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to insecticide	Ferrochelatase, mitochondrial	Homo sapiens (human)
erythrocyte differentiation	Ferrochelatase, mitochondrial	Homo sapiens (human)
very-low-density lipoprotein particle assembly	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to ethanol	Ferrochelatase, mitochondrial	Homo sapiens (human)
protoporphyrinogen IX metabolic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to arsenic-containing substance	Ferrochelatase, mitochondrial	Homo sapiens (human)
regulation of hemoglobin biosynthetic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
heme O biosynthetic process	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to methylmercury	Ferrochelatase, mitochondrial	Homo sapiens (human)
multicellular organismal-level iron ion homeostasis	Ferrochelatase, mitochondrial	Homo sapiens (human)
response to platinum ion	Ferrochelatase, mitochondrial	Homo sapiens (human)
cellular response to dexamethasone stimulus	Ferrochelatase, mitochondrial	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
behavioral fear response	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
skeletal muscle contraction	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
apoptotic process	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
germ cell development	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
long-term memory	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to xenobiotic stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to mechanical stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to toxic substance	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to glucose	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
skeletal muscle atrophy	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to electrical stimulus involved in regulation of muscle adaptation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cell migration	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to nutrient levels	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to nutrient	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
TOR signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to lipopolysaccharide	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to testosterone	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to glucagon	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to tumor necrosis factor	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of apoptotic process	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to L-leucine	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
long-chain fatty acid import into cell	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to ethanol	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of translation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of mitotic cell cycle	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of translational initiation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
regulation of glucose import	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of skeletal muscle tissue growth	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
modulation of chemical synaptic transmission	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to type II interferon	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to growth factor stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to dexamethasone stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
positive regulation of TORC1 signaling	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cellular response to insulin stimulus	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
response to antibiotic	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
positive regulation of homotypic cell-cell adhesion	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-15-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-4-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-2-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-9-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-11-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
type III interferon-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
type II interferon-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
type I interferon-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
T-helper 17 cell lineage commitment	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cellular response to virus	Tyrosine-protein kinase JAK1	Homo sapiens (human)
interleukin-10-mediated signaling pathway	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein localization to cell-cell junction	Tyrosine-protein kinase JAK1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Tyrosine-protein kinase JAK1	Homo sapiens (human)
positive regulation of sprouting angiogenesis	Tyrosine-protein kinase JAK1	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase JAK1	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase JAK1	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein phosphorylation	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	G1/S-specific cyclin-E1	Homo sapiens (human)
telomere maintenance	G1/S-specific cyclin-E1	Homo sapiens (human)
DNA replication initiation	G1/S-specific cyclin-E1	Homo sapiens (human)
homologous chromosome pairing at meiosis	G1/S-specific cyclin-E1	Homo sapiens (human)
Wnt signaling pathway	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of protein localization	G1/S-specific cyclin-E1	Homo sapiens (human)
cell division	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferation	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 2	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
potassium ion transport	Cyclin-dependent kinase 2	Homo sapiens (human)
centriole replication	Cyclin-dependent kinase 2	Homo sapiens (human)
Ras protein signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of heterochromatin formation	Cyclin-dependent kinase 2	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiation	Cyclin-dependent kinase 2	Homo sapiens (human)
telomere maintenance in response to DNA damage	Cyclin-dependent kinase 2	Homo sapiens (human)
post-translational protein modification	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome duplication	Cyclin-dependent kinase 2	Homo sapiens (human)
cell division	Cyclin-dependent kinase 2	Homo sapiens (human)
meiotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular response to nitric oxide	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular senescence	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 2	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 2	Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signal	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
tachykinin receptor signaling pathway	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
heart development	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
viral genome replication	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
receptor internalization	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
positive regulation of catecholamine secretion	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of striated muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
symbiont entry into host cell	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cardiac muscle contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
negative regulation of relaxation of smooth muscle	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
regulation of the force of heart contraction	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein phosphorylation	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
P-body assembly	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translation	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
negative regulation of translation	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
viral RNA genome packaging	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
stem cell population maintenance	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
neuron differentiation	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
P-body assembly	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
negative regulation of neuron differentiation	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
stress granule assembly	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
positive regulation of macrophage chemotaxis	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of macrophage proliferation	Mitogen-activated protein kinase 3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase 3	Homo sapiens (human)
DNA-templated transcription	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase 3	Homo sapiens (human)
apoptotic process	Mitogen-activated protein kinase 3	Homo sapiens (human)
insulin receptor signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
Schwann cell development	Mitogen-activated protein kinase 3	Homo sapiens (human)
phosphorylation	Mitogen-activated protein kinase 3	Homo sapiens (human)
sensory perception of pain	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of ossification	Mitogen-activated protein kinase 3	Homo sapiens (human)
BMP signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of cellular pH	Mitogen-activated protein kinase 3	Homo sapiens (human)
thyroid gland development	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of cyclase activity	Mitogen-activated protein kinase 3	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of stress-activated MAPK cascade	Mitogen-activated protein kinase 3	Homo sapiens (human)
cellular response to amino acid starvation	Mitogen-activated protein kinase 3	Homo sapiens (human)
cellular response to reactive oxygen species	Mitogen-activated protein kinase 3	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Mitogen-activated protein kinase 3	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
outer ear morphogenesis	Mitogen-activated protein kinase 3	Homo sapiens (human)
myelination	Mitogen-activated protein kinase 3	Homo sapiens (human)
signal transduction in response to DNA damage	Mitogen-activated protein kinase 3	Homo sapiens (human)
response to exogenous dsRNA	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Mitogen-activated protein kinase 3	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
thymus development	Mitogen-activated protein kinase 3	Homo sapiens (human)
modulation of chemical synaptic transmission	Mitogen-activated protein kinase 3	Homo sapiens (human)
cartilage development	Mitogen-activated protein kinase 3	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of cytoskeleton organization	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of telomerase activity	Mitogen-activated protein kinase 3	Homo sapiens (human)
Bergmann glial cell differentiation	Mitogen-activated protein kinase 3	Homo sapiens (human)
face development	Mitogen-activated protein kinase 3	Homo sapiens (human)
lung morphogenesis	Mitogen-activated protein kinase 3	Homo sapiens (human)
trachea formation	Mitogen-activated protein kinase 3	Homo sapiens (human)
cardiac neural crest cell development involved in heart development	Mitogen-activated protein kinase 3	Homo sapiens (human)
ERK1 and ERK2 cascade	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mitogen-activated protein kinase 3	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Mitogen-activated protein kinase 3	Homo sapiens (human)
response to epidermal growth factor	Mitogen-activated protein kinase 3	Homo sapiens (human)
cellular response to mechanical stimulus	Mitogen-activated protein kinase 3	Homo sapiens (human)
cellular response to cadmium ion	Mitogen-activated protein kinase 3	Homo sapiens (human)
cellular response to tumor necrosis factor	Mitogen-activated protein kinase 3	Homo sapiens (human)
caveolin-mediated endocytosis	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of Golgi inheritance	Mitogen-activated protein kinase 3	Homo sapiens (human)
xenophagy	Mitogen-activated protein kinase 3	Homo sapiens (human)
negative regulation of TORC1 signaling	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of telomere capping	Mitogen-activated protein kinase 3	Homo sapiens (human)
positive regulation of xenophagy	Mitogen-activated protein kinase 3	Homo sapiens (human)
regulation of early endosome to late endosome transport	Mitogen-activated protein kinase 3	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein phosphorylation	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
peptidyl-serine phosphorylation	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
positive regulation of protein binding	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
negative regulation of hippo signaling	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
peptidyl-serine autophosphorylation	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
negative regulation of protein localization to nucleus	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
intracellular signal transduction	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
pyrimidine nucleotide metabolic process	Deoxycytidine kinase	Homo sapiens (human)
CMP biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
dAMP salvage	Deoxycytidine kinase	Homo sapiens (human)
nucleoside phosphate biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
positive regulation of macrophage chemotaxis	Mitogen-activated protein kinase 1	Homo sapiens (human)
positive regulation of macrophage proliferation	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase 1	Homo sapiens (human)
apoptotic process	Mitogen-activated protein kinase 1	Homo sapiens (human)
chemotaxis	Mitogen-activated protein kinase 1	Homo sapiens (human)
DNA damage response	Mitogen-activated protein kinase 1	Homo sapiens (human)
signal transduction	Mitogen-activated protein kinase 1	Homo sapiens (human)
chemical synaptic transmission	Mitogen-activated protein kinase 1	Homo sapiens (human)
learning or memory	Mitogen-activated protein kinase 1	Homo sapiens (human)
insulin receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Mitogen-activated protein kinase 1	Homo sapiens (human)
Schwann cell development	Mitogen-activated protein kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytosine metabolic process	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of ossification	Mitogen-activated protein kinase 1	Homo sapiens (human)
androgen receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of cellular pH	Mitogen-activated protein kinase 1	Homo sapiens (human)
thyroid gland development	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of protein stability	Mitogen-activated protein kinase 1	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of stress-activated MAPK cascade	Mitogen-activated protein kinase 1	Homo sapiens (human)
mammary gland epithelial cell proliferation	Mitogen-activated protein kinase 1	Homo sapiens (human)
cellular response to amino acid starvation	Mitogen-activated protein kinase 1	Homo sapiens (human)
cellular response to reactive oxygen species	Mitogen-activated protein kinase 1	Homo sapiens (human)
response to nicotine	Mitogen-activated protein kinase 1	Homo sapiens (human)
ERBB signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
outer ear morphogenesis	Mitogen-activated protein kinase 1	Homo sapiens (human)
myelination	Mitogen-activated protein kinase 1	Homo sapiens (human)
response to exogenous dsRNA	Mitogen-activated protein kinase 1	Homo sapiens (human)
steroid hormone mediated signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
negative regulation of cell differentiation	Mitogen-activated protein kinase 1	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
thymus development	Mitogen-activated protein kinase 1	Homo sapiens (human)
progesterone receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
T cell receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
B cell receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of cytoskeleton organization	Mitogen-activated protein kinase 1	Homo sapiens (human)
positive regulation of telomerase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
Bergmann glial cell differentiation	Mitogen-activated protein kinase 1	Homo sapiens (human)
long-term synaptic potentiation	Mitogen-activated protein kinase 1	Homo sapiens (human)
face development	Mitogen-activated protein kinase 1	Homo sapiens (human)
lung morphogenesis	Mitogen-activated protein kinase 1	Homo sapiens (human)
trachea formation	Mitogen-activated protein kinase 1	Homo sapiens (human)
labyrinthine layer blood vessel development	Mitogen-activated protein kinase 1	Homo sapiens (human)
cardiac neural crest cell development involved in heart development	Mitogen-activated protein kinase 1	Homo sapiens (human)
ERK1 and ERK2 cascade	Mitogen-activated protein kinase 1	Homo sapiens (human)
response to epidermal growth factor	Mitogen-activated protein kinase 1	Homo sapiens (human)
cellular response to cadmium ion	Mitogen-activated protein kinase 1	Homo sapiens (human)
cellular response to tumor necrosis factor	Mitogen-activated protein kinase 1	Homo sapiens (human)
caveolin-mediated endocytosis	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of Golgi inheritance	Mitogen-activated protein kinase 1	Homo sapiens (human)
positive regulation of telomere capping	Mitogen-activated protein kinase 1	Homo sapiens (human)
regulation of early endosome to late endosome transport	Mitogen-activated protein kinase 1	Homo sapiens (human)
cell surface receptor signaling pathway	Mitogen-activated protein kinase 1	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 1	Homo sapiens (human)
skeletal system development	Ephrin type-A receptor 2	Homo sapiens (human)
vasculogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
osteoblast differentiation	Ephrin type-A receptor 2	Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
inflammatory response	Ephrin type-A receptor 2	Homo sapiens (human)
cell adhesion	Ephrin type-A receptor 2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Ephrin type-A receptor 2	Homo sapiens (human)
regulation of lamellipodium assembly	Ephrin type-A receptor 2	Homo sapiens (human)
notochord formation	Ephrin type-A receptor 2	Homo sapiens (human)
cell migration	Ephrin type-A receptor 2	Homo sapiens (human)
negative regulation of angiogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
neural tube development	Ephrin type-A receptor 2	Homo sapiens (human)
neuron differentiation	Ephrin type-A receptor 2	Homo sapiens (human)
keratinocyte differentiation	Ephrin type-A receptor 2	Homo sapiens (human)
osteoclast differentiation	Ephrin type-A receptor 2	Homo sapiens (human)
positive regulation of cell migration	Ephrin type-A receptor 2	Homo sapiens (human)
negative regulation of chemokine production	Ephrin type-A receptor 2	Homo sapiens (human)
mammary gland epithelial cell proliferation	Ephrin type-A receptor 2	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Ephrin type-A receptor 2	Homo sapiens (human)
post-anal tail morphogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
regulation of blood vessel endothelial cell migration	Ephrin type-A receptor 2	Homo sapiens (human)
regulation of angiogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
cAMP metabolic process	Ephrin type-A receptor 2	Homo sapiens (human)
symbiont entry into host cell	Ephrin type-A receptor 2	Homo sapiens (human)
bone remodeling	Ephrin type-A receptor 2	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-A receptor 2	Homo sapiens (human)
axial mesoderm formation	Ephrin type-A receptor 2	Homo sapiens (human)
cell motility	Ephrin type-A receptor 2	Homo sapiens (human)
defense response to Gram-positive bacterium	Ephrin type-A receptor 2	Homo sapiens (human)
notochord cell development	Ephrin type-A receptor 2	Homo sapiens (human)
cell chemotaxis	Ephrin type-A receptor 2	Homo sapiens (human)
branching involved in mammary gland duct morphogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
lens fiber cell morphogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Ephrin type-A receptor 2	Homo sapiens (human)
response to growth factor	Ephrin type-A receptor 2	Homo sapiens (human)
protein localization to plasma membrane	Ephrin type-A receptor 2	Homo sapiens (human)
activation of GTPase activity	Ephrin type-A receptor 2	Homo sapiens (human)
negative regulation of lymphangiogenesis	Ephrin type-A receptor 2	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Ephrin type-A receptor 2	Homo sapiens (human)
positive regulation of bicellular tight junction assembly	Ephrin type-A receptor 2	Homo sapiens (human)
pericyte cell differentiation	Ephrin type-A receptor 2	Homo sapiens (human)
positive regulation of kinase activity	Ephrin type-A receptor 2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Ephrin type-A receptor 2	Homo sapiens (human)
multicellular organism development	Ephrin type-A receptor 2	Homo sapiens (human)
negative regulation of protein kinase activity	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of autophagosome assembly	Ephrin type-B receptor 2	Homo sapiens (human)
angiogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
urogenital system development	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of protein phosphorylation	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of immunoglobulin production	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of cell adhesion	Ephrin type-B receptor 2	Homo sapiens (human)
nervous system development	Ephrin type-B receptor 2	Homo sapiens (human)
axon guidance	Ephrin type-B receptor 2	Homo sapiens (human)
axonal fasciculation	Ephrin type-B receptor 2	Homo sapiens (human)
learning or memory	Ephrin type-B receptor 2	Homo sapiens (human)
learning	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of gene expression	Ephrin type-B receptor 2	Homo sapiens (human)
phosphorylation	Ephrin type-B receptor 2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Ephrin type-B receptor 2	Homo sapiens (human)
optic nerve morphogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
hindbrain tangential cell migration	Ephrin type-B receptor 2	Homo sapiens (human)
central nervous system projection neuron axonogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
corpus callosum development	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of blood coagulation	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of cell migration	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of B cell proliferation	Ephrin type-B receptor 2	Homo sapiens (human)
retinal ganglion cell axon guidance	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Ephrin type-B receptor 2	Homo sapiens (human)
B cell activation	Ephrin type-B receptor 2	Homo sapiens (human)
inner ear morphogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of Ras protein signal transduction	Ephrin type-B receptor 2	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of neuronal synaptic plasticity	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticity	Ephrin type-B receptor 2	Homo sapiens (human)
camera-type eye morphogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of axonogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of body fluid levels	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of filopodium assembly	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of synapse assembly	Ephrin type-B receptor 2	Homo sapiens (human)
roof of mouth development	Ephrin type-B receptor 2	Homo sapiens (human)
dendritic spine development	Ephrin type-B receptor 2	Homo sapiens (human)
dendritic spine morphogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of dendritic spine morphogenesis	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Ephrin type-B receptor 2	Homo sapiens (human)
cellular response to lipopolysaccharide	Ephrin type-B receptor 2	Homo sapiens (human)
commissural neuron axon guidance	Ephrin type-B receptor 2	Homo sapiens (human)
postsynaptic membrane assembly	Ephrin type-B receptor 2	Homo sapiens (human)
trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission	Ephrin type-B receptor 2	Homo sapiens (human)
neuron projection retraction	Ephrin type-B receptor 2	Homo sapiens (human)
vesicle-mediated intercellular transport	Ephrin type-B receptor 2	Homo sapiens (human)
tight junction assembly	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Ephrin type-B receptor 2	Homo sapiens (human)
cellular response to amyloid-beta	Ephrin type-B receptor 2	Homo sapiens (human)
negative regulation of NMDA glutamate receptor activity	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of NMDA glutamate receptor activity	Ephrin type-B receptor 2	Homo sapiens (human)
positive regulation of protein localization to cell surface	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of T-helper 17 type immune response	Ephrin type-B receptor 2	Homo sapiens (human)
regulation of behavioral fear response	Ephrin type-B receptor 2	Homo sapiens (human)
protein phosphorylation	Ephrin type-B receptor 2	Homo sapiens (human)
protein phosphorylation	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
immune response	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytokine-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of type II interferon production	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of interleukin-17 production	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of natural killer cell proliferation	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
interleukin-12-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
type III interferon-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of T cell proliferation	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of NK T cell proliferation	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
type II interferon-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
type I interferon-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cellular response to virus	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
interleukin-10-mediated signaling pathway	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of protein localization to nucleus	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
intracellular signal transduction	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cell differentiation	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
negative regulation of MAPK cascade	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Wee1-like protein kinase	Homo sapiens (human)
microtubule cytoskeleton organization	Wee1-like protein kinase	Homo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycle	Wee1-like protein kinase	Homo sapiens (human)
establishment of cell polarity	Wee1-like protein kinase	Homo sapiens (human)
positive regulation of DNA replication	Wee1-like protein kinase	Homo sapiens (human)
neuron projection morphogenesis	Wee1-like protein kinase	Homo sapiens (human)
cell division	Wee1-like protein kinase	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	Wee1-like protein kinase	Homo sapiens (human)
protein phosphorylation	Wee1-like protein kinase	Homo sapiens (human)
response to hypoxia	Heme oxygenase 2	Homo sapiens (human)
response to oxidative stress	Heme oxygenase 2	Homo sapiens (human)
heme catabolic process	Heme oxygenase 2	Homo sapiens (human)
heme oxidation	Heme oxygenase 2	Homo sapiens (human)
S-adenosylmethionine biosynthetic process	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
one-carbon metabolic process	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
protein hexamerization	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
protein heterooligomerization	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
cellular response to methionine	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
positive regulation of TORC1 signaling	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
cellular response to leukemia inhibitory factor	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
protein folding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
response to unfolded protein	DnaJ homolog subfamily A member 1	Homo sapiens (human)
spermatogenesis	DnaJ homolog subfamily A member 1	Homo sapiens (human)
response to heat	DnaJ homolog subfamily A member 1	Homo sapiens (human)
flagellated sperm motility	DnaJ homolog subfamily A member 1	Homo sapiens (human)
androgen receptor signaling pathway	DnaJ homolog subfamily A member 1	Homo sapiens (human)
negative regulation of protein ubiquitination	DnaJ homolog subfamily A member 1	Homo sapiens (human)
positive regulation of apoptotic process	DnaJ homolog subfamily A member 1	Homo sapiens (human)
negative regulation of apoptotic process	DnaJ homolog subfamily A member 1	Homo sapiens (human)
negative regulation of JUN kinase activity	DnaJ homolog subfamily A member 1	Homo sapiens (human)
regulation of protein transport	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein localization to mitochondrion	DnaJ homolog subfamily A member 1	Homo sapiens (human)
negative regulation of establishment of protein localization to mitochondrion	DnaJ homolog subfamily A member 1	Homo sapiens (human)
negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein refolding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
activation-induced cell death of T cells	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
osteoblast differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
maternal placenta development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell migration involved in sprouting angiogenesis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glucose metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of translation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein import into nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nitric oxide biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
inflammatory response	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to oxidative stress	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
G protein-coupled receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
canonical NF-kappaB signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell population proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
insulin receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
apoptotic mitochondrial changes	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to heat	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of autophagy	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of gene expression	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
fibroblast migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fibroblast migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of sodium ion transport	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of endopeptidase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of neuron projection development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of macroautophagy	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein ubiquitination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-threonine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
virus-mediated perturbation of host defense response	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytokine-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mammalian oogenesis stage	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell growth	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
T cell costimulation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein ubiquitination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of myelination	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
TOR signaling	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of fatty acid beta-oxidation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endodeoxyribonuclease activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to food	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
peripheral nervous system myelin maintenance	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to insulin stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to fluid shear stress	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to reactive oxygen species	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
interleukin-18-mediated signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to decreased oxygen levels	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glucose homeostasis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
anoikis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of mRNA stability	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fat cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of Notch signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of proteolysis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of DNA-templated transcription	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose import	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of organ growth	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein autophosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of lipid biosynthetic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
behavioral response to pain	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
striated muscle cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein metabolic process	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
excitatory postsynaptic potential	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to growth hormone	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mammary gland epithelial cell differentiation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
labyrinthine layer blood vessel development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to UV-A	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to growth factor	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to cadmium ion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to tumor necrosis factor	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to prostaglandin E stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
establishment of protein localization to mitochondrion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
maintenance of protein location in mitochondrion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
execution phase of apoptosis	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of postsynapse organization	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of tRNA methylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to oxidised low-density lipoprotein particle stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of protein localization to lysosome	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cGAS/STING signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to peptide	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cilium assembly	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of leukocyte cell-cell adhesion	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of I-kappaB phosphorylation	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of TORC1 signaling	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to endoplasmic reticulum	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cellular response to nerve growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
response to insulin-like growth factor stimulus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein localization to cell surface	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
regulation of type B pancreatic cell development	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of lymphocyte migration	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glycogen biosynthetic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
glucose metabolic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of translation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
insulin receptor signaling pathway	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose metabolic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell migration	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of fatty acid beta-oxidation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
peripheral nervous system myelin maintenance	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cellular response to insulin stimulus	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein modification process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
fat cell differentiation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glycogen biosynthetic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of glucose import	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell cycle	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
mammary gland epithelial cell differentiation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cellular response to high light intensity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
organic substance transport	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein localization to plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of protein targeting to membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
retinal rod cell apoptotic process	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell motility	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
spindle organization	Dual specificity protein kinase TTK	Homo sapiens (human)
mitotic spindle organization	Dual specificity protein kinase TTK	Homo sapiens (human)
positive regulation of cell population proliferation	Dual specificity protein kinase TTK	Homo sapiens (human)
female meiosis chromosome segregation	Dual specificity protein kinase TTK	Homo sapiens (human)
protein localization to meiotic spindle midzone	Dual specificity protein kinase TTK	Homo sapiens (human)
chromosome segregation	Dual specificity protein kinase TTK	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity protein kinase TTK	Homo sapiens (human)
protein localization to kinetochore	Dual specificity protein kinase TTK	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Dual specificity protein kinase TTK	Homo sapiens (human)
meiotic spindle assembly checkpoint signaling	Dual specificity protein kinase TTK	Homo sapiens (human)
DNA replication	DNA replication licensing factor MCM4	Homo sapiens (human)
DNA unwinding involved in DNA replication	DNA replication licensing factor MCM4	Homo sapiens (human)
regulation of DNA-templated DNA replication initiation	DNA replication licensing factor MCM4	Homo sapiens (human)
double-strand break repair via break-induced replication	DNA replication licensing factor MCM4	Homo sapiens (human)
DNA strand elongation involved in DNA replication	DNA replication licensing factor MCM4	Homo sapiens (human)
mitotic DNA replication initiation	DNA replication licensing factor MCM4	Homo sapiens (human)
mitotic cytokinesis	Myosin-10	Homo sapiens (human)
actin filament-based movement	Myosin-10	Homo sapiens (human)
cell adhesion	Myosin-10	Homo sapiens (human)
actomyosin structure organization	Myosin-10	Homo sapiens (human)
positive regulation of protein secretion	Myosin-10	Homo sapiens (human)
mitotic cytokinesis	Myosin-10	Homo sapiens (human)
regulation of cell shape	Myosin-10	Homo sapiens (human)
heart development	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
positive regulation of gene expression	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
Schwann cell development	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
thyroid gland development	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
regulation of stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
peptidyl-serine autophosphorylation	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
myelination	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
thymus development	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
regulation of axon regeneration	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
positive regulation of axonogenesis	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
face development	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
trachea formation	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesis	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
ERK1 and ERK2 cascade	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
regulation of Golgi inheritance	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
positive regulation of cell motility	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
regulation of early endosome to late endosome transport	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
hemopoiesis	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
leukocyte homeostasis	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
myeloid progenitor cell differentiation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
pro-B cell differentiation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
response to organonitrogen compound	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cytokine-mediated signaling pathway	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
B cell differentiation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
animal organ regeneration	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
common myeloid progenitor cell proliferation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
regulation of apoptotic process	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of MAP kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of MAPK cascade	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
lymphocyte proliferation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein autophosphorylation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cellular response to cytokine stimulus	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
dendritic cell differentiation	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
positive regulation of kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
multicellular organism development	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
regulation of cardiac muscle cell apoptotic process	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
regulation of neural crest cell differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of gene expression	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
negative regulation of gene expression	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of transforming growth factor beta2 production	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
angiogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
osteoblast differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
in utero embryonic development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
mesoderm formation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
somitogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
Mullerian duct regression	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of mesenchymal cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
chondrocyte differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
outflow tract septum morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
outflow tract morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
cardiac conduction system development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
atrioventricular valve development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
mitral valve morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
tricuspid valve morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
endocardial cushion morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
cardiac right ventricle morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
ventricular trabecula myocardium morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
ventricular compact myocardium morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
endocardial cushion formation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
immune response	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
ectoderm development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
dorsal/ventral axis specification	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
neural crest cell development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
negative regulation of smooth muscle cell migration	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
central nervous system neuron differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
pituitary gland development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
neural plate mediolateral regionalization	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
lung development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of bone mineralization	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
BMP signaling pathway	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
somatic stem cell population maintenance	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
hindlimb morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
dorsal aorta morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
embryonic digit morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of osteoblast differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
paraxial mesoderm structural organization	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
lateral mesoderm development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
regulation of lateral mesodermal cell fate specification	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
mesendoderm development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
embryonic organ development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
developmental growth	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
epithelial cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
negative regulation of neurogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
negative regulation of muscle cell differentiation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
roof of mouth development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
regulation of cardiac muscle cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
ventricular septum morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
heart formation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
atrioventricular node cell development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
pharyngeal arch artery morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
cellular response to BMP stimulus	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of miRNA transcription	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of cardiac ventricle development	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
fibrous ring of heart morphogenesis	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
regulation of cellular senescence	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
protein phosphorylation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
dorsal/ventral pattern formation	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
cellular response to growth factor stimulus	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Activin receptor type-1B	Homo sapiens (human)
in utero embryonic development	Activin receptor type-1B	Homo sapiens (human)
hair follicle development	Activin receptor type-1B	Homo sapiens (human)
regulation of DNA-templated transcription	Activin receptor type-1B	Homo sapiens (human)
signal transduction	Activin receptor type-1B	Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathway	Activin receptor type-1B	Homo sapiens (human)
positive regulation of gene expression	Activin receptor type-1B	Homo sapiens (human)
negative regulation of gene expression	Activin receptor type-1B	Homo sapiens (human)
peptidyl-threonine phosphorylation	Activin receptor type-1B	Homo sapiens (human)
negative regulation of cell growth	Activin receptor type-1B	Homo sapiens (human)
activin receptor signaling pathway	Activin receptor type-1B	Homo sapiens (human)
positive regulation of activin receptor signaling pathway	Activin receptor type-1B	Homo sapiens (human)
nodal signaling pathway	Activin receptor type-1B	Homo sapiens (human)
positive regulation of erythrocyte differentiation	Activin receptor type-1B	Homo sapiens (human)
protein autophosphorylation	Activin receptor type-1B	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Activin receptor type-1B	Homo sapiens (human)
positive regulation of trophoblast cell migration	Activin receptor type-1B	Homo sapiens (human)
cellular response to growth factor stimulus	Activin receptor type-1B	Homo sapiens (human)
protein phosphorylation	Activin receptor type-1B	Homo sapiens (human)
nervous system development	Activin receptor type-1B	Homo sapiens (human)
proepicardium development	TGF-beta receptor type-1	Homo sapiens (human)
negative regulation of cell migration	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of extracellular matrix assembly	TGF-beta receptor type-1	Homo sapiens (human)
skeletal system development	TGF-beta receptor type-1	Homo sapiens (human)
in utero embryonic development	TGF-beta receptor type-1	Homo sapiens (human)
kidney development	TGF-beta receptor type-1	Homo sapiens (human)
blastocyst development	TGF-beta receptor type-1	Homo sapiens (human)
epithelial to mesenchymal transition	TGF-beta receptor type-1	Homo sapiens (human)
endothelial cell proliferation	TGF-beta receptor type-1	Homo sapiens (human)
negative regulation of endothelial cell proliferation	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of endothelial cell proliferation	TGF-beta receptor type-1	Homo sapiens (human)
lens development in camera-type eye	TGF-beta receptor type-1	Homo sapiens (human)
ventricular trabecula myocardium morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
ventricular compact myocardium morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
regulation of DNA-templated transcription	TGF-beta receptor type-1	Homo sapiens (human)
apoptotic process	TGF-beta receptor type-1	Homo sapiens (human)
signal transduction	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	TGF-beta receptor type-1	Homo sapiens (human)
heart development	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of cell population proliferation	TGF-beta receptor type-1	Homo sapiens (human)
germ cell migration	TGF-beta receptor type-1	Homo sapiens (human)
male gonad development	TGF-beta receptor type-1	Homo sapiens (human)
post-embryonic development	TGF-beta receptor type-1	Homo sapiens (human)
anterior/posterior pattern specification	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of gene expression	TGF-beta receptor type-1	Homo sapiens (human)
regulation of epithelial to mesenchymal transition	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	TGF-beta receptor type-1	Homo sapiens (human)
peptidyl-serine phosphorylation	TGF-beta receptor type-1	Homo sapiens (human)
collagen fibril organization	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of cell growth	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of cell migration	TGF-beta receptor type-1	Homo sapiens (human)
regulation of protein ubiquitination	TGF-beta receptor type-1	Homo sapiens (human)
negative regulation of chondrocyte differentiation	TGF-beta receptor type-1	Homo sapiens (human)
activin receptor signaling pathway	TGF-beta receptor type-1	Homo sapiens (human)
intracellular signal transduction	TGF-beta receptor type-1	Homo sapiens (human)
myofibroblast differentiation	TGF-beta receptor type-1	Homo sapiens (human)
wound healing	TGF-beta receptor type-1	Homo sapiens (human)
endothelial cell activation	TGF-beta receptor type-1	Homo sapiens (human)
extracellular structure organization	TGF-beta receptor type-1	Homo sapiens (human)
endothelial cell migration	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of DNA-templated transcription	TGF-beta receptor type-1	Homo sapiens (human)
filopodium assembly	TGF-beta receptor type-1	Homo sapiens (human)
thymus development	TGF-beta receptor type-1	Homo sapiens (human)
neuron fate commitment	TGF-beta receptor type-1	Homo sapiens (human)
embryonic cranial skeleton morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
skeletal system morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
mesenchymal cell differentiation	TGF-beta receptor type-1	Homo sapiens (human)
artery morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
cell motility	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of filopodium assembly	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of stress fiber assembly	TGF-beta receptor type-1	Homo sapiens (human)
regulation of cell cycle	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	TGF-beta receptor type-1	Homo sapiens (human)
parathyroid gland development	TGF-beta receptor type-1	Homo sapiens (human)
roof of mouth development	TGF-beta receptor type-1	Homo sapiens (human)
pharyngeal system development	TGF-beta receptor type-1	Homo sapiens (human)
regulation of cardiac muscle cell proliferation	TGF-beta receptor type-1	Homo sapiens (human)
cardiac epithelial to mesenchymal transition	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	TGF-beta receptor type-1	Homo sapiens (human)
ventricular septum morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
coronary artery morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
response to cholesterol	TGF-beta receptor type-1	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferation	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of vasculature development	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of tight junction disassembly	TGF-beta receptor type-1	Homo sapiens (human)
epicardium morphogenesis	TGF-beta receptor type-1	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	TGF-beta receptor type-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	TGF-beta receptor type-1	Homo sapiens (human)
protein phosphorylation	TGF-beta receptor type-1	Homo sapiens (human)
cellular response to growth factor stimulus	TGF-beta receptor type-1	Homo sapiens (human)
nervous system development	TGF-beta receptor type-1	Homo sapiens (human)
cell proliferation involved in endocardial cushion morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
superior endocardial cushion morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
blood vessel development	TGF-beta receptor type-2	Homo sapiens (human)
branching involved in blood vessel morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
vasculogenesis	TGF-beta receptor type-2	Homo sapiens (human)
in utero embryonic development	TGF-beta receptor type-2	Homo sapiens (human)
epithelial to mesenchymal transition	TGF-beta receptor type-2	Homo sapiens (human)
heart looping	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of mesenchymal cell proliferation	TGF-beta receptor type-2	Homo sapiens (human)
lens development in camera-type eye	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of tolerance induction to self antigen	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of B cell tolerance induction	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of T cell tolerance induction	TGF-beta receptor type-2	Homo sapiens (human)
outflow tract septum morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
membranous septum morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
outflow tract morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
aortic valve morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
atrioventricular valve morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
tricuspid valve morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
cardiac left ventricle morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
endocardial cushion fusion	TGF-beta receptor type-2	Homo sapiens (human)
growth plate cartilage chondrocyte growth	TGF-beta receptor type-2	Homo sapiens (human)
apoptotic process	TGF-beta receptor type-2	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	TGF-beta receptor type-2	Homo sapiens (human)
Notch signaling pathway	TGF-beta receptor type-2	Homo sapiens (human)
smoothened signaling pathway	TGF-beta receptor type-2	Homo sapiens (human)
gastrulation	TGF-beta receptor type-2	Homo sapiens (human)
brain development	TGF-beta receptor type-2	Homo sapiens (human)
heart development	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of cell population proliferation	TGF-beta receptor type-2	Homo sapiens (human)
response to xenobiotic stimulus	TGF-beta receptor type-2	Homo sapiens (human)
regulation of gene expression	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of epithelial cell migration	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	TGF-beta receptor type-2	Homo sapiens (human)
activation of protein kinase activity	TGF-beta receptor type-2	Homo sapiens (human)
activin receptor signaling pathway	TGF-beta receptor type-2	Homo sapiens (human)
embryonic hemopoiesis	TGF-beta receptor type-2	Homo sapiens (human)
aorta morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
regulation of cell population proliferation	TGF-beta receptor type-2	Homo sapiens (human)
myeloid dendritic cell differentiation	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of angiogenesis	TGF-beta receptor type-2	Homo sapiens (human)
embryonic cranial skeleton morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
artery morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of NK T cell differentiation	TGF-beta receptor type-2	Homo sapiens (human)
roof of mouth development	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	TGF-beta receptor type-2	Homo sapiens (human)
SMAD protein signal transduction	TGF-beta receptor type-2	Homo sapiens (human)
ventricular septum morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
bronchus morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
trachea formation	TGF-beta receptor type-2	Homo sapiens (human)
mammary gland morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
lung lobe morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
Langerhans cell differentiation	TGF-beta receptor type-2	Homo sapiens (human)
secondary palate development	TGF-beta receptor type-2	Homo sapiens (human)
response to cholesterol	TGF-beta receptor type-2	Homo sapiens (human)
regulation of stem cell proliferation	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation	TGF-beta receptor type-2	Homo sapiens (human)
inferior endocardial cushion morphogenesis	TGF-beta receptor type-2	Homo sapiens (human)
lens fiber cell apoptotic process	TGF-beta receptor type-2	Homo sapiens (human)
miRNA transport	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	TGF-beta receptor type-2	Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferation	TGF-beta receptor type-2	Homo sapiens (human)
regulation of stem cell differentiation	TGF-beta receptor type-2	Homo sapiens (human)
cellular response to growth factor stimulus	TGF-beta receptor type-2	Homo sapiens (human)
protein phosphorylation	TGF-beta receptor type-2	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase CSK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of low-density lipoprotein particle clearance	Tyrosine-protein kinase CSK	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of interleukin-6 production	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of Golgi to plasma membrane protein transport	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of bone resorption	Tyrosine-protein kinase CSK	Homo sapiens (human)
oligodendrocyte differentiation	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of phagocytosis	Tyrosine-protein kinase CSK	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase CSK	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase CSK	Homo sapiens (human)
cellular response to peptide hormone stimulus	Tyrosine-protein kinase CSK	Homo sapiens (human)
regulation of Fc receptor mediated stimulatory signaling pathway	Tyrosine-protein kinase CSK	Homo sapiens (human)
adherens junction organization	Tyrosine-protein kinase CSK	Homo sapiens (human)
tRNA aminoacylation for protein translation	Glycine--tRNA ligase	Homo sapiens (human)
diadenosine tetraphosphate biosynthetic process	Glycine--tRNA ligase	Homo sapiens (human)
mitochondrial glycyl-tRNA aminoacylation	Glycine--tRNA ligase	Homo sapiens (human)
protein phosphorylation	Protein kinase C iota type	Homo sapiens (human)
protein targeting to membrane	Protein kinase C iota type	Homo sapiens (human)
cytoskeleton organization	Protein kinase C iota type	Homo sapiens (human)
actin filament organization	Protein kinase C iota type	Homo sapiens (human)
positive regulation of neuron projection development	Protein kinase C iota type	Homo sapiens (human)
vesicle-mediated transport	Protein kinase C iota type	Homo sapiens (human)
cell migration	Protein kinase C iota type	Homo sapiens (human)
cellular response to insulin stimulus	Protein kinase C iota type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C iota type	Homo sapiens (human)
establishment of apical/basal cell polarity	Protein kinase C iota type	Homo sapiens (human)
eye photoreceptor cell development	Protein kinase C iota type	Homo sapiens (human)
negative regulation of apoptotic process	Protein kinase C iota type	Homo sapiens (human)
negative regulation of neuron apoptotic process	Protein kinase C iota type	Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarity	Protein kinase C iota type	Homo sapiens (human)
cell-cell junction organization	Protein kinase C iota type	Homo sapiens (human)
positive regulation of Notch signaling pathway	Protein kinase C iota type	Homo sapiens (human)
positive regulation of glucose import	Protein kinase C iota type	Homo sapiens (human)
secretion	Protein kinase C iota type	Homo sapiens (human)
Golgi vesicle budding	Protein kinase C iota type	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Protein kinase C iota type	Homo sapiens (human)
positive regulation of glial cell proliferation	Protein kinase C iota type	Homo sapiens (human)
membrane organization	Protein kinase C iota type	Homo sapiens (human)
cellular response to chemical stress	Protein kinase C iota type	Homo sapiens (human)
response to interleukin-1	Protein kinase C iota type	Homo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levels	Protein kinase C iota type	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Protein kinase C iota type	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	Protein kinase C iota type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C iota type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C iota type	Homo sapiens (human)
mRNA splicing, via spliceosome	Exosome RNA helicase MTR4	Homo sapiens (human)
maturation of 5.8S rRNA	Exosome RNA helicase MTR4	Homo sapiens (human)
rRNA processing	Exosome RNA helicase MTR4	Homo sapiens (human)
RNA catabolic process	Exosome RNA helicase MTR4	Homo sapiens (human)
DNA damage response	Exosome RNA helicase MTR4	Homo sapiens (human)
snRNA catabolic process	Exosome RNA helicase MTR4	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Tec	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase Tec	Homo sapiens (human)
regulation of platelet activation	Tyrosine-protein kinase Tec	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Tec	Homo sapiens (human)
tissue regeneration	Tyrosine-protein kinase Tec	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase Tec	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase Tec	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase Tec	Homo sapiens (human)
positive regulation of cytokine production	Tyrosine-protein kinase TXK	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase TXK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase TXK	Homo sapiens (human)
activation of phospholipase C activity	Tyrosine-protein kinase TXK	Homo sapiens (human)
regulation of gene expression	Tyrosine-protein kinase TXK	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase TXK	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase TXK	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase TXK	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase TXK	Homo sapiens (human)
positive regulation of type II interferon-mediated signaling pathway	Tyrosine-protein kinase TXK	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase ABL2	Homo sapiens (human)
positive regulation of phospholipase C activity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
negative regulation of Rho protein signal transduction	Tyrosine-protein kinase ABL2	Homo sapiens (human)
exploration behavior	Tyrosine-protein kinase ABL2	Homo sapiens (human)
cell adhesion	Tyrosine-protein kinase ABL2	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase ABL2	Homo sapiens (human)
regulation of autophagy	Tyrosine-protein kinase ABL2	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase ABL2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ABL2	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein kinase ABL2	Homo sapiens (human)
regulation of cell adhesion	Tyrosine-protein kinase ABL2	Homo sapiens (human)
regulation of actin cytoskeleton organization	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein modification process	Tyrosine-protein kinase ABL2	Homo sapiens (human)
positive regulation of oxidoreductase activity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
cellular response to retinoic acid	Tyrosine-protein kinase ABL2	Homo sapiens (human)
positive regulation of establishment of T cell polarity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
regulation of cell motility	Tyrosine-protein kinase ABL2	Homo sapiens (human)
positive regulation of T cell migration	Tyrosine-protein kinase ABL2	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ABL2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tyrosine-protein kinase FRK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase FRK	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase FRK	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase FRK	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase FRK	Homo sapiens (human)
G protein-coupled receptor signaling pathway	G protein-coupled receptor kinase 6	Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathway	G protein-coupled receptor kinase 6	Homo sapiens (human)
Wnt signaling pathway	G protein-coupled receptor kinase 6	Homo sapiens (human)
regulation of signal transduction	G protein-coupled receptor kinase 6	Homo sapiens (human)
protein phosphorylation	G protein-coupled receptor kinase 6	Homo sapiens (human)
protein import into nucleus	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
angiogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
lymph vessel development	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of receptor internalization	Tyrosine-protein kinase SYK	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
macrophage activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
neutrophil activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukocyte activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
serotonin secretion by platelet	Tyrosine-protein kinase SYK	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukocyte cell-cell adhesion	Tyrosine-protein kinase SYK	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
animal organ morphogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of platelet activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukotriene biosynthetic process	Tyrosine-protein kinase SYK	Homo sapiens (human)
calcium-mediated signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
platelet activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
neutrophil chemotaxis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Tyrosine-protein kinase SYK	Homo sapiens (human)
receptor internalization	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of type I interferon production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-10 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-12 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-3 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-4 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-6 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-8 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of mast cell cytokine production	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of superoxide anion generation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of superoxide anion generation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Tyrosine-protein kinase SYK	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase SYK	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase SYK	Homo sapiens (human)
interleukin-3-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
gamma-delta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
defense response to bacterium	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase SYK	Homo sapiens (human)
mast cell degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of mast cell degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of neutrophil degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
beta selection	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase SYK	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of B cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of gamma-delta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of bone resorption	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of alpha-beta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of alpha-beta T cell proliferation	Tyrosine-protein kinase SYK	Homo sapiens (human)
blood vessel morphogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of phagocytosis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of killing of cells of another organism	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to molecule of fungal origin	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to lipid	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of arachidonic acid secretion	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of platelet aggregation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of TORC1 signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to lectin	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
blastocyst development	26S proteasome regulatory subunit 6B	Homo sapiens (human)
proteolysis	26S proteasome regulatory subunit 6B	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	26S proteasome regulatory subunit 6B	Homo sapiens (human)
positive regulation of proteasomal protein catabolic process	26S proteasome regulatory subunit 6B	Homo sapiens (human)
JUN phosphorylation	Mitogen-activated protein kinase 8	Homo sapiens (human)
response to UV	Mitogen-activated protein kinase 8	Homo sapiens (human)
negative regulation of apoptotic process	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to lipopolysaccharide	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase 8	Homo sapiens (human)
response to oxidative stress	Mitogen-activated protein kinase 8	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase 8	Homo sapiens (human)
JUN phosphorylation	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of gene expression	Mitogen-activated protein kinase 8	Homo sapiens (human)
regulation of macroautophagy	Mitogen-activated protein kinase 8	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase 8	Homo sapiens (human)
peptidyl-threonine phosphorylation	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of cyclase activity	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of cell killing	Mitogen-activated protein kinase 8	Homo sapiens (human)
negative regulation of protein binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
regulation of protein localization	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to amino acid starvation	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to oxidative stress	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to reactive oxygen species	Mitogen-activated protein kinase 8	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Mitogen-activated protein kinase 8	Homo sapiens (human)
regulation of circadian rhythm	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of apoptotic process	Mitogen-activated protein kinase 8	Homo sapiens (human)
negative regulation of apoptotic process	Mitogen-activated protein kinase 8	Homo sapiens (human)
rhythmic process	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of protein metabolic process	Mitogen-activated protein kinase 8	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to mechanical stimulus	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular response to cadmium ion	Mitogen-activated protein kinase 8	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase 8	Homo sapiens (human)
energy homeostasis	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	Mitogen-activated protein kinase 8	Homo sapiens (human)
response to mechanical stimulus	Mitogen-activated protein kinase 8	Homo sapiens (human)
positive regulation of establishment of protein localization to mitochondrion	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase 9	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of gene expression	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of protein ubiquitination	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Mitogen-activated protein kinase 9	Homo sapiens (human)
cellular response to reactive oxygen species	Mitogen-activated protein kinase 9	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Mitogen-activated protein kinase 9	Homo sapiens (human)
regulation of circadian rhythm	Mitogen-activated protein kinase 9	Homo sapiens (human)
rhythmic process	Mitogen-activated protein kinase 9	Homo sapiens (human)
modulation of chemical synaptic transmission	Mitogen-activated protein kinase 9	Homo sapiens (human)
protein localization to tricellular tight junction	Mitogen-activated protein kinase 9	Homo sapiens (human)
cellular response to cadmium ion	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of podosome assembly	Mitogen-activated protein kinase 9	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase 9	Homo sapiens (human)
inflammatory response to wounding	Mitogen-activated protein kinase 9	Homo sapiens (human)
apoptotic signaling pathway	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Mitogen-activated protein kinase 9	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Mitogen-activated protein kinase 9	Homo sapiens (human)
regulation of cytokine production	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
response to ischemia	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
inflammatory response	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
heart development	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
negative regulation of hippo signaling	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
p38MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
positive regulation of MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
positive regulation of protein kinase activity	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cardiac muscle contraction	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cellular response to lipopolysaccharide	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cellular response to sorbitol	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
regulation of autophagy	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
megakaryocyte development	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
autophagosome-lysosome fusion	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
vesicle-mediated cholesterol transport	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
positive regulation of autophagosome assembly	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
microtubule nucleation	Casein kinase I isoform delta	Homo sapiens (human)
Golgi organization	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to Golgi apparatus	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to cilium	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to centrosome	Casein kinase I isoform delta	Homo sapiens (human)
non-motile cilium assembly	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of protein phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase I isoform delta	Homo sapiens (human)
circadian regulation of gene expression	Casein kinase I isoform delta	Homo sapiens (human)
regulation of circadian rhythm	Casein kinase I isoform delta	Homo sapiens (human)
COPII vesicle coating	Casein kinase I isoform delta	Homo sapiens (human)
spindle assembly	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
midbrain dopaminergic neuron differentiation	Casein kinase I isoform delta	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of non-canonical Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
signal transduction	Casein kinase I isoform delta	Homo sapiens (human)
non-motile cilium assembly	Casein kinase I isoform delta	Homo sapiens (human)
endocytosis	Casein kinase I isoform delta	Homo sapiens (human)
MAPK cascade	MAP kinase-activated protein kinase 2	Homo sapiens (human)
toll-like receptor signaling pathway	MAP kinase-activated protein kinase 2	Homo sapiens (human)
protein phosphorylation	MAP kinase-activated protein kinase 2	Homo sapiens (human)
leukotriene metabolic process	MAP kinase-activated protein kinase 2	Homo sapiens (human)
inflammatory response	MAP kinase-activated protein kinase 2	Homo sapiens (human)
DNA damage response	MAP kinase-activated protein kinase 2	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	MAP kinase-activated protein kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	MAP kinase-activated protein kinase 2	Homo sapiens (human)
response to lipopolysaccharide	MAP kinase-activated protein kinase 2	Homo sapiens (human)
regulation of interleukin-6 production	MAP kinase-activated protein kinase 2	Homo sapiens (human)
regulation of tumor necrosis factor production	MAP kinase-activated protein kinase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	MAP kinase-activated protein kinase 2	Homo sapiens (human)
response to cytokine	MAP kinase-activated protein kinase 2	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	MAP kinase-activated protein kinase 2	Homo sapiens (human)
p38MAPK cascade	MAP kinase-activated protein kinase 2	Homo sapiens (human)
regulation of mRNA stability	MAP kinase-activated protein kinase 2	Homo sapiens (human)
macropinocytosis	MAP kinase-activated protein kinase 2	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	MAP kinase-activated protein kinase 2	Homo sapiens (human)
inner ear development	MAP kinase-activated protein kinase 2	Homo sapiens (human)
positive regulation of macrophage cytokine production	MAP kinase-activated protein kinase 2	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	MAP kinase-activated protein kinase 2	Homo sapiens (human)
regulation of cellular response to heat	MAP kinase-activated protein kinase 2	Homo sapiens (human)
protein autophosphorylation	MAP kinase-activated protein kinase 2	Homo sapiens (human)
intracellular signal transduction	MAP kinase-activated protein kinase 2	Homo sapiens (human)
translational elongation	Elongation factor Tu, mitochondrial	Homo sapiens (human)
response to ethanol	Elongation factor Tu, mitochondrial	Homo sapiens (human)
mitochondrial translational elongation	Elongation factor Tu, mitochondrial	Homo sapiens (human)
phosphatidylcholine biosynthetic process	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
CDP-choline pathway	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
DNA repair	Casein kinase I isoform epsilon	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform epsilon	Homo sapiens (human)
protein localization	Casein kinase I isoform epsilon	Homo sapiens (human)
negative regulation of Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
negative regulation of protein binding	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase I isoform epsilon	Homo sapiens (human)
regulation of protein localization	Casein kinase I isoform epsilon	Homo sapiens (human)
circadian regulation of gene expression	Casein kinase I isoform epsilon	Homo sapiens (human)
regulation of circadian rhythm	Casein kinase I isoform epsilon	Homo sapiens (human)
circadian behavior	Casein kinase I isoform epsilon	Homo sapiens (human)
canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of amyloid-beta formation	Casein kinase I isoform epsilon	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of non-canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform epsilon	Homo sapiens (human)
endocytosis	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
signal transduction	Casein kinase I isoform epsilon	Homo sapiens (human)
temperature homeostasis	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
response to cold	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
energy derivation by oxidation of organic compounds	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
epithelial cell differentiation	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenase	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
negative regulation of fatty acid biosynthetic process	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
negative regulation of fatty acid oxidation	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
regulation of cholesterol metabolic process	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
regulation of RNA splicing	Dual specificity protein kinase CLK1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein phosphorylation	Dual specificity protein kinase CLK2	Homo sapiens (human)
response to ionizing radiation	Dual specificity protein kinase CLK2	Homo sapiens (human)
regulation of RNA splicing	Dual specificity protein kinase CLK2	Homo sapiens (human)
negative regulation of gluconeogenesis	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein autophosphorylation	Dual specificity protein kinase CLK2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity protein kinase CLK2	Homo sapiens (human)
regulation of systemic arterial blood pressure	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cardiac left ventricle morphogenesis	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nervous system development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of UDP-glucose catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell migration	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to insulin stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of heart contraction	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glucose import	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to lithium ion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
autosome genomic imprinting	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of mitophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of amyloid-beta formation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphate	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ER overload response	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of apoptotic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
epithelial to mesenchymal transition	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 beta	Homo sapiens (human)
hippocampus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
establishment of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
maintenance of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of cell migration	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axon extension	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of phosphoprotein phosphatase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule-based process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of GTPase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of osteoblast differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cilium assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein autophosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of dendrite morphogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axonogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Glycogen synthase kinase-3 beta	Homo sapiens (human)
superior temporal gyrus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to retinoic acid	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule anchoring at centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of cellular response to heat	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein localization to nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of long-term synaptic potentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein acetylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to cilium	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of dopaminergic neuron differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to amyloid-beta	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex disassembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of mesenchymal stem cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	Cyclin-dependent kinase 7	Homo sapiens (human)
snRNA transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 7	Homo sapiens (human)
protein stabilization	Cyclin-dependent kinase 7	Homo sapiens (human)
cell division	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 7	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 7	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 9	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 9	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of DNA repair	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription initiation at RNA polymerase II promoter	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
cell population proliferation	Cyclin-dependent kinase 9	Homo sapiens (human)
replication fork processing	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of mRNA 3'-end processing	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation by host of viral transcription	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of muscle cell differentiation	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleus localization	Cyclin-dependent kinase 9	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 9	Homo sapiens (human)
cellular response to cytokine stimulus	Cyclin-dependent kinase 9	Homo sapiens (human)
negative regulation of protein localization to chromatin	Cyclin-dependent kinase 9	Homo sapiens (human)
positive regulation of protein localization to chromatin	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation-coupled chromatin remodeling	Cyclin-dependent kinase 9	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 9	Homo sapiens (human)
exocytosis	Ras-related protein Rab-27A	Homo sapiens (human)
blood coagulation	Ras-related protein Rab-27A	Homo sapiens (human)
protein secretion	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of gene expression	Ras-related protein Rab-27A	Homo sapiens (human)
antigen processing and presentation	Ras-related protein Rab-27A	Homo sapiens (human)
melanocyte differentiation	Ras-related protein Rab-27A	Homo sapiens (human)
melanosome localization	Ras-related protein Rab-27A	Homo sapiens (human)
melanosome transport	Ras-related protein Rab-27A	Homo sapiens (human)
multivesicular body organization	Ras-related protein Rab-27A	Homo sapiens (human)
cytotoxic T cell degranulation	Ras-related protein Rab-27A	Homo sapiens (human)
natural killer cell degranulation	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of exocytosis	Ras-related protein Rab-27A	Homo sapiens (human)
synaptic vesicle transport	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of phagocytosis	Ras-related protein Rab-27A	Homo sapiens (human)
multivesicular body sorting pathway	Ras-related protein Rab-27A	Homo sapiens (human)
complement-dependent cytotoxicity	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of regulated secretory pathway	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic process	Ras-related protein Rab-27A	Homo sapiens (human)
positive regulation of constitutive secretory pathway	Ras-related protein Rab-27A	Homo sapiens (human)
exosomal secretion	Ras-related protein Rab-27A	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Blk	Homo sapiens (human)
positive regulation of insulin secretion	Tyrosine-protein kinase Blk	Homo sapiens (human)
positive regulation of protein binding	Tyrosine-protein kinase Blk	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Blk	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase Blk	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Blk	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Blk	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Blk	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Blk	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein autophosphorylation	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
regulation of cytokine-mediated signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
JNK cascade	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of type I interferon production	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
response to lipopolysaccharide	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
toll-like receptor 2 signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
toll-like receptor 9 signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
cellular response to heat	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
interleukin-33-mediated signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein autophosphorylation	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
response to interleukin-1	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
cellular response to hypoxia	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
positive regulation of MAP kinase activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
cellular response to lipopolysaccharide	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
intracellular signal transduction	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
Toll signaling pathway	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
innate immune response	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
skeletal system development	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
toll-like receptor signaling pathway	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
chemical synaptic transmission	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
central nervous system development	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
positive regulation of cell growth	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
response to lipopolysaccharide	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
intracellular signal transduction	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
negative regulation of apoptotic process	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
regulation of translation in response to stress	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
positive regulation of cell differentiation	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein phosphorylation	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
phosphatidylinositol biosynthetic process	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
apoptotic process	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
cell adhesion	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
signal transduction	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
mesoderm development	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
intracellular signal transduction	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
protein autophosphorylation	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
B cell receptor signaling pathway	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
adaptive immune response	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
angiogenesis	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
endothelial cell proliferation	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
cell adhesion	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
peptidyl-serine phosphorylation	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
myeloid cell differentiation	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
regulation of cell adhesion	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
regulation of cell migration	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
cell-substrate adhesion	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
endothelial cell migration	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
protein autophosphorylation	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
epithelial tube morphogenesis	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
kidney morphogenesis	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
regulation of epithelial cell differentiation involved in kidney development	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
blastocyst development	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
chromosome segregation	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
regulation of mitotic nuclear division	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
regulation of mitotic centrosome separation	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
spindle assembly	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
centrosome separation	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
cell division	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
meiotic cell cycle	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
positive regulation of telomerase activity	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
regulation of attachment of spindle microtubules to kinetochore	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
mitotic spindle assembly	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
negative regulation of centriole-centriole cohesion	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
positive regulation of telomere capping	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
establishment of cell polarity	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
neuron projection morphogenesis	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
cell division	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
regulation of tubulin deacetylation	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of dendritic cell cytokine production	Tyrosine-protein kinase JAK3	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK3	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
B cell differentiation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of interleukin-10 production	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of interleukin-12 production	Tyrosine-protein kinase JAK3	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase JAK3	Homo sapiens (human)
interleukin-15-mediated signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
interleukin-4-mediated signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
interleukin-2-mediated signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
interleukin-9-mediated signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
T cell homeostasis	Tyrosine-protein kinase JAK3	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of FasL production	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of T-helper 1 cell differentiation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of T cell activation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK3	Homo sapiens (human)
regulation of T cell apoptotic process	Tyrosine-protein kinase JAK3	Homo sapiens (human)
negative regulation of thymocyte apoptotic process	Tyrosine-protein kinase JAK3	Homo sapiens (human)
response to interleukin-2	Tyrosine-protein kinase JAK3	Homo sapiens (human)
response to interleukin-4	Tyrosine-protein kinase JAK3	Homo sapiens (human)
response to interleukin-15	Tyrosine-protein kinase JAK3	Homo sapiens (human)
response to interleukin-9	Tyrosine-protein kinase JAK3	Homo sapiens (human)
regulation of apoptotic process	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase JAK3	Homo sapiens (human)
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
osteoblast differentiation	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of protein phosphorylation	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
response to ischemia	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
apoptotic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
response to xenobiotic stimulus	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
ovulation cycle process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of prostaglandin secretion	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
p38MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
signal transduction in response to DNA damage	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of apoptotic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
regulation of cell cycle	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cardiac muscle contraction	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
bone development	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cellular response to sorbitol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
establishment of protein localization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic sister chromatid segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
establishment of mitotic spindle orientation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule bundle formation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
sister chromatid cohesion	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic chromosome condensation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
female meiosis chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein ubiquitination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic metaphase/anaphase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein destabilization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
homologous chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteolysis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
Golgi inheritance	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to nuclear envelope	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joining	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic spindle assembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin protein ligase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein localization to cell cortex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein phosphorylation	LIM domain kinase 1	Homo sapiens (human)
signal transduction	LIM domain kinase 1	Homo sapiens (human)
Rho protein signal transduction	LIM domain kinase 1	Homo sapiens (human)
nervous system development	LIM domain kinase 1	Homo sapiens (human)
positive regulation of actin filament bundle assembly	LIM domain kinase 1	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	LIM domain kinase 1	Homo sapiens (human)
stress fiber assembly	LIM domain kinase 1	Homo sapiens (human)
positive regulation of axon extension	LIM domain kinase 1	Homo sapiens (human)
axon extension	LIM domain kinase 1	Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activity	LIM domain kinase 1	Homo sapiens (human)
positive regulation of stress fiber assembly	LIM domain kinase 1	Homo sapiens (human)
actin cytoskeleton organization	LIM domain kinase 1	Homo sapiens (human)
positive regulation of protein phosphorylation	LIM domain kinase 2	Homo sapiens (human)
protein phosphorylation	LIM domain kinase 2	Homo sapiens (human)
spermatogenesis	LIM domain kinase 2	Homo sapiens (human)
phosphorylation	LIM domain kinase 2	Homo sapiens (human)
astral microtubule organization	LIM domain kinase 2	Homo sapiens (human)
establishment of vesicle localization	LIM domain kinase 2	Homo sapiens (human)
head development	LIM domain kinase 2	Homo sapiens (human)
cornea development in camera-type eye	LIM domain kinase 2	Homo sapiens (human)
positive regulation of protein localization to nucleus	LIM domain kinase 2	Homo sapiens (human)
negative regulation of cilium assembly	LIM domain kinase 2	Homo sapiens (human)
actin cytoskeleton organization	LIM domain kinase 2	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase 10	Homo sapiens (human)
signal transduction	Mitogen-activated protein kinase 10	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase 10	Homo sapiens (human)
response to light stimulus	Mitogen-activated protein kinase 10	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Mitogen-activated protein kinase 10	Homo sapiens (human)
regulation of circadian rhythm	Mitogen-activated protein kinase 10	Homo sapiens (human)
rhythmic process	Mitogen-activated protein kinase 10	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase 10	Homo sapiens (human)
tyrosyl-tRNA aminoacylation	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
apoptotic process	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
response to starvation	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
regulation of glycolytic process	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
protein phosphorylation	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
fatty acid biosynthetic process	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
signal transduction	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
spermatogenesis	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
positive regulation of gene expression	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
cellular response to nutrient levels	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
positive regulation of protein kinase activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
import into nucleus	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
regulation of catalytic activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
angiogenesis	Ephrin type-B receptor 3	Homo sapiens (human)
urogenital system development	Ephrin type-B receptor 3	Homo sapiens (human)
axon guidance	Ephrin type-B receptor 3	Homo sapiens (human)
axonal fasciculation	Ephrin type-B receptor 3	Homo sapiens (human)
cell migration	Ephrin type-B receptor 3	Homo sapiens (human)
central nervous system projection neuron axonogenesis	Ephrin type-B receptor 3	Homo sapiens (human)
corpus callosum development	Ephrin type-B receptor 3	Homo sapiens (human)
regulation of cell-cell adhesion	Ephrin type-B receptor 3	Homo sapiens (human)
retinal ganglion cell axon guidance	Ephrin type-B receptor 3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Ephrin type-B receptor 3	Homo sapiens (human)
regulation of GTPase activity	Ephrin type-B receptor 3	Homo sapiens (human)
protein autophosphorylation	Ephrin type-B receptor 3	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 3	Homo sapiens (human)
thymus development	Ephrin type-B receptor 3	Homo sapiens (human)
digestive tract morphogenesis	Ephrin type-B receptor 3	Homo sapiens (human)
regulation of axonogenesis	Ephrin type-B receptor 3	Homo sapiens (human)
positive regulation of synapse assembly	Ephrin type-B receptor 3	Homo sapiens (human)
roof of mouth development	Ephrin type-B receptor 3	Homo sapiens (human)
dendritic spine development	Ephrin type-B receptor 3	Homo sapiens (human)
dendritic spine morphogenesis	Ephrin type-B receptor 3	Homo sapiens (human)
protein phosphorylation	Ephrin type-B receptor 3	Homo sapiens (human)
axon guidance	Ephrin type-A receptor 5	Homo sapiens (human)
cAMP-mediated signaling	Ephrin type-A receptor 5	Homo sapiens (human)
hippocampus development	Ephrin type-A receptor 5	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Ephrin type-A receptor 5	Homo sapiens (human)
regulation of actin cytoskeleton organization	Ephrin type-A receptor 5	Homo sapiens (human)
regulation of GTPase activity	Ephrin type-A receptor 5	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-A receptor 5	Homo sapiens (human)
neuron development	Ephrin type-A receptor 5	Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulus	Ephrin type-A receptor 5	Homo sapiens (human)
protein phosphorylation	Ephrin type-A receptor 5	Homo sapiens (human)
angiogenesis	Ephrin type-B receptor 4	Homo sapiens (human)
cell migration involved in sprouting angiogenesis	Ephrin type-B receptor 4	Homo sapiens (human)
heart morphogenesis	Ephrin type-B receptor 4	Homo sapiens (human)
cell adhesion	Ephrin type-B receptor 4	Homo sapiens (human)
protein autophosphorylation	Ephrin type-B receptor 4	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 4	Homo sapiens (human)
multicellular organism development	Ephrin type-B receptor 4	Homo sapiens (human)
positive regulation of kinase activity	Ephrin type-B receptor 4	Homo sapiens (human)
negative regulation of cellular response to hypoxia	Ephrin type-A receptor 4	Homo sapiens (human)
cell adhesion	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of cell adhesion	Ephrin type-A receptor 4	Homo sapiens (human)
adult walking behavior	Ephrin type-A receptor 4	Homo sapiens (human)
motor neuron axon guidance	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of cell population proliferation	Ephrin type-A receptor 4	Homo sapiens (human)
glial cell migration	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of epithelial to mesenchymal transition	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of neuron projection development	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of translation	Ephrin type-A receptor 4	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Ephrin type-A receptor 4	Homo sapiens (human)
corticospinal tract morphogenesis	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of cell migration	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of cell migration	Ephrin type-A receptor 4	Homo sapiens (human)
adherens junction organization	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of GTPase activity	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of cell adhesion	Ephrin type-A receptor 4	Homo sapiens (human)
protein autophosphorylation	Ephrin type-A receptor 4	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of axon regeneration	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of astrocyte differentiation	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of axonogenesis	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of dendrite morphogenesis	Ephrin type-A receptor 4	Homo sapiens (human)
protein stabilization	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of dendritic spine morphogenesis	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of protein tyrosine kinase activity	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Ephrin type-A receptor 4	Homo sapiens (human)
nephric duct morphogenesis	Ephrin type-A receptor 4	Homo sapiens (human)
cochlea development	Ephrin type-A receptor 4	Homo sapiens (human)
fasciculation of sensory neuron axon	Ephrin type-A receptor 4	Homo sapiens (human)
fasciculation of motor neuron axon	Ephrin type-A receptor 4	Homo sapiens (human)
neuron projection guidance	Ephrin type-A receptor 4	Homo sapiens (human)
synapse pruning	Ephrin type-A receptor 4	Homo sapiens (human)
neuron projection fasciculation	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of amyloid-beta formation	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process	Ephrin type-A receptor 4	Homo sapiens (human)
negative regulation of proteolysis involved in protein catabolic process	Ephrin type-A receptor 4	Homo sapiens (human)
cellular response to amyloid-beta	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of modification of synaptic structure	Ephrin type-A receptor 4	Homo sapiens (human)
regulation of synapse pruning	Ephrin type-A receptor 4	Homo sapiens (human)
positive regulation of Rho guanyl-nucleotide exchange factor activity	Ephrin type-A receptor 4	Homo sapiens (human)
protein phosphorylation	Ephrin type-A receptor 4	Homo sapiens (human)
axon guidance	Ephrin type-A receptor 4	Homo sapiens (human)
ADP biosynthetic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
nucleobase-containing small molecule interconversion	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
AMP metabolic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
ATP metabolic process	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
nucleoside monophosphate phosphorylation	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
purine ribonucleoside salvage	Adenosine kinase	Homo sapiens (human)
dATP biosynthetic process	Adenosine kinase	Homo sapiens (human)
ribonucleoside monophosphate biosynthetic process	Adenosine kinase	Homo sapiens (human)
GMP salvage	Adenosine kinase	Homo sapiens (human)
AMP salvage	Adenosine kinase	Homo sapiens (human)
dAMP salvage	Adenosine kinase	Homo sapiens (human)
purine nucleobase metabolic process	Adenosine kinase	Homo sapiens (human)
Golgi to plasma membrane transport	Ras-related protein Rab-10	Homo sapiens (human)
axonogenesis	Ras-related protein Rab-10	Homo sapiens (human)
vesicle-mediated transport	Ras-related protein Rab-10	Homo sapiens (human)
endosomal transport	Ras-related protein Rab-10	Homo sapiens (human)
antigen processing and presentation	Ras-related protein Rab-10	Homo sapiens (human)
polarized epithelial cell differentiation	Ras-related protein Rab-10	Homo sapiens (human)
cellular response to insulin stimulus	Ras-related protein Rab-10	Homo sapiens (human)
Golgi to plasma membrane protein transport	Ras-related protein Rab-10	Homo sapiens (human)
regulated exocytosis	Ras-related protein Rab-10	Homo sapiens (human)
establishment of neuroblast polarity	Ras-related protein Rab-10	Homo sapiens (human)
endoplasmic reticulum tubular network organization	Ras-related protein Rab-10	Homo sapiens (human)
protein localization to plasma membrane	Ras-related protein Rab-10	Homo sapiens (human)
establishment of protein localization to membrane	Ras-related protein Rab-10	Homo sapiens (human)
establishment of protein localization to endoplasmic reticulum membrane	Ras-related protein Rab-10	Homo sapiens (human)
cell-cell adhesion	Ras-related protein Rab-10	Homo sapiens (human)
protein localization to basolateral plasma membrane	Ras-related protein Rab-10	Homo sapiens (human)
exocytosis	Ras-related protein Rab-10	Homo sapiens (human)
protein secretion	Ras-related protein Rab-10	Homo sapiens (human)
establishment or maintenance of cell polarity	Actin-related protein 3	Homo sapiens (human)
asymmetric cell division	Actin-related protein 3	Homo sapiens (human)
positive regulation of lamellipodium assembly	Actin-related protein 3	Homo sapiens (human)
meiotic chromosome movement towards spindle pole	Actin-related protein 3	Homo sapiens (human)
meiotic cytokinesis	Actin-related protein 3	Homo sapiens (human)
Arp2/3 complex-mediated actin nucleation	Actin-related protein 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Actin-related protein 3	Homo sapiens (human)
spindle localization	Actin-related protein 3	Homo sapiens (human)
cilium assembly	Actin-related protein 3	Homo sapiens (human)
actin polymerization-dependent cell motility	Actin-related protein 3	Homo sapiens (human)
cellular response to type II interferon	Actin-related protein 3	Homo sapiens (human)
regulation of double-strand break repair via nonhomologous end joining	Actin-related protein 2	Homo sapiens (human)
cilium assembly	Actin-related protein 2	Homo sapiens (human)
establishment or maintenance of cell polarity	Actin-related protein 2	Homo sapiens (human)
asymmetric cell division	Actin-related protein 2	Homo sapiens (human)
positive regulation of lamellipodium assembly	Actin-related protein 2	Homo sapiens (human)
meiotic chromosome movement towards spindle pole	Actin-related protein 2	Homo sapiens (human)
cytosolic transport	Actin-related protein 2	Homo sapiens (human)
meiotic cytokinesis	Actin-related protein 2	Homo sapiens (human)
Arp2/3 complex-mediated actin nucleation	Actin-related protein 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Actin-related protein 2	Homo sapiens (human)
spindle localization	Actin-related protein 2	Homo sapiens (human)
cellular response to type II interferon	Actin-related protein 2	Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombination	Actin-related protein 2	Homo sapiens (human)
ribosomal large subunit export from nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
ribosomal small subunit export from nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
mitotic sister chromatid segregation	GTP-binding nuclear protein Ran	Homo sapiens (human)
mitotic cell cycle	GTP-binding nuclear protein Ran	Homo sapiens (human)
DNA metabolic process	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein import into nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein export from nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
mitotic spindle organization	GTP-binding nuclear protein Ran	Homo sapiens (human)
spermatid development	GTP-binding nuclear protein Ran	Homo sapiens (human)
viral process	GTP-binding nuclear protein Ran	Homo sapiens (human)
hippocampus development	GTP-binding nuclear protein Ran	Homo sapiens (human)
actin cytoskeleton organization	GTP-binding nuclear protein Ran	Homo sapiens (human)
positive regulation of protein binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
pre-miRNA export from nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
positive regulation of protein import into nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
GTP metabolic process	GTP-binding nuclear protein Ran	Homo sapiens (human)
cell division	GTP-binding nuclear protein Ran	Homo sapiens (human)
snRNA import into nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
cellular response to mineralocorticoid stimulus	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein localization to nucleolus	GTP-binding nuclear protein Ran	Homo sapiens (human)
ribosomal subunit export from nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform gamma-2	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform gamma-2	Homo sapiens (human)
sphingolipid biosynthetic process	Casein kinase I isoform gamma-2	Homo sapiens (human)
signal transduction	Casein kinase I isoform gamma-2	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform gamma-2	Homo sapiens (human)
endocytosis	Casein kinase I isoform gamma-2	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform gamma-2	Homo sapiens (human)
DNA damage response	Cyclin-dependent kinase 3	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 3	Homo sapiens (human)
cell population proliferation	Cyclin-dependent kinase 3	Homo sapiens (human)
G0 to G1 transition	Cyclin-dependent kinase 3	Homo sapiens (human)
negative regulation of Notch signaling pathway	Cyclin-dependent kinase 3	Homo sapiens (human)
cell division	Cyclin-dependent kinase 3	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 3	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 3	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 3	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 3	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 3	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 6	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Cyclin-dependent kinase 6	Homo sapiens (human)
type B pancreatic cell development	Cyclin-dependent kinase 6	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 6	Homo sapiens (human)
Notch signaling pathway	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of cell population proliferation	Cyclin-dependent kinase 6	Homo sapiens (human)
response to virus	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 6	Homo sapiens (human)
positive regulation of gene expression	Cyclin-dependent kinase 6	Homo sapiens (human)
astrocyte development	Cyclin-dependent kinase 6	Homo sapiens (human)
dentate gyrus development	Cyclin-dependent kinase 6	Homo sapiens (human)
lateral ventricle development	Cyclin-dependent kinase 6	Homo sapiens (human)
T cell differentiation in thymus	Cyclin-dependent kinase 6	Homo sapiens (human)
gliogenesis	Cyclin-dependent kinase 6	Homo sapiens (human)
cell dedifferentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of cell differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of myeloid cell differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of erythrocyte differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of monocyte differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of osteoblast differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of cell cycle	Cyclin-dependent kinase 6	Homo sapiens (human)
positive regulation of fibroblast proliferation	Cyclin-dependent kinase 6	Homo sapiens (human)
generation of neurons	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Cyclin-dependent kinase 6	Homo sapiens (human)
cell division	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 6	Homo sapiens (human)
hematopoietic stem cell differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of hematopoietic stem cell differentiation	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of cell motility	Cyclin-dependent kinase 6	Homo sapiens (human)
negative regulation of cellular senescence	Cyclin-dependent kinase 6	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 6	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 6	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 6	Homo sapiens (human)
microtubule cytoskeleton organization	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron migration	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic transmission, dopaminergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
intracellular protein transport	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell-matrix adhesion	Cyclin-dependent-like kinase 5	Homo sapiens (human)
chemical synaptic transmission	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synapse assembly	Cyclin-dependent-like kinase 5	Homo sapiens (human)
skeletal muscle tissue development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
motor neuron axon guidance	Cyclin-dependent-like kinase 5	Homo sapiens (human)
visual learning	Cyclin-dependent-like kinase 5	Homo sapiens (human)
Schwann cell development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle exocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of macroautophagy	Cyclin-dependent-like kinase 5	Homo sapiens (human)
phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
peptidyl-threonine phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
sensory perception of pain	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cerebellar cortex formation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
hippocampus development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
layer formation in cerebral cortex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
central nervous system neuron development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
corpus callosum development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron differentiation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of cell migration	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of axon extension	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron projection development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of protein ubiquitination	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of synaptic plasticity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
receptor catabolic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic transmission, glutamatergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein localization to synapse	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
receptor clustering	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of cell cycle	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of proteolysis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of protein export from nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
behavioral response to cocaine	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic plasticity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle endocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
rhythmic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axon extension	Cyclin-dependent-like kinase 5	Homo sapiens (human)
oligodendrocyte differentiation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
dendrite morphogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell division	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
excitatory postsynaptic potential	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of dendritic spine morphogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
calcium ion import	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of protein targeting to membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of protein localization to plasma membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic vesicle recycling	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cellular response to amyloid-beta	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axonogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle transport	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 16	Homo sapiens (human)
exocytosis	Cyclin-dependent kinase 16	Homo sapiens (human)
spermatogenesis	Cyclin-dependent kinase 16	Homo sapiens (human)
positive regulation of autophagy	Cyclin-dependent kinase 16	Homo sapiens (human)
growth hormone secretion	Cyclin-dependent kinase 16	Homo sapiens (human)
neuron projection development	Cyclin-dependent kinase 16	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 16	Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulus	Cyclin-dependent kinase 16	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 17	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 17	Homo sapiens (human)
cellular response to leukemia inhibitory factor	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
canonical glycolysis	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
fructose 1,6-bisphosphate metabolic process	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
fructose 6-phosphate metabolic process	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
chemotaxis	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
heart development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
negative regulation of cell population proliferation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of gene expression	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
Schwann cell development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
cerebellar cortex formation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
keratinocyte differentiation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
thyroid gland development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
regulation of stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
endodermal cell differentiation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
myelination	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
type B pancreatic cell proliferation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
thymus development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
regulation of axon regeneration	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
cell motility	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of axonogenesis	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
Bergmann glial cell differentiation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
face development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
trachea formation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesis	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
placenta blood vessel development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
labyrinthine layer development	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
ERK1 and ERK2 cascade	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
regulation of Golgi inheritance	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
positive regulation of endodermal cell differentiation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
regulation of early endosome to late endosome transport	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
neuron differentiation	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
neuron migration	DNA topoisomerase 2-beta	Homo sapiens (human)
DNA topological change	DNA topoisomerase 2-beta	Homo sapiens (human)
axonogenesis	DNA topoisomerase 2-beta	Homo sapiens (human)
B cell differentiation	DNA topoisomerase 2-beta	Homo sapiens (human)
forebrain development	DNA topoisomerase 2-beta	Homo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	DNA topoisomerase 2-beta	Homo sapiens (human)
cellular response to hydrogen peroxide	DNA topoisomerase 2-beta	Homo sapiens (human)
cellular response to ATP	DNA topoisomerase 2-beta	Homo sapiens (human)
cellular senescence	DNA topoisomerase 2-beta	Homo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joining	DNA topoisomerase 2-beta	Homo sapiens (human)
sister chromatid segregation	DNA topoisomerase 2-beta	Homo sapiens (human)
resolution of meiotic recombination intermediates	DNA topoisomerase 2-beta	Homo sapiens (human)
regulation of cell growth	Protein kinase C theta type	Homo sapiens (human)
regulation of DNA-templated transcription	Protein kinase C theta type	Homo sapiens (human)
protein phosphorylation	Protein kinase C theta type	Homo sapiens (human)
membrane protein ectodomain proteolysis	Protein kinase C theta type	Homo sapiens (human)
inflammatory response	Protein kinase C theta type	Homo sapiens (human)
axon guidance	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-17 production	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-2 production	Protein kinase C theta type	Homo sapiens (human)
positive regulation of interleukin-4 production	Protein kinase C theta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C theta type	Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferation	Protein kinase C theta type	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Protein kinase C theta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T cell activation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomerase activity	Protein kinase C theta type	Homo sapiens (human)
cell chemotaxis	Protein kinase C theta type	Homo sapiens (human)
negative regulation of T cell apoptotic process	Protein kinase C theta type	Homo sapiens (human)
regulation of platelet aggregation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of telomere capping	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Protein kinase C theta type	Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferation	Protein kinase C theta type	Homo sapiens (human)
positive regulation of T-helper 2 cell activation	Protein kinase C theta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C theta type	Homo sapiens (human)
outflow tract septum morphogenesis	Activin receptor type-1	Homo sapiens (human)
branching involved in blood vessel morphogenesis	Activin receptor type-1	Homo sapiens (human)
in utero embryonic development	Activin receptor type-1	Homo sapiens (human)
gastrulation with mouth forming second	Activin receptor type-1	Homo sapiens (human)
mesoderm formation	Activin receptor type-1	Homo sapiens (human)
neural crest cell migration	Activin receptor type-1	Homo sapiens (human)
acute inflammatory response	Activin receptor type-1	Homo sapiens (human)
embryonic heart tube morphogenesis	Activin receptor type-1	Homo sapiens (human)
atrioventricular valve morphogenesis	Activin receptor type-1	Homo sapiens (human)
mitral valve morphogenesis	Activin receptor type-1	Homo sapiens (human)
endocardial cushion formation	Activin receptor type-1	Homo sapiens (human)
endocardial cushion fusion	Activin receptor type-1	Homo sapiens (human)
atrial septum primum morphogenesis	Activin receptor type-1	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Activin receptor type-1	Homo sapiens (human)
germ cell development	Activin receptor type-1	Homo sapiens (human)
determination of left/right symmetry	Activin receptor type-1	Homo sapiens (human)
negative regulation of signal transduction	Activin receptor type-1	Homo sapiens (human)
regulation of ossification	Activin receptor type-1	Homo sapiens (human)
positive regulation of cell migration	Activin receptor type-1	Homo sapiens (human)
positive regulation of bone mineralization	Activin receptor type-1	Homo sapiens (human)
BMP signaling pathway	Activin receptor type-1	Homo sapiens (human)
activin receptor signaling pathway	Activin receptor type-1	Homo sapiens (human)
negative regulation of activin receptor signaling pathway	Activin receptor type-1	Homo sapiens (human)
positive regulation of osteoblast differentiation	Activin receptor type-1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Activin receptor type-1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Activin receptor type-1	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Activin receptor type-1	Homo sapiens (human)
smooth muscle cell differentiation	Activin receptor type-1	Homo sapiens (human)
pharyngeal system development	Activin receptor type-1	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Activin receptor type-1	Homo sapiens (human)
ventricular septum morphogenesis	Activin receptor type-1	Homo sapiens (human)
cardiac muscle cell fate commitment	Activin receptor type-1	Homo sapiens (human)
endocardial cushion cell fate commitment	Activin receptor type-1	Homo sapiens (human)
positive regulation of cardiac epithelial to mesenchymal transition	Activin receptor type-1	Homo sapiens (human)
cellular response to BMP stimulus	Activin receptor type-1	Homo sapiens (human)
positive regulation of determination of dorsal identity	Activin receptor type-1	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	Activin receptor type-1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Activin receptor type-1	Homo sapiens (human)
dorsal/ventral pattern formation	Activin receptor type-1	Homo sapiens (human)
heart development	Activin receptor type-1	Homo sapiens (human)
protein phosphorylation	Activin receptor type-1	Homo sapiens (human)
cellular response to growth factor stimulus	Activin receptor type-1	Homo sapiens (human)
defense response	Macrophage-stimulating protein receptor	Homo sapiens (human)
signal transduction	Macrophage-stimulating protein receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Macrophage-stimulating protein receptor	Homo sapiens (human)
single fertilization	Macrophage-stimulating protein receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Macrophage-stimulating protein receptor	Homo sapiens (human)
response to virus	Macrophage-stimulating protein receptor	Homo sapiens (human)
macrophage colony-stimulating factor signaling pathway	Macrophage-stimulating protein receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Macrophage-stimulating protein receptor	Homo sapiens (human)
innate immune response	Macrophage-stimulating protein receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Macrophage-stimulating protein receptor	Homo sapiens (human)
nervous system development	Macrophage-stimulating protein receptor	Homo sapiens (human)
cell migration	Macrophage-stimulating protein receptor	Homo sapiens (human)
phagocytosis	Macrophage-stimulating protein receptor	Homo sapiens (human)
positive regulation of kinase activity	Macrophage-stimulating protein receptor	Homo sapiens (human)
multicellular organism development	Macrophage-stimulating protein receptor	Homo sapiens (human)
positive regulation of macrophage chemotaxis	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of macrophage proliferation	Focal adhesion kinase 1	Homo sapiens (human)
angiogenesis	Focal adhesion kinase 1	Homo sapiens (human)
placenta development	Focal adhesion kinase 1	Homo sapiens (human)
regulation of protein phosphorylation	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of protein phosphorylation	Focal adhesion kinase 1	Homo sapiens (human)
heart morphogenesis	Focal adhesion kinase 1	Homo sapiens (human)
signal complex assembly	Focal adhesion kinase 1	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
integrin-mediated signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
axon guidance	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Focal adhesion kinase 1	Homo sapiens (human)
regulation of cell shape	Focal adhesion kinase 1	Homo sapiens (human)
regulation of endothelial cell migration	Focal adhesion kinase 1	Homo sapiens (human)
regulation of epithelial cell migration	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of epithelial cell migration	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of fibroblast migration	Focal adhesion kinase 1	Homo sapiens (human)
cell migration	Focal adhesion kinase 1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Focal adhesion kinase 1	Homo sapiens (human)
negative regulation of cell-cell adhesion	Focal adhesion kinase 1	Homo sapiens (human)
establishment of cell polarity	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of cell migration	Focal adhesion kinase 1	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Focal adhesion kinase 1	Homo sapiens (human)
detection of muscle stretch	Focal adhesion kinase 1	Homo sapiens (human)
netrin-activated signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Focal adhesion kinase 1	Homo sapiens (human)
regulation of cell population proliferation	Focal adhesion kinase 1	Homo sapiens (human)
negative regulation of apoptotic process	Focal adhesion kinase 1	Homo sapiens (human)
regulation of GTPase activity	Focal adhesion kinase 1	Homo sapiens (human)
regulation of osteoblast differentiation	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of protein kinase activity	Focal adhesion kinase 1	Homo sapiens (human)
protein autophosphorylation	Focal adhesion kinase 1	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
ephrin receptor signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
cell motility	Focal adhesion kinase 1	Homo sapiens (human)
regulation of cytoskeleton organization	Focal adhesion kinase 1	Homo sapiens (human)
regulation of focal adhesion assembly	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Focal adhesion kinase 1	Homo sapiens (human)
growth hormone receptor signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of wound healing	Focal adhesion kinase 1	Homo sapiens (human)
regulation of substrate adhesion-dependent cell spreading	Focal adhesion kinase 1	Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic process	Focal adhesion kinase 1	Homo sapiens (human)
negative regulation of anoikis	Focal adhesion kinase 1	Homo sapiens (human)
protein phosphorylation	Focal adhesion kinase 1	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Focal adhesion kinase 1	Homo sapiens (human)
regulation of cell adhesion	Focal adhesion kinase 1	Homo sapiens (human)
protein phosphorylation	Protein kinase C delta type	Homo sapiens (human)
apoptotic process	Protein kinase C delta type	Homo sapiens (human)
DNA damage response	Protein kinase C delta type	Homo sapiens (human)
signal transduction	Protein kinase C delta type	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Protein kinase C delta type	Homo sapiens (human)
regulation of signaling receptor activity	Protein kinase C delta type	Homo sapiens (human)
immunoglobulin mediated immune response	Protein kinase C delta type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
termination of signal transduction	Protein kinase C delta type	Homo sapiens (human)
negative regulation of actin filament polymerization	Protein kinase C delta type	Homo sapiens (human)
positive regulation of endodeoxyribonuclease activity	Protein kinase C delta type	Homo sapiens (human)
negative regulation of protein binding	Protein kinase C delta type	Homo sapiens (human)
activation of protein kinase activity	Protein kinase C delta type	Homo sapiens (human)
positive regulation of superoxide anion generation	Protein kinase C delta type	Homo sapiens (human)
regulation of actin cytoskeleton organization	Protein kinase C delta type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C delta type	Homo sapiens (human)
cellular response to UV	Protein kinase C delta type	Homo sapiens (human)
positive regulation of protein dephosphorylation	Protein kinase C delta type	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Protein kinase C delta type	Homo sapiens (human)
B cell proliferation	Protein kinase C delta type	Homo sapiens (human)
neutrophil activation	Protein kinase C delta type	Homo sapiens (human)
positive regulation of protein import into nucleus	Protein kinase C delta type	Homo sapiens (human)
defense response to bacterium	Protein kinase C delta type	Homo sapiens (human)
negative regulation of MAP kinase activity	Protein kinase C delta type	Homo sapiens (human)
regulation of mRNA stability	Protein kinase C delta type	Homo sapiens (human)
post-translational protein modification	Protein kinase C delta type	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Protein kinase C delta type	Homo sapiens (human)
negative regulation of inflammatory response	Protein kinase C delta type	Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylation	Protein kinase C delta type	Homo sapiens (human)
protein stabilization	Protein kinase C delta type	Homo sapiens (human)
negative regulation of filopodium assembly	Protein kinase C delta type	Homo sapiens (human)
cell chemotaxis	Protein kinase C delta type	Homo sapiens (human)
cellular response to hydrogen peroxide	Protein kinase C delta type	Homo sapiens (human)
cellular response to hydroperoxide	Protein kinase C delta type	Homo sapiens (human)
negative regulation of platelet aggregation	Protein kinase C delta type	Homo sapiens (human)
cellular senescence	Protein kinase C delta type	Homo sapiens (human)
positive regulation of phospholipid scramblase activity	Protein kinase C delta type	Homo sapiens (human)
cellular response to angiotensin	Protein kinase C delta type	Homo sapiens (human)
regulation of ceramide biosynthetic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of ceramide biosynthetic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of glucosylceramide catabolic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of sphingomyelin catabolic process	Protein kinase C delta type	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Protein kinase C delta type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C delta type	Homo sapiens (human)
neutrophil homeostasis	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of type III hypersensitivity	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of type I hypersensitivity	Tyrosine-protein kinase BTK	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase BTK	Homo sapiens (human)
B cell affinity maturation	Tyrosine-protein kinase BTK	Homo sapiens (human)
histamine secretion by mast cell	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of immunoglobulin production	Tyrosine-protein kinase BTK	Homo sapiens (human)
regulation of B cell cytokine production	Tyrosine-protein kinase BTK	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Tyrosine-protein kinase BTK	Homo sapiens (human)
regulation of B cell apoptotic process	Tyrosine-protein kinase BTK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase BTK	Homo sapiens (human)
mesoderm development	Tyrosine-protein kinase BTK	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase BTK	Homo sapiens (human)
calcium-mediated signaling	Tyrosine-protein kinase BTK	Homo sapiens (human)
proteoglycan catabolic process	Tyrosine-protein kinase BTK	Homo sapiens (human)
negative regulation of B cell proliferation	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of B cell proliferation	Tyrosine-protein kinase BTK	Homo sapiens (human)
response to lipopolysaccharide	Tyrosine-protein kinase BTK	Homo sapiens (human)
negative regulation of interleukin-10 production	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of interleukin-6 production	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase BTK	Homo sapiens (human)
cellular response to reactive oxygen species	Tyrosine-protein kinase BTK	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase BTK	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Tyrosine-protein kinase BTK	Homo sapiens (human)
B cell activation	Tyrosine-protein kinase BTK	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of B cell differentiation	Tyrosine-protein kinase BTK	Homo sapiens (human)
cell maturation	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of phagocytosis	Tyrosine-protein kinase BTK	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
monocyte proliferation	Tyrosine-protein kinase BTK	Homo sapiens (human)
cellular response to molecule of fungal origin	Tyrosine-protein kinase BTK	Homo sapiens (human)
apoptotic signaling pathway	Tyrosine-protein kinase BTK	Homo sapiens (human)
cellular response to interleukin-7	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of interleukin-17A production	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	Tyrosine-protein kinase BTK	Homo sapiens (human)
positive regulation of synoviocyte proliferation	Tyrosine-protein kinase BTK	Homo sapiens (human)
eosinophil homeostasis	Tyrosine-protein kinase BTK	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase BTK	Homo sapiens (human)
endocytosis	Activated CDC42 kinase 1	Homo sapiens (human)
cell surface receptor signaling pathway	Activated CDC42 kinase 1	Homo sapiens (human)
small GTPase-mediated signal transduction	Activated CDC42 kinase 1	Homo sapiens (human)
phosphorylation	Activated CDC42 kinase 1	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Activated CDC42 kinase 1	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	Activated CDC42 kinase 1	Homo sapiens (human)
protein phosphorylation	Activated CDC42 kinase 1	Homo sapiens (human)
regulation of cell growth	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
regulation of cell-matrix adhesion	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
cell adhesion	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
embryo implantation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
lactation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
cell population proliferation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
negative regulation of cell population proliferation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
regulation of extracellular matrix disassembly	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
smooth muscle cell migration	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
ear development	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
wound healing, spreading of cells	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
protein autophosphorylation	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
branching involved in mammary gland duct morphogenesis	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
mammary gland alveolus development	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
smooth muscle cell-matrix adhesion	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
axon development	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
neuron projection extension	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
multicellular organism development	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
positive regulation of kinase activity	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
positive regulation of neuron projection development	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
positive regulation of cytokine production	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
cellular defense response	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
activation of phospholipase C activity	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
T cell activation	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
gamma-delta T cell activation	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
NK T cell differentiation	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
vesicle targeting	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
immune response	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
positive regulation of JUN kinase activity	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
innate immune response	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
positive regulation of JNK cascade	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
natural killer cell differentiation	Tyrosine-protein kinase Mer	Homo sapiens (human)
negative regulation of cytokine production	Tyrosine-protein kinase Mer	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Mer	Homo sapiens (human)
phagocytosis	Tyrosine-protein kinase Mer	Homo sapiens (human)
cell surface receptor signaling pathway	Tyrosine-protein kinase Mer	Homo sapiens (human)
cell-cell signaling	Tyrosine-protein kinase Mer	Homo sapiens (human)
spermatogenesis	Tyrosine-protein kinase Mer	Homo sapiens (human)
platelet activation	Tyrosine-protein kinase Mer	Homo sapiens (human)
secretion by cell	Tyrosine-protein kinase Mer	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Tyrosine-protein kinase Mer	Homo sapiens (human)
positive regulation of phagocytosis	Tyrosine-protein kinase Mer	Homo sapiens (human)
negative regulation of lymphocyte activation	Tyrosine-protein kinase Mer	Homo sapiens (human)
establishment of localization in cell	Tyrosine-protein kinase Mer	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase Mer	Homo sapiens (human)
retina development in camera-type eye	Tyrosine-protein kinase Mer	Homo sapiens (human)
vagina development	Tyrosine-protein kinase Mer	Homo sapiens (human)
neutrophil clearance	Tyrosine-protein kinase Mer	Homo sapiens (human)
negative regulation of leukocyte apoptotic process	Tyrosine-protein kinase Mer	Homo sapiens (human)
nervous system development	Tyrosine-protein kinase Mer	Homo sapiens (human)
positive regulation of kinase activity	Tyrosine-protein kinase Mer	Homo sapiens (human)
cell migration	Tyrosine-protein kinase Mer	Homo sapiens (human)
multicellular organism development	Tyrosine-protein kinase Mer	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Mer	Homo sapiens (human)
cell morphogenesis	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of protein phosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of protein binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein stabilization	Serine/threonine-protein kinase 4	Homo sapiens (human)
branching involved in blood vessel morphogenesis	Serine/threonine-protein kinase 4	Homo sapiens (human)
neural tube formation	Serine/threonine-protein kinase 4	Homo sapiens (human)
endocardium development	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein import into nucleus	Serine/threonine-protein kinase 4	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase 4	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase 4	Homo sapiens (human)
central nervous system development	Serine/threonine-protein kinase 4	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Serine/threonine-protein kinase 4	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase 4	Homo sapiens (human)
keratinocyte differentiation	Serine/threonine-protein kinase 4	Homo sapiens (human)
organ growth	Serine/threonine-protein kinase 4	Homo sapiens (human)
hippo signaling	Serine/threonine-protein kinase 4	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of apoptotic process	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of fat cell differentiation	Serine/threonine-protein kinase 4	Homo sapiens (human)
negative regulation of organ growth	Serine/threonine-protein kinase 4	Homo sapiens (human)
epithelial cell proliferation	Serine/threonine-protein kinase 4	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein tetramerization	Serine/threonine-protein kinase 4	Homo sapiens (human)
canonical Wnt signaling pathway	Serine/threonine-protein kinase 4	Homo sapiens (human)
primitive hemopoiesis	Serine/threonine-protein kinase 4	Homo sapiens (human)
cell differentiation involved in embryonic placenta development	Serine/threonine-protein kinase 4	Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta development	Serine/threonine-protein kinase 4	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Serine/threonine-protein kinase 4	Homo sapiens (human)
hepatocyte apoptotic process	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of hepatocyte apoptotic process	Serine/threonine-protein kinase 4	Homo sapiens (human)
positive regulation of substrate-dependent cell migration, cell attachment to substrate	Serine/threonine-protein kinase 4	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase 4	Homo sapiens (human)
lipid droplet disassembly	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to hypoxia	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
glucose metabolic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
chromatin remodeling	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein phosphorylation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
fatty acid biosynthetic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cholesterol biosynthetic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
autophagy	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
signal transduction	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of cell population proliferation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
lipid biosynthetic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to UV	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cold acclimation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to gamma radiation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of autophagy	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of gene expression	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of gene expression	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
bile acid and bile salt transport	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
Wnt signaling pathway	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
fatty acid oxidation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to caffeine	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to nutrient levels	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of TOR signaling	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of peptidyl-serine phosphorylation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to oxidative stress	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
bile acid signaling pathway	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to glucose starvation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
glucose homeostasis	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of circadian rhythm	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of apoptotic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
response to estrogen	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of cholesterol biosynthetic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of glycolytic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of DNA-templated transcription	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
rhythmic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of skeletal muscle tissue development	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of lipid catabolic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
fatty acid homeostasis	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of vesicle-mediated transport	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
motor behavior	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
CAMKK-AMPK signaling cascade	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of stress granule assembly	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
neuron cellular homeostasis	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to hydrogen peroxide	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to calcium ion	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to glucose stimulus	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to ethanol	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to prostaglandin E stimulus	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to organonitrogen compound	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to hypoxia	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cellular response to xenobiotic stimulus	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
energy homeostasis	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
regulation of bile acid secretion	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of mitochondrial transcription	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of protein localization	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of hepatocyte apoptotic process	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of adipose tissue development	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of TORC1 signaling	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of tubulin deacetylation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein localization to lipid droplet	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
heart development	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
positive regulation of cell growth	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of interleukin-8 production	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesion	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
positive regulation of MAP kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
positive regulation of protein metabolic process	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of response to cytokine stimulus	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
ERK5 cascade	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
cellular response to growth factor stimulus	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
cellular response to laminar fluid shear stress	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesis	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of chemokine (C-X-C motif) ligand 2 production	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase 7	Homo sapiens (human)
signal transduction	Mitogen-activated protein kinase 7	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Mitogen-activated protein kinase 7	Homo sapiens (human)
cell differentiation	Mitogen-activated protein kinase 7	Homo sapiens (human)
calcineurin-NFAT signaling cascade	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesion	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Mitogen-activated protein kinase 7	Homo sapiens (human)
regulation of angiogenesis	Mitogen-activated protein kinase 7	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of inflammatory response	Mitogen-activated protein kinase 7	Homo sapiens (human)
positive regulation of protein metabolic process	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of response to cytokine stimulus	Mitogen-activated protein kinase 7	Homo sapiens (human)
cellular response to hydrogen peroxide	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Mitogen-activated protein kinase 7	Homo sapiens (human)
cellular response to growth factor stimulus	Mitogen-activated protein kinase 7	Homo sapiens (human)
cellular response to laminar fluid shear stress	Mitogen-activated protein kinase 7	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Mitogen-activated protein kinase 7	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Mitogen-activated protein kinase 7	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 7	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cardiac muscle hypertrophy	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
negative regulation of protein kinase activity	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
phosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
adherens junction assembly	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
regulation of cytoskeleton organization	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
negative regulation of stress fiber assembly	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
dendritic spine development	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
bicellular tight junction assembly	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cellular response to organic cyclic compound	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein localization to cell-cell junction	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
regulation of axonogenesis	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
positive regulation of protein binding	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein stabilization	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Serine/threonine-protein kinase 3	Homo sapiens (human)
neural tube formation	Serine/threonine-protein kinase 3	Homo sapiens (human)
endocardium development	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein import into nucleus	Serine/threonine-protein kinase 3	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase 3	Homo sapiens (human)
JNK cascade	Serine/threonine-protein kinase 3	Homo sapiens (human)
central nervous system development	Serine/threonine-protein kinase 3	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Serine/threonine-protein kinase 3	Homo sapiens (human)
organ growth	Serine/threonine-protein kinase 3	Homo sapiens (human)
hippo signaling	Serine/threonine-protein kinase 3	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of apoptotic process	Serine/threonine-protein kinase 3	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of fat cell differentiation	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of JNK cascade	Serine/threonine-protein kinase 3	Homo sapiens (human)
negative regulation of organ growth	Serine/threonine-protein kinase 3	Homo sapiens (human)
epithelial cell proliferation	Serine/threonine-protein kinase 3	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein tetramerization	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase 3	Homo sapiens (human)
canonical Wnt signaling pathway	Serine/threonine-protein kinase 3	Homo sapiens (human)
primitive hemopoiesis	Serine/threonine-protein kinase 3	Homo sapiens (human)
cell differentiation involved in embryonic placenta development	Serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta development	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein localization to centrosome	Serine/threonine-protein kinase 3	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Serine/threonine-protein kinase 3	Homo sapiens (human)
hepatocyte apoptotic process	Serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors	Serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase 3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
cellular response to mechanical stimulus	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
cell morphogenesis	Integrin-linked protein kinase	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin-linked protein kinase	Homo sapiens (human)
branching involved in ureteric bud morphogenesis	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin-linked protein kinase	Homo sapiens (human)
outflow tract morphogenesis	Integrin-linked protein kinase	Homo sapiens (human)
protein phosphorylation	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of cell population proliferation	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of signal transduction	Integrin-linked protein kinase	Homo sapiens (human)
fibroblast migration	Integrin-linked protein kinase	Homo sapiens (human)
nerve development	Integrin-linked protein kinase	Homo sapiens (human)
myelination in peripheral nervous system	Integrin-linked protein kinase	Homo sapiens (human)
cell projection organization	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of BMP signaling pathway	Integrin-linked protein kinase	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Integrin-linked protein kinase	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of phosphorylation	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Integrin-linked protein kinase	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Integrin-linked protein kinase	Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarity	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of osteoblast differentiation	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of DNA-templated transcription	Integrin-linked protein kinase	Homo sapiens (human)
neural precursor cell proliferation	Integrin-linked protein kinase	Homo sapiens (human)
platelet aggregation	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Integrin-linked protein kinase	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin-linked protein kinase	Homo sapiens (human)
negative regulation of neural precursor cell proliferation	Integrin-linked protein kinase	Homo sapiens (human)
cell-matrix adhesion	Integrin-linked protein kinase	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin-linked protein kinase	Homo sapiens (human)
epithelial to mesenchymal transition	Rho-associated protein kinase 1	Homo sapiens (human)
aortic valve morphogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
apical constriction	Rho-associated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte cell-cell adhesion	Rho-associated protein kinase 1	Homo sapiens (human)
signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
Rho protein signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of autophagy	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of gene expression	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of phosphatase activity	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of angiogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
membrane to membrane docking	Rho-associated protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell adhesion	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell migration	Rho-associated protein kinase 1	Homo sapiens (human)
cortical actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
neuron projection development	Rho-associated protein kinase 1	Homo sapiens (human)
bleb assembly	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of dephosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of MAPK cascade	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of keratinocyte differentiation	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of neuron differentiation	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte migration	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte tethering or rolling	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysis	Rho-associated protein kinase 1	Homo sapiens (human)
myoblast migration	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of stress fiber assembly	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of focal adhesion assembly	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of focal adhesion assembly	Rho-associated protein kinase 1	Homo sapiens (human)
mRNA destabilization	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of biomineral tissue development	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
response to transforming growth factor beta	Rho-associated protein kinase 1	Homo sapiens (human)
protein localization to plasma membrane	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of synapse maturation	Rho-associated protein kinase 1	Homo sapiens (human)
podocyte cell migration	Rho-associated protein kinase 1	Homo sapiens (human)
motor neuron apoptotic process	Rho-associated protein kinase 1	Homo sapiens (human)
blood vessel diameter maintenance	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of angiotensin-activated signaling pathway	Rho-associated protein kinase 1	Homo sapiens (human)
neuron projection arborization	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of amyloid-beta clearance	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of synaptic vesicle endocytosis	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of amyloid-beta formation	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic process	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of establishment of endothelial barrier	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of connective tissue replacement	Rho-associated protein kinase 1	Homo sapiens (human)
response to angiotensin	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of establishment of cell polarity	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell motility	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of motor neuron apoptotic process	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell junction assembly	Rho-associated protein kinase 1	Homo sapiens (human)
mitotic cytokinesis	Rho-associated protein kinase 1	Homo sapiens (human)
embryonic morphogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
actomyosin structure organization	Rho-associated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
protein autophosphorylation	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
nervous system development	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
regulation of neuron projection development	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
regulation of skeletal muscle adaptation	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
insulin secretion	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
cell differentiation	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
regulation of calcium ion transport	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
regulation of cell growth	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of the force of heart contraction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of membrane depolarization	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein phosphorylation	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of heart contraction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cell communication by electrical coupling	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
peptidyl-serine phosphorylation	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasis	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein autophosphorylation	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
relaxation of cardiac muscle	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cellular localization	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cellular response to calcium ion	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cardiac muscle cell contraction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cardiac muscle cell action potential	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cardiac muscle cell action potential involved in regulation of contraction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conduction	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of relaxation of cardiac muscle	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
negative regulation of sodium ion transmembrane transport	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
negative regulation of sodium ion transmembrane transporter activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
chromatin remodeling	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nervous system development	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
circadian rhythm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of microtubule polymerization	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of RNA splicing	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
amyloid-beta formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-serine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein autophosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of mRNA splicing, via spliceosome	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of protein deacetylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Activin receptor type-2B	Homo sapiens (human)
gastrulation with mouth forming second	Activin receptor type-2B	Homo sapiens (human)
kidney development	Activin receptor type-2B	Homo sapiens (human)
lymphangiogenesis	Activin receptor type-2B	Homo sapiens (human)
blood vessel remodeling	Activin receptor type-2B	Homo sapiens (human)
regulation of DNA-templated transcription	Activin receptor type-2B	Homo sapiens (human)
signal transduction	Activin receptor type-2B	Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathway	Activin receptor type-2B	Homo sapiens (human)
determination of left/right symmetry	Activin receptor type-2B	Homo sapiens (human)
mesoderm development	Activin receptor type-2B	Homo sapiens (human)
heart development	Activin receptor type-2B	Homo sapiens (human)
response to glucose	Activin receptor type-2B	Homo sapiens (human)
post-embryonic development	Activin receptor type-2B	Homo sapiens (human)
anterior/posterior pattern specification	Activin receptor type-2B	Homo sapiens (human)
insulin secretion	Activin receptor type-2B	Homo sapiens (human)
lung development	Activin receptor type-2B	Homo sapiens (human)
positive regulation of bone mineralization	Activin receptor type-2B	Homo sapiens (human)
BMP signaling pathway	Activin receptor type-2B	Homo sapiens (human)
pancreas development	Activin receptor type-2B	Homo sapiens (human)
activin receptor signaling pathway	Activin receptor type-2B	Homo sapiens (human)
positive regulation of activin receptor signaling pathway	Activin receptor type-2B	Homo sapiens (human)
organ growth	Activin receptor type-2B	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Activin receptor type-2B	Homo sapiens (human)
positive regulation of osteoblast differentiation	Activin receptor type-2B	Homo sapiens (human)
embryonic foregut morphogenesis	Activin receptor type-2B	Homo sapiens (human)
skeletal system morphogenesis	Activin receptor type-2B	Homo sapiens (human)
roof of mouth development	Activin receptor type-2B	Homo sapiens (human)
lymphatic endothelial cell differentiation	Activin receptor type-2B	Homo sapiens (human)
artery development	Activin receptor type-2B	Homo sapiens (human)
venous blood vessel development	Activin receptor type-2B	Homo sapiens (human)
retina vasculature development in camera-type eye	Activin receptor type-2B	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Activin receptor type-2B	Homo sapiens (human)
cellular response to growth factor stimulus	Activin receptor type-2B	Homo sapiens (human)
protein phosphorylation	Activin receptor type-2B	Homo sapiens (human)
outflow tract septum morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
atrioventricular valve morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cardiac muscle tissue development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
pharyngeal arch artery morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of gene expression	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
osteoblast differentiation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
mesoderm formation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
maternal placenta development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
endothelial cell proliferation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
lymphangiogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
blood vessel remodeling	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
chondrocyte development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
outflow tract morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
aortic valve development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
pulmonary valve development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
mitral valve morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
tricuspid valve morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
endocardial cushion development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of cell proliferation involved in heart valve morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathway	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cellular response to starvation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
anterior/posterior pattern specification	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of epithelial cell migration	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
regulation of lung blood pressure	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
proteoglycan biosynthetic process	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of cell growth	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of bone mineralization	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
BMP signaling pathway	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
activin receptor signaling pathway	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
regulation of cell population proliferation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of osteoblast differentiation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of ossification	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of vasoconstriction	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
lung alveolus development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of axon extension involved in axon guidance	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of muscle cell differentiation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
limb development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
endochondral bone morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
ventricular septum morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
atrial septum morphogenesis	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
lung vasculature development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
lymphatic endothelial cell differentiation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
artery development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
venous blood vessel development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
positive regulation of cartilage development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
retina vasculature development in camera-type eye	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cellular response to BMP stimulus	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
endothelial cell apoptotic process	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
negative regulation of chondrocyte proliferation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
semi-lunar valve development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cellular response to growth factor stimulus	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
blood vessel development	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
protein phosphorylation	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
protein phosphorylation	Protein-tyrosine kinase 6	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of neuron projection development	Protein-tyrosine kinase 6	Homo sapiens (human)
cell migration	Protein-tyrosine kinase 6	Homo sapiens (human)
ERBB2 signaling pathway	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of DNA replication	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of cell cycle	Protein-tyrosine kinase 6	Homo sapiens (human)
negative regulation of growth	Protein-tyrosine kinase 6	Homo sapiens (human)
protein autophosphorylation	Protein-tyrosine kinase 6	Homo sapiens (human)
intestinal epithelial cell differentiation	Protein-tyrosine kinase 6	Homo sapiens (human)
negative regulation of protein tyrosine kinase activity	Protein-tyrosine kinase 6	Homo sapiens (human)
cellular response to retinoic acid	Protein-tyrosine kinase 6	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Protein-tyrosine kinase 6	Homo sapiens (human)
innate immune response	Protein-tyrosine kinase 6	Homo sapiens (human)
cell differentiation	Protein-tyrosine kinase 6	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Protein-tyrosine kinase 6	Homo sapiens (human)
protein phosphorylation	cGMP-dependent protein kinase 1	Homo sapiens (human)
neuron migration	cGMP-dependent protein kinase 1	Homo sapiens (human)
signal transduction	cGMP-dependent protein kinase 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	cGMP-dependent protein kinase 1	Homo sapiens (human)
spermatid development	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of inositol phosphate biosynthetic process	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of glutamate secretion	cGMP-dependent protein kinase 1	Homo sapiens (human)
dendrite development	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP-mediated signaling	cGMP-dependent protein kinase 1	Homo sapiens (human)
cerebellum development	cGMP-dependent protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	cGMP-dependent protein kinase 1	Homo sapiens (human)
forebrain development	cGMP-dependent protein kinase 1	Homo sapiens (human)
positive regulation of circadian rhythm	cGMP-dependent protein kinase 1	Homo sapiens (human)
regulation of GTPase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
collateral sprouting	cGMP-dependent protein kinase 1	Homo sapiens (human)
relaxation of vascular associated smooth muscle	cGMP-dependent protein kinase 1	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of platelet aggregation	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migration	cGMP-dependent protein kinase 1	Homo sapiens (human)
regulation of testosterone biosynthetic process	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein kinase A signaling	cGMP-dependent protein kinase 1	Homo sapiens (human)
alternative mRNA splicing, via spliceosome	Cyclin-dependent kinase 13	Homo sapiens (human)
regulation of signal transduction	Cyclin-dependent kinase 13	Homo sapiens (human)
hemopoiesis	Cyclin-dependent kinase 13	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Cyclin-dependent kinase 13	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 13	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 13	Homo sapiens (human)
negative regulation of stem cell differentiation	Cyclin-dependent kinase 13	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 13	Homo sapiens (human)
immune response	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
gene expression	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of lipid storage	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of type I interferon production	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
response to interferon-beta	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
regulation of protein-containing complex assembly	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
mRNA stabilization	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
defense response to virus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
type I interferon-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
interleukin-17-mediated signaling pathway	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cellular response to virus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
peptidyl-serine phosphorylation	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
MAPK cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
oocyte maturation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hypoxia	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
sprouting angiogenesis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
adaptive immune response	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
marginal zone B cell differentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to ischemia	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein phosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular defense response	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
signal transduction	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell surface receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
signal complex assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
integrin-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell population proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of cell population proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of cell shape	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to xenobiotic stimulus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to mechanical stimulus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hormone	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to glucose	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of endothelial cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of muscle cell apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of macrophage chemotaxis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of neuron projection development	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glial cell proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of cell adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell growth	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of bone mineralization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of actin filament polymerization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cortical cytoskeleton organization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neuron projection development	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of actin cytoskeleton organization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to immobilization stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cocaine	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hydrogen peroxide	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
activation of Janus kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
stress fiber assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cation stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of potassium ion transport	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of neuron apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
blood vessel endothelial cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
bone resorption	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to ethanol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of myeloid cell differentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of translation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of angiogenesis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of protein kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of JNK cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein autophosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of synaptic plasticity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cAMP	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to calcium ion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
long-term synaptic potentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
long-term synaptic depression	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein-containing complex assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
chemokine-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular response to retinoic acid	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular response to fluid shear stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
endothelin receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of postsynaptic density assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of B cell chemotaxis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
apoptotic process	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
cell population proliferation	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
hemopoiesis	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
positive regulation of apoptotic process	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
protein autophosphorylation	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
neural precursor cell proliferation	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
protein phosphorylation	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
mitotic sister chromatid segregation	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
DNA repair	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
sister chromatid cohesion	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
mitotic sister chromatid cohesion	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
response to radiation	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
establishment of mitotic sister chromatid cohesion	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
establishment of meiotic sister chromatid cohesion	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
somatic stem cell population maintenance	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
cell division	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
meiotic cell cycle	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
response to DNA damage checkpoint signaling	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
mitotic spindle assembly	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
double-strand break repair via homologous recombination	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
chromatin remodeling	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
negative regulation of gene expression	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
regulation of cell fate specification	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
negative regulation of DNA-templated transcription	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
regulation of synapse assembly	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
terminal button organization	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
regulation of stem cell differentiation	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
DNA damage checkpoint signaling	Serine/threonine-protein kinase 38	Homo sapiens (human)
chromatin organization	Serine/threonine-protein kinase 38	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 38	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase 38	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase 38	Homo sapiens (human)
protein modification process	Serine/threonine-protein kinase 38	Homo sapiens (human)
negative regulation of MAP kinase activity	Serine/threonine-protein kinase 38	Homo sapiens (human)
postsynapse organization	Serine/threonine-protein kinase 38	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase 38	Homo sapiens (human)
neural crest cell migration	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of protein phosphorylation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
signal transduction	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
nervous system development	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
synapse assembly	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
heart development	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
lactation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
negative regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
embryonic pattern specification	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cell migration	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
central nervous system morphogenesis	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
olfactory bulb interneuron differentiation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
regulation of cell migration	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
ERBB2-ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
ERBB4-ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic process	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cell fate commitment	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
protein autophosphorylation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
mammary gland epithelial cell differentiation	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
mammary gland alveolus development	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cardiac muscle tissue regeneration	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesis	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of protein localization to cell surface	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
negative regulation of apoptotic process	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of kinase activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
multicellular organism development	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
neurogenesis	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
positive regulation of protein phosphorylation	Ephrin type-A receptor 7	Homo sapiens (human)
brain development	Ephrin type-A receptor 7	Homo sapiens (human)
phosphorylation	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of cell-cell adhesion	Ephrin type-A receptor 7	Homo sapiens (human)
retinal ganglion cell axon guidance	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of protein autophosphorylation	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of cysteine-type endopeptidase activity involved in apoptotic process	Ephrin type-A receptor 7	Homo sapiens (human)
positive regulation of neuron apoptotic process	Ephrin type-A receptor 7	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-A receptor 7	Homo sapiens (human)
negative regulation of collateral sprouting	Ephrin type-A receptor 7	Homo sapiens (human)
branching morphogenesis of a nerve	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Ephrin type-A receptor 7	Homo sapiens (human)
modulation of chemical synaptic transmission	Ephrin type-A receptor 7	Homo sapiens (human)
negative chemotaxis	Ephrin type-A receptor 7	Homo sapiens (human)
neuron apoptotic process	Ephrin type-A receptor 7	Homo sapiens (human)
negative regulation of synapse assembly	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Ephrin type-A receptor 7	Homo sapiens (human)
nephric duct morphogenesis	Ephrin type-A receptor 7	Homo sapiens (human)
regulation of postsynapse organization	Ephrin type-A receptor 7	Homo sapiens (human)
axon guidance	Ephrin type-A receptor 7	Homo sapiens (human)
protein phosphorylation	Ephrin type-A receptor 7	Homo sapiens (human)
cholesterol biosynthetic process	Delta(24)-sterol reductase	Homo sapiens (human)
cholesterol biosynthetic process	Delta(24)-sterol reductase	Homo sapiens (human)
Ras protein signal transduction	Delta(24)-sterol reductase	Homo sapiens (human)
protein localization	Delta(24)-sterol reductase	Homo sapiens (human)
negative regulation of cell population proliferation	Delta(24)-sterol reductase	Homo sapiens (human)
response to hormone	Delta(24)-sterol reductase	Homo sapiens (human)
tissue development	Delta(24)-sterol reductase	Homo sapiens (human)
male genitalia development	Delta(24)-sterol reductase	Homo sapiens (human)
plasminogen activation	Delta(24)-sterol reductase	Homo sapiens (human)
cholesterol biosynthetic process via desmosterol	Delta(24)-sterol reductase	Homo sapiens (human)
cholesterol biosynthetic process via lathosterol	Delta(24)-sterol reductase	Homo sapiens (human)
amyloid precursor protein catabolic process	Delta(24)-sterol reductase	Homo sapiens (human)
skin development	Delta(24)-sterol reductase	Homo sapiens (human)
membrane organization	Delta(24)-sterol reductase	Homo sapiens (human)
steroid metabolic process	Delta(24)-sterol reductase	Homo sapiens (human)
protein phosphorylation	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
chemical synaptic transmission	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
positive regulation of cell growth	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
negative regulation of TOR signaling	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
intracellular signal transduction	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
negative regulation of apoptotic process	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
regulation of translation in response to stress	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
positive regulation of cell differentiation	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
hepatocyte proliferation	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
positive regulation of hepatic stellate cell activation	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
protein phosphorylation	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
smooth muscle contraction	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
tonic smooth muscle contraction	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of cell migration	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
bleb assembly	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of calcium ion transport	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
aorta smooth muscle tissue morphogenesis	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cellular hypotonic response	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of wound healing	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of erythrocyte differentiation	Mitogen-activated protein kinase 11	Homo sapiens (human)
osteoblast differentiation	Mitogen-activated protein kinase 11	Homo sapiens (human)
positive regulation of gene expression	Mitogen-activated protein kinase 11	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Mitogen-activated protein kinase 11	Homo sapiens (human)
positive regulation of interleukin-12 production	Mitogen-activated protein kinase 11	Homo sapiens (human)
p38MAPK cascade	Mitogen-activated protein kinase 11	Homo sapiens (human)
positive regulation of muscle cell differentiation	Mitogen-activated protein kinase 11	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 11	Homo sapiens (human)
cardiac muscle cell proliferation	Mitogen-activated protein kinase 11	Homo sapiens (human)
negative regulation of cardiac muscle cell proliferation	Mitogen-activated protein kinase 11	Homo sapiens (human)
bone development	Mitogen-activated protein kinase 11	Homo sapiens (human)
cellular response to interleukin-1	Mitogen-activated protein kinase 11	Homo sapiens (human)
cellular response to UV-B	Mitogen-activated protein kinase 11	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase 11	Homo sapiens (human)
cellular response to virus	Mitogen-activated protein kinase 11	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 11	Homo sapiens (human)
G1 to G0 transition	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of cell growth	Serine/threonine-protein kinase STK11	Homo sapiens (human)
tissue homeostasis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
vasculature development	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein dephosphorylation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase STK11	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase STK11	Homo sapiens (human)
spermatogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
axonogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of cell population proliferation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
response to ionizing radiation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase STK11	Homo sapiens (human)
response to activity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
establishment of cell polarity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of cell growth	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathway	Serine/threonine-protein kinase STK11	Homo sapiens (human)
activation of protein kinase activity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
response to glucagon	Serine/threonine-protein kinase STK11	Homo sapiens (human)
response to lipid	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein localization to nucleus	Serine/threonine-protein kinase STK11	Homo sapiens (human)
glucose homeostasis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
anoikis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive thymic T cell selection	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of gluconeogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of dendrite morphogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of axonogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
T cell receptor signaling pathway	Serine/threonine-protein kinase STK11	Homo sapiens (human)
Golgi localization	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of cell cycle	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase STK11	Homo sapiens (human)
epithelial cell proliferation involved in prostate gland development	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of epithelial cell proliferation involved in prostate gland development	Serine/threonine-protein kinase STK11	Homo sapiens (human)
cellular response to UV-B	Serine/threonine-protein kinase STK11	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Serine/threonine-protein kinase STK11	Homo sapiens (human)
response to thyroid hormone	Serine/threonine-protein kinase STK11	Homo sapiens (human)
dendrite extension	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of protein localization to nucleus	Serine/threonine-protein kinase STK11	Homo sapiens (human)
positive regulation of vesicle transport along microtubule	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase STK11	Homo sapiens (human)
negative regulation of TORC1 signaling	Serine/threonine-protein kinase STK11	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase STK11	Homo sapiens (human)
regulation of Wnt signaling pathway	Serine/threonine-protein kinase STK11	Homo sapiens (human)
B cell homeostasis	Serine/threonine-protein kinase N1	Homo sapiens (human)
B cell apoptotic process	Serine/threonine-protein kinase N1	Homo sapiens (human)
negative regulation of protein phosphorylation	Serine/threonine-protein kinase N1	Homo sapiens (human)
regulation of germinal center formation	Serine/threonine-protein kinase N1	Homo sapiens (human)
regulation of immunoglobulin production	Serine/threonine-protein kinase N1	Homo sapiens (human)
renal system process	Serine/threonine-protein kinase N1	Homo sapiens (human)
chromatin remodeling	Serine/threonine-protein kinase N1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase N1	Homo sapiens (human)
hyperosmotic response	Serine/threonine-protein kinase N1	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase N1	Homo sapiens (human)
epithelial cell migration	Serine/threonine-protein kinase N1	Homo sapiens (human)
negative regulation of B cell proliferation	Serine/threonine-protein kinase N1	Homo sapiens (human)
post-translational protein modification	Serine/threonine-protein kinase N1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Serine/threonine-protein kinase N1	Homo sapiens (human)
spleen development	Serine/threonine-protein kinase N1	Homo sapiens (human)
regulation of androgen receptor signaling pathway	Serine/threonine-protein kinase N1	Homo sapiens (human)
regulation of cell motility	Serine/threonine-protein kinase N1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase N1	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase N2	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase N2	Homo sapiens (human)
cell adhesion	Serine/threonine-protein kinase N2	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase N2	Homo sapiens (human)
epithelial cell migration	Serine/threonine-protein kinase N2	Homo sapiens (human)
cell projection organization	Serine/threonine-protein kinase N2	Homo sapiens (human)
positive regulation of cytokinesis	Serine/threonine-protein kinase N2	Homo sapiens (human)
apical junction assembly	Serine/threonine-protein kinase N2	Homo sapiens (human)
positive regulation of viral genome replication	Serine/threonine-protein kinase N2	Homo sapiens (human)
positive regulation of mitotic cell cycle	Serine/threonine-protein kinase N2	Homo sapiens (human)
cell division	Serine/threonine-protein kinase N2	Homo sapiens (human)
regulation of cell motility	Serine/threonine-protein kinase N2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase N2	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase N2	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to lipopolysaccharide	Mitogen-activated protein kinase 14	Homo sapiens (human)
DNA damage checkpoint signaling	Mitogen-activated protein kinase 14	Homo sapiens (human)
cell morphogenesis	Mitogen-activated protein kinase 14	Homo sapiens (human)
cartilage condensation	Mitogen-activated protein kinase 14	Homo sapiens (human)
angiogenesis	Mitogen-activated protein kinase 14	Homo sapiens (human)
osteoblast differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
placenta development	Mitogen-activated protein kinase 14	Homo sapiens (human)
response to dietary excess	Mitogen-activated protein kinase 14	Homo sapiens (human)
chondrocyte differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Mitogen-activated protein kinase 14	Homo sapiens (human)
glucose metabolic process	Mitogen-activated protein kinase 14	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mitogen-activated protein kinase 14	Homo sapiens (human)
transcription by RNA polymerase II	Mitogen-activated protein kinase 14	Homo sapiens (human)
apoptotic process	Mitogen-activated protein kinase 14	Homo sapiens (human)
chemotaxis	Mitogen-activated protein kinase 14	Homo sapiens (human)
signal transduction	Mitogen-activated protein kinase 14	Homo sapiens (human)
cell surface receptor signaling pathway	Mitogen-activated protein kinase 14	Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathway	Mitogen-activated protein kinase 14	Homo sapiens (human)
skeletal muscle tissue development	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of gene expression	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of myotube differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase 14	Homo sapiens (human)
fatty acid oxidation	Mitogen-activated protein kinase 14	Homo sapiens (human)
platelet activation	Mitogen-activated protein kinase 14	Homo sapiens (human)
regulation of ossification	Mitogen-activated protein kinase 14	Homo sapiens (human)
osteoclast differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of cyclase activity	Mitogen-activated protein kinase 14	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Mitogen-activated protein kinase 14	Homo sapiens (human)
response to muramyl dipeptide	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of interleukin-12 production	Mitogen-activated protein kinase 14	Homo sapiens (human)
response to insulin	Mitogen-activated protein kinase 14	Homo sapiens (human)
negative regulation of hippo signaling	Mitogen-activated protein kinase 14	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Mitogen-activated protein kinase 14	Homo sapiens (human)
response to muscle stretch	Mitogen-activated protein kinase 14	Homo sapiens (human)
p38MAPK cascade	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of protein import into nucleus	Mitogen-activated protein kinase 14	Homo sapiens (human)
signal transduction in response to DNA damage	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of erythrocyte differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of myoblast differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Mitogen-activated protein kinase 14	Homo sapiens (human)
glucose import	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of glucose import	Mitogen-activated protein kinase 14	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Mitogen-activated protein kinase 14	Homo sapiens (human)
stem cell differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
striated muscle cell differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of muscle cell differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of cardiac muscle cell proliferation	Mitogen-activated protein kinase 14	Homo sapiens (human)
bone development	Mitogen-activated protein kinase 14	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to lipoteichoic acid	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to tumor necrosis factor	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to ionizing radiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to UV-B	Mitogen-activated protein kinase 14	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase 14	Homo sapiens (human)
stress-induced premature senescence	Mitogen-activated protein kinase 14	Homo sapiens (human)
cellular response to virus	Mitogen-activated protein kinase 14	Homo sapiens (human)
regulation of synaptic membrane adhesion	Mitogen-activated protein kinase 14	Homo sapiens (human)
regulation of cytokine production involved in inflammatory response	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of myoblast fusion	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Mitogen-activated protein kinase 14	Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine production	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
adaptive immune response	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
protein phosphorylation	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
inflammatory response	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
signal transduction	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
long-term memory	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
regulation of T cell differentiation in thymus	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
myeloid dendritic cell differentiation	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
regulation of osteoclast differentiation	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
positive regulation of DNA-templated transcription	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
protein autophosphorylation	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
peptidyl-serine phosphorylation	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
intracellular signal transduction	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
microtubule-based process	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
positive regulation of JUN kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
positive regulation of neuron apoptotic process	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
cell cycle G1/S phase transition	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
positive regulation of JNK cascade	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
positive regulation of apoptotic process	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
MAPK cascade	MAP kinase-activated protein kinase 3	Homo sapiens (human)
toll-like receptor signaling pathway	MAP kinase-activated protein kinase 3	Homo sapiens (human)
signal transduction	MAP kinase-activated protein kinase 3	Homo sapiens (human)
peptidyl-serine phosphorylation	MAP kinase-activated protein kinase 3	Homo sapiens (human)
response to lipopolysaccharide	MAP kinase-activated protein kinase 3	Homo sapiens (human)
response to cytokine	MAP kinase-activated protein kinase 3	Homo sapiens (human)
macropinocytosis	MAP kinase-activated protein kinase 3	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	MAP kinase-activated protein kinase 3	Homo sapiens (human)
intracellular signal transduction	MAP kinase-activated protein kinase 3	Homo sapiens (human)
protein autophosphorylation	MAP kinase-activated protein kinase 3	Homo sapiens (human)
ossification	Discoidin domain-containing receptor 2	Homo sapiens (human)
endochondral bone growth	Discoidin domain-containing receptor 2	Homo sapiens (human)
cell adhesion	Discoidin domain-containing receptor 2	Homo sapiens (human)
signal transduction	Discoidin domain-containing receptor 2	Homo sapiens (human)
regulation of extracellular matrix disassembly	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of fibroblast migration	Discoidin domain-containing receptor 2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Discoidin domain-containing receptor 2	Homo sapiens (human)
collagen fibril organization	Discoidin domain-containing receptor 2	Homo sapiens (human)
regulation of bone mineralization	Discoidin domain-containing receptor 2	Homo sapiens (human)
biomineral tissue development	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Discoidin domain-containing receptor 2	Homo sapiens (human)
regulation of tissue remodeling	Discoidin domain-containing receptor 2	Homo sapiens (human)
chondrocyte proliferation	Discoidin domain-containing receptor 2	Homo sapiens (human)
response to muscle stretch	Discoidin domain-containing receptor 2	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Discoidin domain-containing receptor 2	Homo sapiens (human)
negative regulation of apoptotic process	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of osteoblast differentiation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of protein kinase activity	Discoidin domain-containing receptor 2	Homo sapiens (human)
protein autophosphorylation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of fibroblast proliferation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Discoidin domain-containing receptor 2	Homo sapiens (human)
cellular response to hypoxia	Discoidin domain-containing receptor 2	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of extracellular matrix disassembly	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of wound healing	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Discoidin domain-containing receptor 2	Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell death	Discoidin domain-containing receptor 2	Homo sapiens (human)
cellular response to angiotensin	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of hepatic stellate cell proliferation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of hepatic stellate cell activation	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of neuron projection development	Discoidin domain-containing receptor 2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Discoidin domain-containing receptor 2	Homo sapiens (human)
multicellular organism development	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of kinase activity	Discoidin domain-containing receptor 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Discoidin domain-containing receptor 2	Homo sapiens (human)
protein phosphorylation	AP2-associated protein kinase 1	Homo sapiens (human)
regulation of protein localization	AP2-associated protein kinase 1	Homo sapiens (human)
positive regulation of Notch signaling pathway	AP2-associated protein kinase 1	Homo sapiens (human)
protein stabilization	AP2-associated protein kinase 1	Homo sapiens (human)
membrane organization	AP2-associated protein kinase 1	Homo sapiens (human)
presynaptic endocytosis	AP2-associated protein kinase 1	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	AP2-associated protein kinase 1	Homo sapiens (human)
regulation of vascular permeability involved in acute inflammatory response	Myosin light chain kinase 3	Homo sapiens (human)
protein phosphorylation	Myosin light chain kinase 3	Homo sapiens (human)
sarcomere organization	Myosin light chain kinase 3	Homo sapiens (human)
sarcomerogenesis	Myosin light chain kinase 3	Homo sapiens (human)
cardiac myofibril assembly	Myosin light chain kinase 3	Homo sapiens (human)
positive regulation of sarcomere organization	Myosin light chain kinase 3	Homo sapiens (human)
cellular response to interleukin-1	Myosin light chain kinase 3	Homo sapiens (human)
biological_process	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
cellular response to heat	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
protein stabilization	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
protein folding	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
natural killer cell differentiation	Rab-like protein 3	Homo sapiens (human)
B cell differentiation	Rab-like protein 3	Homo sapiens (human)
T cell differentiation in thymus	Rab-like protein 3	Homo sapiens (human)
regulation of Ras protein signal transduction	Rab-like protein 3	Homo sapiens (human)
protein stabilization	Rab-like protein 3	Homo sapiens (human)
regulation of protein lipidation	Rab-like protein 3	Homo sapiens (human)
intracellular protein transport	Rab-like protein 3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cell migration	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
actin cytoskeleton organization	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
actomyosin structure organization	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
actin cytoskeleton organization	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
actomyosin structure organization	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
fatty acid beta-oxidation	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenase	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
smoothened signaling pathway	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
negative regulation of smoothened signaling pathway	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
positive regulation of smoothened signaling pathway	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
fibroblast activation	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
cellular senescence	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
reticulophagy	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
piecemeal microautophagy of the nucleus	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
response to starvation	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
autophagosome assembly	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
regulation of autophagy	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
fatty acid beta-oxidation	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenase	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
mRNA processing	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
rRNA catabolic process	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
apoptotic chromosome condensation	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
IRE1-mediated unfolded protein response	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
neuron migration	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
positive regulation of neuron projection development	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
Wnt signaling pathway	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
establishment of cell polarity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
activation of protein kinase activity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
regulation of axonogenesis	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
regulation of cytoskeleton organization	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
mitochondrion localization	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
axon development	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
establishment or maintenance of cell polarity regulating cell shape	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
regulation of microtubule binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
microtubule cytoskeleton organization	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
central nervous system development	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
DNA duplex unwinding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
mitochondrial large ribosomal subunit assembly	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
microtubule cytoskeleton organization	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
DNA repair	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
negative regulation of microtubule depolymerization	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
phosphorylation	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
central nervous system neuron development	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
positive regulation of JNK cascade	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
regulation of cytoskeleton organization	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
neuron cellular homeostasis	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
execution phase of apoptosis	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
positive regulation of protein acetylation	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein phosphorylation	STE20-related kinase adapter protein alpha	Homo sapiens (human)
G1 to G0 transition	STE20-related kinase adapter protein alpha	Homo sapiens (human)
protein export from nucleus	STE20-related kinase adapter protein alpha	Homo sapiens (human)
activation of protein kinase activity	STE20-related kinase adapter protein alpha	Homo sapiens (human)
skeletal muscle contraction	Myosin-14	Homo sapiens (human)
mitochondrion organization	Myosin-14	Homo sapiens (human)
skeletal muscle tissue development	Myosin-14	Homo sapiens (human)
sensory perception of sound	Myosin-14	Homo sapiens (human)
regulation of cell shape	Myosin-14	Homo sapiens (human)
neuronal action potential	Myosin-14	Homo sapiens (human)
actin filament-based movement	Myosin-14	Homo sapiens (human)
actomyosin structure organization	Myosin-14	Homo sapiens (human)
vocalization behavior	Myosin-14	Homo sapiens (human)
negative regulation of mitochondrial fusion	AarF domain-containing protein kinase 1	Homo sapiens (human)
positive regulation of cristae formation	AarF domain-containing protein kinase 1	Homo sapiens (human)
mitochondrion organization	AarF domain-containing protein kinase 1	Homo sapiens (human)
lipid homeostasis	AarF domain-containing protein kinase 1	Homo sapiens (human)
protein localization	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
regulation of apoptotic process	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
U2-type prespliceosome assembly	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
response to UV	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
response to tumor necrosis factor	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
MAPK cascade	MAP kinase-activated protein kinase 5	Homo sapiens (human)
regulation of translation	MAP kinase-activated protein kinase 5	Homo sapiens (human)
signal transduction	MAP kinase-activated protein kinase 5	Homo sapiens (human)
Ras protein signal transduction	MAP kinase-activated protein kinase 5	Homo sapiens (human)
negative regulation of TOR signaling	MAP kinase-activated protein kinase 5	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein autophosphorylation	MAP kinase-activated protein kinase 5	Homo sapiens (human)
positive regulation of telomerase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
positive regulation of dendritic spine development	MAP kinase-activated protein kinase 5	Homo sapiens (human)
cellular senescence	MAP kinase-activated protein kinase 5	Homo sapiens (human)
stress-induced premature senescence	MAP kinase-activated protein kinase 5	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	MAP kinase-activated protein kinase 5	Homo sapiens (human)
positive regulation of telomere capping	MAP kinase-activated protein kinase 5	Homo sapiens (human)
peptidyl-serine phosphorylation	MAP kinase-activated protein kinase 5	Homo sapiens (human)
microvillus assembly	Misshapen-like kinase 1	Homo sapiens (human)
regulation of cell-matrix adhesion	Misshapen-like kinase 1	Homo sapiens (human)
protein phosphorylation	Misshapen-like kinase 1	Homo sapiens (human)
JNK cascade	Misshapen-like kinase 1	Homo sapiens (human)
chemical synaptic transmission	Misshapen-like kinase 1	Homo sapiens (human)
brain development	Misshapen-like kinase 1	Homo sapiens (human)
regulation of cell-cell adhesion	Misshapen-like kinase 1	Homo sapiens (human)
actin cytoskeleton organization	Misshapen-like kinase 1	Homo sapiens (human)
regulation of cell migration	Misshapen-like kinase 1	Homo sapiens (human)
positive regulation of JNK cascade	Misshapen-like kinase 1	Homo sapiens (human)
protein autophosphorylation	Misshapen-like kinase 1	Homo sapiens (human)
dendrite morphogenesis	Misshapen-like kinase 1	Homo sapiens (human)
positive regulation of p38MAPK cascade	Misshapen-like kinase 1	Homo sapiens (human)
regulation of AMPA receptor activity	Misshapen-like kinase 1	Homo sapiens (human)
MAPK cascade	Misshapen-like kinase 1	Homo sapiens (human)
neuron projection morphogenesis	Misshapen-like kinase 1	Homo sapiens (human)
regulation of MAPK cascade	Misshapen-like kinase 1	Homo sapiens (human)
protein phosphorylation	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
ubiquinone biosynthetic process	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
phosphorylation	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
regulation of autophagy	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
positive regulation of autophagosome assembly	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase 15	Homo sapiens (human)
regulation of COPII vesicle coating	Mitogen-activated protein kinase 15	Homo sapiens (human)
DNA damage response	Mitogen-activated protein kinase 15	Homo sapiens (human)
endoplasmic reticulum organization	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of cell population proliferation	Mitogen-activated protein kinase 15	Homo sapiens (human)
regulation of autophagy	Mitogen-activated protein kinase 15	Homo sapiens (human)
negative regulation of cell migration	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of telomerase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
dopamine uptake	Mitogen-activated protein kinase 15	Homo sapiens (human)
regulation of cilium assembly	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of telomere capping	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein localization to ciliary transition zone	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of metaphase/anaphase transition of meiosis I	Mitogen-activated protein kinase 15	Homo sapiens (human)
positive regulation of spindle assembly	Mitogen-activated protein kinase 15	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase 15	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
regulation of mitotic cell cycle	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
cell division	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
regulation of mitotic cell cycle	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
cellular response to potassium ion	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
spindle assembly	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
positive regulation of telomerase activity	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
positive regulation of telomere capping	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
spliceosomal complex assembly	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine production	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
double-strand break repair	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
tRNA splicing, via endonucleolytic cleavage and ligation	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
regulation of translational initiation	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
DNA duplex unwinding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
response to exogenous dsRNA	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
innate immune response	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
defense response to virus	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
nucleic acid metabolic process	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
protein localization to cytoplasmic stress granule	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
gastrulation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of glucose transmembrane transport	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
animal organ regeneration	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of mast cell cytokine production	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
intracellular signal transduction	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
common myeloid progenitor cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of mast cell activation by Fc-epsilon receptor signaling pathway	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
mast cell degranulation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
steroid hormone mediated signaling pathway	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
cellular response to leptin stimulus	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
cellular respiration	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
fat cell differentiation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
regulation of type B pancreatic cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulus	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
cellular response to catecholamine stimulus	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
energy homeostasis	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of monocyte aggregation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migration	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
positive regulation of feeding behavior	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
cell population proliferation	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
positive regulation of MAPK cascade	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristate	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Aurora kinase B	Homo sapiens (human)
mitotic cell cycle	Aurora kinase B	Homo sapiens (human)
mitotic cytokinesis	Aurora kinase B	Homo sapiens (human)
negative regulation of B cell apoptotic process	Aurora kinase B	Homo sapiens (human)
protein phosphorylation	Aurora kinase B	Homo sapiens (human)
spindle organization	Aurora kinase B	Homo sapiens (human)
attachment of spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
abscission	Aurora kinase B	Homo sapiens (human)
negative regulation of protein binding	Aurora kinase B	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Aurora kinase B	Homo sapiens (human)
negative regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
positive regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
protein localization to kinetochore	Aurora kinase B	Homo sapiens (human)
cellular response to UV	Aurora kinase B	Homo sapiens (human)
cleavage furrow formation	Aurora kinase B	Homo sapiens (human)
post-translational protein modification	Aurora kinase B	Homo sapiens (human)
cell cycle G2/M phase transition	Aurora kinase B	Homo sapiens (human)
mitotic cytokinesis checkpoint signaling	Aurora kinase B	Homo sapiens (human)
negative regulation of innate immune response	Aurora kinase B	Homo sapiens (human)
protein autophosphorylation	Aurora kinase B	Homo sapiens (human)
mitotic spindle midzone assembly	Aurora kinase B	Homo sapiens (human)
positive regulation of telomerase activity	Aurora kinase B	Homo sapiens (human)
regulation of chromosome segregation	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic sister chromatid segregation	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpoint	Aurora kinase B	Homo sapiens (human)
mitotic spindle assembly	Aurora kinase B	Homo sapiens (human)
negative regulation of cGAS/STING signaling pathway	Aurora kinase B	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic sister chromatid separation	Aurora kinase B	Homo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic cytokinesis	Aurora kinase B	Homo sapiens (human)
positive regulation of telomere capping	Aurora kinase B	Homo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
mitotic spindle organization	Aurora kinase B	Homo sapiens (human)
regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
microtubule cytoskeleton organization	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
positive regulation of cell cycle	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
microtubule cytoskeleton organization	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
microtubule bundle formation	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
protein phosphorylation	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
nervous system development	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
positive regulation of programmed cell death	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cilium organization	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
positive regulation of cilium assembly	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
regulation of centrosome cycle	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cell division	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
positive regulation of protein localization to centrosome	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
intracellular signal transduction	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
peptidyl-serine phosphorylation	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
cell division	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein phosphorylation	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
regulation of respiratory gaseous exchange	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of translation	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
protein autophosphorylation	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
regulation of glucagon secretion	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
energy homeostasis	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
MAPK cascade	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein phosphorylation	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
calcium-mediated signaling	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
cellular response to reactive oxygen species	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
regulation of protein kinase activity	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein autophosphorylation	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
CAMKK-AMPK signaling cascade	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
positive regulation of autophagy of mitochondrion	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein phosphorylation	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
tRNA processing	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
tRNA threonylcarbamoyladenosine metabolic process	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
mitotic cell cycle	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
regulation of mitotic nuclear division	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycle	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
protein phosphorylation	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
negative regulation of G2/MI transition of meiotic cell cycle	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
meiotic cell cycle	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
response to ischemia	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular response to amino acid starvation	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
response to endoplasmic reticulum stress	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
neuron intrinsic apoptotic signaling pathway in response to oxidative stress	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of apoptotic process	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of JUN kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
innate immune response	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of myoblast differentiation	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of protein kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of DNA-templated transcription	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of JNK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
neuron apoptotic process	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular response to hydrogen peroxide	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular response to tumor necrosis factor	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
endothelial cell apoptotic process	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular senescence	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
apoptotic signaling pathway	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
programmed necrotic cell death	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular response to reactive nitrogen species	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cellular response to stress	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
blood vessel development	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
positive regulation of cell proliferation in bone marrow	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
positive regulation of p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
negative regulation of cellular senescence	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
acute inflammatory response	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
phagocytosis	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
negative regulation of cell population proliferation	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
regulation of eIF2 alpha phosphorylation by heme	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
macrophage differentiation	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
negative regulation of translational initiation by iron	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
protoporphyrinogen IX metabolic process	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
protein autophosphorylation	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
negative regulation of hemoglobin biosynthetic process	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
establishment of localization in cell	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
multicellular organismal-level iron ion homeostasis	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
integrated stress response signaling	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
HRI-mediated signaling	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
positive regulation of mitophagy	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
response to iron ion starvation	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylation	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
regulation of osteoclast differentiation	Peroxiredoxin-like 2A	Homo sapiens (human)
cellular oxidant detoxification	Peroxiredoxin-like 2A	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Nucleolar GTP-binding protein 1	Homo sapiens (human)
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)	Nucleolar GTP-binding protein 1	Homo sapiens (human)
osteoblast differentiation	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of DNA replication	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of cell population proliferation	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of cell-cell adhesion	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of cell migration	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of protein ubiquitination	Nucleolar GTP-binding protein 1	Homo sapiens (human)
negative regulation of collagen binding	Nucleolar GTP-binding protein 1	Homo sapiens (human)
ribosomal large subunit biogenesis	Nucleolar GTP-binding protein 1	Homo sapiens (human)
protein stabilization	Nucleolar GTP-binding protein 1	Homo sapiens (human)
angiogenesis	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Serine/threonine-protein kinase D2	Homo sapiens (human)
adaptive immune response	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase D2	Homo sapiens (human)
cell adhesion	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of endothelial cell migration	Serine/threonine-protein kinase D2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase D2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase D2	Homo sapiens (human)
sphingolipid biosynthetic process	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of interleukin-2 production	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of interleukin-8 production	Serine/threonine-protein kinase D2	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase D2	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of angiogenesis	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of cell adhesion	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase D2	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
T cell receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of T cell receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
endothelial tube morphogenesis	Serine/threonine-protein kinase D2	Homo sapiens (human)
regulation of T cell apoptotic process	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Serine/threonine-protein kinase D2	Homo sapiens (human)
positive regulation of endothelial cell chemotaxis	Serine/threonine-protein kinase D2	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein phosphorylation	NUAK family SNF1-like kinase 2	Homo sapiens (human)
apoptotic process	NUAK family SNF1-like kinase 2	Homo sapiens (human)
actin cytoskeleton organization	NUAK family SNF1-like kinase 2	Homo sapiens (human)
protein localization to nucleus	NUAK family SNF1-like kinase 2	Homo sapiens (human)
regulation of hippo signaling	NUAK family SNF1-like kinase 2	Homo sapiens (human)
cellular response to glucose starvation	NUAK family SNF1-like kinase 2	Homo sapiens (human)
negative regulation of apoptotic process	NUAK family SNF1-like kinase 2	Homo sapiens (human)
rRNA modification	RNA cytidine acetyltransferase	Homo sapiens (human)
regulation of translation	RNA cytidine acetyltransferase	Homo sapiens (human)
protein acetylation	RNA cytidine acetyltransferase	Homo sapiens (human)
regulation of centrosome duplication	RNA cytidine acetyltransferase	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	RNA cytidine acetyltransferase	Homo sapiens (human)
ribosomal small subunit biogenesis	RNA cytidine acetyltransferase	Homo sapiens (human)
positive regulation of translation	RNA cytidine acetyltransferase	Homo sapiens (human)
tRNA acetylation	RNA cytidine acetyltransferase	Homo sapiens (human)
rRNA acetylation involved in maturation of SSU-rRNA	RNA cytidine acetyltransferase	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
regulation of insulin receptor signaling pathway	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
apoptotic process	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
regulation of cell migration	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
cytoplasmic microtubule organization	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
regulation of apoptotic process	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein autophosphorylation	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
regulation of focal adhesion assembly	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
MAPK cascade	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
DNA repair	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
positive regulation of JUN kinase activity	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
negative regulation of JNK cascade	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
positive regulation of JNK cascade	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
neuron projection morphogenesis	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
dTTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate catabolic process	dCTP pyrophosphatase 1	Homo sapiens (human)
DNA protection	dCTP pyrophosphatase 1	Homo sapiens (human)
regulation of RNA splicing	Dual specificity protein kinase CLK4	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Dual specificity protein kinase CLK4	Homo sapiens (human)
positive regulation of platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet activation	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
immune response-regulating signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform gamma-1	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform gamma-1	Homo sapiens (human)
signal transduction	Casein kinase I isoform gamma-1	Homo sapiens (human)
endocytosis	Casein kinase I isoform gamma-1	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform gamma-1	Homo sapiens (human)
regulation of DNA-templated transcription	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cytoskeleton organization	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
learning	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
memory	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
locomotory behavior	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
neuron projection arborization	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
neuron projection extension	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
regulation of MAPK cascade	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
translation	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
phenylalanyl-tRNA aminoacylation	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
protein heterotetramerization	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
positive regulation of Notch signaling pathway	BMP-2-inducible protein kinase	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	BMP-2-inducible protein kinase	Homo sapiens (human)
regulation of bone mineralization	BMP-2-inducible protein kinase	Homo sapiens (human)
ATP metabolic process	Obg-like ATPase 1	Homo sapiens (human)
ribosomal large subunit assembly	Midasin	Homo sapiens (human)
ribosomal large subunit export from nucleus	Midasin	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
neutrophil mediated immunity	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
JNK cascade	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
toll-like receptor 9 signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
interleukin-33-mediated signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
innate immune response	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
neutrophil migration	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
cytokine-mediated signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
Toll signaling pathway	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
cellular response to lipopolysaccharide	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
intracellular signal transduction	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
positive regulation of programmed cell death	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
GCN2-mediated signaling	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
pyroptosis	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
DNA damage checkpoint signaling	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
inflammatory response	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cytoskeleton organization	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
JNK cascade	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cell death	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cell differentiation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
embryonic digit morphogenesis	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
positive regulation of apoptotic process	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein autophosphorylation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
stress-activated MAPK cascade	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
limb development	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cellular response to gamma radiation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cellular response to UV-B	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
positive regulation of mitotic DNA damage checkpoint	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
peptidyl-serine phosphorylation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
regulation of mitotic metaphase/anaphase transition	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
chromosome segregation	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
transcription by RNA polymerase II	Cyclin-dependent kinase 12	Homo sapiens (human)
mRNA processing	Cyclin-dependent kinase 12	Homo sapiens (human)
RNA splicing	Cyclin-dependent kinase 12	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Cyclin-dependent kinase 12	Homo sapiens (human)
regulation of MAP kinase activity	Cyclin-dependent kinase 12	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 12	Homo sapiens (human)
protein autophosphorylation	Cyclin-dependent kinase 12	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent kinase 12	Homo sapiens (human)
negative regulation of stem cell differentiation	Cyclin-dependent kinase 12	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 12	Homo sapiens (human)
aerobic respiration	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
negative regulation of cell growth	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrial respiratory chain complex I assembly	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
cellular response to interferon-beta	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
proton motive force-driven mitochondrial ATP synthesis	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
protein insertion into mitochondrial inner membrane	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
positive regulation of protein catabolic process	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
negative regulation of DNA-templated transcription	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
cellular response to retinoic acid	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
reactive oxygen species metabolic process	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
apoptotic signaling pathway	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
extrinsic apoptotic signaling pathway	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
positive regulation of execution phase of apoptosis	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 26	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase 26	Homo sapiens (human)
cellular response to starvation	Serine/threonine-protein kinase 26	Homo sapiens (human)
microvillus assembly	Serine/threonine-protein kinase 26	Homo sapiens (human)
negative regulation of cell migration	Serine/threonine-protein kinase 26	Homo sapiens (human)
cellular response to oxidative stress	Serine/threonine-protein kinase 26	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase 26	Homo sapiens (human)
regulation of apoptotic process	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 26	Homo sapiens (human)
tricarboxylic acid cycle	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinate metabolic process	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinyl-CoA pathway	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinyl-CoA catabolic process	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinyl-CoA metabolic process	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
MAPK cascade	Serine/threonine-protein kinase NLK	Homo sapiens (human)
regulation of DNA-templated transcription	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase NLK	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Serine/threonine-protein kinase NLK	Homo sapiens (human)
Wnt signaling pathway, calcium modulating pathway	Serine/threonine-protein kinase NLK	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase NLK	Homo sapiens (human)
negative regulation of Wnt signaling pathway	Serine/threonine-protein kinase NLK	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein stabilization	Serine/threonine-protein kinase NLK	Homo sapiens (human)
cellular response to osmotic stress	Serine/threonine-protein kinase NLK	Homo sapiens (human)
negative regulation of TORC1 signaling	Serine/threonine-protein kinase NLK	Homo sapiens (human)
positive regulation of receptor signaling pathway via STAT	Serine/threonine-protein kinase NLK	Homo sapiens (human)
glycogen metabolic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
regulation of glycolytic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
negative regulation of protein kinase activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
fatty acid biosynthetic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
ATP biosynthetic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
sterol biosynthetic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
regulation of fatty acid metabolic process	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cellular response to nutrient levels	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
intracellular signal transduction	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
positive regulation of protein kinase activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
regulation of fatty acid oxidation	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
regulation of glucose import	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
regulation of catalytic activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
protein phosphorylation	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
activation of innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
inflammatory response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
response to virus	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
negative regulation of gene expression	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of macroautophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
regulation of type I interferon production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of type I interferon production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of interferon-alpha production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of interferon-beta production	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
dendritic cell proliferation	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
defense response to Gram-positive bacterium	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
defense response to virus	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
type I interferon-mediated signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
antiviral innate immune response	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cGAS/STING signaling pathway	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
negative regulation of TORC1 signaling	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of TORC1 signaling	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of xenophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
positive regulation of non-motile cilium assembly	Septin-9	Homo sapiens (human)
protein localization	Septin-9	Homo sapiens (human)
cytoskeleton-dependent cytokinesis	Septin-9	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
signal transduction	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
central nervous system development	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
negative regulation of embryonic development	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
negative regulation of mesoderm development	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
positive regulation of protein phosphorylation	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein phosphorylation	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
cytoskeleton organization	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
response to organonitrogen compound	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
Wnt signaling pathway	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
microvillus assembly	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
actin cytoskeleton organization	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
intracellular signal transduction	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
positive regulation of JNK cascade	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein autophosphorylation	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
regulation of dendrite morphogenesis	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein localization to plasma membrane	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
neuron projection morphogenesis	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
regulation of MAPK cascade	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
MAPK cascade	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
regulation of cell growth	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein targeting to membrane	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
axonogenesis	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
regulation of cell shape	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
cell migration	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
actin cytoskeleton organization	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
positive regulation of protein autophosphorylation	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
activation of protein kinase activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
regulation of actin cytoskeleton organization	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
positive regulation of MAPK cascade	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
positive regulation of JNK cascade	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
focal adhesion assembly	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
stress-activated MAPK cascade	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
basal dendrite morphogenesis	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
basal dendrite arborization	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase ICK	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase ICK	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase ICK	Homo sapiens (human)
intraciliary anterograde transport	Serine/threonine-protein kinase ICK	Homo sapiens (human)
intraciliary retrograde transport	Serine/threonine-protein kinase ICK	Homo sapiens (human)
intraciliary transport	Serine/threonine-protein kinase ICK	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase ICK	Homo sapiens (human)
mitochondrial genome maintenance	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of endothelial cell proliferation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
signal transduction	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of TOR signaling	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of angiogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell size	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
brain morphogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
homeostasis of number of cells within a tissue	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
positive regulation of artery morphogenesis	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
negative regulation of cellular senescence	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
intracellular signal transduction	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
positive regulation of TORC1 signaling	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
positive regulation of TORC2 signaling	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
microtubule cytoskeleton organization	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
intracellular signal transduction	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
regulation of alternative mRNA splicing, via spliceosome	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nuclear-transcribed mRNA catabolic process	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
mRNA processing	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
circadian rhythm	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
RNA splicing	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
positive regulation of circadian rhythm	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
positive regulation of DNA-templated transcription	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosome	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
mRNA stabilization	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
DNA repair	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
myoblast fusion	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
positive regulation of DNA-templated transcription	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
adipose tissue development	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
peptidyl-serine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
peptidyl-threonine phosphorylation	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
protein phosphorylation	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
regulation of T cell mediated cytotoxicity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of adaptive immune response	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of phosphatase activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
activation of protein kinase activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of type II interferon production	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
T cell differentiation in thymus	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein modification process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of apoptotic process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
T cell homeostasis	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of DNA-templated transcription	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of activated T cell proliferation	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein autophosphorylation	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
lymph node development	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
spleen development	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
thymus development	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
defense response to virus	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of necroptotic process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of activation-induced cell death of T cells	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
necroptotic process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
cellular response to hydrogen peroxide	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
reactive oxygen species metabolic process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
apoptotic signaling pathway	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
programmed necrotic cell death	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
necroptotic signaling pathway	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
execution phase of necroptosis	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
amyloid fibril formation	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
signal transduction	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cytoskeleton organization	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
establishment or maintenance of cell polarity	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cell migration	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
actin cytoskeleton organization	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
actomyosin structure organization	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
positive regulation of cytokine production	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of cytokine-mediated signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein phosphorylation	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
response to virus	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
positive regulation of macrophage tolerance induction	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of macrophage cytokine production	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
cytokine-mediated signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
response to peptidoglycan	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
response to lipopolysaccharide	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of interleukin-12 production	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of interleukin-6 production	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of protein catabolic process	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
regulation of protein-containing complex disassembly	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
response to exogenous dsRNA	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of MAP kinase activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
negative regulation of innate immune response	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
response to interleukin-1	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
Toll signaling pathway	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
cellular response to lipopolysaccharide	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
intracellular signal transduction	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase 24	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase 24	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Serine/threonine-protein kinase 24	Homo sapiens (human)
cellular response to starvation	Serine/threonine-protein kinase 24	Homo sapiens (human)
negative regulation of cell migration	Serine/threonine-protein kinase 24	Homo sapiens (human)
cellular response to oxidative stress	Serine/threonine-protein kinase 24	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase 24	Homo sapiens (human)
regulation of axon regeneration	Serine/threonine-protein kinase 24	Homo sapiens (human)
positive regulation of axon regeneration	Serine/threonine-protein kinase 24	Homo sapiens (human)
execution phase of apoptosis	Serine/threonine-protein kinase 24	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform gamma-3	Homo sapiens (human)
protein modification process	Casein kinase I isoform gamma-3	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform gamma-3	Homo sapiens (human)
signal transduction	Casein kinase I isoform gamma-3	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform gamma-3	Homo sapiens (human)
endocytosis	Casein kinase I isoform gamma-3	Homo sapiens (human)
MAPK cascade	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
placenta development	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
response to UV-C	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
regulation of gene expression	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
male germ-line sex determination	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
intracellular signal transduction	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
positive regulation of JUN kinase activity	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
positive regulation of telomerase activity	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
chorionic trophoblast cell differentiation	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
positive regulation of p38MAPK cascade	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
positive regulation of telomere capping	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (529)

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane signaling receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ATP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
SMAD binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
metal ion binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
ATP binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
metal ion binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
DNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
DNA helicase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA helicase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
mRNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
GTPase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ATP binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
transcription factor binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
poly(A) binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
eukaryotic initiation factor 4E binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ribonucleoside triphosphate phosphatase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
translation initiation factor binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA strand annealing activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
signaling adaptor activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA stem-loop binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
gamma-tubulin binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ribosomal small subunit binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
CTPase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein serine/threonine kinase activator activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cadherin binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
mRNA 5'-UTR binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
magnesium ion binding	Pyridoxal kinase	Homo sapiens (human)
ATP binding	Pyridoxal kinase	Homo sapiens (human)
zinc ion binding	Pyridoxal kinase	Homo sapiens (human)
pyridoxal kinase activity	Pyridoxal kinase	Homo sapiens (human)
pyridoxal phosphate binding	Pyridoxal kinase	Homo sapiens (human)
potassium ion binding	Pyridoxal kinase	Homo sapiens (human)
sodium ion binding	Pyridoxal kinase	Homo sapiens (human)
lithium ion binding	Pyridoxal kinase	Homo sapiens (human)
protein homodimerization activity	Pyridoxal kinase	Homo sapiens (human)
transcription coactivator binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
ATP binding	Citron Rho-interacting kinase	Homo sapiens (human)
SH3 domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein kinase binding	Citron Rho-interacting kinase	Homo sapiens (human)
PDZ domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase inhibitor activity	Citron Rho-interacting kinase	Homo sapiens (human)
metal ion binding	Citron Rho-interacting kinase	Homo sapiens (human)
scaffold protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein domain specific binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
histone H3T11 kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Aurora kinase A	Homo sapiens (human)
protein binding	Aurora kinase A	Homo sapiens (human)
ATP binding	Aurora kinase A	Homo sapiens (human)
protein kinase binding	Aurora kinase A	Homo sapiens (human)
ubiquitin protein ligase binding	Aurora kinase A	Homo sapiens (human)
histone H3S10 kinase activity	Aurora kinase A	Homo sapiens (human)
protein heterodimerization activity	Aurora kinase A	Homo sapiens (human)
protein serine kinase activity	Aurora kinase A	Homo sapiens (human)
molecular function activator activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
protein binding	Cyclin-G-associated kinase	Homo sapiens (human)
ATP binding	Cyclin-G-associated kinase	Homo sapiens (human)
cyclin binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein-folding chaperone binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein serine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin binding	Cyclin-G-associated kinase	Homo sapiens (human)
ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
protein binding	Ephrin type-B receptor 6	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 6	Homo sapiens (human)
signaling receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
FAD binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
flavin adenine dinucleotide binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
pristanoyl-CoA oxidase activity	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
fatty acid binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling receptor binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
ATP binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
LIM domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling adaptor activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
identical protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein homodimerization activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
CARD domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
caspase binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
JUN kinase kinase kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein binding	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
ATP binding	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein serine kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
histone H2A kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
magnesium ion binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTPase activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
protein binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTP binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
phosphatidic acid binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTPase-dependent fusogenic activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane bending activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cardiolipin binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
microtubule binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
ATP binding	Putative nucleoside diphosphate kinase	Homo sapiens (human)
metal ion binding	Putative nucleoside diphosphate kinase	Homo sapiens (human)
nucleoside diphosphate kinase activity	Putative nucleoside diphosphate kinase	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
heme binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type 1 angiotensin receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
acetylcholine receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone H3Y41 kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
insulin receptor substrate binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptide hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protease binding	Rho-associated protein kinase 2	Homo sapiens (human)
RNA binding	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
structural molecule activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 2	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 2	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
endopeptidase activator activity	Rho-associated protein kinase 2	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
RNA endonuclease activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
platelet-derived growth factor receptor binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
enzyme binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp70 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ADP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp90 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
unfolded protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein tyrosine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H2AS1 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
RNA binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
RNA helicase activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
helicase activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
protein binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
ATP binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
ATP hydrolysis activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
identical protein binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
single-stranded DNA binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
protein binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
ATP binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
ATP hydrolysis activity	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
chromatin binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
creatine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
microtubule binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nuclear estrogen receptor binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cadherin binding involved in cell-cell adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
supercoiled DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
four-way junction DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
bubble DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transcription coactivator activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase C binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
syntaxin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitogen-activated protein kinase binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
proline-rich region binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
delta-catenin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
growth factor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
RNA polymerase I core binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane signaling receptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signaling receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ATP binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
coreceptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor tyrosine kinase binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
identical protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ErbB-3 class receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein heterodimerization activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein tyrosine kinase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
GPI-linked ephrin receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin p75 receptor binding	High affinity nerve growth factor receptor	Homo sapiens (human)
protein binding	High affinity nerve growth factor receptor	Homo sapiens (human)
ATP binding	High affinity nerve growth factor receptor	Homo sapiens (human)
nerve growth factor receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
kinase binding	High affinity nerve growth factor receptor	Homo sapiens (human)
identical protein binding	High affinity nerve growth factor receptor	Homo sapiens (human)
protein homodimerization activity	High affinity nerve growth factor receptor	Homo sapiens (human)
nerve growth factor binding	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin binding	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
protein binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
GTP binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
metal ion binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G-protein beta/gamma-subunit complex binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G protein-coupled receptor binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
GTPase activity	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
adenine nucleotide transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
RNA binding	ADP/ATP translocase 2	Homo sapiens (human)
ATP:ADP antiporter activity	ADP/ATP translocase 2	Homo sapiens (human)
protein binding	ADP/ATP translocase 2	Homo sapiens (human)
proton transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
adenine transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
oxidative phosphorylation uncoupler activity	ADP/ATP translocase 2	Homo sapiens (human)
ubiquitin protein ligase binding	ADP/ATP translocase 2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
chromatin binding	Protein kinase C beta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
protein kinase C binding	Protein kinase C beta type	Homo sapiens (human)
calcium channel regulator activity	Protein kinase C beta type	Homo sapiens (human)
protein binding	Protein kinase C beta type	Homo sapiens (human)
ATP binding	Protein kinase C beta type	Homo sapiens (human)
zinc ion binding	Protein kinase C beta type	Homo sapiens (human)
nuclear receptor coactivator activity	Protein kinase C beta type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C beta type	Homo sapiens (human)
histone binding	Protein kinase C beta type	Homo sapiens (human)
nuclear androgen receptor binding	Protein kinase C beta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C beta type	Homo sapiens (human)
amyloid-beta binding	Insulin receptor	Homo sapiens (human)
protein tyrosine kinase activity	Insulin receptor	Homo sapiens (human)
insulin receptor activity	Insulin receptor	Homo sapiens (human)
insulin-like growth factor receptor binding	Insulin receptor	Homo sapiens (human)
protein binding	Insulin receptor	Homo sapiens (human)
ATP binding	Insulin receptor	Homo sapiens (human)
GTP binding	Insulin receptor	Homo sapiens (human)
protein domain specific binding	Insulin receptor	Homo sapiens (human)
insulin-like growth factor I binding	Insulin receptor	Homo sapiens (human)
insulin-like growth factor II binding	Insulin receptor	Homo sapiens (human)
cargo receptor activity	Insulin receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Insulin receptor	Homo sapiens (human)
insulin binding	Insulin receptor	Homo sapiens (human)
insulin receptor substrate binding	Insulin receptor	Homo sapiens (human)
protein-containing complex binding	Insulin receptor	Homo sapiens (human)
PTB domain binding	Insulin receptor	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein serine/threonine phosphatase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein phosphatase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
T cell receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
CD4 receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
CD8 receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
ATPase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
alpha-tubulin binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau-protein kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
growth factor receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
disordered domain specific binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
virus receptor activity	Cyclin-dependent kinase 1	Homo sapiens (human)
chromatin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 1	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
Hsp70 protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
purine nucleobase binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
ATP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glucose binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glycogen phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
AMP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
vitamin binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
bile acid binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
identical protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
linear malto-oligosaccharide phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
SHG alpha-glucan phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
pyridoxal phosphate binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
microtubule binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
immunoglobulin receptor binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
phosphatidylinositol binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
protein tyrosine kinase activity	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
macrophage colony-stimulating factor receptor activity	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
protein binding	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
ATP binding	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
protein phosphatase binding	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cytokine binding	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
protein homodimerization activity	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
growth factor binding	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
adenine phosphoribosyltransferase activity	Adenine phosphoribosyltransferase	Homo sapiens (human)
protein binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
AMP binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
adenine binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Yes	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
platelet-derived growth factor receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
integrin binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ubiquitin protein ligase binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
gamma-tubulin binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
glycosphingolipid binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphoprotein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphorylation-dependent protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
calcium ion binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
protein binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
ATP binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
signaling receptor activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
G-protein alpha-subunit binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein tyrosine kinase activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor receptor activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
ATP binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor I binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
identical protein binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor substrate binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein-containing complex binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein transporter activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
RNA binding	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
GTP binding	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
ATP hydrolysis activity	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
signal recognition particle binding	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
GTPase activity	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
protein binding	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
ubiquinol-cytochrome-c reductase activity	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
heme binding	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
metal ion binding	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
protein tyrosine kinase activity	Hepatocyte growth factor receptor	Homo sapiens (human)
protein binding	Hepatocyte growth factor receptor	Homo sapiens (human)
ATP binding	Hepatocyte growth factor receptor	Homo sapiens (human)
semaphorin receptor activity	Hepatocyte growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Hepatocyte growth factor receptor	Homo sapiens (human)
identical protein binding	Hepatocyte growth factor receptor	Homo sapiens (human)
molecular function activator activity	Hepatocyte growth factor receptor	Homo sapiens (human)
hepatocyte growth factor receptor activity	Hepatocyte growth factor receptor	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase HCK	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase HCK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase HCK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase HCK	Homo sapiens (human)
lipid binding	Tyrosine-protein kinase HCK	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase HCK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase HCK	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
protein kinase activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
protein tyrosine kinase activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet activating factor receptor activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor receptor activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor beta-receptor activity	Platelet-derived growth factor receptor beta	Homo sapiens (human)
signaling receptor binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor receptor binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
protein binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
ATP binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
enzyme binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
protein kinase binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
vascular endothelial growth factor binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
platelet-derived growth factor binding	Platelet-derived growth factor receptor beta	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fgr	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
immunoglobulin receptor binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
Fc-gamma receptor I complex binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Fgr	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
MAP kinase kinase kinase activity	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C8	Homo sapiens (human)
protein binding	Cytochrome P450 2C8	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C8	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C8	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C8	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 2C8	Homo sapiens (human)
heme binding	Cytochrome P450 2C8	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C8	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
protein binding	Glycogen phosphorylase, brain form	Homo sapiens (human)
glycogen phosphorylase activity	Glycogen phosphorylase, brain form	Homo sapiens (human)
linear malto-oligosaccharide phosphorylase activity	Glycogen phosphorylase, brain form	Homo sapiens (human)
SHG alpha-glucan phosphorylase activity	Glycogen phosphorylase, brain form	Homo sapiens (human)
pyridoxal phosphate binding	Glycogen phosphorylase, brain form	Homo sapiens (human)
protein serine/threonine kinase activity	Breakpoint cluster region protein	Homo sapiens (human)
protein tyrosine kinase activity	Breakpoint cluster region protein	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Breakpoint cluster region protein	Homo sapiens (human)
GTPase activator activity	Breakpoint cluster region protein	Homo sapiens (human)
protein binding	Breakpoint cluster region protein	Homo sapiens (human)
ATP binding	Breakpoint cluster region protein	Homo sapiens (human)
protein serine kinase activity	Breakpoint cluster region protein	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
transcription factor binding	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
manganese ion binding	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
ribosomal small subunit binding	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
protein tyrosine kinase activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
fibroblast growth factor receptor activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
protein binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
ATP binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
heparin binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
fibroblast growth factor binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
SH2 domain binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
identical protein binding	Fibroblast growth factor receptor 1	Homo sapiens (human)
protein homodimerization activity	Fibroblast growth factor receptor 1	Homo sapiens (human)
receptor-receptor interaction	Fibroblast growth factor receptor 1	Homo sapiens (human)
magnesium ion binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
RNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein kinase C binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP-dependent activity, acting on DNA	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding, bending	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein homodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
ubiquitin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein heterodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 4	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 4	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 4	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 4	Homo sapiens (human)
ATP:ADP antiporter activity	ADP/ATP translocase 3	Homo sapiens (human)
protein binding	ADP/ATP translocase 3	Homo sapiens (human)
nucleotide binding	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
DNA binding	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
RNA binding	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
IMP dehydrogenase activity	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
protein binding	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
metal ion binding	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
protein kinase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein kinase C binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
signaling receptor binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
insulin receptor binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
integrin binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
protein binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ATP binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
phospholipase activator activity	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
enzyme binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
heme binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
nuclear estrogen receptor binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
SH2 domain binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
phospholipase binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
transmembrane transporter binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cadherin binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ephrin receptor binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ATPase binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
phosphoprotein binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
BMP receptor binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
connexin binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
scaffold protein binding	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cAMP-dependent protein kinase regulator activity	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
protein domain specific binding	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
ubiquitin protein ligase binding	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
protein kinase A catalytic subunit binding	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cAMP binding	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
MAP kinase kinase activity	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
calcium ion binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
scaffold protein binding	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
MAP kinase kinase kinase activity	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
phosphorylase kinase activity	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
protein binding	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
calmodulin binding	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
ATP binding	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
enzyme binding	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
tau-protein kinase activity	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
dihydronicotinamide riboside quinone reductase activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
protein binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
zinc ion binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
electron transfer activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
oxidoreductase activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donors	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
chloride ion binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
protein homodimerization activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
FAD binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
melatonin binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
resveratrol binding	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activity	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fer	Homo sapiens (human)
epidermal growth factor receptor binding	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fer	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein phosphatase 1 binding	Tyrosine-protein kinase Fer	Homo sapiens (human)
lipid binding	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fer	Homo sapiens (human)
protein kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
integrin binding	Protein kinase C alpha type	Homo sapiens (human)
protein binding	Protein kinase C alpha type	Homo sapiens (human)
ATP binding	Protein kinase C alpha type	Homo sapiens (human)
zinc ion binding	Protein kinase C alpha type	Homo sapiens (human)
enzyme binding	Protein kinase C alpha type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol binding	Protein kinase C alpha type	Homo sapiens (human)
magnesium ion binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein domain specific binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
manganese ion binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase A regulatory subunit binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
channel activator activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein binding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
ATP binding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
ATP hydrolysis activity	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
protein-macromolecule adaptor activity	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
5'-3' DNA helicase activity	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
metal ion binding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
4 iron, 4 sulfur cluster binding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
DNA helicase activity	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
damaged DNA binding	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha'	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha'	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
GTPase activity	Ras-related protein Rab-6A	Homo sapiens (human)
protein binding	Ras-related protein Rab-6A	Homo sapiens (human)
GTP binding	Ras-related protein Rab-6A	Homo sapiens (human)
protein domain specific binding	Ras-related protein Rab-6A	Homo sapiens (human)
myosin V binding	Ras-related protein Rab-6A	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
fibronectin binding	Ephrin type-A receptor 1	Homo sapiens (human)
protein kinase activity	Ephrin type-A receptor 1	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-A receptor 1	Homo sapiens (human)
ATP binding	Ephrin type-A receptor 1	Homo sapiens (human)
protein kinase binding	Ephrin type-A receptor 1	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Ephrin type-A receptor 1	Homo sapiens (human)
protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
transmembrane signaling receptor activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
protein binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
ATP binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
growth factor binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
protein tyrosine kinase activator activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
ubiquitin protein ligase binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
neuregulin binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
identical protein binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
ErbB-3 class receptor binding	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
protein heterodimerization activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
neuregulin receptor activity	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
phosphoribosylaminoimidazole carboxylase activity	Multifunctional protein ADE2	Homo sapiens (human)
phosphoribosylaminoimidazolesuccinocarboxamide synthase activity	Multifunctional protein ADE2	Homo sapiens (human)
protein binding	Multifunctional protein ADE2	Homo sapiens (human)
ATP binding	Multifunctional protein ADE2	Homo sapiens (human)
identical protein binding	Multifunctional protein ADE2	Homo sapiens (human)
5-amino-4-imidazole carboxylate lyase activity	Multifunctional protein ADE2	Homo sapiens (human)
cadherin binding	Multifunctional protein ADE2	Homo sapiens (human)
DNA binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
transcription coactivator activity	Nucleoside diphosphate kinase B	Homo sapiens (human)
nucleoside diphosphate kinase activity	Nucleoside diphosphate kinase B	Homo sapiens (human)
protein histidine kinase activity	Nucleoside diphosphate kinase B	Homo sapiens (human)
protein binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
ATP binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
GDP binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
metal ion binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
G-quadruplex DNA binding	Nucleoside diphosphate kinase B	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein kinase A regulatory subunit binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
magnesium ion binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ubiquitin protein ligase binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ferrochelatase activity	Ferrochelatase, mitochondrial	Homo sapiens (human)
protein binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
ferrous iron binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
heme binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
iron-responsive element binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
identical protein binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
protein homodimerization activity	Ferrochelatase, mitochondrial	Homo sapiens (human)
2 iron, 2 sulfur cluster binding	Ferrochelatase, mitochondrial	Homo sapiens (human)
protein kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
PDZ domain binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
peptide binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
identical protein binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein phosphatase 2A binding	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK1	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein phosphatase binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
ubiquitin protein ligase binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
CCR5 chemokine receptor binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase JAK1	Homo sapiens (human)
protein binding	G1/S-specific cyclin-E1	Homo sapiens (human)
kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-E1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
magnesium ion binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 2	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein domain specific binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
protein binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
ATP binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
beta-adrenergic receptor kinase activity	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
G protein-coupled receptor binding	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
RNA binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
RNA helicase activity	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
helicase activity	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
protein binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
ATP binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
ATP hydrolysis activity	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
protein domain specific binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cadherin binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
mRNA binding	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
phosphotyrosine residue binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 3	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
phosphatase binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 3	Homo sapiens (human)
DNA-binding transcription factor binding	Mitogen-activated protein kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
protein binding	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
ATP binding	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
tau protein binding	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
tau-protein kinase activity	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
protein serine kinase activity	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
deoxyadenosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxycytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxyguanosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
ATP binding	Deoxycytidine kinase	Homo sapiens (human)
protein homodimerization activity	Deoxycytidine kinase	Homo sapiens (human)
cytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
phosphotyrosine residue binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
DNA binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
phosphatase binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 1	Homo sapiens (human)
virus receptor activity	Ephrin type-A receptor 2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Ephrin type-A receptor 2	Homo sapiens (human)
ephrin receptor activity	Ephrin type-A receptor 2	Homo sapiens (human)
protein binding	Ephrin type-A receptor 2	Homo sapiens (human)
ATP binding	Ephrin type-A receptor 2	Homo sapiens (human)
growth factor binding	Ephrin type-A receptor 2	Homo sapiens (human)
cadherin binding	Ephrin type-A receptor 2	Homo sapiens (human)
molecular function activator activity	Ephrin type-A receptor 2	Homo sapiens (human)
amyloid-beta binding	Ephrin type-B receptor 2	Homo sapiens (human)
protein tyrosine kinase activity	Ephrin type-B receptor 2	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-B receptor 2	Homo sapiens (human)
signaling receptor binding	Ephrin type-B receptor 2	Homo sapiens (human)
protein binding	Ephrin type-B receptor 2	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 2	Homo sapiens (human)
axon guidance receptor activity	Ephrin type-B receptor 2	Homo sapiens (human)
identical protein binding	Ephrin type-B receptor 2	Homo sapiens (human)
protein-containing complex binding	Ephrin type-B receptor 2	Homo sapiens (human)
protein tyrosine kinase activity	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
growth hormone receptor binding	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
protein binding	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
ATP binding	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
type 1 angiotensin receptor binding	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
RNA binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
protein binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
ATP binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
phosphatidylethanolamine binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
enzyme binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
protein kinase binding	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
magnesium ion binding	Wee1-like protein kinase	Homo sapiens (human)
protein tyrosine kinase activity	Wee1-like protein kinase	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Wee1-like protein kinase	Homo sapiens (human)
protein binding	Wee1-like protein kinase	Homo sapiens (human)
ATP binding	Wee1-like protein kinase	Homo sapiens (human)
heme oxygenase (decyclizing) activity	Heme oxygenase 2	Homo sapiens (human)
protein binding	Heme oxygenase 2	Homo sapiens (human)
metal ion binding	Heme oxygenase 2	Homo sapiens (human)
heme binding	Heme oxygenase 2	Homo sapiens (human)
methionine adenosyltransferase activity	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
protein binding	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
ATP binding	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
small molecule binding	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
identical protein binding	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
metal ion binding	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
G protein-coupled receptor binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
ATPase activator activity	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
ATP binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
Hsp70 protein binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
Tat protein binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
ubiquitin protein ligase binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
metal ion binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
low-density lipoprotein particle receptor binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
unfolded protein binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein-folding chaperone binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
C3HC4-type RING finger domain binding	DnaJ homolog subfamily A member 1	Homo sapiens (human)
protein kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
calmodulin binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
enzyme binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein kinase binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nitric-oxide synthase regulator activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase inhibitor activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
identical protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein homodimerization activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol-3,4-bisphosphate binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
14-3-3 protein binding	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
potassium channel activator activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
metal ion binding	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
molecular function activator activity	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase TTK	Homo sapiens (human)
protein binding	Dual specificity protein kinase TTK	Homo sapiens (human)
ATP binding	Dual specificity protein kinase TTK	Homo sapiens (human)
identical protein binding	Dual specificity protein kinase TTK	Homo sapiens (human)
kinetochore binding	Dual specificity protein kinase TTK	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase TTK	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase TTK	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase TTK	Homo sapiens (human)
DNA helicase activity	DNA replication licensing factor MCM4	Homo sapiens (human)
single-stranded DNA binding	DNA replication licensing factor MCM4	Homo sapiens (human)
protein binding	DNA replication licensing factor MCM4	Homo sapiens (human)
ATP binding	DNA replication licensing factor MCM4	Homo sapiens (human)
ATP hydrolysis activity	DNA replication licensing factor MCM4	Homo sapiens (human)
single-stranded DNA helicase activity	DNA replication licensing factor MCM4	Homo sapiens (human)
microfilament motor activity	Myosin-10	Homo sapiens (human)
actin filament binding	Myosin-10	Homo sapiens (human)
microfilament motor activity	Myosin-10	Homo sapiens (human)
actin binding	Myosin-10	Homo sapiens (human)
protein binding	Myosin-10	Homo sapiens (human)
calmodulin binding	Myosin-10	Homo sapiens (human)
ATP binding	Myosin-10	Homo sapiens (human)
RNA stem-loop binding	Myosin-10	Homo sapiens (human)
ADP binding	Myosin-10	Homo sapiens (human)
mRNA 5'-UTR binding	Myosin-10	Homo sapiens (human)
actin filament binding	Myosin-10	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
MAP-kinase scaffold activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
PDZ domain binding	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein serine/threonine kinase activator activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
metal ion binding	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
scaffold protein binding	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
protein tyrosine kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
cytokine receptor activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
ATP binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein-containing complex binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
growth factor binding	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
protein binding	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
ATP binding	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
BMP binding	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
protein homodimerization activity	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
SMAD binding	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
metal ion binding	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
BMP receptor activity	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
activin receptor activity	Activin receptor type-1B	Homo sapiens (human)
growth factor binding	Activin receptor type-1B	Homo sapiens (human)
activin binding	Activin receptor type-1B	Homo sapiens (human)
protein serine/threonine kinase activity	Activin receptor type-1B	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Activin receptor type-1B	Homo sapiens (human)
protein binding	Activin receptor type-1B	Homo sapiens (human)
ATP binding	Activin receptor type-1B	Homo sapiens (human)
activin receptor activity, type I	Activin receptor type-1B	Homo sapiens (human)
activin receptor activity	Activin receptor type-1B	Homo sapiens (human)
ubiquitin protein ligase binding	Activin receptor type-1B	Homo sapiens (human)
inhibin binding	Activin receptor type-1B	Homo sapiens (human)
SMAD binding	Activin receptor type-1B	Homo sapiens (human)
metal ion binding	Activin receptor type-1B	Homo sapiens (human)
I-SMAD binding	Activin receptor type-1B	Homo sapiens (human)
transforming growth factor beta receptor activity	TGF-beta receptor type-1	Homo sapiens (human)
growth factor binding	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta binding	TGF-beta receptor type-1	Homo sapiens (human)
protein kinase activity	TGF-beta receptor type-1	Homo sapiens (human)
protein serine/threonine kinase activity	TGF-beta receptor type-1	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta receptor activity	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	TGF-beta receptor type-1	Homo sapiens (human)
type II transforming growth factor beta receptor binding	TGF-beta receptor type-1	Homo sapiens (human)
protein binding	TGF-beta receptor type-1	Homo sapiens (human)
ATP binding	TGF-beta receptor type-1	Homo sapiens (human)
ubiquitin protein ligase binding	TGF-beta receptor type-1	Homo sapiens (human)
SMAD binding	TGF-beta receptor type-1	Homo sapiens (human)
metal ion binding	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta binding	TGF-beta receptor type-1	Homo sapiens (human)
I-SMAD binding	TGF-beta receptor type-1	Homo sapiens (human)
activin receptor activity, type I	TGF-beta receptor type-1	Homo sapiens (human)
activin binding	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta binding	TGF-beta receptor type-2	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	TGF-beta receptor type-2	Homo sapiens (human)
transforming growth factor beta receptor activity	TGF-beta receptor type-2	Homo sapiens (human)
transforming growth factor beta receptor activity, type II	TGF-beta receptor type-2	Homo sapiens (human)
protein binding	TGF-beta receptor type-2	Homo sapiens (human)
ATP binding	TGF-beta receptor type-2	Homo sapiens (human)
glycosaminoglycan binding	TGF-beta receptor type-2	Homo sapiens (human)
kinase activator activity	TGF-beta receptor type-2	Homo sapiens (human)
type I transforming growth factor beta receptor binding	TGF-beta receptor type-2	Homo sapiens (human)
SMAD binding	TGF-beta receptor type-2	Homo sapiens (human)
metal ion binding	TGF-beta receptor type-2	Homo sapiens (human)
transforming growth factor beta binding	TGF-beta receptor type-2	Homo sapiens (human)
molecular adaptor activity	TGF-beta receptor type-2	Homo sapiens (human)
activin receptor activity	TGF-beta receptor type-2	Homo sapiens (human)
activin binding	TGF-beta receptor type-2	Homo sapiens (human)
protein serine/threonine kinase activity	TGF-beta receptor type-2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase CSK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
protein phosphatase binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
protein kinase A catalytic subunit binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
proline-rich region binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
protein tyrosine kinase binding	Tyrosine-protein kinase CSK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase CSK	Homo sapiens (human)
bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity	Glycine--tRNA ligase	Homo sapiens (human)
glycine-tRNA ligase activity	Glycine--tRNA ligase	Homo sapiens (human)
protein binding	Glycine--tRNA ligase	Homo sapiens (human)
ATP binding	Glycine--tRNA ligase	Homo sapiens (human)
transferase activity	Glycine--tRNA ligase	Homo sapiens (human)
identical protein binding	Glycine--tRNA ligase	Homo sapiens (human)
protein dimerization activity	Glycine--tRNA ligase	Homo sapiens (human)
protein kinase activity	Protein kinase C iota type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C iota type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C iota type	Homo sapiens (human)
protein binding	Protein kinase C iota type	Homo sapiens (human)
ATP binding	Protein kinase C iota type	Homo sapiens (human)
phospholipid binding	Protein kinase C iota type	Homo sapiens (human)
metal ion binding	Protein kinase C iota type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C iota type	Homo sapiens (human)
RNA binding	Exosome RNA helicase MTR4	Homo sapiens (human)
RNA helicase activity	Exosome RNA helicase MTR4	Homo sapiens (human)
protein binding	Exosome RNA helicase MTR4	Homo sapiens (human)
ATP binding	Exosome RNA helicase MTR4	Homo sapiens (human)
ATP hydrolysis activity	Exosome RNA helicase MTR4	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Tec	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Tec	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Tec	Homo sapiens (human)
phospholipid binding	Tyrosine-protein kinase Tec	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase Tec	Homo sapiens (human)
protein binding	Tyrosine-protein kinase TXK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase TXK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase TXK	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
actin filament binding	Tyrosine-protein kinase ABL2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase FRK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase FRK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase FRK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase FRK	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase FRK	Homo sapiens (human)
protein binding	G protein-coupled receptor kinase 6	Homo sapiens (human)
ATP binding	G protein-coupled receptor kinase 6	Homo sapiens (human)
beta-adrenergic receptor kinase activity	G protein-coupled receptor kinase 6	Homo sapiens (human)
G protein-coupled receptor kinase activity	G protein-coupled receptor kinase 6	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein serine/threonine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
integrin binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
interleukin-15 receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
phosphatase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
Toll-like receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein binding	26S proteasome regulatory subunit 6B	Homo sapiens (human)
ATP binding	26S proteasome regulatory subunit 6B	Homo sapiens (human)
ATP hydrolysis activity	26S proteasome regulatory subunit 6B	Homo sapiens (human)
proteasome-activating activity	26S proteasome regulatory subunit 6B	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 8	Homo sapiens (human)
JUN kinase activity	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
enzyme binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein phosphatase binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
histone deacetylase regulator activity	Mitogen-activated protein kinase 8	Homo sapiens (human)
histone deacetylase binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein serine/threonine kinase binding	Mitogen-activated protein kinase 8	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 9	Homo sapiens (human)
JUN kinase activity	Mitogen-activated protein kinase 9	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Mitogen-activated protein kinase 9	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 9	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 9	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 9	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
protein kinase binding	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
protein binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
ATP binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
protein homodimerization activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein binding	Casein kinase I isoform delta	Homo sapiens (human)
ATP binding	Casein kinase I isoform delta	Homo sapiens (human)
cadherin binding	Casein kinase I isoform delta	Homo sapiens (human)
tau-protein kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein kinase activity	MAP kinase-activated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	MAP kinase-activated protein kinase 2	Homo sapiens (human)
protein binding	MAP kinase-activated protein kinase 2	Homo sapiens (human)
ATP binding	MAP kinase-activated protein kinase 2	Homo sapiens (human)
protein serine kinase activity	MAP kinase-activated protein kinase 2	Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activity	MAP kinase-activated protein kinase 2	Homo sapiens (human)
calmodulin binding	MAP kinase-activated protein kinase 2	Homo sapiens (human)
calmodulin-dependent protein kinase activity	MAP kinase-activated protein kinase 2	Homo sapiens (human)
mitogen-activated protein kinase binding	MAP kinase-activated protein kinase 2	Homo sapiens (human)
RNA binding	Elongation factor Tu, mitochondrial	Homo sapiens (human)
translation elongation factor activity	Elongation factor Tu, mitochondrial	Homo sapiens (human)
GTPase activity	Elongation factor Tu, mitochondrial	Homo sapiens (human)
protein binding	Elongation factor Tu, mitochondrial	Homo sapiens (human)
GTP binding	Elongation factor Tu, mitochondrial	Homo sapiens (human)
choline-phosphate cytidylyltransferase activity	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
protein binding	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
calmodulin binding	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
identical protein binding	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
protein homodimerization activity	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
molecular function inhibitor activity	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
phosphatidylcholine binding	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
RNA binding	Casein kinase I isoform epsilon	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
protein binding	Casein kinase I isoform epsilon	Homo sapiens (human)
ATP binding	Casein kinase I isoform epsilon	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
acyl-CoA dehydrogenase activity	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activity	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
protein binding	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activity	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
identical protein binding	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
flavin adenine dinucleotide binding	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
fatty-acyl-CoA binding	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein binding	Dual specificity protein kinase CLK1	Homo sapiens (human)
ATP binding	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase CLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein binding	Dual specificity protein kinase CLK2	Homo sapiens (human)
ATP binding	Dual specificity protein kinase CLK2	Homo sapiens (human)
identical protein binding	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase CLK2	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
signaling receptor binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protease binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
p53 binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ubiquitin protein ligase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dynactin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
NF-kappaB binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 7	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 7	Homo sapiens (human)
ATP-dependent activity, acting on DNA	Cyclin-dependent kinase 7	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 7	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription coactivator binding	Cyclin-dependent kinase 9	Homo sapiens (human)
DNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
chromatin binding	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation factor activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 9	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 9	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
protein kinase binding	Cyclin-dependent kinase 9	Homo sapiens (human)
7SK snRNA binding	Cyclin-dependent kinase 9	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 9	Homo sapiens (human)
GTPase activity	Ras-related protein Rab-27A	Homo sapiens (human)
G protein activity	Ras-related protein Rab-27A	Homo sapiens (human)
protein binding	Ras-related protein Rab-27A	Homo sapiens (human)
GTP binding	Ras-related protein Rab-27A	Homo sapiens (human)
GDP binding	Ras-related protein Rab-27A	Homo sapiens (human)
protein domain specific binding	Ras-related protein Rab-27A	Homo sapiens (human)
myosin V binding	Ras-related protein Rab-27A	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Blk	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Blk	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Blk	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Blk	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Blk	Homo sapiens (human)
protein kinase activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein binding	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
ATP binding	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
kinase activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein kinase binding	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
heat shock protein binding	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
identical protein binding	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein homodimerization activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein heterodimerization activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein serine kinase activity	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein kinase activity	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein kinase binding	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
protein tyrosine kinase activity	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
protein binding	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
ATP binding	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
metal ion binding	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein phosphatase binding	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK3	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK3	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK3	Homo sapiens (human)
protein phosphatase binding	Tyrosine-protein kinase JAK3	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK3	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK3	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein kinase binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
anaphase-promoting complex binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	LIM domain kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	LIM domain kinase 1	Homo sapiens (human)
protein binding	LIM domain kinase 1	Homo sapiens (human)
ATP binding	LIM domain kinase 1	Homo sapiens (human)
heat shock protein binding	LIM domain kinase 1	Homo sapiens (human)
metal ion binding	LIM domain kinase 1	Homo sapiens (human)
protein serine kinase activity	LIM domain kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	LIM domain kinase 2	Homo sapiens (human)
protein binding	LIM domain kinase 2	Homo sapiens (human)
ATP binding	LIM domain kinase 2	Homo sapiens (human)
metal ion binding	LIM domain kinase 2	Homo sapiens (human)
protein serine kinase activity	LIM domain kinase 2	Homo sapiens (human)
JUN kinase activity	Mitogen-activated protein kinase 10	Homo sapiens (human)
MAP kinase kinase activity	Mitogen-activated protein kinase 10	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 10	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 10	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 10	Homo sapiens (human)
tRNA binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
RNA binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
tyrosine-tRNA ligase activity	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
interleukin-8 receptor binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
protein binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
ATP binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
small molecule binding	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
protein kinase activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
cAMP-dependent protein kinase activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
protein binding	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
ATP binding	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
cAMP-dependent protein kinase regulator activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
AMP binding	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
protein kinase regulator activity	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
protein kinase binding	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
ADP binding	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
ephrin receptor activity	Ephrin type-B receptor 3	Homo sapiens (human)
protein binding	Ephrin type-B receptor 3	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 3	Homo sapiens (human)
axon guidance receptor activity	Ephrin type-B receptor 3	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-B receptor 3	Homo sapiens (human)
ephrin receptor activity	Ephrin type-A receptor 5	Homo sapiens (human)
GPI-linked ephrin receptor activity	Ephrin type-A receptor 5	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-A receptor 5	Homo sapiens (human)
protein binding	Ephrin type-A receptor 5	Homo sapiens (human)
ATP binding	Ephrin type-A receptor 5	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Ephrin type-B receptor 4	Homo sapiens (human)
ephrin receptor activity	Ephrin type-B receptor 4	Homo sapiens (human)
protein binding	Ephrin type-B receptor 4	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 4	Homo sapiens (human)
amyloid-beta binding	Ephrin type-A receptor 4	Homo sapiens (human)
protein kinase activity	Ephrin type-A receptor 4	Homo sapiens (human)
protein tyrosine kinase activity	Ephrin type-A receptor 4	Homo sapiens (human)
GPI-linked ephrin receptor activity	Ephrin type-A receptor 4	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-A receptor 4	Homo sapiens (human)
protein binding	Ephrin type-A receptor 4	Homo sapiens (human)
ATP binding	Ephrin type-A receptor 4	Homo sapiens (human)
kinase activity	Ephrin type-A receptor 4	Homo sapiens (human)
PH domain binding	Ephrin type-A receptor 4	Homo sapiens (human)
identical protein binding	Ephrin type-A receptor 4	Homo sapiens (human)
ephrin receptor binding	Ephrin type-A receptor 4	Homo sapiens (human)
DH domain binding	Ephrin type-A receptor 4	Homo sapiens (human)
protein tyrosine kinase binding	Ephrin type-A receptor 4	Homo sapiens (human)
adenylate kinase activity	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
protein binding	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
ATP binding	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
RNA binding	Adenosine kinase	Homo sapiens (human)
deoxyadenosine kinase activity	Adenosine kinase	Homo sapiens (human)
ATP binding	Adenosine kinase	Homo sapiens (human)
metal ion binding	Adenosine kinase	Homo sapiens (human)
adenosine kinase activity	Adenosine kinase	Homo sapiens (human)
G protein activity	Ras-related protein Rab-10	Homo sapiens (human)
protein binding	Ras-related protein Rab-10	Homo sapiens (human)
GTP binding	Ras-related protein Rab-10	Homo sapiens (human)
GDP binding	Ras-related protein Rab-10	Homo sapiens (human)
myosin V binding	Ras-related protein Rab-10	Homo sapiens (human)
cadherin binding involved in cell-cell adhesion	Ras-related protein Rab-10	Homo sapiens (human)
actin filament binding	Actin-related protein 3	Homo sapiens (human)
structural constituent of cytoskeleton	Actin-related protein 3	Homo sapiens (human)
protein binding	Actin-related protein 3	Homo sapiens (human)
ATP binding	Actin-related protein 3	Homo sapiens (human)
actin filament binding	Actin-related protein 2	Homo sapiens (human)
structural constituent of cytoskeleton	Actin-related protein 2	Homo sapiens (human)
protein binding	Actin-related protein 2	Homo sapiens (human)
ATP binding	Actin-related protein 2	Homo sapiens (human)
nuclear export signal receptor activity	GTP-binding nuclear protein Ran	Homo sapiens (human)
pre-miRNA binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
magnesium ion binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
chromatin binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
RNA binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
GTPase activity	GTP-binding nuclear protein Ran	Homo sapiens (human)
G protein activity	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
GTP binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
GDP binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein domain specific binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
cadherin binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
dynein intermediate chain binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein heterodimerization activity	GTP-binding nuclear protein Ran	Homo sapiens (human)
importin-alpha family protein binding	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein binding	Casein kinase I isoform gamma-2	Homo sapiens (human)
ATP binding	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 3	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 3	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 3	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 3	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 3	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 6	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 6	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 6	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 6	Homo sapiens (human)
FBXO family protein binding	Cyclin-dependent kinase 6	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 6	Homo sapiens (human)
microtubule binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
p53 binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ErbB-2 class receptor binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ATP binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
acetylcholine receptor activator activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ErbB-3 class receptor binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
tau protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
tau-protein kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
Hsp90 protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 16	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 16	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 16	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 16	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 16	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 17	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 17	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 17	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 17	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 17	Homo sapiens (human)
6-phosphofructokinase activity	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
protein binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
protein-containing complex binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
cadherin binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
metal ion binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
ATP binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
monosaccharide binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
AMP binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
identical protein binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
fructose-6-phosphate binding	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
protein kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
MAP-kinase scaffold activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein kinase activator activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein serine/threonine kinase activator activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
scaffold protein binding	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-beta	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-beta	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-beta	Homo sapiens (human)
protein binding	DNA topoisomerase 2-beta	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-beta	Homo sapiens (human)
ribonucleoprotein complex binding	DNA topoisomerase 2-beta	Homo sapiens (human)
metal ion binding	DNA topoisomerase 2-beta	Homo sapiens (human)
protein kinase activity	Protein kinase C theta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C theta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C theta type	Homo sapiens (human)
protein binding	Protein kinase C theta type	Homo sapiens (human)
ATP binding	Protein kinase C theta type	Homo sapiens (human)
metal ion binding	Protein kinase C theta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C theta type	Homo sapiens (human)
activin receptor activity, type I	Activin receptor type-1	Homo sapiens (human)
protein kinase activity	Activin receptor type-1	Homo sapiens (human)
protein serine/threonine kinase activity	Activin receptor type-1	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Activin receptor type-1	Homo sapiens (human)
protein binding	Activin receptor type-1	Homo sapiens (human)
ATP binding	Activin receptor type-1	Homo sapiens (human)
peptide hormone binding	Activin receptor type-1	Homo sapiens (human)
protein homodimerization activity	Activin receptor type-1	Homo sapiens (human)
cadherin binding	Activin receptor type-1	Homo sapiens (human)
SMAD binding	Activin receptor type-1	Homo sapiens (human)
metal ion binding	Activin receptor type-1	Homo sapiens (human)
activin binding	Activin receptor type-1	Homo sapiens (human)
transforming growth factor beta binding	Activin receptor type-1	Homo sapiens (human)
BMP receptor activity	Activin receptor type-1	Homo sapiens (human)
protein tyrosine kinase binding	Activin receptor type-1	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	Activin receptor type-1	Homo sapiens (human)
macrophage colony-stimulating factor receptor activity	Macrophage-stimulating protein receptor	Homo sapiens (human)
protein binding	Macrophage-stimulating protein receptor	Homo sapiens (human)
ATP binding	Macrophage-stimulating protein receptor	Homo sapiens (human)
enzyme binding	Macrophage-stimulating protein receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Macrophage-stimulating protein receptor	Homo sapiens (human)
actin binding	Focal adhesion kinase 1	Homo sapiens (human)
protein tyrosine kinase activity	Focal adhesion kinase 1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Focal adhesion kinase 1	Homo sapiens (human)
protein tyrosine phosphatase activity	Focal adhesion kinase 1	Homo sapiens (human)
integrin binding	Focal adhesion kinase 1	Homo sapiens (human)
protein binding	Focal adhesion kinase 1	Homo sapiens (human)
ATP binding	Focal adhesion kinase 1	Homo sapiens (human)
JUN kinase binding	Focal adhesion kinase 1	Homo sapiens (human)
protein kinase binding	Focal adhesion kinase 1	Homo sapiens (human)
protein phosphatase binding	Focal adhesion kinase 1	Homo sapiens (human)
SH2 domain binding	Focal adhesion kinase 1	Homo sapiens (human)
molecular function activator activity	Focal adhesion kinase 1	Homo sapiens (human)
protein kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activity	Protein kinase C delta type	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein binding	Protein kinase C delta type	Homo sapiens (human)
ATP binding	Protein kinase C delta type	Homo sapiens (human)
enzyme activator activity	Protein kinase C delta type	Homo sapiens (human)
enzyme binding	Protein kinase C delta type	Homo sapiens (human)
protein kinase binding	Protein kinase C delta type	Homo sapiens (human)
insulin receptor substrate binding	Protein kinase C delta type	Homo sapiens (human)
metal ion binding	Protein kinase C delta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C delta type	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
protein serine/threonine kinase activity	Activated CDC42 kinase 1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Activated CDC42 kinase 1	Homo sapiens (human)
protein tyrosine kinase activity	Activated CDC42 kinase 1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Activated CDC42 kinase 1	Homo sapiens (human)
GTPase inhibitor activity	Activated CDC42 kinase 1	Homo sapiens (human)
epidermal growth factor receptor binding	Activated CDC42 kinase 1	Homo sapiens (human)
protein binding	Activated CDC42 kinase 1	Homo sapiens (human)
ATP binding	Activated CDC42 kinase 1	Homo sapiens (human)
ubiquitin protein ligase binding	Activated CDC42 kinase 1	Homo sapiens (human)
identical protein binding	Activated CDC42 kinase 1	Homo sapiens (human)
metal ion binding	Activated CDC42 kinase 1	Homo sapiens (human)
WW domain binding	Activated CDC42 kinase 1	Homo sapiens (human)
protein serine kinase activity	Activated CDC42 kinase 1	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
protein binding	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
collagen binding	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
ATP binding	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
protein tyrosine kinase collagen receptor activity	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
metal ion binding	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
mitogen-activated protein kinase kinase kinase binding	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Mer	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Mer	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Tyrosine-protein kinase Mer	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein serine/threonine kinase activator activity	Serine/threonine-protein kinase 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 4	Homo sapiens (human)
chromatin binding	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein serine/threonine kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
AMP-activated protein kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cAMP-dependent protein kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein binding	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
ATP binding	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
metal ion binding	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
tau protein binding	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
tau-protein kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein serine kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
histone H2BS36 kinase activity	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
protein kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
metal ion binding	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 7	Homo sapiens (human)
enzyme inhibitor activity	Mitogen-activated protein kinase 7	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 7	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 7	Homo sapiens (human)
mitogen-activated protein kinase binding	Mitogen-activated protein kinase 7	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 7	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 7	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein tyrosine kinase activator activity	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 3	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein serine/threonine kinase activator activity	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
zinc ion binding	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein kinase binding	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Integrin-linked protein kinase	Homo sapiens (human)
protein binding	Integrin-linked protein kinase	Homo sapiens (human)
ATP binding	Integrin-linked protein kinase	Homo sapiens (human)
protein kinase binding	Integrin-linked protein kinase	Homo sapiens (human)
protein serine kinase activity	Integrin-linked protein kinase	Homo sapiens (human)
protein kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 1	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 1	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 1	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein tyrosine kinase activity	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
protein binding	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
ATP binding	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
calcium-dependent protein serine/threonine phosphatase activity	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
protein binding	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
ATP binding	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
identical protein binding	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
protein homodimerization activity	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
protein serine kinase activity	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
protein serine/threonine kinase activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
ATP binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
sodium channel inhibitor activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
titin binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
identical protein binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein homodimerization activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
transmembrane transporter binding	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein serine kinase activity	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
identical protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
tau-protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
histone H3T45 kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
transcription coactivator activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
activin receptor activity, type II	Activin receptor type-2B	Homo sapiens (human)
protein serine/threonine kinase activity	Activin receptor type-2B	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Activin receptor type-2B	Homo sapiens (human)
protein binding	Activin receptor type-2B	Homo sapiens (human)
ATP binding	Activin receptor type-2B	Homo sapiens (human)
activin receptor activity, type II	Activin receptor type-2B	Homo sapiens (human)
kinase activator activity	Activin receptor type-2B	Homo sapiens (human)
growth factor binding	Activin receptor type-2B	Homo sapiens (human)
metal ion binding	Activin receptor type-2B	Homo sapiens (human)
activin binding	Activin receptor type-2B	Homo sapiens (human)
activin receptor activity	Activin receptor type-2B	Homo sapiens (human)
protein binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
ATP binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
activin receptor activity, type II	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
growth factor binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
BMP binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cadherin binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
metal ion binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
BMP receptor activity	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
protein tyrosine kinase binding	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
transforming growth factor beta receptor activity	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
protein tyrosine kinase activity	Protein-tyrosine kinase 6	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Protein-tyrosine kinase 6	Homo sapiens (human)
protein binding	Protein-tyrosine kinase 6	Homo sapiens (human)
ATP binding	Protein-tyrosine kinase 6	Homo sapiens (human)
identical protein binding	Protein-tyrosine kinase 6	Homo sapiens (human)
signaling receptor binding	Protein-tyrosine kinase 6	Homo sapiens (human)
protein kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP-dependent protein kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
calcium channel regulator activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
ATP binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
identical protein binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
mitogen-activated protein kinase p38 binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein serine kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
RNA binding	Cyclin-dependent kinase 13	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 13	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 13	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 13	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 13	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 13	Homo sapiens (human)
protein kinase binding	Cyclin-dependent kinase 13	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 13	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 13	Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein serine/threonine kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
ATP binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
IkappaB kinase activity	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
protein phosphatase binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
ubiquitin protein ligase binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
K48-linked polyubiquitin modification-dependent protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
identical protein binding	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein tyrosine kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ATP binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ubiquitin protein ligase binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glutamate receptor binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
3-phosphoinositide-dependent protein kinase binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein-containing complex binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neurotransmitter receptor regulator activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein serine/threonine kinase activity	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
calcium ion binding	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
protein binding	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
ATP binding	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
lipid binding	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
protein serine kinase activity	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
chromatin binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
RNA binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
protein binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
ATP binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
ATP hydrolysis activity	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
mediator complex binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
protein heterodimerization activity	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
DNA binding	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
nucleosomal DNA binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
transcription coregulator binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
transcription corepressor activity	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
helicase activity	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
protein binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
ATP binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
zinc ion binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
ATP hydrolysis activity	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
histone deacetylase binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
ATP-dependent chromatin remodeler activity	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
chromatin binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
DNA binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
histone binding	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase 38	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 38	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 38	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 38	Homo sapiens (human)
mitogen-activated protein kinase kinase kinase binding	Serine/threonine-protein kinase 38	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase 38	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 38	Homo sapiens (human)
histone reader activity	Serine/threonine-protein kinase 38	Homo sapiens (human)
UFM1-modified protein reader activity	Serine/threonine-protein kinase 38	Homo sapiens (human)
transcription cis-regulatory region binding	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
epidermal growth factor receptor activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
epidermal growth factor receptor binding	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
protein binding	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
ATP binding	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
neuregulin receptor activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
protein homodimerization activity	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
GABA receptor binding	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
protein tyrosine kinase activity	Ephrin type-A receptor 7	Homo sapiens (human)
GPI-linked ephrin receptor activity	Ephrin type-A receptor 7	Homo sapiens (human)
protein binding	Ephrin type-A receptor 7	Homo sapiens (human)
ATP binding	Ephrin type-A receptor 7	Homo sapiens (human)
axon guidance receptor activity	Ephrin type-A receptor 7	Homo sapiens (human)
growth factor binding	Ephrin type-A receptor 7	Homo sapiens (human)
chemorepellent activity	Ephrin type-A receptor 7	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-A receptor 7	Homo sapiens (human)
delta24(24-1) sterol reductase activity	Delta(24)-sterol reductase	Homo sapiens (human)
protein binding	Delta(24)-sterol reductase	Homo sapiens (human)
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	Delta(24)-sterol reductase	Homo sapiens (human)
enzyme binding	Delta(24)-sterol reductase	Homo sapiens (human)
peptide antigen binding	Delta(24)-sterol reductase	Homo sapiens (human)
delta24-sterol reductase activity	Delta(24)-sterol reductase	Homo sapiens (human)
FAD binding	Delta(24)-sterol reductase	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
actin binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
myosin light chain kinase activity	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
protein binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
calmodulin binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
ATP binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
metal ion binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 11	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 11	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 11	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 11	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 11	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
p53 binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
LRR domain binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein kinase activator activity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase STK11	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase STK11	Homo sapiens (human)
chromatin binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein kinase C binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
nuclear receptor coactivator activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
histone H3T11 kinase activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
histone binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
histone deacetylase binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
nuclear androgen receptor binding	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase N1	Homo sapiens (human)
RNA binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase N2	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase N2	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
histone deacetylase binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
RNA polymerase binding	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 14	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 14	Homo sapiens (human)
MAP kinase kinase activity	Mitogen-activated protein kinase 14	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
enzyme binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
protein phosphatase binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
mitogen-activated protein kinase p38 binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
NFAT protein binding	Mitogen-activated protein kinase 14	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 14	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
ATP binding	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
protein serine kinase activity	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activity	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
JUN kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
small GTPase binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
mitogen-activated protein kinase kinase kinase binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein homodimerization activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
protein serine/threonine kinase activity	MAP kinase-activated protein kinase 3	Homo sapiens (human)
MAP kinase kinase activity	MAP kinase-activated protein kinase 3	Homo sapiens (human)
protein binding	MAP kinase-activated protein kinase 3	Homo sapiens (human)
ATP binding	MAP kinase-activated protein kinase 3	Homo sapiens (human)
protein serine kinase activity	MAP kinase-activated protein kinase 3	Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activity	MAP kinase-activated protein kinase 3	Homo sapiens (human)
calmodulin binding	MAP kinase-activated protein kinase 3	Homo sapiens (human)
calmodulin-dependent protein kinase activity	MAP kinase-activated protein kinase 3	Homo sapiens (human)
mitogen-activated protein kinase binding	MAP kinase-activated protein kinase 3	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Discoidin domain-containing receptor 2	Homo sapiens (human)
protein binding	Discoidin domain-containing receptor 2	Homo sapiens (human)
collagen binding	Discoidin domain-containing receptor 2	Homo sapiens (human)
ATP binding	Discoidin domain-containing receptor 2	Homo sapiens (human)
protein tyrosine kinase collagen receptor activity	Discoidin domain-containing receptor 2	Homo sapiens (human)
protein serine/threonine kinase activity	AP2-associated protein kinase 1	Homo sapiens (human)
Notch binding	AP2-associated protein kinase 1	Homo sapiens (human)
protein binding	AP2-associated protein kinase 1	Homo sapiens (human)
ATP binding	AP2-associated protein kinase 1	Homo sapiens (human)
AP-2 adaptor complex binding	AP2-associated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	AP2-associated protein kinase 1	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Myosin light chain kinase 3	Homo sapiens (human)
myosin light chain kinase activity	Myosin light chain kinase 3	Homo sapiens (human)
protein binding	Myosin light chain kinase 3	Homo sapiens (human)
ATP binding	Myosin light chain kinase 3	Homo sapiens (human)
molecular_function	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
ATP hydrolysis activity	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
ATP-dependent protein folding chaperone	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
disordered domain specific binding	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
ATP binding	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
unfolded protein binding	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
protein binding	Rab-like protein 3	Homo sapiens (human)
GTP binding	Rab-like protein 3	Homo sapiens (human)
protein homodimerization activity	Rab-like protein 3	Homo sapiens (human)
GTPase activity	Rab-like protein 3	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
acyl-CoA dehydrogenase activity	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
flavin adenine dinucleotide binding	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
acyl-CoA dehydrogenase activity	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activity	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
protein binding	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activity	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
flavin adenine dinucleotide binding	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
medium-chain fatty acyl-CoA dehydrogenase activity	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
endonuclease activity	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
RNA endonuclease activity	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
unfolded protein binding	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
RNA binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
lipid binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein kinase activator activity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
tau protein binding	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
tau-protein kinase activity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
chromatin binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
RNA binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
RNA helicase activity	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
double-stranded RNA binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
protein binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
ATP binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
G-quadruplex RNA binding	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
DNA helicase activity	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
transferase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
alpha-tubulin binding	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein serine/threonine kinase activator activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
tau protein binding	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
beta-tubulin binding	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
tau-protein kinase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
protein kinase activity	STE20-related kinase adapter protein alpha	Homo sapiens (human)
protein binding	STE20-related kinase adapter protein alpha	Homo sapiens (human)
ATP binding	STE20-related kinase adapter protein alpha	Homo sapiens (human)
kinase binding	STE20-related kinase adapter protein alpha	Homo sapiens (human)
protein kinase activator activity	STE20-related kinase adapter protein alpha	Homo sapiens (human)
protein serine/threonine kinase activator activity	STE20-related kinase adapter protein alpha	Homo sapiens (human)
microfilament motor activity	Myosin-14	Homo sapiens (human)
actin filament binding	Myosin-14	Homo sapiens (human)
calmodulin binding	Myosin-14	Homo sapiens (human)
ATP binding	Myosin-14	Homo sapiens (human)
protein serine/threonine kinase activity	AarF domain-containing protein kinase 1	Homo sapiens (human)
ATP binding	AarF domain-containing protein kinase 1	Homo sapiens (human)
RNA binding	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
RNA helicase activity	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
protein binding	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
ATP binding	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
p53 binding	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
MAP kinase kinase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein binding	MAP kinase-activated protein kinase 5	Homo sapiens (human)
ATP binding	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein serine kinase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
calmodulin-dependent protein kinase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
mitogen-activated protein kinase binding	MAP kinase-activated protein kinase 5	Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activity	MAP kinase-activated protein kinase 5	Homo sapiens (human)
calmodulin binding	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein kinase activity	Misshapen-like kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Misshapen-like kinase 1	Homo sapiens (human)
protein binding	Misshapen-like kinase 1	Homo sapiens (human)
ATP binding	Misshapen-like kinase 1	Homo sapiens (human)
protein serine kinase activity	Misshapen-like kinase 1	Homo sapiens (human)
protein kinase activity	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
protein binding	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
ATP binding	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
kinase activity	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
ADP binding	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
protein binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
ATP binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
identical protein binding	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activity	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
chromatin binding	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
MAP kinase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase 15	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase 15	Homo sapiens (human)
kinase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
SH3 domain binding	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase 15	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein kinase activator activity	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
molecular function activator activity	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
DNA binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
chromatin binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
transcription coregulator activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
RNA binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
RNA helicase activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
double-stranded RNA binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
nuclease activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
exonuclease activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
protein binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
ATP binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
poly(A) binding	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
DNA/RNA helicase activity	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
DNA binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
nuclear steroid receptor activity	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
protein binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
zinc ion binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
protein kinase binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
cAMP response element binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
protein homodimerization activity	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase B	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase B	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Aurora kinase B	Homo sapiens (human)
protein binding	Aurora kinase B	Homo sapiens (human)
ATP binding	Aurora kinase B	Homo sapiens (human)
kinase binding	Aurora kinase B	Homo sapiens (human)
protein serine kinase activity	Aurora kinase B	Homo sapiens (human)
protein serine/threonine kinase activity	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
protein binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
ATP binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
microtubule binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cytoskeletal anchor activity	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
gamma-tubulin binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
ubiquitin binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
tau protein binding	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
tau-protein kinase activity	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
protein serine kinase activity	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
protein binding	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
ATP binding	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
protein serine kinase activity	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein tyrosine kinase activity	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
14-3-3 protein binding	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
protein serine/threonine kinase activity	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
protein binding	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
phosphatidylinositol binding	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein tyrosine kinase activity	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
calcium ion binding	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
calmodulin binding	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
ATP binding	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein serine kinase activity	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
p53 binding	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
protein serine/threonine kinase activity	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
protein binding	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
ATP binding	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
hydrolase activity	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
protein serine kinase activity	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
protein serine/threonine kinase activity	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
protein binding	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
ATP binding	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
kinase activity	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
metal ion binding	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
protein serine kinase activity	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
protein kinase activity	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
JUN kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein kinase binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein phosphatase binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein domain specific binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
identical protein binding	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein homodimerization activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
metal ion binding	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activity	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
protein binding	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
ATP binding	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
heme binding	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
protein homodimerization activity	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
protein serine kinase activity	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
antioxidant activity	Peroxiredoxin-like 2A	Homo sapiens (human)
RNA binding	Nucleolar GTP-binding protein 1	Homo sapiens (human)
GTPase activity	Nucleolar GTP-binding protein 1	Homo sapiens (human)
protein binding	Nucleolar GTP-binding protein 1	Homo sapiens (human)
GTP binding	Nucleolar GTP-binding protein 1	Homo sapiens (human)
preribosome binding	Nucleolar GTP-binding protein 1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein kinase C binding	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase D2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase D2	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase D2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase D2	Homo sapiens (human)
magnesium ion binding	NUAK family SNF1-like kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	NUAK family SNF1-like kinase 2	Homo sapiens (human)
protein binding	NUAK family SNF1-like kinase 2	Homo sapiens (human)
ATP binding	NUAK family SNF1-like kinase 2	Homo sapiens (human)
protein serine kinase activity	NUAK family SNF1-like kinase 2	Homo sapiens (human)
RNA binding	RNA cytidine acetyltransferase	Homo sapiens (human)
protein binding	RNA cytidine acetyltransferase	Homo sapiens (human)
ATP binding	RNA cytidine acetyltransferase	Homo sapiens (human)
N-acetyltransferase activity	RNA cytidine acetyltransferase	Homo sapiens (human)
tRNA N-acetyltransferase activity	RNA cytidine acetyltransferase	Homo sapiens (human)
DNA polymerase binding	RNA cytidine acetyltransferase	Homo sapiens (human)
mRNA N-acetyltransferase activity	RNA cytidine acetyltransferase	Homo sapiens (human)
tRNA binding	RNA cytidine acetyltransferase	Homo sapiens (human)
rRNA cytidine N-acetyltransferase activity	RNA cytidine acetyltransferase	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
protein serine/threonine kinase activity	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein binding	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
identical protein binding	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein homodimerization activity	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
cadherin binding	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
protein kinase inhibitor activity	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
transferase activity	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
magnesium ion binding	dCTP pyrophosphatase 1	Homo sapiens (human)
protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
pyrimidine deoxyribonucleotide binding	dCTP pyrophosphatase 1	Homo sapiens (human)
identical protein binding	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoside triphosphate diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
dCTP diphosphatase activity	dCTP pyrophosphatase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein binding	Dual specificity protein kinase CLK4	Homo sapiens (human)
ATP binding	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein serine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity protein kinase CLK4	Homo sapiens (human)
transmembrane signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein binding	Platelet glycoprotein VI	Homo sapiens (human)
collagen binding	Platelet glycoprotein VI	Homo sapiens (human)
signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
collagen receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein tyrosine kinase binding	Platelet glycoprotein VI	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform gamma-1	Homo sapiens (human)
protein binding	Casein kinase I isoform gamma-1	Homo sapiens (human)
ATP binding	Casein kinase I isoform gamma-1	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform gamma-1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
magnesium ion binding	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
RNA binding	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
phenylalanine-tRNA ligase activity	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
protein binding	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
ATP binding	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
protein binding	BMP-2-inducible protein kinase	Homo sapiens (human)
ATP binding	BMP-2-inducible protein kinase	Homo sapiens (human)
protein serine kinase activity	BMP-2-inducible protein kinase	Homo sapiens (human)
phosphatase regulator activity	BMP-2-inducible protein kinase	Homo sapiens (human)
AP-2 adaptor complex binding	BMP-2-inducible protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	BMP-2-inducible protein kinase	Homo sapiens (human)
protein binding	Obg-like ATPase 1	Homo sapiens (human)
ATP binding	Obg-like ATPase 1	Homo sapiens (human)
GTP binding	Obg-like ATPase 1	Homo sapiens (human)
ATP hydrolysis activity	Obg-like ATPase 1	Homo sapiens (human)
ribosomal large subunit binding	Obg-like ATPase 1	Homo sapiens (human)
cadherin binding	Obg-like ATPase 1	Homo sapiens (human)
metal ion binding	Obg-like ATPase 1	Homo sapiens (human)
protein binding	Midasin	Homo sapiens (human)
ATP binding	Midasin	Homo sapiens (human)
ATP hydrolysis activity	Midasin	Homo sapiens (human)
magnesium ion binding	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
protein serine/threonine kinase activity	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
interleukin-1 receptor binding	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
protein binding	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
ATP binding	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
kinase activity	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
protein kinase binding	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
protein serine kinase activity	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
RNA binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
JUN kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein kinase activator activity	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
ribosome binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
small ribosomal subunit rRNA binding	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 12	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 12	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 12	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 12	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 12	Homo sapiens (human)
protein kinase binding	Cyclin-dependent kinase 12	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 12	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 12	Homo sapiens (human)
protein binding	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
ATP binding	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
endopeptidase activator activity	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 26	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 26	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 26	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 26	Homo sapiens (human)
magnesium ion binding	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinate-CoA ligase (ADP-forming) activity	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
protein binding	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
ATP binding	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase NLK	Homo sapiens (human)
MAP kinase activity	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
ubiquitin protein ligase binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
SH2 domain binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase NLK	Homo sapiens (human)
DNA-binding transcription factor binding	Serine/threonine-protein kinase NLK	Homo sapiens (human)
AMP-activated protein kinase activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
protein binding	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
ATP binding	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cAMP-dependent protein kinase regulator activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
phosphorylase kinase regulator activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
protein kinase regulator activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
protein kinase binding	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
protein kinase activator activity	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
ADP binding	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
AMP binding	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
nucleic acid binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein phosphatase binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
phosphoprotein binding	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
protein binding	Septin-9	Homo sapiens (human)
GTP binding	Septin-9	Homo sapiens (human)
cadherin binding	Septin-9	Homo sapiens (human)
GTPase activity	Septin-9	Homo sapiens (human)
molecular adaptor activity	Septin-9	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
protein kinase activity	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
protein kinase activity	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein binding	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
ATP binding	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein serine kinase activity	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
MAP kinase kinase kinase activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
neuropilin binding	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein serine/threonine kinase activator activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
tau protein binding	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
tau-protein kinase activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase ICK	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase ICK	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ICK	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ICK	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ICK	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ICK	Homo sapiens (human)
protein kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein binding	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
ATP binding	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
protein serine kinase activity	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
tau-protein kinase activity	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
protein kinase binding	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
metal ion binding	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
transcription coregulator activity	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
transcription coactivator activity	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
RNA binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
protein binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
ATP binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nuclear receptor coactivator activity	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nuclear vitamin D receptor binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nuclear thyroid hormone receptor binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
phosphoprotein binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
DNA binding	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
transcription coactivator activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
ATP binding	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein serine/threonine kinase activity	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
protein kinase activity	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
transcription coactivator activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein kinase activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein binding	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
ATP binding	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
identical protein binding	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein-containing complex binding	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein serine kinase activity	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
magnesium ion binding	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein binding	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
ATP binding	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein kinase binding	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein homodimerization activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein heterodimerization activity	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase 24	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 24	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 24	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 24	Homo sapiens (human)
cadherin binding	Serine/threonine-protein kinase 24	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase 24	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 24	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform gamma-3	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform gamma-3	Homo sapiens (human)
ATP binding	Casein kinase I isoform gamma-3	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform gamma-3	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
metal ion binding	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (400)

Process	via Protein(s)	Taxonomy
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dendrite	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
neuronal cell body	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
HFE-transferrin receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
intercellular bridge	Cell division cycle 7-related protein kinase	Homo sapiens (human)
mitotic spindle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
XY body	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
deuterosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole replication complex	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
eukaryotic translation initiation factor 3 complex	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosolic small ribosomal subunit	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular region	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
centrosome	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosol	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
plasma membrane	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasmic stress granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
lamellipodium	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cell leading edge	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
secretory granule lumen	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular exosome	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ficolin-1-rich granule lumen	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
NLRP3 inflammasome complex	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
P granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular region	Pyridoxal kinase	Homo sapiens (human)
nucleus	Pyridoxal kinase	Homo sapiens (human)
nucleoplasm	Pyridoxal kinase	Homo sapiens (human)
cytosol	Pyridoxal kinase	Homo sapiens (human)
secretory granule lumen	Pyridoxal kinase	Homo sapiens (human)
specific granule lumen	Pyridoxal kinase	Homo sapiens (human)
extracellular exosome	Pyridoxal kinase	Homo sapiens (human)
cytosol	Pyridoxal kinase	Homo sapiens (human)
cytosol	Citron Rho-interacting kinase	Homo sapiens (human)
membrane	Citron Rho-interacting kinase	Homo sapiens (human)
chromosome, telomeric region	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
condensed nuclear chromosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
extracellular space	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replication fork	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
spindle microtubule	Aurora kinase A	Homo sapiens (human)
nucleus	Aurora kinase A	Homo sapiens (human)
nucleoplasm	Aurora kinase A	Homo sapiens (human)
centrosome	Aurora kinase A	Homo sapiens (human)
centriole	Aurora kinase A	Homo sapiens (human)
spindle	Aurora kinase A	Homo sapiens (human)
cytosol	Aurora kinase A	Homo sapiens (human)
postsynaptic density	Aurora kinase A	Homo sapiens (human)
microtubule cytoskeleton	Aurora kinase A	Homo sapiens (human)
basolateral plasma membrane	Aurora kinase A	Homo sapiens (human)
midbody	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
ciliary basal body	Aurora kinase A	Homo sapiens (human)
germinal vesicle	Aurora kinase A	Homo sapiens (human)
axon hillock	Aurora kinase A	Homo sapiens (human)
pronucleus	Aurora kinase A	Homo sapiens (human)
perinuclear region of cytoplasm	Aurora kinase A	Homo sapiens (human)
mitotic spindle	Aurora kinase A	Homo sapiens (human)
meiotic spindle	Aurora kinase A	Homo sapiens (human)
mitotic spindle pole	Aurora kinase A	Homo sapiens (human)
glutamatergic synapse	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
chromosome passenger complex	Aurora kinase A	Homo sapiens (human)
spindle midzone	Aurora kinase A	Homo sapiens (human)
kinetochore	Aurora kinase A	Homo sapiens (human)
Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
cytosol	Cyclin-G-associated kinase	Homo sapiens (human)
focal adhesion	Cyclin-G-associated kinase	Homo sapiens (human)
membrane	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-coated vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
presynapse	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 6	Homo sapiens (human)
cytosol	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
dendrite	Ephrin type-B receptor 6	Homo sapiens (human)
peroxisome	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
peroxisomal matrix	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
cytosol	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
membrane	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
peroxisome	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
plasma membrane	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasm	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytosol	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoskeleton	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
vesicle	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein-containing complex	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleoplasm	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
cytosol	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
membrane	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
intracellular membrane-bounded organelle	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
outer kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleus	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial outer membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial intermembrane space	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cytosol	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial crista	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
dendrite	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
axon cytoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial intermembrane space	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cytoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
microtubule	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
nucleus	Putative nucleoside diphosphate kinase	Homo sapiens (human)
extracellular exosome	Putative nucleoside diphosphate kinase	Homo sapiens (human)
extrinsic component of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK2	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
caveola	Tyrosine-protein kinase JAK2	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
endosome lumen	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-23 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
euchromatin	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytosol	Rho-associated protein kinase 2	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
mitochondrial outer membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
recycling endosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
omegasome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
Atg1/ULK1 kinase complex	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
nuclear inner membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Ire1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
AIP1-IRE1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-TRAF2-ASK1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-RACK1-PP2A complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleus	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
nucleoplasm	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
membrane	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U4/U6 x U5 tri-snRNP complex	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
spliceosomal complex	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U5 snRNP	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U2-type precatalytic spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U2-type catalytic step 1 spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
catalytic step 2 spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
synapse	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi-associated vesicle	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 16	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 16	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 10	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
specific granule membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 10	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 10	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
nuclear chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed nuclear chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensin complex	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleus	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleoplasm	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleolus	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytoplasm	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytosol	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
extracellular exosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
chromatin	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
adherens junction	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
focal adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
ruffle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
dendrite	Tyrosine-protein kinase ABL1	Homo sapiens (human)
growth cone	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuronal cell body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase ABL1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
semaphorin receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
early endosome	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cytosol	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
endosome membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basolateral plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
apical plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ruffle membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
presynaptic membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelin sheath	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
perinuclear region of cytoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB3:ERBB2 complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basal plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
early endosome	High affinity nerve growth factor receptor	Homo sapiens (human)
late endosome	High affinity nerve growth factor receptor	Homo sapiens (human)
plasma membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
cell surface	High affinity nerve growth factor receptor	Homo sapiens (human)
endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
dendrite	High affinity nerve growth factor receptor	Homo sapiens (human)
early endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
late endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
neuronal cell body	High affinity nerve growth factor receptor	Homo sapiens (human)
recycling endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
protein-containing complex	High affinity nerve growth factor receptor	Homo sapiens (human)
receptor complex	High affinity nerve growth factor receptor	Homo sapiens (human)
axon	High affinity nerve growth factor receptor	Homo sapiens (human)
plasma membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
nucleoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
centrosome	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytosol	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
membrane	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
dendrite	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
midbody	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cell body	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
synapse	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
extracellular exosome	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
neuronal dense core vesicle	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
extracellular vesicle	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
heterotrimeric G-protein complex	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
nucleus	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrion	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial inner membrane	ADP/ATP translocase 2	Homo sapiens (human)
plasma membrane	ADP/ATP translocase 2	Homo sapiens (human)
membrane	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial nucleoid	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial permeability transition pore complex	ADP/ATP translocase 2	Homo sapiens (human)
MMXD complex	ADP/ATP translocase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
nucleus	Protein kinase C beta type	Homo sapiens (human)
nucleoplasm	Protein kinase C beta type	Homo sapiens (human)
cytoplasm	Protein kinase C beta type	Homo sapiens (human)
centrosome	Protein kinase C beta type	Homo sapiens (human)
cytosol	Protein kinase C beta type	Homo sapiens (human)
plasma membrane	Protein kinase C beta type	Homo sapiens (human)
brush border membrane	Protein kinase C beta type	Homo sapiens (human)
calyx of Held	Protein kinase C beta type	Homo sapiens (human)
extracellular exosome	Protein kinase C beta type	Homo sapiens (human)
presynaptic cytosol	Protein kinase C beta type	Homo sapiens (human)
spectrin	Protein kinase C beta type	Homo sapiens (human)
nuclear envelope	Insulin receptor	Homo sapiens (human)
nuclear lumen	Insulin receptor	Homo sapiens (human)
lysosome	Insulin receptor	Homo sapiens (human)
late endosome	Insulin receptor	Homo sapiens (human)
plasma membrane	Insulin receptor	Homo sapiens (human)
caveola	Insulin receptor	Homo sapiens (human)
external side of plasma membrane	Insulin receptor	Homo sapiens (human)
endosome membrane	Insulin receptor	Homo sapiens (human)
membrane	Insulin receptor	Homo sapiens (human)
dendrite membrane	Insulin receptor	Homo sapiens (human)
neuronal cell body membrane	Insulin receptor	Homo sapiens (human)
extracellular exosome	Insulin receptor	Homo sapiens (human)
insulin receptor complex	Insulin receptor	Homo sapiens (human)
receptor complex	Insulin receptor	Homo sapiens (human)
plasma membrane	Insulin receptor	Homo sapiens (human)
axon	Insulin receptor	Homo sapiens (human)
pericentriolar material	Tyrosine-protein kinase Lck	Homo sapiens (human)
immunological synapse	Tyrosine-protein kinase Lck	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Lck	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lck	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Lck	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Lck	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lck	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase Fyn	Homo sapiens (human)
endosome	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
postsynaptic density	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perikaryon	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell body	Tyrosine-protein kinase Fyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear endoplasmic reticulum	Tyrosine-protein kinase Fyn	Homo sapiens (human)
glial cell projection	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrial matrix	Cyclin-dependent kinase 1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
mitochondrion	Cyclin-dependent kinase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 1	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 1	Homo sapiens (human)
spindle microtubule	Cyclin-dependent kinase 1	Homo sapiens (human)
membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
midbody	Cyclin-dependent kinase 1	Homo sapiens (human)
extracellular exosome	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic spindle	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A2-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin B1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
extracellular region	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytosol	Glycogen phosphorylase, liver form	Homo sapiens (human)
secretory granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
extracellular exosome	Glycogen phosphorylase, liver form	Homo sapiens (human)
ficolin-1-rich granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytoplasm	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytoplasmic vesicle	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
microtubule cytoskeleton	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
nucleoplasm	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
plasma membrane	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
cell surface	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
CSF1-CSF1R complex	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
receptor complex	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
plasma membrane	Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)
extracellular region	Adenine phosphoribosyltransferase	Homo sapiens (human)
nucleoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytosol	Adenine phosphoribosyltransferase	Homo sapiens (human)
secretory granule lumen	Adenine phosphoribosyltransferase	Homo sapiens (human)
extracellular exosome	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Yes	Homo sapiens (human)
centrosome	Tyrosine-protein kinase Yes	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Yes	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Yes	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase Yes	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Lyn	Homo sapiens (human)
lysosomal membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Lyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
adherens junction	Tyrosine-protein kinase Lyn	Homo sapiens (human)
mitochondrial crista	Tyrosine-protein kinase Lyn	Homo sapiens (human)
endocytic vesicle membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
intracellular membrane-bounded organelle	Tyrosine-protein kinase Lyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Lyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Lyn	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Lyn	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase Lyn	Homo sapiens (human)
postsynaptic specialization, intracellular component	Tyrosine-protein kinase Lyn	Homo sapiens (human)
integrin alpha2-beta1 complex	Tyrosine-protein kinase Lyn	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
early endosome	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
endosome membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
dendrite	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
neuronal cell body	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
receptor complex	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane protein complex	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
axon	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane	Insulin-like growth factor 1 receptor	Homo sapiens (human)
caveola	Insulin-like growth factor 1 receptor	Homo sapiens (human)
membrane	Insulin-like growth factor 1 receptor	Homo sapiens (human)
T-tubule	Insulin-like growth factor 1 receptor	Homo sapiens (human)
neuronal cell body	Insulin-like growth factor 1 receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Insulin-like growth factor 1 receptor	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Insulin-like growth factor 1 receptor	Homo sapiens (human)
receptor complex	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein kinase complex	Insulin-like growth factor 1 receptor	Homo sapiens (human)
axon	Insulin-like growth factor 1 receptor	Homo sapiens (human)
plasma membrane	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor complex	Insulin-like growth factor 1 receptor	Homo sapiens (human)
signal recognition particle receptor complex	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
membrane	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
extracellular exosome	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Signal recognition particle receptor subunit alpha	Homo sapiens (human)
nucleus	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
mitochondrion	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
mitochondrial respiratory chain complex III	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
membrane	Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)
extracellular region	Hepatocyte growth factor receptor	Homo sapiens (human)
plasma membrane	Hepatocyte growth factor receptor	Homo sapiens (human)
basal plasma membrane	Hepatocyte growth factor receptor	Homo sapiens (human)
cell surface	Hepatocyte growth factor receptor	Homo sapiens (human)
membrane	Hepatocyte growth factor receptor	Homo sapiens (human)
postsynapse	Hepatocyte growth factor receptor	Homo sapiens (human)
basal plasma membrane	Hepatocyte growth factor receptor	Homo sapiens (human)
plasma membrane	Hepatocyte growth factor receptor	Homo sapiens (human)
receptor complex	Hepatocyte growth factor receptor	Homo sapiens (human)
actin filament	Tyrosine-protein kinase HCK	Homo sapiens (human)
nucleus	Tyrosine-protein kinase HCK	Homo sapiens (human)
lysosome	Tyrosine-protein kinase HCK	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase HCK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase HCK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase HCK	Homo sapiens (human)
caveola	Tyrosine-protein kinase HCK	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase HCK	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase HCK	Homo sapiens (human)
transport vesicle	Tyrosine-protein kinase HCK	Homo sapiens (human)
cell projection	Tyrosine-protein kinase HCK	Homo sapiens (human)
intracellular membrane-bounded organelle	Tyrosine-protein kinase HCK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase HCK	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
nucleus	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cytoplasm	Platelet-derived growth factor receptor beta	Homo sapiens (human)
Golgi apparatus	Platelet-derived growth factor receptor beta	Homo sapiens (human)
plasma membrane	Platelet-derived growth factor receptor beta	Homo sapiens (human)
focal adhesion	Platelet-derived growth factor receptor beta	Homo sapiens (human)
membrane	Platelet-derived growth factor receptor beta	Homo sapiens (human)
apical plasma membrane	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cytoplasmic vesicle	Platelet-derived growth factor receptor beta	Homo sapiens (human)
lysosomal lumen	Platelet-derived growth factor receptor beta	Homo sapiens (human)
intracellular membrane-bounded organelle	Platelet-derived growth factor receptor beta	Homo sapiens (human)
plasma membrane	Platelet-derived growth factor receptor beta	Homo sapiens (human)
receptor complex	Platelet-derived growth factor receptor beta	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase Fgr	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase Fgr	Homo sapiens (human)
ruffle membrane	Tyrosine-protein kinase Fgr	Homo sapiens (human)
extracellular region	Tyrosine-protein kinase Fgr	Homo sapiens (human)
mitochondrial inner membrane	Tyrosine-protein kinase Fgr	Homo sapiens (human)
mitochondrial intermembrane space	Tyrosine-protein kinase Fgr	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fgr	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fgr	Homo sapiens (human)
aggresome	Tyrosine-protein kinase Fgr	Homo sapiens (human)
secretory granule lumen	Tyrosine-protein kinase Fgr	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Fgr	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fgr	Homo sapiens (human)
cellular_component	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase A-Raf	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C8	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C8	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C8	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
extracellular region	Glycogen phosphorylase, brain form	Homo sapiens (human)
cytoplasm	Glycogen phosphorylase, brain form	Homo sapiens (human)
membrane	Glycogen phosphorylase, brain form	Homo sapiens (human)
azurophil granule lumen	Glycogen phosphorylase, brain form	Homo sapiens (human)
extracellular exosome	Glycogen phosphorylase, brain form	Homo sapiens (human)
cytoplasm	Glycogen phosphorylase, brain form	Homo sapiens (human)
cytosol	Breakpoint cluster region protein	Homo sapiens (human)
plasma membrane	Breakpoint cluster region protein	Homo sapiens (human)
postsynaptic density	Breakpoint cluster region protein	Homo sapiens (human)
membrane	Breakpoint cluster region protein	Homo sapiens (human)
axon	Breakpoint cluster region protein	Homo sapiens (human)
dendritic spine	Breakpoint cluster region protein	Homo sapiens (human)
extracellular exosome	Breakpoint cluster region protein	Homo sapiens (human)
protein-containing complex	Breakpoint cluster region protein	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Breakpoint cluster region protein	Homo sapiens (human)
glutamatergic synapse	Breakpoint cluster region protein	Homo sapiens (human)
membrane	Breakpoint cluster region protein	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase pim-1	Homo sapiens (human)
extracellular region	Fibroblast growth factor receptor 1	Homo sapiens (human)
nucleus	Fibroblast growth factor receptor 1	Homo sapiens (human)
cytosol	Fibroblast growth factor receptor 1	Homo sapiens (human)
plasma membrane	Fibroblast growth factor receptor 1	Homo sapiens (human)
membrane	Fibroblast growth factor receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Fibroblast growth factor receptor 1	Homo sapiens (human)
receptor complex	Fibroblast growth factor receptor 1	Homo sapiens (human)
plasma membrane	Fibroblast growth factor receptor 1	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nuclear chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
centriole	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome, centromeric region	DNA topoisomerase 2-alpha	Homo sapiens (human)
condensed chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
male germ cell nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
cytoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein-containing complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleolus	Cyclin-dependent kinase 4	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 4	Homo sapiens (human)
bicellular tight junction	Cyclin-dependent kinase 4	Homo sapiens (human)
nuclear membrane	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D1-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D2-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin D3-CDK4 complex	Cyclin-dependent kinase 4	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 4	Homo sapiens (human)
chromatin	Cyclin-dependent kinase 4	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 4	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 4	Homo sapiens (human)
nucleus	ADP/ATP translocase 3	Homo sapiens (human)
mitochondrion	ADP/ATP translocase 3	Homo sapiens (human)
mitochondrial inner membrane	ADP/ATP translocase 3	Homo sapiens (human)
membrane	ADP/ATP translocase 3	Homo sapiens (human)
TIM23 mitochondrial import inner membrane translocase complex	ADP/ATP translocase 3	Homo sapiens (human)
extracellular region	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
nucleus	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
cytoplasm	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
peroxisomal membrane	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
cytosol	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
membrane	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
secretory granule lumen	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
extracellular exosome	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
ficolin-1-rich granule lumen	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
cytoplasm	Inosine-5'-monophosphate dehydrogenase 2	Homo sapiens (human)
podosome	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
nucleoplasm	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cytoplasm	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
mitochondrion	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
mitochondrial inner membrane	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
lysosome	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
late endosome	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cytosol	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
actin filament	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
caveola	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
focal adhesion	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
cell junction	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
ruffle membrane	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
neuronal cell body	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
dendritic growth cone	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
membrane raft	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
perinuclear region of cytoplasm	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
extracellular exosome	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
synaptic membrane	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
glutamatergic synapse	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
postsynaptic specialization, intracellular component	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
dendritic filopodium	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)
axoneme	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
centrosome	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
plasma membrane	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
focal adhesion	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
membrane	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
plasma membrane raft	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
extracellular exosome	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
nucleotide-activated protein kinase complex	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
protein-containing complex	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
neuron projection	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cell body	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
presynapse	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase B-raf	Homo sapiens (human)
cytosol	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
phosphorylase kinase complex	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)
nucleoplasm	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
cytosol	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
extracellular exosome	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
cytosol	Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase Fer	Homo sapiens (human)
microtubule cytoskeleton	Tyrosine-protein kinase Fer	Homo sapiens (human)
lamellipodium	Tyrosine-protein kinase Fer	Homo sapiens (human)
cell junction	Tyrosine-protein kinase Fer	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Fer	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Fer	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fer	Homo sapiens (human)
adherens junction	Tyrosine-protein kinase Fer	Homo sapiens (human)
cell cortex	Tyrosine-protein kinase Fer	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase Fer	Homo sapiens (human)
chromatin	Tyrosine-protein kinase Fer	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fer	Homo sapiens (human)
ciliary basal body	Protein kinase C alpha type	Homo sapiens (human)
nucleoplasm	Protein kinase C alpha type	Homo sapiens (human)
cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
mitochondrion	Protein kinase C alpha type	Homo sapiens (human)
endoplasmic reticulum	Protein kinase C alpha type	Homo sapiens (human)
cytosol	Protein kinase C alpha type	Homo sapiens (human)
plasma membrane	Protein kinase C alpha type	Homo sapiens (human)
mitochondrial membrane	Protein kinase C alpha type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
extracellular exosome	Protein kinase C alpha type	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Protein kinase C alpha type	Homo sapiens (human)
axoneme	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
acrosomal vesicle	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mitochondrial matrix	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
centrosome	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
plasma membrane	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nuclear speck	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
neuromuscular junction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
sperm flagellum	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
dendritic spine	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
plasma membrane raft	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
extracellular exosome	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
glutamatergic synapse	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
calcium channel complex	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleus	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
nucleoplasm	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
cytoplasm	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
spindle	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
cytosol	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription factor TFIIH core complex	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription factor TFIID complex	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
transcription factor TFIIH holo complex	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
CAK-ERCC2 complex	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
MMXD complex	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
nucleus	General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha'	Homo sapiens (human)
acrosomal vesicle	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha'	Homo sapiens (human)
chromatin	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
Golgi membrane	Ras-related protein Rab-6A	Homo sapiens (human)
acrosomal membrane	Ras-related protein Rab-6A	Homo sapiens (human)
endoplasmic reticulum membrane	Ras-related protein Rab-6A	Homo sapiens (human)
Golgi apparatus	Ras-related protein Rab-6A	Homo sapiens (human)
trans-Golgi network	Ras-related protein Rab-6A	Homo sapiens (human)
cytosol	Ras-related protein Rab-6A	Homo sapiens (human)
plasma membrane	Ras-related protein Rab-6A	Homo sapiens (human)
membrane	Ras-related protein Rab-6A	Homo sapiens (human)
secretory granule membrane	Ras-related protein Rab-6A	Homo sapiens (human)
cytoplasmic vesicle	Ras-related protein Rab-6A	Homo sapiens (human)
trans-Golgi network membrane	Ras-related protein Rab-6A	Homo sapiens (human)
extracellular exosome	Ras-related protein Rab-6A	Homo sapiens (human)
endosome to plasma membrane transport vesicle	Ras-related protein Rab-6A	Homo sapiens (human)
Golgi apparatus	Ras-related protein Rab-6A	Homo sapiens (human)
endomembrane system	Ras-related protein Rab-6A	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 1	Homo sapiens (human)
receptor complex	Ephrin type-A receptor 1	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 1	Homo sapiens (human)
extracellular space	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
basolateral plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
apical plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
lateral plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
ERBB3:ERBB2 complex	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
receptor complex	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
basal plasma membrane	Receptor tyrosine-protein kinase erbB-3	Homo sapiens (human)
cytoplasm	Multifunctional protein ADE2	Homo sapiens (human)
cytosol	Multifunctional protein ADE2	Homo sapiens (human)
membrane	Multifunctional protein ADE2	Homo sapiens (human)
extracellular exosome	Multifunctional protein ADE2	Homo sapiens (human)
focal adhesion	Nucleoside diphosphate kinase B	Homo sapiens (human)
ruffle	Nucleoside diphosphate kinase B	Homo sapiens (human)
extracellular region	Nucleoside diphosphate kinase B	Homo sapiens (human)
nucleus	Nucleoside diphosphate kinase B	Homo sapiens (human)
cytoplasm	Nucleoside diphosphate kinase B	Homo sapiens (human)
cytosol	Nucleoside diphosphate kinase B	Homo sapiens (human)
lamellipodium	Nucleoside diphosphate kinase B	Homo sapiens (human)
secretory granule lumen	Nucleoside diphosphate kinase B	Homo sapiens (human)
perinuclear region of cytoplasm	Nucleoside diphosphate kinase B	Homo sapiens (human)
extracellular exosome	Nucleoside diphosphate kinase B	Homo sapiens (human)
cell periphery	Nucleoside diphosphate kinase B	Homo sapiens (human)
ficolin-1-rich granule lumen	Nucleoside diphosphate kinase B	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
centrosome	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
plasma membrane	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
extracellular exosome	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
mitochondrial inner membrane	Ferrochelatase, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Ferrochelatase, mitochondrial	Homo sapiens (human)
mitochondrion	Ferrochelatase, mitochondrial	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
mitochondrion	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
mitochondrial outer membrane	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cell surface	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
neuron projection	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
perinuclear region of cytoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
postsynapse	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
glutamatergic synapse	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase beta-1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK1	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK1	Homo sapiens (human)
endosome	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK1	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase JAK1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
cytosol	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin E1-CDK2 complex	G1/S-specific cyclin-E1	Homo sapiens (human)
centrosome	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 2	Homo sapiens (human)
condensed chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
X chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
Y chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nuclear envelope	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
endosome	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 2	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 2	Homo sapiens (human)
Cajal body	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 2	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cytosol	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
plasma membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
cilium	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
membrane	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
presynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
postsynapse	Beta-adrenergic receptor kinase 1	Homo sapiens (human)
P-body	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
nucleus	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cytoplasm	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cytosol	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cytoplasmic stress granule	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
membrane	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
RISC complex	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
cytoplasmic stress granule	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
P-body	Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 3	Homo sapiens (human)
nuclear envelope	Mitogen-activated protein kinase 3	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 3	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 3	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 3	Homo sapiens (human)
early endosome	Mitogen-activated protein kinase 3	Homo sapiens (human)
late endosome	Mitogen-activated protein kinase 3	Homo sapiens (human)
endoplasmic reticulum lumen	Mitogen-activated protein kinase 3	Homo sapiens (human)
Golgi apparatus	Mitogen-activated protein kinase 3	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 3	Homo sapiens (human)
cytoskeleton	Mitogen-activated protein kinase 3	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase 3	Homo sapiens (human)
caveola	Mitogen-activated protein kinase 3	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase 3	Homo sapiens (human)
pseudopodium	Mitogen-activated protein kinase 3	Homo sapiens (human)
glutamatergic synapse	Mitogen-activated protein kinase 3	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 3	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 3	Homo sapiens (human)
cytoplasm	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
cytosol	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
plasma membrane	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
dendrite	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
extracellular exosome	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
plasma membrane	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
cytoplasm	MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)
nucleoplasm	Deoxycytidine kinase	Homo sapiens (human)
cytosol	Deoxycytidine kinase	Homo sapiens (human)
mitochondrion	Deoxycytidine kinase	Homo sapiens (human)
cytoplasm	Deoxycytidine kinase	Homo sapiens (human)
extracellular region	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 1	Homo sapiens (human)
early endosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
late endosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
endoplasmic reticulum lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
Golgi apparatus	Mitogen-activated protein kinase 1	Homo sapiens (human)
centrosome	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoskeleton	Mitogen-activated protein kinase 1	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase 1	Homo sapiens (human)
caveola	Mitogen-activated protein kinase 1	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase 1	Homo sapiens (human)
pseudopodium	Mitogen-activated protein kinase 1	Homo sapiens (human)
azurophil granule lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
synapse	Mitogen-activated protein kinase 1	Homo sapiens (human)
mitotic spindle	Mitogen-activated protein kinase 1	Homo sapiens (human)
ficolin-1-rich granule lumen	Mitogen-activated protein kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 1	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 1	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 2	Homo sapiens (human)
focal adhesion	Ephrin type-A receptor 2	Homo sapiens (human)
cell surface	Ephrin type-A receptor 2	Homo sapiens (human)
lamellipodium	Ephrin type-A receptor 2	Homo sapiens (human)
leading edge membrane	Ephrin type-A receptor 2	Homo sapiens (human)
lamellipodium membrane	Ephrin type-A receptor 2	Homo sapiens (human)
ruffle membrane	Ephrin type-A receptor 2	Homo sapiens (human)
tight junction	Ephrin type-A receptor 2	Homo sapiens (human)
receptor complex	Ephrin type-A receptor 2	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 2	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 2	Homo sapiens (human)
nucleoplasm	Ephrin type-B receptor 2	Homo sapiens (human)
cytosol	Ephrin type-B receptor 2	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 2	Homo sapiens (human)
cell surface	Ephrin type-B receptor 2	Homo sapiens (human)
axon	Ephrin type-B receptor 2	Homo sapiens (human)
dendrite	Ephrin type-B receptor 2	Homo sapiens (human)
presynaptic membrane	Ephrin type-B receptor 2	Homo sapiens (human)
neuronal cell body	Ephrin type-B receptor 2	Homo sapiens (human)
dendritic spine	Ephrin type-B receptor 2	Homo sapiens (human)
postsynaptic membrane	Ephrin type-B receptor 2	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Ephrin type-B receptor 2	Homo sapiens (human)
postsynapse	Ephrin type-B receptor 2	Homo sapiens (human)
glutamatergic synapse	Ephrin type-B receptor 2	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 2	Homo sapiens (human)
dendrite	Ephrin type-B receptor 2	Homo sapiens (human)
plasma membrane	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytoplasmic side of plasma membrane	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
extrinsic component of plasma membrane	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
nucleus	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytoplasm	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytosol	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytoskeleton	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
plasma membrane	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
interleukin-12 receptor complex	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
extracellular exosome	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
interleukin-23 receptor complex	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
cytosol	Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)
nucleus	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
cytosol	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
extracellular exosome	Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)
nucleus	Wee1-like protein kinase	Homo sapiens (human)
nucleoplasm	Wee1-like protein kinase	Homo sapiens (human)
nucleolus	Wee1-like protein kinase	Homo sapiens (human)
cytoplasm	Wee1-like protein kinase	Homo sapiens (human)
endoplasmic reticulum membrane	Heme oxygenase 2	Homo sapiens (human)
plasma membrane	Heme oxygenase 2	Homo sapiens (human)
membrane	Heme oxygenase 2	Homo sapiens (human)
specific granule membrane	Heme oxygenase 2	Homo sapiens (human)
cytosol	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
methionine adenosyltransferase complex	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
cytosol	S-adenosylmethionine synthase isoform type-2	Homo sapiens (human)
nucleus	DnaJ homolog subfamily A member 1	Homo sapiens (human)
mitochondrion	DnaJ homolog subfamily A member 1	Homo sapiens (human)
cytosol	DnaJ homolog subfamily A member 1	Homo sapiens (human)
microtubule cytoskeleton	DnaJ homolog subfamily A member 1	Homo sapiens (human)
membrane	DnaJ homolog subfamily A member 1	Homo sapiens (human)
perinuclear region of cytoplasm	DnaJ homolog subfamily A member 1	Homo sapiens (human)
extracellular exosome	DnaJ homolog subfamily A member 1	Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membrane	DnaJ homolog subfamily A member 1	Homo sapiens (human)
cytoplasm	DnaJ homolog subfamily A member 1	Homo sapiens (human)
cytosol	DnaJ homolog subfamily A member 1	Homo sapiens (human)
cytoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
mitochondrial intermembrane space	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleus	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
spindle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cytosol	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
plasma membrane	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell-cell junction	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
cell cortex	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
microtubule cytoskeleton	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
lamellipodium	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
vesicle	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
ciliary basal body	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
postsynapse	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
glutamatergic synapse	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
protein-containing complex	RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)
nucleus	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
early endosome	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cytosol	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
plasma membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
cell cortex	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
ruffle membrane	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	RAC-beta serine/threonine-protein kinase	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Dual specificity protein kinase TTK	Homo sapiens (human)
spindle	Dual specificity protein kinase TTK	Homo sapiens (human)
membrane	Dual specificity protein kinase TTK	Homo sapiens (human)
kinetochore	Dual specificity protein kinase TTK	Homo sapiens (human)
nucleus	Dual specificity protein kinase TTK	Homo sapiens (human)
chromosome, telomeric region	DNA replication licensing factor MCM4	Homo sapiens (human)
nucleus	DNA replication licensing factor MCM4	Homo sapiens (human)
nucleoplasm	DNA replication licensing factor MCM4	Homo sapiens (human)
membrane	DNA replication licensing factor MCM4	Homo sapiens (human)
MCM complex	DNA replication licensing factor MCM4	Homo sapiens (human)
CMG complex	DNA replication licensing factor MCM4	Homo sapiens (human)
nucleus	DNA replication licensing factor MCM4	Homo sapiens (human)
postsynaptic actin cytoskeleton	Myosin-10	Homo sapiens (human)
stress fiber	Myosin-10	Homo sapiens (human)
nucleus	Myosin-10	Homo sapiens (human)
cytoplasm	Myosin-10	Homo sapiens (human)
cytosol	Myosin-10	Homo sapiens (human)
cell cortex	Myosin-10	Homo sapiens (human)
lamellipodium	Myosin-10	Homo sapiens (human)
midbody	Myosin-10	Homo sapiens (human)
cleavage furrow	Myosin-10	Homo sapiens (human)
actomyosin	Myosin-10	Homo sapiens (human)
extracellular exosome	Myosin-10	Homo sapiens (human)
myosin II filament	Myosin-10	Homo sapiens (human)
myosin complex	Myosin-10	Homo sapiens (human)
myosin II complex	Myosin-10	Homo sapiens (human)
myosin filament	Myosin-10	Homo sapiens (human)
cytoplasm	Myosin-10	Homo sapiens (human)
extracellular region	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
nucleus	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
mitochondrion	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
early endosome	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
late endosome	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
peroxisomal membrane	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
endoplasmic reticulum	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
Golgi apparatus	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
microtubule	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
cell-cell junction	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
focal adhesion	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
cytoplasmic side of plasma membrane	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
perinuclear region of cytoplasm	Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)
endoplasmic reticulum	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
endoplasmic reticulum lumen	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
plasma membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
endosome membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
receptor complex	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
plasma membrane	Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)
caveola	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
external side of plasma membrane	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
membrane	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
dendrite	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
neuronal cell body	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
HFE-transferrin receptor complex	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
receptor complex	Bone morphogenetic protein receptor type-1A	Homo sapiens (human)
cytosol	Activin receptor type-1B	Homo sapiens (human)
plasma membrane	Activin receptor type-1B	Homo sapiens (human)
cell surface	Activin receptor type-1B	Homo sapiens (human)
receptor complex	Activin receptor type-1B	Homo sapiens (human)
activin receptor complex	Activin receptor type-1B	Homo sapiens (human)
plasma membrane	Activin receptor type-1B	Homo sapiens (human)
nucleus	TGF-beta receptor type-1	Homo sapiens (human)
endosome	TGF-beta receptor type-1	Homo sapiens (human)
plasma membrane	TGF-beta receptor type-1	Homo sapiens (human)
bicellular tight junction	TGF-beta receptor type-1	Homo sapiens (human)
cell surface	TGF-beta receptor type-1	Homo sapiens (human)
membrane raft	TGF-beta receptor type-1	Homo sapiens (human)
transforming growth factor beta ligand-receptor complex	TGF-beta receptor type-1	Homo sapiens (human)
receptor complex	TGF-beta receptor type-1	Homo sapiens (human)
plasma membrane	TGF-beta receptor type-1	Homo sapiens (human)
activin receptor complex	TGF-beta receptor type-1	Homo sapiens (human)
extracellular region	TGF-beta receptor type-2	Homo sapiens (human)
cytosol	TGF-beta receptor type-2	Homo sapiens (human)
plasma membrane	TGF-beta receptor type-2	Homo sapiens (human)
caveola	TGF-beta receptor type-2	Homo sapiens (human)
external side of plasma membrane	TGF-beta receptor type-2	Homo sapiens (human)
membrane	TGF-beta receptor type-2	Homo sapiens (human)
membrane raft	TGF-beta receptor type-2	Homo sapiens (human)
transforming growth factor beta ligand-receptor complex	TGF-beta receptor type-2	Homo sapiens (human)
receptor complex	TGF-beta receptor type-2	Homo sapiens (human)
plasma membrane	TGF-beta receptor type-2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase CSK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase CSK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase CSK	Homo sapiens (human)
cell-cell junction	Tyrosine-protein kinase CSK	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase CSK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase CSK	Homo sapiens (human)
mitochondrial matrix	Glycine--tRNA ligase	Homo sapiens (human)
cytosol	Glycine--tRNA ligase	Homo sapiens (human)
secretory granule	Glycine--tRNA ligase	Homo sapiens (human)
axon	Glycine--tRNA ligase	Homo sapiens (human)
extracellular exosome	Glycine--tRNA ligase	Homo sapiens (human)
cytoplasm	Glycine--tRNA ligase	Homo sapiens (human)
mitochondrion	Glycine--tRNA ligase	Homo sapiens (human)
Golgi membrane	Protein kinase C iota type	Homo sapiens (human)
nucleus	Protein kinase C iota type	Homo sapiens (human)
nucleoplasm	Protein kinase C iota type	Homo sapiens (human)
endosome	Protein kinase C iota type	Homo sapiens (human)
cytosol	Protein kinase C iota type	Homo sapiens (human)
plasma membrane	Protein kinase C iota type	Homo sapiens (human)
brush border	Protein kinase C iota type	Homo sapiens (human)
bicellular tight junction	Protein kinase C iota type	Homo sapiens (human)
microtubule cytoskeleton	Protein kinase C iota type	Homo sapiens (human)
apical plasma membrane	Protein kinase C iota type	Homo sapiens (human)
cell leading edge	Protein kinase C iota type	Homo sapiens (human)
Schmidt-Lanterman incisure	Protein kinase C iota type	Homo sapiens (human)
intercellular bridge	Protein kinase C iota type	Homo sapiens (human)
extracellular exosome	Protein kinase C iota type	Homo sapiens (human)
tight junction	Protein kinase C iota type	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Protein kinase C iota type	Homo sapiens (human)
glutamatergic synapse	Protein kinase C iota type	Homo sapiens (human)
PAR polarity complex	Protein kinase C iota type	Homo sapiens (human)
nuclear exosome (RNase complex)	Exosome RNA helicase MTR4	Homo sapiens (human)
exosome (RNase complex)	Exosome RNA helicase MTR4	Homo sapiens (human)
nucleus	Exosome RNA helicase MTR4	Homo sapiens (human)
nucleoplasm	Exosome RNA helicase MTR4	Homo sapiens (human)
nucleolus	Exosome RNA helicase MTR4	Homo sapiens (human)
nuclear speck	Exosome RNA helicase MTR4	Homo sapiens (human)
TRAMP complex	Exosome RNA helicase MTR4	Homo sapiens (human)
catalytic step 2 spliceosome	Exosome RNA helicase MTR4	Homo sapiens (human)
nucleus	Exosome RNA helicase MTR4	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Tec	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase Tec	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Tec	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Tec	Homo sapiens (human)
nucleus	Tyrosine-protein kinase TXK	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase TXK	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase TXK	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase TXK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase TXK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase TXK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase TXK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL2	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL2	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL2	Homo sapiens (human)
extracellular region	Tyrosine-protein kinase FRK	Homo sapiens (human)
nucleus	Tyrosine-protein kinase FRK	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase FRK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase FRK	Homo sapiens (human)
azurophil granule lumen	Tyrosine-protein kinase FRK	Homo sapiens (human)
specific granule lumen	Tyrosine-protein kinase FRK	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase FRK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase FRK	Homo sapiens (human)
plasma membrane	G protein-coupled receptor kinase 6	Homo sapiens (human)
membrane	G protein-coupled receptor kinase 6	Homo sapiens (human)
cytoplasm	G protein-coupled receptor kinase 6	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase SYK	Homo sapiens (human)
nucleus	Tyrosine-protein kinase SYK	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase SYK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase SYK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase SYK	Homo sapiens (human)
early phagosome	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell receptor complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
T cell receptor complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase SYK	Homo sapiens (human)
proteasome complex	26S proteasome regulatory subunit 6B	Homo sapiens (human)
nucleus	26S proteasome regulatory subunit 6B	Homo sapiens (human)
nucleoplasm	26S proteasome regulatory subunit 6B	Homo sapiens (human)
cytosol	26S proteasome regulatory subunit 6B	Homo sapiens (human)
membrane	26S proteasome regulatory subunit 6B	Homo sapiens (human)
inclusion body	26S proteasome regulatory subunit 6B	Homo sapiens (human)
synapse	26S proteasome regulatory subunit 6B	Homo sapiens (human)
proteasome accessory complex	26S proteasome regulatory subunit 6B	Homo sapiens (human)
cytosolic proteasome complex	26S proteasome regulatory subunit 6B	Homo sapiens (human)
proteasome regulatory particle, base subcomplex	26S proteasome regulatory subunit 6B	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 8	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 8	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 8	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 8	Homo sapiens (human)
axon	Mitogen-activated protein kinase 8	Homo sapiens (human)
synapse	Mitogen-activated protein kinase 8	Homo sapiens (human)
basal dendrite	Mitogen-activated protein kinase 8	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 8	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 9	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 9	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 9	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase 9	Homo sapiens (human)
nuclear speck	Mitogen-activated protein kinase 9	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Mitogen-activated protein kinase 9	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 9	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 9	Homo sapiens (human)
cytoplasm	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
nucleoplasm	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
membrane	Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)
photoreceptor outer segment	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
photoreceptor inner segment	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
lysosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
autophagosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)
nucleus	Casein kinase I isoform delta	Homo sapiens (human)
nucleoplasm	Casein kinase I isoform delta	Homo sapiens (human)
Golgi apparatus	Casein kinase I isoform delta	Homo sapiens (human)
centrosome	Casein kinase I isoform delta	Homo sapiens (human)
spindle	Casein kinase I isoform delta	Homo sapiens (human)
cytosol	Casein kinase I isoform delta	Homo sapiens (human)
spindle microtubule	Casein kinase I isoform delta	Homo sapiens (human)
plasma membrane	Casein kinase I isoform delta	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Casein kinase I isoform delta	Homo sapiens (human)
ciliary basal body	Casein kinase I isoform delta	Homo sapiens (human)
perinuclear region of cytoplasm	Casein kinase I isoform delta	Homo sapiens (human)
nucleus	Casein kinase I isoform delta	Homo sapiens (human)
cytoplasm	Casein kinase I isoform delta	Homo sapiens (human)
spindle microtubule	Casein kinase I isoform delta	Homo sapiens (human)
nucleus	MAP kinase-activated protein kinase 2	Homo sapiens (human)
nucleoplasm	MAP kinase-activated protein kinase 2	Homo sapiens (human)
cytoplasm	MAP kinase-activated protein kinase 2	Homo sapiens (human)
centrosome	MAP kinase-activated protein kinase 2	Homo sapiens (human)
cytosol	MAP kinase-activated protein kinase 2	Homo sapiens (human)
extracellular exosome	MAP kinase-activated protein kinase 2	Homo sapiens (human)
nucleus	MAP kinase-activated protein kinase 2	Homo sapiens (human)
cytoplasm	MAP kinase-activated protein kinase 2	Homo sapiens (human)
mitochondrion	Elongation factor Tu, mitochondrial	Homo sapiens (human)
mitochondrial outer membrane	Elongation factor Tu, mitochondrial	Homo sapiens (human)
membrane	Elongation factor Tu, mitochondrial	Homo sapiens (human)
mitochondrial nucleoid	Elongation factor Tu, mitochondrial	Homo sapiens (human)
synapse	Elongation factor Tu, mitochondrial	Homo sapiens (human)
extracellular exosome	Elongation factor Tu, mitochondrial	Homo sapiens (human)
mitochondrion	Elongation factor Tu, mitochondrial	Homo sapiens (human)
nucleus	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
nuclear envelope	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
endoplasmic reticulum	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
endoplasmic reticulum membrane	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
cytosol	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
glycogen granule	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
endoplasmic reticulum	Choline-phosphate cytidylyltransferase A	Homo sapiens (human)
nucleus	Casein kinase I isoform epsilon	Homo sapiens (human)
nucleoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
cytoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
cytosol	Casein kinase I isoform epsilon	Homo sapiens (human)
growth cone	Casein kinase I isoform epsilon	Homo sapiens (human)
neuronal cell body	Casein kinase I isoform epsilon	Homo sapiens (human)
ribonucleoprotein complex	Casein kinase I isoform epsilon	Homo sapiens (human)
cytoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
nucleus	Casein kinase I isoform epsilon	Homo sapiens (human)
nucleoplasm	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
nucleolus	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrion	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrial membrane	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
mitochondrial nucleoid	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK1	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK2	Homo sapiens (human)
nucleoplasm	Dual specificity protein kinase CLK2	Homo sapiens (human)
nuclear body	Dual specificity protein kinase CLK2	Homo sapiens (human)
nuclear speck	Dual specificity protein kinase CLK2	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK2	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
neuronal cell body	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
apical dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proximal dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
axon	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glutamatergic synapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
plasma membrane	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dendrite	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
Wnt signalosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 7	Homo sapiens (human)
fibrillar center	Cyclin-dependent kinase 7	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 7	Homo sapiens (human)
plasma membrane	Cyclin-dependent kinase 7	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIH core complex	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIH holo complex	Cyclin-dependent kinase 7	Homo sapiens (human)
CAK-ERCC2 complex	Cyclin-dependent kinase 7	Homo sapiens (human)
transcription factor TFIIK complex	Cyclin-dependent kinase 7	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 7	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 9	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 9	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-dependent kinase 9	Homo sapiens (human)
membrane	Cyclin-dependent kinase 9	Homo sapiens (human)
PML body	Cyclin-dependent kinase 9	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Cyclin-dependent kinase 9	Homo sapiens (human)
transcription elongation factor complex	Cyclin-dependent kinase 9	Homo sapiens (human)
P-TEFb complex	Cyclin-dependent kinase 9	Homo sapiens (human)
photoreceptor outer segment	Ras-related protein Rab-27A	Homo sapiens (human)
extracellular region	Ras-related protein Rab-27A	Homo sapiens (human)
lysosome	Ras-related protein Rab-27A	Homo sapiens (human)
late endosome	Ras-related protein Rab-27A	Homo sapiens (human)
cytosol	Ras-related protein Rab-27A	Homo sapiens (human)
dendrite	Ras-related protein Rab-27A	Homo sapiens (human)
multivesicular body membrane	Ras-related protein Rab-27A	Homo sapiens (human)
Weibel-Palade body	Ras-related protein Rab-27A	Homo sapiens (human)
melanosome membrane	Ras-related protein Rab-27A	Homo sapiens (human)
specific granule lumen	Ras-related protein Rab-27A	Homo sapiens (human)
melanosome	Ras-related protein Rab-27A	Homo sapiens (human)
extracellular exosome	Ras-related protein Rab-27A	Homo sapiens (human)
exocytic vesicle	Ras-related protein Rab-27A	Homo sapiens (human)
exocytic vesicle	Ras-related protein Rab-27A	Homo sapiens (human)
apical plasma membrane	Ras-related protein Rab-27A	Homo sapiens (human)
Golgi apparatus	Ras-related protein Rab-27A	Homo sapiens (human)
secretory granule	Ras-related protein Rab-27A	Homo sapiens (human)
melanosome	Ras-related protein Rab-27A	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Blk	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Blk	Homo sapiens (human)
cytoplasm	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
cell surface	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
nucleoplasm	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
lipid droplet	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
cytosol	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
plasma membrane	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
endosome membrane	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
protein-containing complex	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
nucleus	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
plasma membrane	Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
nucleolus	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
synapse	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)
nucleoplasm	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
cytosol	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
plasma membrane	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
ruffle membrane	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
plasma membrane	Cytoplasmic tyrosine-protein kinase BMX	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase catalytic subunit PRKX	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
condensed nuclear chromosome	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
microtubule	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
midbody	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Nek2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
axon	Serine/threonine-protein kinase Nek3	Homo sapiens (human)
extrinsic component of plasma membrane	Tyrosine-protein kinase JAK3	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK3	Homo sapiens (human)
endosome	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK3	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK3	Homo sapiens (human)
cytoplasm	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
nucleoplasm	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytoskeleton	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
spindle microtubule	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule cytoskeleton	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriolar satellite	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle midzone	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
outer kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
postsynapse	LIM domain kinase 1	Homo sapiens (human)
glutamatergic synapse	LIM domain kinase 1	Homo sapiens (human)
male germ cell nucleus	LIM domain kinase 1	Homo sapiens (human)
cytoplasm	LIM domain kinase 1	Homo sapiens (human)
cytosol	LIM domain kinase 1	Homo sapiens (human)
cytoskeleton	LIM domain kinase 1	Homo sapiens (human)
focal adhesion	LIM domain kinase 1	Homo sapiens (human)
membrane	LIM domain kinase 1	Homo sapiens (human)
nuclear speck	LIM domain kinase 1	Homo sapiens (human)
lamellipodium	LIM domain kinase 1	Homo sapiens (human)
neuron projection	LIM domain kinase 1	Homo sapiens (human)
nucleus	LIM domain kinase 1	Homo sapiens (human)
neuron projection	LIM domain kinase 1	Homo sapiens (human)
cytoplasm	LIM domain kinase 1	Homo sapiens (human)
nucleus	LIM domain kinase 2	Homo sapiens (human)
cytoplasm	LIM domain kinase 2	Homo sapiens (human)
cis-Golgi network	LIM domain kinase 2	Homo sapiens (human)
centrosome	LIM domain kinase 2	Homo sapiens (human)
perinuclear region of cytoplasm	LIM domain kinase 2	Homo sapiens (human)
mitotic spindle	LIM domain kinase 2	Homo sapiens (human)
nucleus	LIM domain kinase 2	Homo sapiens (human)
cytoplasm	LIM domain kinase 2	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 10	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 10	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 10	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 10	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase 10	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 10	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 10	Homo sapiens (human)
nucleus	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytoplasm	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytosol	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
extracellular space	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
cytosol	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
nuclear body	Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)
nucleus	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
nucleoplasm	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
cytosol	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
membrane	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
nucleotide-activated protein kinase complex	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
nucleus	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
cytoplasm	5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 3	Homo sapiens (human)
cytosol	Ephrin type-B receptor 3	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 3	Homo sapiens (human)
dendrite	Ephrin type-B receptor 3	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 3	Homo sapiens (human)
rough endoplasmic reticulum	Ephrin type-A receptor 5	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 5	Homo sapiens (human)
external side of plasma membrane	Ephrin type-A receptor 5	Homo sapiens (human)
axon	Ephrin type-A receptor 5	Homo sapiens (human)
dendrite	Ephrin type-A receptor 5	Homo sapiens (human)
neuronal cell body	Ephrin type-A receptor 5	Homo sapiens (human)
perinuclear region of cytoplasm	Ephrin type-A receptor 5	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 5	Homo sapiens (human)
dendrite	Ephrin type-A receptor 5	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 4	Homo sapiens (human)
cytosol	Ephrin type-B receptor 4	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 4	Homo sapiens (human)
extracellular exosome	Ephrin type-B receptor 4	Homo sapiens (human)
receptor complex	Ephrin type-B receptor 4	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 4	Homo sapiens (human)
cytoplasm	Ephrin type-A receptor 4	Homo sapiens (human)
mitochondrial outer membrane	Ephrin type-A receptor 4	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 4	Homo sapiens (human)
adherens junction	Ephrin type-A receptor 4	Homo sapiens (human)
cell surface	Ephrin type-A receptor 4	Homo sapiens (human)
filopodium	Ephrin type-A receptor 4	Homo sapiens (human)
axon	Ephrin type-A receptor 4	Homo sapiens (human)
dendrite	Ephrin type-A receptor 4	Homo sapiens (human)
neuromuscular junction	Ephrin type-A receptor 4	Homo sapiens (human)
early endosome membrane	Ephrin type-A receptor 4	Homo sapiens (human)
presynaptic membrane	Ephrin type-A receptor 4	Homo sapiens (human)
dendritic spine	Ephrin type-A receptor 4	Homo sapiens (human)
dendritic shaft	Ephrin type-A receptor 4	Homo sapiens (human)
perikaryon	Ephrin type-A receptor 4	Homo sapiens (human)
axon terminus	Ephrin type-A receptor 4	Homo sapiens (human)
axonal growth cone	Ephrin type-A receptor 4	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Ephrin type-A receptor 4	Homo sapiens (human)
postsynaptic density membrane	Ephrin type-A receptor 4	Homo sapiens (human)
glutamatergic synapse	Ephrin type-A receptor 4	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 4	Homo sapiens (human)
dendrite	Ephrin type-A receptor 4	Homo sapiens (human)
mitochondrial intermembrane space	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
extracellular exosome	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
sperm mitochondrial sheath	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
cytoplasm	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Adenylate kinase 2, mitochondrial	Homo sapiens (human)
nucleoplasm	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
plasma membrane	Adenosine kinase	Homo sapiens (human)
nucleus	Adenosine kinase	Homo sapiens (human)
cytosol	Adenosine kinase	Homo sapiens (human)
exocyst	Ras-related protein Rab-10	Homo sapiens (human)
plasma membrane	Ras-related protein Rab-10	Homo sapiens (human)
Golgi membrane	Ras-related protein Rab-10	Homo sapiens (human)
endosome	Ras-related protein Rab-10	Homo sapiens (human)
endoplasmic reticulum membrane	Ras-related protein Rab-10	Homo sapiens (human)
Golgi apparatus	Ras-related protein Rab-10	Homo sapiens (human)
trans-Golgi network	Ras-related protein Rab-10	Homo sapiens (human)
cytosol	Ras-related protein Rab-10	Homo sapiens (human)
cytoskeleton	Ras-related protein Rab-10	Homo sapiens (human)
plasma membrane	Ras-related protein Rab-10	Homo sapiens (human)
adherens junction	Ras-related protein Rab-10	Homo sapiens (human)
focal adhesion	Ras-related protein Rab-10	Homo sapiens (human)
cilium	Ras-related protein Rab-10	Homo sapiens (human)
endosome membrane	Ras-related protein Rab-10	Homo sapiens (human)
cytoplasmic vesicle membrane	Ras-related protein Rab-10	Homo sapiens (human)
secretory granule membrane	Ras-related protein Rab-10	Homo sapiens (human)
phagocytic vesicle membrane	Ras-related protein Rab-10	Homo sapiens (human)
insulin-responsive compartment	Ras-related protein Rab-10	Homo sapiens (human)
perinuclear region of cytoplasm	Ras-related protein Rab-10	Homo sapiens (human)
recycling endosome	Ras-related protein Rab-10	Homo sapiens (human)
recycling endosome membrane	Ras-related protein Rab-10	Homo sapiens (human)
extracellular exosome	Ras-related protein Rab-10	Homo sapiens (human)
exocytic vesicle	Ras-related protein Rab-10	Homo sapiens (human)
endoplasmic reticulum tubular network	Ras-related protein Rab-10	Homo sapiens (human)
recycling endosome	Ras-related protein Rab-10	Homo sapiens (human)
secretory vesicle	Ras-related protein Rab-10	Homo sapiens (human)
membrane	Ras-related protein Rab-10	Homo sapiens (human)
Golgi apparatus	Ras-related protein Rab-10	Homo sapiens (human)
nucleus	Actin-related protein 3	Homo sapiens (human)
cytoplasm	Actin-related protein 3	Homo sapiens (human)
cytosol	Actin-related protein 3	Homo sapiens (human)
brush border	Actin-related protein 3	Homo sapiens (human)
cell-cell junction	Actin-related protein 3	Homo sapiens (human)
focal adhesion	Actin-related protein 3	Homo sapiens (human)
actin cytoskeleton	Actin-related protein 3	Homo sapiens (human)
membrane	Actin-related protein 3	Homo sapiens (human)
lamellipodium	Actin-related protein 3	Homo sapiens (human)
site of double-strand break	Actin-related protein 3	Homo sapiens (human)
extracellular exosome	Actin-related protein 3	Homo sapiens (human)
Arp2/3 protein complex	Actin-related protein 3	Homo sapiens (human)
extracellular region	Actin-related protein 2	Homo sapiens (human)
nucleus	Actin-related protein 2	Homo sapiens (human)
cytoplasm	Actin-related protein 2	Homo sapiens (human)
cytosol	Actin-related protein 2	Homo sapiens (human)
focal adhesion	Actin-related protein 2	Homo sapiens (human)
actin cytoskeleton	Actin-related protein 2	Homo sapiens (human)
membrane	Actin-related protein 2	Homo sapiens (human)
actin cap	Actin-related protein 2	Homo sapiens (human)
azurophil granule lumen	Actin-related protein 2	Homo sapiens (human)
site of double-strand break	Actin-related protein 2	Homo sapiens (human)
cell projection	Actin-related protein 2	Homo sapiens (human)
extracellular exosome	Actin-related protein 2	Homo sapiens (human)
ficolin-1-rich granule lumen	Actin-related protein 2	Homo sapiens (human)
Arp2/3 protein complex	Actin-related protein 2	Homo sapiens (human)
cell cortex	Actin-related protein 2	Homo sapiens (human)
Flemming body	GTP-binding nuclear protein Ran	Homo sapiens (human)
male germ cell nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
manchette	GTP-binding nuclear protein Ran	Homo sapiens (human)
nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
nuclear envelope	GTP-binding nuclear protein Ran	Homo sapiens (human)
nucleoplasm	GTP-binding nuclear protein Ran	Homo sapiens (human)
nucleolus	GTP-binding nuclear protein Ran	Homo sapiens (human)
cytoplasm	GTP-binding nuclear protein Ran	Homo sapiens (human)
centriole	GTP-binding nuclear protein Ran	Homo sapiens (human)
cytosol	GTP-binding nuclear protein Ran	Homo sapiens (human)
membrane	GTP-binding nuclear protein Ran	Homo sapiens (human)
midbody	GTP-binding nuclear protein Ran	Homo sapiens (human)
sperm flagellum	GTP-binding nuclear protein Ran	Homo sapiens (human)
melanosome	GTP-binding nuclear protein Ran	Homo sapiens (human)
recycling endosome	GTP-binding nuclear protein Ran	Homo sapiens (human)
extracellular exosome	GTP-binding nuclear protein Ran	Homo sapiens (human)
chromatin	GTP-binding nuclear protein Ran	Homo sapiens (human)
nuclear pore	GTP-binding nuclear protein Ran	Homo sapiens (human)
protein-containing complex	GTP-binding nuclear protein Ran	Homo sapiens (human)
RNA nuclear export complex	GTP-binding nuclear protein Ran	Homo sapiens (human)
nucleus	GTP-binding nuclear protein Ran	Homo sapiens (human)
cytoplasm	GTP-binding nuclear protein Ran	Homo sapiens (human)
cytosol	Casein kinase I isoform gamma-2	Homo sapiens (human)
cell cortex	Casein kinase I isoform gamma-2	Homo sapiens (human)
membrane	Casein kinase I isoform gamma-2	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-2	Homo sapiens (human)
plasma membrane	Casein kinase I isoform gamma-2	Homo sapiens (human)
nucleus	Casein kinase I isoform gamma-2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 3	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 3	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 3	Homo sapiens (human)
ruffle	Cyclin-dependent kinase 6	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 6	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 6	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 6	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 6	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 6	Homo sapiens (human)
cyclin D1-CDK6 complex	Cyclin-dependent kinase 6	Homo sapiens (human)
cyclin D3-CDK6 complex	Cyclin-dependent kinase 6	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 6	Homo sapiens (human)
cyclin D2-CDK6 complex	Cyclin-dependent kinase 6	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 6	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 6	Homo sapiens (human)
microtubule	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytosol	Cyclin-dependent-like kinase 5	Homo sapiens (human)
plasma membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
postsynaptic density	Cyclin-dependent-like kinase 5	Homo sapiens (human)
membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein kinase 5 complex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
lamellipodium	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell junction	Cyclin-dependent-like kinase 5	Homo sapiens (human)
filopodium	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axon	Cyclin-dependent-like kinase 5	Homo sapiens (human)
dendrite	Cyclin-dependent-like kinase 5	Homo sapiens (human)
growth cone	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuromuscular junction	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron projection	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuronal cell body	Cyclin-dependent-like kinase 5	Homo sapiens (human)
perikaryon	Cyclin-dependent-like kinase 5	Homo sapiens (human)
presynapse	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle	Cyclin-dependent kinase 16	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 16	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 16	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 16	Homo sapiens (human)
plasma membrane	Cyclin-dependent kinase 16	Homo sapiens (human)
cytoplasmic side of plasma membrane	Cyclin-dependent kinase 16	Homo sapiens (human)
microtubule cytoskeleton	Cyclin-dependent kinase 16	Homo sapiens (human)
neuron projection	Cyclin-dependent kinase 16	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 16	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 16	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 17	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 17	Homo sapiens (human)
nucleus	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
cytoplasm	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
cytosol	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
membrane	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
extracellular exosome	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
membrane	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
6-phosphofructokinase complex	ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)
nucleus	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
mitochondrion	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
early endosome	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
late endosome	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
endoplasmic reticulum	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
Golgi apparatus	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
centrosome	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
plasma membrane	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
focal adhesion	Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-beta	Homo sapiens (human)
heterochromatin	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleus	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-beta	Homo sapiens (human)
cytosol	DNA topoisomerase 2-beta	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleus	DNA topoisomerase 2-beta	Homo sapiens (human)
immunological synapse	Protein kinase C theta type	Homo sapiens (human)
cytosol	Protein kinase C theta type	Homo sapiens (human)
plasma membrane	Protein kinase C theta type	Homo sapiens (human)
aggresome	Protein kinase C theta type	Homo sapiens (human)
centriolar satellite	Protein kinase C theta type	Homo sapiens (human)
plasma membrane	Activin receptor type-1	Homo sapiens (human)
apical part of cell	Activin receptor type-1	Homo sapiens (human)
activin receptor complex	Activin receptor type-1	Homo sapiens (human)
BMP receptor complex	Activin receptor type-1	Homo sapiens (human)
plasma membrane	Activin receptor type-1	Homo sapiens (human)
stress fiber	Macrophage-stimulating protein receptor	Homo sapiens (human)
vacuole	Macrophage-stimulating protein receptor	Homo sapiens (human)
plasma membrane	Macrophage-stimulating protein receptor	Homo sapiens (human)
cell surface	Macrophage-stimulating protein receptor	Homo sapiens (human)
receptor complex	Macrophage-stimulating protein receptor	Homo sapiens (human)
plasma membrane	Macrophage-stimulating protein receptor	Homo sapiens (human)
stress fiber	Focal adhesion kinase 1	Homo sapiens (human)
nucleus	Focal adhesion kinase 1	Homo sapiens (human)
cytoplasm	Focal adhesion kinase 1	Homo sapiens (human)
centrosome	Focal adhesion kinase 1	Homo sapiens (human)
cytosol	Focal adhesion kinase 1	Homo sapiens (human)
cytoskeleton	Focal adhesion kinase 1	Homo sapiens (human)
plasma membrane	Focal adhesion kinase 1	Homo sapiens (human)
focal adhesion	Focal adhesion kinase 1	Homo sapiens (human)
cell cortex	Focal adhesion kinase 1	Homo sapiens (human)
ciliary basal body	Focal adhesion kinase 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Focal adhesion kinase 1	Homo sapiens (human)
perinuclear region of cytoplasm	Focal adhesion kinase 1	Homo sapiens (human)
plasma membrane	Focal adhesion kinase 1	Homo sapiens (human)
focal adhesion	Focal adhesion kinase 1	Homo sapiens (human)
dendritic spine	Focal adhesion kinase 1	Homo sapiens (human)
extracellular region	Protein kinase C delta type	Homo sapiens (human)
nucleus	Protein kinase C delta type	Homo sapiens (human)
nucleoplasm	Protein kinase C delta type	Homo sapiens (human)
cytoplasm	Protein kinase C delta type	Homo sapiens (human)
mitochondrion	Protein kinase C delta type	Homo sapiens (human)
endoplasmic reticulum	Protein kinase C delta type	Homo sapiens (human)
cytosol	Protein kinase C delta type	Homo sapiens (human)
plasma membrane	Protein kinase C delta type	Homo sapiens (human)
cell-cell junction	Protein kinase C delta type	Homo sapiens (human)
nuclear matrix	Protein kinase C delta type	Homo sapiens (human)
azurophil granule lumen	Protein kinase C delta type	Homo sapiens (human)
endolysosome	Protein kinase C delta type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C delta type	Homo sapiens (human)
extracellular exosome	Protein kinase C delta type	Homo sapiens (human)
nucleus	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase BTK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytoplasmic vesicle	Tyrosine-protein kinase BTK	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase BTK	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase BTK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase BTK	Homo sapiens (human)
nucleus	Activated CDC42 kinase 1	Homo sapiens (human)
cytoplasm	Activated CDC42 kinase 1	Homo sapiens (human)
endosome	Activated CDC42 kinase 1	Homo sapiens (human)
cytosol	Activated CDC42 kinase 1	Homo sapiens (human)
plasma membrane	Activated CDC42 kinase 1	Homo sapiens (human)
clathrin-coated pit	Activated CDC42 kinase 1	Homo sapiens (human)
adherens junction	Activated CDC42 kinase 1	Homo sapiens (human)
membrane	Activated CDC42 kinase 1	Homo sapiens (human)
clathrin-coated vesicle	Activated CDC42 kinase 1	Homo sapiens (human)
cytoplasmic vesicle membrane	Activated CDC42 kinase 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Activated CDC42 kinase 1	Homo sapiens (human)
perinuclear region of cytoplasm	Activated CDC42 kinase 1	Homo sapiens (human)
cytoophidium	Activated CDC42 kinase 1	Homo sapiens (human)
Grb2-EGFR complex	Activated CDC42 kinase 1	Homo sapiens (human)
plasma membrane	Activated CDC42 kinase 1	Homo sapiens (human)
extracellular space	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
plasma membrane	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
extracellular exosome	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
receptor complex	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
plasma membrane	Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
cell-cell junction	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ITK/TSK	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
Golgi membrane	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
basolateral plasma membrane	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)
photoreceptor outer segment	Tyrosine-protein kinase Mer	Homo sapiens (human)
extracellular space	Tyrosine-protein kinase Mer	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Mer	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Mer	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Mer	Homo sapiens (human)
receptor complex	Tyrosine-protein kinase Mer	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 4	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 4	Homo sapiens (human)
nuclear body	Serine/threonine-protein kinase 4	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase 4	Homo sapiens (human)
cytoplasm	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
nucleus	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
nucleoplasm	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cytoplasm	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
cytosol	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
apical plasma membrane	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
nuclear speck	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
axon	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
dendrite	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
nucleotide-activated protein kinase complex	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
neuronal cell body	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
chromatin	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
nucleus	5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)
spindle	Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 7	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 7	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 7	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 7	Homo sapiens (human)
PML body	Mitogen-activated protein kinase 7	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 7	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 7	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cell-cell junction	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
postsynaptic density	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
secretory granule	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
glutamatergic synapse	Serine/threonine-protein kinase PAK 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 3	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase 3	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 3	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase 3	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)
cytosol	Integrin-linked protein kinase	Homo sapiens (human)
plasma membrane	Integrin-linked protein kinase	Homo sapiens (human)
focal adhesion	Integrin-linked protein kinase	Homo sapiens (human)
membrane	Integrin-linked protein kinase	Homo sapiens (human)
sarcomere	Integrin-linked protein kinase	Homo sapiens (human)
lamellipodium	Integrin-linked protein kinase	Homo sapiens (human)
focal adhesion	Integrin-linked protein kinase	Homo sapiens (human)
stress fiber	Integrin-linked protein kinase	Homo sapiens (human)
Golgi membrane	Rho-associated protein kinase 1	Homo sapiens (human)
ruffle	Rho-associated protein kinase 1	Homo sapiens (human)
extracellular region	Rho-associated protein kinase 1	Homo sapiens (human)
centriole	Rho-associated protein kinase 1	Homo sapiens (human)
cytosol	Rho-associated protein kinase 1	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 1	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasmic stress granule	Rho-associated protein kinase 1	Homo sapiens (human)
lamellipodium	Rho-associated protein kinase 1	Homo sapiens (human)
bleb	Rho-associated protein kinase 1	Homo sapiens (human)
secretory granule lumen	Rho-associated protein kinase 1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Rho-associated protein kinase 1	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasmic stress granule	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasm	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
membrane	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
plasma membrane	Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)
nucleoplasm	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
membrane	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
endocytic vesicle membrane	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
sarcoplasmic reticulum membrane	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
calcium- and calmodulin-dependent protein kinase complex	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
neuron projection	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
cytoplasm	Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)
nucleus	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
nucleoplasm	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cytoplasm	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
membrane	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
endocytic vesicle membrane	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
sarcoplasmic reticulum membrane	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
sarcolemma	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
calcium- and calmodulin-dependent protein kinase complex	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cytoplasm	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
neuron projection	Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)
cytoskeleton	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
cytoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
nuclear speck	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
axon	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
dendrite	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
ribonucleoprotein complex	Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)
cytoplasm	Activin receptor type-2B	Homo sapiens (human)
plasma membrane	Activin receptor type-2B	Homo sapiens (human)
protein-containing complex	Activin receptor type-2B	Homo sapiens (human)
receptor complex	Activin receptor type-2B	Homo sapiens (human)
activin receptor complex	Activin receptor type-2B	Homo sapiens (human)
plasma membrane	Activin receptor type-2B	Homo sapiens (human)
caveola	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
extracellular space	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
nucleoplasm	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
clathrin-coated pit	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
adherens junction	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
basal plasma membrane	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
cell surface	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
postsynaptic density	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
apical plasma membrane	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
axon	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
dendrite	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
neuronal cell body	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
receptor complex	Bone morphogenetic protein receptor type-2	Homo sapiens (human)
ruffle	Protein-tyrosine kinase 6	Homo sapiens (human)
nucleus	Protein-tyrosine kinase 6	Homo sapiens (human)
nucleoplasm	Protein-tyrosine kinase 6	Homo sapiens (human)
cytoplasm	Protein-tyrosine kinase 6	Homo sapiens (human)
cytosol	Protein-tyrosine kinase 6	Homo sapiens (human)
plasma membrane	Protein-tyrosine kinase 6	Homo sapiens (human)
nuclear body	Protein-tyrosine kinase 6	Homo sapiens (human)
plasma membrane	Protein-tyrosine kinase 6	Homo sapiens (human)
acrosomal vesicle	cGMP-dependent protein kinase 1	Homo sapiens (human)
nucleoplasm	cGMP-dependent protein kinase 1	Homo sapiens (human)
cytoplasm	cGMP-dependent protein kinase 1	Homo sapiens (human)
Golgi apparatus	cGMP-dependent protein kinase 1	Homo sapiens (human)
cytosol	cGMP-dependent protein kinase 1	Homo sapiens (human)
plasma membrane	cGMP-dependent protein kinase 1	Homo sapiens (human)
sarcolemma	cGMP-dependent protein kinase 1	Homo sapiens (human)
cyclin K-CDK13 complex	Cyclin-dependent kinase 13	Homo sapiens (human)
extracellular region	Cyclin-dependent kinase 13	Homo sapiens (human)
extracellular space	Cyclin-dependent kinase 13	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 13	Homo sapiens (human)
Golgi apparatus	Cyclin-dependent kinase 13	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 13	Homo sapiens (human)
nuclear speck	Cyclin-dependent kinase 13	Homo sapiens (human)
ficolin-1-rich granule lumen	Cyclin-dependent kinase 13	Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 13	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 13	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-dependent kinase 13	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
nucleus	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
nucleoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cytoplasm	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
cytosol	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
PML body	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
mitochondrial membrane	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
serine/threonine protein kinase complex	Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)
NMDA selective glutamate receptor complex	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
nucleus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytoplasm	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytosol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytoskeleton	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell cortex	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic density	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
lamellipodium	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
dendrite	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
growth cone	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neuronal cell body	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell body	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
apical dendrite	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
presynapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glutamatergic synapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic density, intracellular component	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
dendritic spine	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
plasma membrane	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
plasma membrane	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
cell cortex	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
membrane	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
cytoplasm	Maternal embryonic leucine zipper kinase	Homo sapiens (human)
chromosome, centromeric region	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
kinetochore	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
condensed nuclear chromosome	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
nucleus	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
nucleoplasm	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
chromosome	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
cytosol	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
nuclear matrix	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
mitotic cohesin complex	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
meiotic cohesin complex	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
mitotic spindle pole	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
cohesin complex	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
nucleus	Structural maintenance of chromosomes protein 1A	Homo sapiens (human)
chromosome, telomeric region	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
nucleus	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
nucleoplasm	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
cytoplasm	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
centrosome	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
membrane	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
NuRD complex	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
site of DNA damage	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
cerebellar granule cell to Purkinje cell synapse	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
chromatin	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
protein-containing complex	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
nucleus	Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)
site of double-strand break	Serine/threonine-protein kinase 38	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 38	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 38	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 38	Homo sapiens (human)
glutamatergic synapse	Serine/threonine-protein kinase 38	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
extracellular region	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
nucleus	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
nucleoplasm	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
mitochondrion	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
mitochondrial matrix	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
cytosol	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
basolateral plasma membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
neuromuscular junction	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
presynaptic membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
postsynaptic membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
postsynaptic density membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
glutamatergic synapse	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
GABA-ergic synapse	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
receptor complex	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
basal plasma membrane	Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 7	Homo sapiens (human)
glutamatergic synapse	Ephrin type-A receptor 7	Homo sapiens (human)
plasma membrane	Ephrin type-A receptor 7	Homo sapiens (human)
dendrite	Ephrin type-A receptor 7	Homo sapiens (human)
Golgi membrane	Delta(24)-sterol reductase	Homo sapiens (human)
nucleus	Delta(24)-sterol reductase	Homo sapiens (human)
endoplasmic reticulum	Delta(24)-sterol reductase	Homo sapiens (human)
endoplasmic reticulum membrane	Delta(24)-sterol reductase	Homo sapiens (human)
membrane	Delta(24)-sterol reductase	Homo sapiens (human)
cytoplasm	Delta(24)-sterol reductase	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
synapse	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)
stress fiber	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytoplasm	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytosol	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
plasma membrane	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
actin cytoskeleton	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
lamellipodium	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cleavage furrow	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cleavage furrow	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
stress fiber	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
lamellipodium	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytoplasm	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 11	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 11	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 11	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 11	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase STK11	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase STK11	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase STK11	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase STK11	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase STK11	Homo sapiens (human)
membrane	Serine/threonine-protein kinase STK11	Homo sapiens (human)
Z disc	Serine/threonine-protein kinase STK11	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase STK11	Homo sapiens (human)
serine/threonine protein kinase complex	Serine/threonine-protein kinase STK11	Homo sapiens (human)
intracellular protein-containing complex	Serine/threonine-protein kinase STK11	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase STK11	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase STK11	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase N1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase N1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase N1	Homo sapiens (human)
endosome	Serine/threonine-protein kinase N1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase N1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase N1	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase N1	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase N1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase N2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase N2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase N2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase N2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase N2	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase N2	Homo sapiens (human)
nuclear body	Serine/threonine-protein kinase N2	Homo sapiens (human)
lamellipodium	Serine/threonine-protein kinase N2	Homo sapiens (human)
midbody	Serine/threonine-protein kinase N2	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase N2	Homo sapiens (human)
apical junction complex	Serine/threonine-protein kinase N2	Homo sapiens (human)
intermediate filament cytoskeleton	Serine/threonine-protein kinase N2	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase N2	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase N2	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 14	Homo sapiens (human)
spindle pole	Mitogen-activated protein kinase 14	Homo sapiens (human)
extracellular region	Mitogen-activated protein kinase 14	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 14	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase 14	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 14	Homo sapiens (human)
mitochondrion	Mitogen-activated protein kinase 14	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase 14	Homo sapiens (human)
nuclear speck	Mitogen-activated protein kinase 14	Homo sapiens (human)
secretory granule lumen	Mitogen-activated protein kinase 14	Homo sapiens (human)
glutamatergic synapse	Mitogen-activated protein kinase 14	Homo sapiens (human)
ficolin-1-rich granule lumen	Mitogen-activated protein kinase 14	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 14	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 14	Homo sapiens (human)
fibrillar center	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
nucleoplasm	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
extracellular exosome	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
cytoplasm	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
nucleus	Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)
centrosome	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
microtubule	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
membrane	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
centrosome	Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)
nucleoplasm	MAP kinase-activated protein kinase 3	Homo sapiens (human)
cytosol	MAP kinase-activated protein kinase 3	Homo sapiens (human)
cytoplasm	MAP kinase-activated protein kinase 3	Homo sapiens (human)
nucleus	MAP kinase-activated protein kinase 3	Homo sapiens (human)
plasma membrane	Discoidin domain-containing receptor 2	Homo sapiens (human)
focal adhesion	Discoidin domain-containing receptor 2	Homo sapiens (human)
actin cytoskeleton	Discoidin domain-containing receptor 2	Homo sapiens (human)
apical plasma membrane	Discoidin domain-containing receptor 2	Homo sapiens (human)
receptor complex	Discoidin domain-containing receptor 2	Homo sapiens (human)
plasma membrane	Discoidin domain-containing receptor 2	Homo sapiens (human)
cytosol	AP2-associated protein kinase 1	Homo sapiens (human)
plasma membrane	AP2-associated protein kinase 1	Homo sapiens (human)
clathrin-coated pit	AP2-associated protein kinase 1	Homo sapiens (human)
clathrin-coated vesicle	AP2-associated protein kinase 1	Homo sapiens (human)
cell leading edge	AP2-associated protein kinase 1	Homo sapiens (human)
terminal bouton	AP2-associated protein kinase 1	Homo sapiens (human)
intracellular membrane-bounded organelle	AP2-associated protein kinase 1	Homo sapiens (human)
presynapse	AP2-associated protein kinase 1	Homo sapiens (human)
cytoplasm	Myosin light chain kinase 3	Homo sapiens (human)
cytosol	Myosin light chain kinase 3	Homo sapiens (human)
cytoplasm	Myosin light chain kinase 3	Homo sapiens (human)
actin cytoskeleton	Myosin light chain kinase 3	Homo sapiens (human)
extracellular exosome	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
perinuclear region of cytoplasm	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
protein-containing complex	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
plasma membrane	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
cytosol	Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)
endomembrane system	Rab-like protein 3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cell-cell junction	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
lamellipodium	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cell leading edge	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
actomyosin	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
actomyosin	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cytoskeleton	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
cell leading edge	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
centriolar satellite	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
cytoskeleton	Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)
mitochondrion	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
mitochondrial matrix	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
cytoplasm	Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
ciliary tip	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK3	Homo sapiens (human)
nucleus	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
mitochondrial inner membrane	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
peroxisome	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
mitochondrial membrane	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
mitochondrion	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
cytoplasm	Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)
endoplasmic reticulum	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
endoplasmic reticulum quality control compartment	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
IRE1-TRAF2-ASK1 complex	Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
actin filament	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
membrane	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
lateral plasma membrane	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
microtubule bundle	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase MARK2	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
mitochondrion	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
cytosol	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
ribonucleoprotein granule	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
mitochondrial nucleoid	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
intracellular anatomical structure	ATP-dependent RNA helicase DHX30	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
microtubule cytoskeleton	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TAO1	Homo sapiens (human)
nucleus	STE20-related kinase adapter protein alpha	Homo sapiens (human)
nucleoplasm	STE20-related kinase adapter protein alpha	Homo sapiens (human)
cytoplasm	STE20-related kinase adapter protein alpha	Homo sapiens (human)
cytosol	STE20-related kinase adapter protein alpha	Homo sapiens (human)
serine/threonine protein kinase complex	STE20-related kinase adapter protein alpha	Homo sapiens (human)
intracellular protein-containing complex	STE20-related kinase adapter protein alpha	Homo sapiens (human)
stress fiber	Myosin-14	Homo sapiens (human)
cytosol	Myosin-14	Homo sapiens (human)
brush border	Myosin-14	Homo sapiens (human)
membrane	Myosin-14	Homo sapiens (human)
growth cone	Myosin-14	Homo sapiens (human)
actomyosin	Myosin-14	Homo sapiens (human)
extracellular exosome	Myosin-14	Homo sapiens (human)
myosin II filament	Myosin-14	Homo sapiens (human)
myosin II complex	Myosin-14	Homo sapiens (human)
cytoplasm	Myosin-14	Homo sapiens (human)
myosin filament	Myosin-14	Homo sapiens (human)
mitochondrion	AarF domain-containing protein kinase 1	Homo sapiens (human)
mitochondrial inner membrane	AarF domain-containing protein kinase 1	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
nucleoplasm	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
cytosol	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
Cajal body	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
membrane	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
nuclear speck	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
U2-type prespliceosome	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX42	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)
nucleoplasm	MAP kinase-activated protein kinase 5	Homo sapiens (human)
cytosol	MAP kinase-activated protein kinase 5	Homo sapiens (human)
septin cytoskeleton	MAP kinase-activated protein kinase 5	Homo sapiens (human)
protein-containing complex	MAP kinase-activated protein kinase 5	Homo sapiens (human)
cytoplasm	MAP kinase-activated protein kinase 5	Homo sapiens (human)
nucleus	MAP kinase-activated protein kinase 5	Homo sapiens (human)
cytoplasm	Misshapen-like kinase 1	Homo sapiens (human)
Golgi apparatus	Misshapen-like kinase 1	Homo sapiens (human)
cytosol	Misshapen-like kinase 1	Homo sapiens (human)
postsynaptic density	Misshapen-like kinase 1	Homo sapiens (human)
axon	Misshapen-like kinase 1	Homo sapiens (human)
dendrite	Misshapen-like kinase 1	Homo sapiens (human)
extracellular exosome	Misshapen-like kinase 1	Homo sapiens (human)
cytoplasm	Misshapen-like kinase 1	Homo sapiens (human)
mitochondrion	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
membrane	Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
autophagosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
endoplasmic reticulum	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
cytosol	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
intracellular organelle	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
extracellular exosome	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)
axoneme	Mitogen-activated protein kinase 15	Homo sapiens (human)
extracellular region	Mitogen-activated protein kinase 15	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 15	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 15	Homo sapiens (human)
autophagosome	Mitogen-activated protein kinase 15	Homo sapiens (human)
Golgi apparatus	Mitogen-activated protein kinase 15	Homo sapiens (human)
centriole	Mitogen-activated protein kinase 15	Homo sapiens (human)
cell-cell junction	Mitogen-activated protein kinase 15	Homo sapiens (human)
bicellular tight junction	Mitogen-activated protein kinase 15	Homo sapiens (human)
cytoplasmic vesicle	Mitogen-activated protein kinase 15	Homo sapiens (human)
ciliary basal body	Mitogen-activated protein kinase 15	Homo sapiens (human)
meiotic spindle	Mitogen-activated protein kinase 15	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase 15	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase 15	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Nek9	Homo sapiens (human)
microtubule organizing center	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
microtubule	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Nek7	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
nucleoplasm	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
mitochondrion	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
cytosol	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
cytoplasmic stress granule	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
membrane	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
cleavage body	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
tRNA-splicing ligase complex	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
ribonucleoprotein complex	ATP-dependent RNA helicase DDX1	Homo sapiens (human)
nucleus	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
nucleoplasm	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
chromatin	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
nucleus	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
transcription regulator complex	Nuclear receptor subfamily 4 group A member 3	Homo sapiens (human)
membrane	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)
kinetochore	Aurora kinase B	Homo sapiens (human)
condensed chromosome, centromeric region	Aurora kinase B	Homo sapiens (human)
nucleus	Aurora kinase B	Homo sapiens (human)
nucleoplasm	Aurora kinase B	Homo sapiens (human)
spindle	Aurora kinase B	Homo sapiens (human)
cytosol	Aurora kinase B	Homo sapiens (human)
chromocenter	Aurora kinase B	Homo sapiens (human)
microtubule cytoskeleton	Aurora kinase B	Homo sapiens (human)
midbody	Aurora kinase B	Homo sapiens (human)
chromosome passenger complex	Aurora kinase B	Homo sapiens (human)
mitotic spindle pole	Aurora kinase B	Homo sapiens (human)
mitotic spindle midzone	Aurora kinase B	Homo sapiens (human)
kinetochore	Aurora kinase B	Homo sapiens (human)
spindle pole centrosome	Aurora kinase B	Homo sapiens (human)
spindle microtubule	Aurora kinase B	Homo sapiens (human)
spindle midzone	Aurora kinase B	Homo sapiens (human)
microtubule organizing center	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cytoplasm	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
centrosome	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
microtubule organizing center	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cytosol	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
microtubule cytoskeleton	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
dendrite	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
midbody	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
neuron projection	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
gamma-tubulin complex	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
ciliary basal body	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
cytoplasm	MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)
Golgi membrane	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
plasma membrane	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
calcium- and calmodulin-dependent protein kinase complex	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
intracellular anatomical structure	Calcium/calmodulin-dependent protein kinase type 1G	Homo sapiens (human)
pericentriolar material	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
centriolar satellite	Serine/threonine-protein kinase Nek1	Homo sapiens (human)
nucleus	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
cytosol	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
cytosol	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
nucleus	PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
cytosol	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
neuron projection	Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)
nucleus	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
nucleoplasm	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
cytoplasm	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
EKC/KEOPS complex	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
cytosol	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
nucleus	EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)
Golgi membrane	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
nucleoplasm	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
nucleolus	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
endoplasmic reticulum	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
endoplasmic reticulum membrane	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
Golgi apparatus	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
cytosol	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
membrane	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
cytoplasm	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
nucleus	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
external side of plasma membrane	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein-containing complex	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
protein kinase complex	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
IRE1-TRAF2-ASK1 complex	Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)
cytosol	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
cytosol	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
nucleus	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
cytoplasm	Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)
extracellular region	Peroxiredoxin-like 2A	Homo sapiens (human)
cytoplasm	Peroxiredoxin-like 2A	Homo sapiens (human)
cytoplasm	Peroxiredoxin-like 2A	Homo sapiens (human)
nucleus	Nucleolar GTP-binding protein 1	Homo sapiens (human)
nucleoplasm	Nucleolar GTP-binding protein 1	Homo sapiens (human)
nucleolus	Nucleolar GTP-binding protein 1	Homo sapiens (human)
cytoplasm	Nucleolar GTP-binding protein 1	Homo sapiens (human)
cytosol	Nucleolar GTP-binding protein 1	Homo sapiens (human)
membrane	Nucleolar GTP-binding protein 1	Homo sapiens (human)
nuclear membrane	Nucleolar GTP-binding protein 1	Homo sapiens (human)
perinuclear region of cytoplasm	Nucleolar GTP-binding protein 1	Homo sapiens (human)
nucleolus	Nucleolar GTP-binding protein 1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase D2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase D2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase D2	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase D2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D2	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase D2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D2	Homo sapiens (human)
chromosome, telomeric region	RNA cytidine acetyltransferase	Homo sapiens (human)
nucleus	RNA cytidine acetyltransferase	Homo sapiens (human)
nucleoplasm	RNA cytidine acetyltransferase	Homo sapiens (human)
nucleolus	RNA cytidine acetyltransferase	Homo sapiens (human)
membrane	RNA cytidine acetyltransferase	Homo sapiens (human)
midbody	RNA cytidine acetyltransferase	Homo sapiens (human)
telomerase holoenzyme complex	RNA cytidine acetyltransferase	Homo sapiens (human)
small-subunit processome	RNA cytidine acetyltransferase	Homo sapiens (human)
nucleolus	RNA cytidine acetyltransferase	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase SIK2	Homo sapiens (human)
cytoplasm	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
cytosol	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
cell leading edge	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
perinuclear region of cytoplasm	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
extracellular exosome	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	STE20-like serine/threonine-protein kinase	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TAO3	Homo sapiens (human)
nucleus	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleoplasm	dCTP pyrophosphatase 1	Homo sapiens (human)
mitochondrion	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
cytosol	dCTP pyrophosphatase 1	Homo sapiens (human)
nucleus	Dual specificity protein kinase CLK4	Homo sapiens (human)
membrane raft	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cell surface	Platelet glycoprotein VI	Homo sapiens (human)
extracellular exosome	Platelet glycoprotein VI	Homo sapiens (human)
tetraspanin-enriched microdomain	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cytosol	Casein kinase I isoform gamma-1	Homo sapiens (human)
nucleus	Casein kinase I isoform gamma-1	Homo sapiens (human)
plasma membrane	Casein kinase I isoform gamma-1	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-1	Homo sapiens (human)
fibrillar center	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
postsynaptic density	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cell junction	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 6	Homo sapiens (human)
cytoplasm	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
cytosol	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
phenylalanine-tRNA ligase complex	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
membrane	Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)
nuclear speck	BMP-2-inducible protein kinase	Homo sapiens (human)
cytoplasm	BMP-2-inducible protein kinase	Homo sapiens (human)
nucleus	BMP-2-inducible protein kinase	Homo sapiens (human)
extracellular region	Obg-like ATPase 1	Homo sapiens (human)
nucleolus	Obg-like ATPase 1	Homo sapiens (human)
cytoplasm	Obg-like ATPase 1	Homo sapiens (human)
centrosome	Obg-like ATPase 1	Homo sapiens (human)
cytosol	Obg-like ATPase 1	Homo sapiens (human)
membrane	Obg-like ATPase 1	Homo sapiens (human)
platelet alpha granule lumen	Obg-like ATPase 1	Homo sapiens (human)
extracellular exosome	Obg-like ATPase 1	Homo sapiens (human)
cytoplasm	Obg-like ATPase 1	Homo sapiens (human)
nucleus	Midasin	Homo sapiens (human)
nucleoplasm	Midasin	Homo sapiens (human)
nucleolus	Midasin	Homo sapiens (human)
cytosol	Midasin	Homo sapiens (human)
membrane	Midasin	Homo sapiens (human)
intermediate filament cytoskeleton	Midasin	Homo sapiens (human)
nucleus	Midasin	Homo sapiens (human)
preribosome, large subunit precursor	Midasin	Homo sapiens (human)
cytoplasm	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
cell surface	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
extrinsic component of plasma membrane	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
extracellular space	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
cytosol	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
plasma membrane	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
endosome membrane	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
nucleus	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
plasma membrane	Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)
nucleus	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)
cyclin K-CDK12 complex	Cyclin-dependent kinase 12	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 12	Homo sapiens (human)
nuclear speck	Cyclin-dependent kinase 12	Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 12	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 12	Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complex	Cyclin-dependent kinase 12	Homo sapiens (human)
nucleoplasm	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
cytoplasm	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrion	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrial inner membrane	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrial respirasome	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrial respiratory chain complex I	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
mitochondrial membrane	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 26	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 26	Homo sapiens (human)
Golgi-associated vesicle	Serine/threonine-protein kinase 26	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 26	Homo sapiens (human)
vesicle membrane	Serine/threonine-protein kinase 26	Homo sapiens (human)
membrane	Serine/threonine-protein kinase 26	Homo sapiens (human)
apical plasma membrane	Serine/threonine-protein kinase 26	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase 26	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 26	Homo sapiens (human)
cell periphery	Serine/threonine-protein kinase 26	Homo sapiens (human)
FAR/SIN/STRIPAK complex	Serine/threonine-protein kinase 26	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 26	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 26	Homo sapiens (human)
mitochondrion	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinate-CoA ligase complex (ADP-forming)	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
extracellular exosome	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
mitochondrion	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
succinate-CoA ligase complex	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase NLK	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase NLK	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase NLK	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase NLK	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase NLK	Homo sapiens (human)
extracellular space	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
nucleoplasm	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cytosol	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
nucleotide-activated protein kinase complex	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cytoplasm	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
nucleus	5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
serine/threonine protein kinase complex	Serine/threonine-protein kinase TBK1	Homo sapiens (human)
stress fiber	Septin-9	Homo sapiens (human)
cytoplasm	Septin-9	Homo sapiens (human)
microtubule	Septin-9	Homo sapiens (human)
axoneme	Septin-9	Homo sapiens (human)
actin cytoskeleton	Septin-9	Homo sapiens (human)
perinuclear region of cytoplasm	Septin-9	Homo sapiens (human)
non-motile cilium	Septin-9	Homo sapiens (human)
septin complex	Septin-9	Homo sapiens (human)
septin ring	Septin-9	Homo sapiens (human)
microtubule cytoskeleton	Septin-9	Homo sapiens (human)
cell division site	Septin-9	Homo sapiens (human)
fibrillar center	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
nucleolus	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
mitochondrion	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)
nucleus	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
nucleoplasm	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
cytoplasm	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
cytosol	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
cytoskeleton	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
apical plasma membrane	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
recycling endosome	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
extracellular exosome	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
presynapse	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
glutamatergic synapse	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
postsynaptic density, intracellular component	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
cytoplasm	TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)
actin cytoskeleton	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
axon	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
cytoplasmic vesicle membrane	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
cytoplasmic vesicle	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
neuron projection	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
dendritic growth cone	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
axonal growth cone	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
receptor complex	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase TAO2	Homo sapiens (human)
fibrillar center	Serine/threonine-protein kinase ICK	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase ICK	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ICK	Homo sapiens (human)
cilium	Serine/threonine-protein kinase ICK	Homo sapiens (human)
ciliary basal body	Serine/threonine-protein kinase ICK	Homo sapiens (human)
ciliary tip	Serine/threonine-protein kinase ICK	Homo sapiens (human)
ciliary base	Serine/threonine-protein kinase ICK	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase ICK	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ICK	Homo sapiens (human)
cilium	Serine/threonine-protein kinase ICK	Homo sapiens (human)
nucleus	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
membrane	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
nucleoplasm	RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase SIK3	Homo sapiens (human)
nucleoplasm	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)
exon-exon junction complex	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nucleus	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nucleoplasm	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nuclear speck	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
extracellular exosome	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
mediator complex	Thyroid hormone receptor-associated protein 3	Homo sapiens (human)
nucleoplasm	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
chromosome	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
nucleolus	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
nucleus	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
cytosol	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
plasma membrane	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)
nucleus	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
nucleus	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
cytosol	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
protein-containing complex	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
cytoplasm	Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cell-cell junction	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
lamellipodium	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cell leading edge	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
actomyosin	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cytoskeleton	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
actomyosin	Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)
nucleus	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
cytoplasm	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
nucleus	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
plasma membrane	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
cytoplasm	Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)
Golgi membrane	Serine/threonine-protein kinase 24	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase 24	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 24	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase 24	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 24	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 24	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 24	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 24	Homo sapiens (human)
FAR/SIN/STRIPAK complex	Serine/threonine-protein kinase 24	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 24	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 24	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-3	Homo sapiens (human)
plasma membrane	Casein kinase I isoform gamma-3	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-3	Homo sapiens (human)
nucleus	Casein kinase I isoform gamma-3	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1205)

Assay ID	Title	Year	Journal	Article
AID1345682	Human BLK proto-oncogene, Src family tyrosine kinase (Src family)	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1345572	Human erb-b2 receptor tyrosine kinase 4 (Type I RTKs: ErbB (epidermal growth factor) receptor family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345682	Human BLK proto-oncogene, Src family tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345705	Human IL2 inducible T cell kinase (Tec family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345882	Human tec protein tyrosine kinase (Tec family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345597	Human FYN proto-oncogene, Src family tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345717	Human LCK proto-oncogene, Src family tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345617	Human Bruton tyrosine kinase (Tec family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345861	Human SRC proto-oncogene, non-receptor tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345502	Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345664	Human BMX non-receptor tyrosine kinase (Tec family)	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1345654	Human HCK proto-oncogene, Src family tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345617	Human Bruton tyrosine kinase (Tec family)	2007	ChemMedChem, Jan, Volume: 2, Issue:1	Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
AID1345849	Human YES proto-oncogene 1, Src family tyrosine kinase (Src family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345860	Human TXK tyrosine kinase (Tec family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345664	Human BMX non-receptor tyrosine kinase (Tec family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345653	Human erb-b2 receptor tyrosine kinase 2 (Type I RTKs: ErbB (epidermal growth factor) receptor family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID1345744	Human Janus kinase 3 (Janus kinase (JakA) family)	2016	The New England journal of medicine, Jan-28, Volume: 374, Issue:4	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1424990	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425168	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499255	Antiproliferative activity against human PF138 cells after 72 hrs by CellTiter-Glo assay
AID1871768	Inhibition of BLK (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1560828	Binding affinity to DNA-tagged recombinant ERBB4 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1472026	Growth inhibition of human OCI-LY10 cells at 0.003 uM after 3 days by AlamarBlue assay (Rvb = - 2 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1720521	Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate preincubated for 1 hr by Z'lyte assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1499257	Antiproliferative activity against human MOLM14 cells after 72 hrs by CellTiter-Glo assay
AID1499264	Antiproliferative activity against human NOMO1 cells after 72 hrs by CellTiter-Glo assay
AID1397229	Inhibition of recombinant human N-terminal GST-tagged JAK3 (781-end residues) expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1871760	Inhibition of BTK (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1412700	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1424902	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469915	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID1527026	Growth inhibition of human OCI-LY10 cells at 10 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1425012	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1673810	In vivo protein occupancy at BTK in Wistar Han rat spleen assessed as BTK level in plasma at 10 mg/kg, po measured after 5 hrs	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1714844	Inhibition of recombinant human JAK2 using Ulight-CAGAGAIETDKEYYTVKD as substrate incubate for 60 mins by LANCE assay
AID1822782	Antitumor activity against human U-937 cells xenografted in Balb/c nude mouse assessed as supression in tumor growth at 25 mg/kg, po administered once daily 14 days
AID1638799	Permeability of the compound assessed as drug flux at 500 uM after 16 hrs by PAMPA	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1738561	Induction of cell cycle arrest in human Ramos cells assessed as S phase accumulation at 5 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 37.38 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1718992	Inhibition of EGFR (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1623563	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 5 uM after 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 0.98%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1324661	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1424992	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1894679	Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, May-05, Volume: 217	Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
AID1399807	Inhibition of EGFR (unknown origin) at 1 uM relative to control	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1375562	Toxicity in CB17 SCID nude mouse xenografted with human TMD8 cells assessed as change in body weight at 25 mg/kg, po qd administered for 13 consecutive days measured during compound dosing up to day 17 post dose	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425058	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468807	Inhibition of recombinant human cytoplasmic GST-tagged EGFR expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1718991	Inhibition of BTK T333M mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1725086	Cmax in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1484559	Cytotoxicity against human PBMC at 5 to 10 uM after 24 hrs by acridine orange/propidium iodide staining-based fluorescent microscopic analysis relative to control	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1549552	Antiproliferative activity against human Daudi cells	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1499239	Antiproliferative activity against human A431 cells after 72 hrs by CellTiter-Glo assay
AID1638810	Efflux ratio of apparent permeability in MDCK2-MDR1 cells at 10 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1714871	Inhibition of recombinant human LCK using Ulight-Poly GAT[EAY(1:1:1)]n as substrate incubate for 10 mins by LANCE assay
AID1718989	Inhibition of SRC T338M/S345C double mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1871766	Inhibition of ERBB2 (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1397248	Induction of apoptosis in human NAMALWA cells assessed as necrotic cells at 5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 4.05%)	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1425145	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425034	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425163	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1418288	Inhibition of CYP2C19 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1334890	Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 4.98 %)	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1425173	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425170	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1571251	Antiproliferative activity against human Raji cells at 5 uM by MTT assay
AID1399797	Inhibition of CYP2C9 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1738556	Induction of apoptosis in human Ramos cells assessed as viable cells at 5 uM incubated for 24 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 93.8 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1488736	Inhibition of BMX (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1375488	Cmax in rat at 3 mg/kg, po	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1869074	Inhibition of His-tagged full-length recombinant wild-type human BTK (Ala2 to Ser659 residues) expressed in baculovirus infected insect cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
AID1425159	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615376	Selectivity ratio of IC50 for TEC (unknown origin) to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1714867	Inhibition of FLT3 (unknown origin)
AID1425193	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424921	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1822762	Inhibition of human BTK using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA
AID1375490	AUC (0 to infinity) in rat at 3 mg/kg, po	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1912478	Inhibition of the Organic Cation Transporter 3 (OCT3, SLC22A3) as assessed by a phenotypic impedance-based assay detecting changes in cell morphology by MPP+ uptake in HEK-293 JumpIN-SLC22A3 cells (PubChem AID: 1745861)	2022	International journal of molecular sciences, Jan-21, Volume: 23, Issue:3	MPP
AID1425027	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425162	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1397230	Inhibition of full length recombinant human N-terminal His-tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) peptide as substrate after 60 mins by ADP-Glo assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1458978	Inhibition of recombinant human GST-tagged EGFR L858R/T790M double mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 20 mins by HTRF assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1424923	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424896	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1718987	Inhibition of SRC T338I mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1425070	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425044	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424925	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1334897	Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1714777	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1375534	Inhibition of recombinant human EPHA2 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425113	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1571257	Cell cycle arrest in human Ramos cells assessed as accumulation of cells at S phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 71.08%)
AID1880571	Invivo induction of BTK degradation in human OCILY10 cells xenografted in SCID mouse assessed as decrease in BTK level in tumor at 10 mg/kg, po administered once daily for 17 days by Western blot analysis	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1425029	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375535	Inhibition of recombinant human CSF1R using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1499268	Antiproliferative activity against human Rec1 cells after 72 hrs by CellTiter-Glo assay
AID1424993	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424966	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1591631	Inhibition of EGFR (unknown origin)	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1615387	Inhibition of EGFR in human A431 cells assessed as reduction in EGFR phosphorylation at Tyr1068 residues preincubated for 1 hr followed by human EGF stimulation and measured after 10 mins by HTRF assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425079	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1650552	Antiproliferative activity against human JeKo1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1424960	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425046	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1470408	Induction of apoptosis in human U2932 cells assessed as induction of caspase-3 cleavage at 10 uM after 48 hrs by immunoblot
AID1499249	Antiproliferative activity against human U2932 cells after 72 hrs by CellTiter-Glo assay
AID1375526	Inhibition of recombinant human TEC using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1574156	Antiproliferative activity against human Mino cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1426158	Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 1.58%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1673811	In vivo protein occupancy at BTK in Wistar Han rat spleen assessed as BTK level in plasma at 10 mg/kg, po measured after 0.5 hrs	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1714863	Inhibition of FGR (unknown origin)
AID1468810	Inhibition of recombinant human cytoplasmic full length His-tagged TEC expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1560831	Selectivity ratio of Kd for DNA-tagged recombinant TEC (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1375523	Inhibition of recombinant human BLK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425186	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424949	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1488738	Inhibition of Her2 (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1738559	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 5 uM incubated for 24 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 2.1 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1424970	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1853204	Inhibition of BTK (unknown origin)	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	Advanced approaches of developing targeted covalent drugs.
AID1870015	Induction of apoptosis in human SU-DHL-6 cells assessed as early apoptotic cells at 1.5 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 8.81 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1425128	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1334899	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1472000	Growth inhibition of human OCI-LY10 cells at 0.0003 uM after 3 days by AlamarBlue assay (Rvb = - 2 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1738562	Induction of cell cycle arrest in human Ramos cells assessed as G2/M phase accumulation at 5 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 20.96 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1425064	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425189	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1337175	Inhibition of PF-06658607 binding to BTK in human Ramos cells after 1 hr by gel-based ABPP assay	2017	Nature reviews. Drug discovery, Jun, Volume: 16, Issue:6	Non-kinase targets of protein kinase inhibitors.
AID1391150	Antiproliferative activity against human Raji cells after 48 hrs by CCK8-based assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1549550	Antiproliferative activity against human Ramos cells	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1425047	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1638807	Protein binding in mouse plasma at 5 uM after 6 hrs by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1560836	Selectivity ratio of Kd for DNA-tagged recombinant JAK3 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1623566	Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 5 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 24.65%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1375486	Volume of distribution at steady state in rat at 1 mg/kg, iv	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1398713	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
AID1499260	Antiproliferative activity against human SKM1 cells after 72 hrs by CellTiter-Glo assay
AID1424953	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425010	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1830230	Inhibition of BTK C481S mutant (unknown origin) in presence of 1 mM ATP by microplate reader assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1571247	Antiproliferative activity against human Ramos cells after 48 hrs by MTT assay
AID1725077	Inhibition of human liver microsome CYP2D6 using dextromethorphan as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1418274	Permeability across apical to basolateral side in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1424920	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1571263	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Try1217 residue at 100 to 3000 nM after 24 hrs by Western blot analysis
AID1499272	Antiproliferative activity against primary CLL cells derived from p13 patient after 72 hrs by CellTiter-Glo assay
AID1499270	Antiproliferative activity against human Z138 cells after 72 hrs by CellTiter-Glo assay
AID1524883	Antiproliferative activity against human Rec1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Cell-titer-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1424928	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425052	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425115	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1587021	Inhibition of full-length human C-terminal His6-tagged BTK C481S mutant expressed in Sf9 insect cells using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1560796	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1623565	Induction of apoptosis in human Ramos cells assessed as viable cells at 5 uM after 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 96.83%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1714778	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1673839	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Tyr223 residue at 5 uM by immunoblot analysis	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1880541	Antiproliferative activity against human MINO cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1334877	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1375479	Inhibition of recombinant human BTK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1424973	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469889	Inhibition of recombinant human N-terminal GST-tagged JAK3 (781 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescen
AID1563062	Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 5.98 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1387235	Inhibition of N-terminal DYKDDDDK tagged biotinylated unactivated human recombinant BTK using FITC-labeled Srctide peptide substrate by by mobility shift assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
AID1772877	Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1738553	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1465441	Inhibition of BTK (unknown origin) preincubated for 1 hr followed by ATP addition measured after 1 hr by immobilized metal ion affinity-based fluorescence polarization assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1876106	Cytotoxicity against human DU-145 cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1499238	Antiproliferative activity against human HCT116 cells after 72 hrs by CellTiter-Glo assay
AID1424995	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1549567	Inhibition of human recombinant JAK3 using Ulight-CAGAGAIETDKEYYTVKD measured after 60 mins in the presence of ATP by LANCE method	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1869076	Inhibition of BTK C481R mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
AID1524888	Inhibition of human BTK assessed as remaining kinase activity at 1 uM using Cdc2 peptide KVEKIGEGTYGVVYK substrate and [gamma-33P]-ATP incubated for 40 mins by radiometric protein kinase assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1418277	Protein binding in human plasma assessed as unbound fraction	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1425206	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425121	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1822772	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID1424929	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1880137	Inhibition of ITK (unknown origin)	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1425026	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1472025	Growth inhibition of human OCI-LY10 cells at 0.001 uM after 3 days by AlamarBlue assay (Rvb = - 2 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1870022	Induction of apoptosis in human DOHH-2 cells assessed as viable cells at 1 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 95.4 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1822765	Selectivity ratio of IC50 for inhibition of human ITK using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA to IC50 for inhibition of human BTK using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA
AID1425153	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1475907	Inhibition of 4EBP1 phosphorylation at Ser 65 residues in human Mino cells at 10 to 25 uM after 48 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.
AID1563070	Cell cycle arrest in human Raji cells assessed as accumulation at S phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 33.18 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1524884	Antiproliferative activity against human JeKo1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Cell-titer-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1738557	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 5 uM incubated for 24 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 1.9 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1638806	Protein binding in human plasma at 5 uM after 6 hrs by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1478517	Cytotoxicity against human Ramos cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo assay	2017	Bioorganic & medicinal chemistry, 06-01, Volume: 25, Issue:11	Identification of spirobisnaphthalene derivatives with anti-tumor activities from the endophytic fungus Rhytidhysteron rufulum AS21B.
AID1772879	Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1527024	Growth inhibition of human OCI-LY10 cells at 2.1 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1656243	Inhibition of BTK in human whole blood cells assessed as apparent second order rate after 1 hr by ELISA	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1488734	Antiproliferative activity against human HCC827 cells harboring EGFR Del19 mutant after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1894183	Inhibition of BTK autophosphorylation in anti-IgG stimulated human DOHH-2 cells preincubated for 1 hr followed by compound washout and anti-IgG stimulation for 2 mins by chemiluminescence based Western blotting analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1571256	Cell cycle arrest in human Ramos cells assessed as accumulation of cells at G0/G1 phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 24.65%)
AID1549564	Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD measured after 15 mins in the presence of ATP by LANCE method	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1425116	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1725072	Cmax in BALB/c mouse 2 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1412711	Inhibition of human ITK using using myelin basic protein as substrate measured after 1 hr in presence of [gamma-33P]ATP	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1692288	Inhibition of human platelet adhesion to immobilised CRP-XL at 1 umol/L preincubated for 4 mins followed by CRP-XL addition and measured after 45 mins relative to control	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID631100	Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
AID1878118	Binding affinity to EGFR (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1425081	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425043	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615380	Selectivity ratio of IC50 for human BMX to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1714854	Inhibition of RSK1 (unknown origin)
AID1615346	Selectivity ratio of IC50 for EGFR (unknown origin) to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1851531	Antiproliferative activity against human Raji cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1714872	Inhibition of recombinant human LYN using biotinyl-beta Abeta-Abeta AKVEKIGEGTYGVVYK as substrate incubate for 120 mins by LANCE assay
AID1880547	Inhibition of BTK (unknown origin)	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1781997	Inhibition of full-length N-terminal GST-tagged BMX (1 to 675 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1499244	Antiproliferative activity against human HeLa cells after 72 hrs by CellTiter-Glo assay
AID1673813	In vivo protein occupancy at BTK in Wistar Han rat spleen at 10 mg/kg, po measured after 5 hrs relative to control	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1412699	Inhibition of recombinant human full-length N-terminal His6-tagged BTK expressed in baculovirus infected Sf21insect cells using poly (4:1 Glu, Tyr) as substrate measured after 1 hr by ELISA	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1424989	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615446	Oral bioavailability in human in fasting state at 560 mg administered daily	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1426139	Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1714775	Aqueous solubility of compound at 1 mg
AID1615377	Selectivity ratio of IC50 for JAK3 (unknown origin) to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425134	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615390	Selectivity ratio of IC50 for EGFR in human A431 cells to IC50 for BTK in human Ramos cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1524891	Hepatic clearance in human liver microsomes further incubated of 5 to 60 mins in presence of NADPH regenerating system by LC/MS analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1424910	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425126	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1591652	Antiproliferative activity against human resistant Jeko cells assessed as reduction in viability after 72 hrs by CellTiter-Glo luminescent assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.
AID1424962	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1481310	Inhibition of Tel-fused EGFR T790M mutant (unknown origin) expressed in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1424996	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1304227	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate at 10 uM incubated for 1 hr by Z-Lyte assay relative to control	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
AID1375487	Half life in rat at 1 mg/kg, iv	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1872694	Antitumor activity against human DOHH-2 cells xenografted in CB17/SCID mouse assessed as reduction in tumor growth at 30 mg/kg, po administered once daily in combination with idelalisib at 50 mg/kg for 30 days and measured twice a week relative to control	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Recent development of BTK-based dual inhibitors in the treatment of cancers.
AID1425172	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1720530	Inhibition of EGFR phosphorylation in human A431 cells	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1720523	Inhibition of His-tagged recombinant full length human His-tagged BMX cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1424898	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425137	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1417604	Volume of distribution at steady state in mouse at 0.2 mg/kg, iv administered as single dose	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1425105	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1880561	Antitumor activity against human OCILY10 cells xenografted in SCID mouse assessed as tumor growth inhibition at 10 mg/kg, po qd measured after 17 days relative to control	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1673828	Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by immunoblot analysis	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1469900	Growth inhibition of human OCI-AML3 cells
AID1417608	Inhibition of BTK in human WBC	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1425090	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714869	Inhibition of recombinant human YES using biotinyl-beta Abeta-Abeta AYQAEENTYDEYEN as substrate incubate for 30 mins by LANCE assay
AID1499266	Antiproliferative activity against human OCI-AML2 cells after 72 hrs by CellTiter-Glo assay
AID1571262	Inhibition of BTK phosphorylation at Tyr223 residue in human Ramos cells at 100 to 3000 nM after 24 hrs by Western blot analysis
AID1418273	Inhibition of BTK in goat anti-human IgM F(ab')2-stimulated human PBMC assessed as suppression of BCR-induced CD69 expression on B cells pretreated for 1 hr followed by blood stimulation measured after overnight incubation by flow cytometry	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1587600	Antiproliferative activity against human Mino cells measured after 72 hrs by calcein AM dye-based fluorescence assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
AID1650556	Metabolic stability in human liver microsomes assessed as compound remaining at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1418280	Half life in mouse at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1553406	Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1424994	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399794	Inhibition of CYP2C8 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1650543	Inhibition of recombinant human N-terminal His-tagged JAK2 (826 to 1132 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1387234	Inhibition of N-terminal DYKDDDDK tagged biotinylated activated human recombinant BTK using FITC-labeled Srctide peptide substrate by mobility shift assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
AID1425037	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1656237	Metabolic stability in human liver microsomes assessed as parent compound remaining after 10 mins	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1375532	Inhibition of recombinant human BMX using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1472027	Growth inhibition of human OCI-LY10 cells at 0.017 uM after 3 days by AlamarBlue assay (Rvb = - 2 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1425198	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1781998	Inhibition of full-length N-terminal GST-tagged ITK (2 to 620 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1465438	Inhibition of human BTK using KVEKIGEGTYGVVYK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition by filter binding method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1822807	Inhibition of EGFR phosphorylation in human A549 cells at 100 nM incubated for 4 hrs by Western blot analysis
AID1851524	Antiproliferative activity against human REC1 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1738555	Inhibition of BTK (unknown origin) by ADP-Glo assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1484555	Antiproliferative activity against human Raji cells over expressing BTK after 48 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1499247	Antiproliferative activity against human C4-2 cells after 72 hrs by CellTiter-Glo assay
AID1563021	Antiproliferative activity against human Ramos cells at 40 uM measured after 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1499252	Antiproliferative activity against human NAMALWA cells after 72 hrs by CellTiter-Glo assay
AID1472052	Antitumor activity against human OCI-LY10 cells xenografted in SCID CB.17 mouse assessed as tumor growth inhibition at 12 mg/kg, po qd after 34 days post inoculation measured on day 51 relative to control	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1878124	Selectivity index, ratio of Kd for EGFR (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1650545	Inhibition of recombinant human N-terminal GST-tagged TYK2 (871 to 1187 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1425086	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425191	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1538544	Inhibition of MKK7 beta1 S273D/T275D double mutant (unknown origin) assessed as residual activity at 50 uM using JNK1 K55M mutant as substrate by ADP-Glo assay relative to control	2019	Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11	Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).
AID1468764	Inhibition of recombinant human cytoplasmic His-tagged ERBB2 expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1399800	Volume of distribution at steady state in rat at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1469901	Growth inhibition of human Pfeiffer cells
AID1399791	Fraction unbound in mouse plasma	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1615343	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue preincubated for 1 hr followed by pervanadate or Na3VO4 stimulation for 20 mins by HTRF assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1401339	Inhibition of BTK phosphorylation in human NAMALWA cells at 10 uM after 48 hrs by immunoblot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1591651	Antiproliferative activity against human Z138 cells assessed as reduction in viability after 72 hrs by CellTiter-Glo luminescent assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.
AID1465440	Selectivity ratio of IC50 for human TEC to IC50 for human BTK	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1425007	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401309	Antiproliferative activity against human Ramos cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1650550	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1424915	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468826	Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1469906	Cytotoxicity against PBMC (unknwon origin)
AID1809419	Inhibition of Btk (unknown origin) assessed as ratio of Kinact/Ki	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (
AID1425094	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1725081	Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1714776	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1399783	Permeability from apical to basolateral side in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1878103	Selectivity index, ratio of Kd for BLK (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1488733	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1425071	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1481311	Growth inhibition of mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1424987	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425077	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1484560	Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1830234	Antiproliferative activity against human OCILY10 cells harboring BTK C481S mutant knockout gene assessed as reduction in cell viability after 96 hrs	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1155538	Toxicity in CB17 SCID mouse xenografted with human DOHH2 cells assessed as body weight fluctuations at 10 mg/kg, iv qd administered for 14 days measured over 14 days of compound treatment	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1615364	Inhibition of ITK (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1469890	Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo
AID1472051	Growth inhibition of human SUDHL2 cells at 0.017 uM after 3 days by AlamarBlue assay (Rvb = - 1 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1425167	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425038	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425207	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1418282	AUC in mouse at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1878125	Selectivity index, ratio of Kd for ERBB2 (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1772885	Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID671744	Inhibition of RET	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1781996	Inhibition of full-length N-terminal GST tagged BTK (2 to 659 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1563020	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1880542	Antiproliferative activity against human TMD8 cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1398711	Antiproliferative activity against human Raji cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
AID1424890	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1673827	Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 24 hrs followed by EGF stimulation and measured after 10 mins by HTRF based immunoassay	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1587597	Inhibition of His-tagged CDK2/Cyclin-E1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured in presence of [gamma-33P]ATP	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
AID1718986	Inhibition of SRC S345C mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1424945	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424958	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425132	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714864	Inhibition of FRK (unknown origin)
AID1425101	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1391149	Antiproliferative activity against human Ramos cells after 48 hrs by CCK8-based assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1425017	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1476271	Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
AID1426146	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1425171	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425019	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424983	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399799	Clearance in rat at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1499235	Inhibition of TEL-fused JAK1 (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1870003	Induction of cell cycle arrest in human SU-DHL-6 cells assessed as accumulation of cells at G2/M phase at 0.5 uM incubated for 24 hrs by PI staining based FACScan flow cytometry analysis (Rvb = 20.21 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1587599	Antiproliferative activity against human OCI-Ly2 cells measured after 72 hrs by calcein AM dye-based fluorescence assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
AID1424934	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401317	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1309831	Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 3 days by presto blue dye based plate reader method	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.
AID1425092	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615381	Selectivity ratio of IC50 for human BRK to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1424937	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468806	Inhibition of recombinant human catalytic GST-tagged JAK3 expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1425065	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499240	Antiproliferative activity against human NCI-H460 cells after 72 hrs by CellTiter-Glo assay
AID1870025	Induction of apoptosis in human DOHH-2 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb =0.29 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1425178	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1870024	Induction of apoptosis in human DOHH-2 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 2.20 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1615384	Selectivity ratio of IC50 for human FRK to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1725078	Inhibition of human liver microsome CYP2C19 using S-mephenytoin as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1720527	Inhibition of recombinant human N-terminal GST-tagged ERBB4 catalytic domain (708 to 993 residues) expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1880523	Induction of BTK degradation in human MINO cells at 1000 nM incubated for 24 hrs by Western blot analysis	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1424950	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1772880	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1851527	Antiproliferative activity against human SU-DHL-4 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1830229	Inhibition of wild type BTK (unknown origin) in presence of 1 mM ATP by microplate reader assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1560881	Covalent binding affinity to BTK in human blood assessed as reduction in biotinylated-probe binding at 300 nM measured up to 100 mins by immunoassay relative to control	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1527023	Growth inhibition of human OCI-LY10 cells at 0.3 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1673823	Immunostimulatory activity in ovalbumin-immunized C57Bl6 mouse assessed as reduction in skin swelling at 30 mg/kg, po administered 2 h prior to OVA immunization and measured after 5 hrs by caliper method relative to control	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1878126	Selectivity index, ratio of Kd for ERBB4 (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1871769	Inhibition of JAK3 (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1615367	Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1851504	Inhibition of BTK (unknown origin) measured by ADP-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1425035	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468772	Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1741721	Inhibition of BTK (unknown origin) using poly(Glu, Tyr) 4:1 as substrate incubated in presence of [gamma33P]ATP by image analyser	2020	European journal of medicinal chemistry, Oct-15, Volume: 204	Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
AID1424977	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563024	Antiproliferative activity against human Raji cells measured after 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1558403	Inhibition of BTK (unknown origin) after 60 mins by FRET assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	The Exploration of Chirality for Improved Druggability within the Human Kinome.
AID1851505	Antiproliferative activity against human TMD8 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1499234	Inhibition of TEL-fused BMX (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1309836	Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 3 days by presto blue dye based plate reader method	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.
AID1560835	Selectivity ratio of Kd for DNA-tagged recombinant ERBB4 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1499273	Antiproliferative activity against primary CLL cells derived from p14 patient after 72 hrs by CellTiter-Glo assay
AID1650541	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1587025	Reversible inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system assessed as ratio of Kinact to Ki using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate after 120 mins by caliper method	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID671742	Inhibition of BLK	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1654023	Inhibition of recombinant human N-terminal GST-tagged JAK3 (781 to end residues) expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1851529	Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1425048	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1476270	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD-F691L mutation after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
AID1425156	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1309834	Cytotoxicity against human HeLa cells expressing GFP assessed as cell growth inhibition after 3 days by presto blue dye based plate reader method	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.
AID1894184	Inhibition of PLCgamma phosphorylation in anti-IgG stimulated human DOHH-2 cells preincubated for 1 hr followed by compound washout and anti-IgG stimulation for 2 mins by chemiluminescence based Western blotting analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1425072	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424968	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425088	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424984	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399795	Inhibition of CYP2B6 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1822764	Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA
AID1822770	Selectivity ratio of IC50 for inhibition of ITK phosphorylation in human Jurkat cells to IC50 for inhibition of BTK phosphorylation in human U-937 cells
AID1417597	Permeability of the compound across apical to basolateral side in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1425062	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399796	Inhibition of CYP2C19 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1822766	Selectivity ratio of IC50 for human EGFR expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA to IC50 for inhibition of human BTK using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA
AID1714774	Inhibition of BTK (unknown origin) by caliper mobility shift assay
AID1469902	Growth inhibition of human U937 cells
AID1418275	Efflux ratio of permeability in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1720525	Inhibition of recombinant human N-terminal GST-tagged TXK (260 to 527 residues) expressed in baculovirus expression system using tyrosine-6 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1499265	Antiproliferative activity against human OCI-AML3 cells after 72 hrs by CellTiter-Glo assay
AID1425139	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425185	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1549553	Inhibition of BTK (unknown origin) in the presence of ATP by caliper mobility shift assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1615389	Inhibition of TEC phosphorylation in HEK293 cells peincubated for 3 hrs followed by pervanadate stimulation and measured after 20 mins by MSD assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1399793	Binding affinity to human ERG	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1488732	Antiproliferative activity against human A549 cells harboring wild type EGFR after 72 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1459010	Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant at 30 uM incubated for 96 hrs measured on day 5 by CellTiterGlo assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1426142	Antiproliferative activity against human Raji cells after 48 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1499248	Antiproliferative activity against human SUDHL2 cells after 72 hrs by CellTiter-Glo assay
AID1623553	Antiproliferative activity against human Ramos cells after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1623567	Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 5 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 71.08%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1425011	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499269	Antiproliferative activity against human JVM2 cells after 72 hrs by CellTiter-Glo assay
AID1587598	Antiproliferative activity against human HT cells measured after 72 hrs by calcein AM dye-based fluorescence assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
AID1563061	Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 56.35 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1425146	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1830233	Inhibition of BTK in human whole blood assessed as activation of anti-IgM-induced CD69 expression by flow cytometry analysis	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1267793	Cytotoxicity against mouse BAF3 cells assessed as cell proliferation after 72 hrs by CelltiterGlo assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
AID1650931	Inhibition of BTK C481S mutant (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3	Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
AID1527029	Growth inhibition of human OCI-LY19 cells at 2.1 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1527025	Growth inhibition of human OCI-LY10 cells at 4.2 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1524890	Intrinsic clearance in human liver microsomes further incubated of 5 to 60 mins in presence of NADPH regenerating system by LC/MS analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1524889	Half life in human liver microsomes further incubated of 5 to 60 mins in presence of NADPH regenerating system by LC/MS analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1426144	Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 94.3%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1425118	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1241391	Inhibition of human recombinant BTK incubated for 5 mins by HTRF kinase assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1425160	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424936	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1591625	Inhibition of BTK (unknown origin) by ELISA	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1399798	Inhibition of CYP3A4 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1720526	Inhibition of His-tagged human recombinant ERBB2 (676 to 1255 residues) expressed in baculovirus expression system using Tyr 06 as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1822774	Induction of apoptosis in human U-937 cells assessed as apoptosis rate at 5 uM measured after 48 hrs by AnnexinV-FITC staining based flow cytometry analysis relative to control (Rvb = 10.12 %)
AID1425002	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1772883	Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1574160	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation at 30 uM after 72 hrs by CellTiter-Glo luminescent cell viability assay relative to control	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1772882	Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1822767	Inhibition of BTK phosphorylation in human U-937 cells incubated for 4 hrs by Western blot assay
AID1418279	Protein binding in rat plasma assessed as unbound fraction	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1623558	Antiproliferative activity against human Raji cells at 5 uM up to 24 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1718985	Inhibition of HCK (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1615378	Selectivity ratio of IC50 for HER2 (unknown origin) to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1587026	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as apparent dissociation half life by kinase tracer 236 based TR-FRET assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1656331	Inhibition of BTK in human whole blood cells after 120 mins by ELISA	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1424933	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1417603	Clearance in mouse at 0.2 mg/kg, iv administered as single dose	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1870016	Induction of apoptosis in human SU-DHL-6 cells assessed as late apoptotic cells at 1.5 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 3.88 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID629929	Inhibition of ErbB1 relative to control	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
AID1615370	Inhibition of human HER4 using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1560829	Binding affinity to DNA-tagged recombinant JAK3 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1424917	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424988	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1574154	Antiproliferative activity against human Raji cells after 48 hrs by CCK8 assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1458988	Efflux ratio of apparent permeability from basolateral side to apical side over apical side to basolateral side over in human Caco2 cells at 5 uM incubated for 2 hrs	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1673837	Inhibition of full length human unphosphorylated BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate incubated for 60 mins in presence of ATP at Km concentration	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1424899	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1324664	Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 42.23%)	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1425123	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499243	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by CellTiter-Glo assay
AID1560823	Binding affinity to DNA-tagged recombinant BMX (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1459011	Kinetic solubility in Hepes buffer at 500 uM at pH 7.4 after 90 mins	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1725079	Inhibition of human liver microsome CYP1A2 using phenacetin as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1656239	Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 sec	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1424909	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425154	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714838	Inhibition of recombinant human EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate incubate for 15 mins by LANCE assay
AID1424978	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563040	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 1.50 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1782001	Selectivity index, ratio of IC50 for inhibition of ITK (unknown origin) to IC50 for inhibition of BTK (unknown origin)	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1591650	Antiproliferative activity against human GRANTA-519 cells assessed as reduction in viability after 72 hrs by CellTiter-Glo luminescent assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.
AID1417605	Half life in mouse at 0.2 mg/kg, iv administered as single dose	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1738568	Inhibition of EGFR (unknown origin) by ADP-Glo assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1538545	Inhibition of MKK7 beta1 S273D/T275D double mutant (unknown origin) using JNK1 K55M mutant as substrate by ADP-Glo assay	2019	Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11	Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).
AID1334878	Antiproliferative activity against human Ramos cells measured after 48 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1469903	Growth inhibition of human NB4 cells
AID1878122	Binding affinity to TXK (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1878104	Binding affinity to ERBB4 (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1738569	Inhibition of ITK (unknown origin) by ADP-Glo assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1397239	Induction of apoptosis in human NAMALWA cells assessed as morphological changes at 5 uM by acridine orange/ethidium bromide staining based phase contrast microscopic assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1469923	Induction of apoptosis in human U2932 cells assessed as induction of PARP cleavage at 10 uM after 48 hrs by immunoblot
AID1425024	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424924	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1718984	Inhibition of SRC (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1458979	Selectivity ratio of IC50 for wild type N-terminal GST-fused human EGFR cytoplasmic domain to IC50 for human recombinant GST-tagged EGFR L858R/T790M double mutant	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1425202	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1155522	Cytotoxicity against human WSU-NHL cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID719893	Inhibition of recombinant Btk after 60 mins	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID1615379	Selectivity ratio of IC50 for human BLK to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1472055	Toxicity in SCID CB.17 mouse xenografted with human OCI-LY10 cells assessed as change in body weight at 12 mg/kg, po qd after 34 days post inoculation measured on day 51	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1418278	Protein binding in mouse plasma assessed as unbound fraction	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1851530	Antiproliferative activity against human MINO cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1425085	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1851523	Selectivity ratio for inhibition of BTK (unknown origin) over EGFR (unknown origin)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1524885	Antiproliferative activity against human Maver1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Cell-titer-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1553437	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1870009	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation of cells at S phase at 1 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 55.11 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1397246	Induction of apoptosis in human NAMALWA cells assessed as early apoptotic cells at 5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0%)	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1469924	Induction of apoptosis in human Pfeiffer cells assessed as induction of PARP cleavage at 10 uM after 48 hrs by immunoblot
AID1484561	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1425142	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1725083	Half life in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1725073	AUC in BALB/c mouse 2 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1424904	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425040	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425147	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425082	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425129	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1549594	Antiarthritic activity in DBA1/J mouse model of collagen-induced arthritis assessed as reduction in bone erosion at 12.5 mg/kg, po qd by H and E staining based assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1425021	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425036	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425188	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425203	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1560795	Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assay	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1615392	Selectivity ratio of IC50 for TEC in HEK293 cells to IC50 for BTK in human Ramos cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1418291	Oral bioavailability in mouse at 0.5 mg/kg	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1738554	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1638805	Stability in mouse plasma assessed as compound remaining at 5 uM after 1 hr by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1692287	Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1424595	Inhibition of BTK (unknown origin)	2017	European journal of medicinal chemistry, Dec-15, Volume: 142	Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.
AID1424930	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425098	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1426145	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.7%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1425025	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563023	Antiproliferative activity against human Raji cells at 40 uM measured after 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1869077	Inhibition of BTK T474I mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
AID1425050	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468848	Inhibition of BTK (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1851556	Toxicity in female CB-17 SCID nude mouse xenografted with human TMD8 cells assessed as effect on body weight at 25 mg/kg, po administered twice daily for 21 days	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1425197	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1304228	Inhibition of BTK (unknown origin) assessed as reduction in phosphorylation of coumarin and fluorescein-labeled FRET peptide substrate incubated for 1 hr by Z-Lyte assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
AID1714866	Inhibition of recombinant human FMS using Ulight-TK peptide as substrate incubate for 15 mins by LANCE assay
AID1615447	Toxicity in NCG mouse xenografted with human OCI-LY10 cells assessed as effect on body weight at 2.5 to 7.5 mg/kg, po BID measured twice weekly	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1424974	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424911	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399792	Fraction unbound in rat plasma	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1465443	Selectivity ratio of IC50 for TEC (unknown origin) to IC50 for BTK (unknown origin)	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1425014	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1725088	AUC (0 to last) in Sprague-Dawley rat at 10 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1469896	Growth inhibition of human SU-DHL-2 cells
AID1822784	Antitumor activity against human U-937 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 25 mg/kg, po administered once daily for 14 days
AID1563079	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1650549	Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1424963	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1324656	Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1623564	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 5 uM after 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 1.11%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1851554	Antitumor activity against human TMD8 cells xenografted in female CB-17 SCID nude mouse assessed as tumor growth inhibition at 25 mg/kg, po administered twice daily for 21 days	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1878120	Binding affinity to JAK3 (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1560832	Selectivity ratio of Kd for DNA-tagged recombinant ITK (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425148	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1692289	Inhibition of human platelet lamellipodia formation on CRP-XL 1 umol/L preincubated for 4 mins followed by CRP-XL addition and measured after 45 mins (Rvb = 69%)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1418294	Intrinsic clearance in human microsomes	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1499254	Antiproliferative activity against human U937 cells after 72 hrs by CellTiter-Glo assay
AID1425001	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425169	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424892	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615388	Inhibition of ITK in human Jurkat cells assessed as reduction in PLCgamma1 phosphorylation at Y783 residues preincubated for 2 hrs followed by H2O2 addition and measured after 10 mins by Western blot analysis	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1424997	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499230	Inhibition of TEL-fused EGFR (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1714842	Inhibition of recombinant human JAK3 using Ulight-CAGAGAIETDKEYYTVKD as substrate incubate for 60 mins by LANCE assay
AID1822768	Inhibition of ITK phosphorylation in human Jurkat cells incubated for 4 hrs by Western blot assay
AID1587024	Reversible inhibition of full-length human His-tagged BTK expressed in baculovirus expression system assessed as ratio of Kinact to Ki by kinase tracer 236 based TR-FRET assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1563054	Induction of apoptosis in human Raji cells assessed as early apoptotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 0.021 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1851532	Antiproliferative activity against human Ramos cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1656240	Half life in human liver microsomes in presence of NAPDH	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1424935	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375528	Inhibition of recombinant human ITK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425199	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1324659	Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry relative to control	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1591627	Antiproliferative activity against human TMD8 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1458992	Intrinsic clearance in mouse liver microsomes at 3 uM after 50 mins by LC-MS method	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1424891	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468805	Inhibition of recombinant human full length His-tagged BLK expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1718990	Inhibition of BTK (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1889499	Inhibition of EGFR (unknown origin) by lanthascreen Tb kinase activity assay	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID1527035	Antitumor activity against human OCI-LY10 cells xenografted in CB.17 SCID mouse assessed as induction of tumor stasis at 12 mg/kg, po QD dosed 34 days after tumor cell inoculation
AID1418272	Inhibition of recombinant human full length N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using FITC-AHA-EEPLYWSFPAKKK-NH2 substrate measured after 90 mins by off-chip mobility shift assay	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1426141	Antiproliferative activity against human Ramos cells after 48 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1468803	Inhibition of cytoplasmic recombinant human full length His-tagged BMX expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1563080	Inhibition of BTK in anti-IgM-stimulated human Raji cells assessed as decrease in auto-phosphorylation at Y223 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1425176	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1417606	Oral bioavailability in mouse at 0.5 mg/kg administered as cassette dosing	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1425149	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425201	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563069	Cell cycle arrest in human Raji cells assessed as accumulation at G0/G1 phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 48.68 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1469898	Growth inhibition of human U2932 cells
AID1425212	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1468804	Inhibition of human full length GST-tagged TXK expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1239424	Antiproliferative activity against mouse BA/F3 cells expressing TEL-JAK3 after 72 hrs by cell titer glo assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	Development of Selective Covalent Janus Kinase 3 Inhibitors.
AID1527028	Growth inhibition of human OCI-LY19 cells at 0.3 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1375529	Inhibition of recombinant human RET using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425013	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424942	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1458980	Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1623568	Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 5 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 4.26%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1469894	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo lumin
AID1725087	AUC (0 to last) in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1772876	Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1553408	Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1424922	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1391148	Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1718988	Inhibition of SRC T338M mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1425187	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1638811	Efflux ratio of apparent permeability in human Caco2 cells at 5 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID671743	Inhibition of BMX	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1714837	Inhibition of BLK (unknown origin)
AID1468802	Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1397235	Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1574153	Antiproliferative activity against human Ramos cells after 48 hrs by CCK8 assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1878127	Selectivity index, ratio of Kd for ITK (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1872692	Antitumor activity against human DOHH-2 cells xenografted in CB17/SCID mouse assessed as reduction in tumor growth at 15 mg/kg, po administered once daily in combination with idelalisib at 25 mg/kg for 30 days and measured twice a week relative to control	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Recent development of BTK-based dual inhibitors in the treatment of cancers.
AID1725094	Oral bioavailability in BALB/c mouse at 2 mg/kg measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1425018	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469909	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID1571253	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 1.08%)
AID1155520	Cytotoxicity against human Pfeiffer cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1615437	Antitumor activity against human OCI-LY10 cells xenografted in NCG mouse assessed as tumor growth inhibition at 7.5 mg/kg, po BID measured on day 28 by caliper method relative to control	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1673832	Inhibition of ERBB4 (unknown origin)	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1499251	Antiproliferative activity against human Ramos cells after 72 hrs by CellTiter-Glo assay
AID1615436	Antitumor activity against human OCI-LY10 cells xenografted in NCG mouse assessed as tumor growth inhibition at 2.5 mg/kg, po BID measured on day 28 by caliper method relative to control	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1526952	Inhibition of IRAK4 in human OCI-LY10 cells assessed as decrease in pIKBalpha levels incubated for 14 hrs by Western blotting analysis
AID1425039	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1822763	Inhibition of human ITK using poly-Glu-Tyr (4:1) as substrate incubated for 1 hr by ELISA
AID1425009	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1656256	Inhibition of HER1 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1871764	Inhibition of BMX (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1425130	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615382	Selectivity ratio of IC50 for human HER4 to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1399784	Efflux ratio of permeability in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1424998	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1889497	Inhibition of ITK (unknown origin) by lanthascreen Tb kinase activity assay	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID1324660	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1878119	Binding affinity to ITK (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1425083	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1475900	Cytotoxicity against human Mino cells assessed as reduction in cell survival at 25 uM after 48 hrs by Annexin V/propidium iodide based flow cytometric analysis	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.
AID1334888	Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 55.07 %)	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1425175	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1673826	Inhibition of BTK in human whole blood assessed as reduction in polyclonal anti-IgM antibody/human IL4-stimulated CD69 cell surface expression on B cells incubated for 16 hrs by FACS analysis	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1587022	Inhibition of full-length human His-tagged BTK expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1714833	Inhibition of BMX (unknown origin)
AID1425180	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1718993	Inhibition of EGFR T790M mutant (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 02-15, Volume: 34	Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
AID1417599	Inhibition of human ERG	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1425022	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1560797	Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1830232	Inhibition of BTK in human Ramos cells assessed as reduction of IgM stimulated PLCgamma2 (Y1217) phosphorylation after 24 hrs by western blot assay	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1499262	Antiproliferative activity against human HL60 cells after 72 hrs by CellTiter-Glo assay
AID1871765	Inhibition of EGFR (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1638804	Stability in human plasma assessed as compound remaining at 5 uM after 1 hr by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1560824	Binding affinity to DNA-tagged recombinant TEC (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1650553	Antiproliferative activity against human OCI-LY10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1725076	Protein binding in mouse plasma at 2 uM incubated for 4 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1714843	Inhibition of JAK1 (unknown origin)
AID1324658	Antiproliferative activity against human Raji cells after 48 hrs by CCK-8 assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1418276	Inhibition of BTK in human whole blood	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1880138	Inhibition of EGFR (unknown origin)	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1425023	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401316	Cytotoxicity against human PBMCs assessed as induction of morphological changes at <10 uM after 24 hrs by AO/PI staining-based phase contrast microscopy	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1425200	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401318	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.5%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1472048	Growth inhibition of human SUDHL2 cells at 0.0003 uM after 3 days by AlamarBlue assay (Rvb = - 1 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1738552	Inhibition of BTK (unknown origin) at 100 nM by ADP-Glo assay relative to control	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1870014	Induction of apoptosis in human SU-DHL-6 cells assessed as viable cells at 1.5 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 87.0 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1419872	Toxicity in SCID CB.17 mouse xenografted with human OCI-LY10 cells harboring MyD88 L256P/CD79MUT double mutant assessed as body weight loss at 12 mg/kg, po qd after 43 days (Rvb = 2%)	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
AID1401307	Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1725091	Clearance in BALB/c mouse at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1524887	Antiproliferative activity against human Mino cells assessed as inhibition of cell proliferation incubated for 72 hrs by Cell-titer-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1425179	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1418293	Induction of CYP3A4 mRNA expression in hepatocytes (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1425084	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1324662	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1478518	Cytotoxicity against human NCI-H1975 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo assay	2017	Bioorganic & medicinal chemistry, 06-01, Volume: 25, Issue:11	Identification of spirobisnaphthalene derivatives with anti-tumor activities from the endophytic fungus Rhytidhysteron rufulum AS21B.
AID1638802	Apparent permeability across apical to basolateral side in MDCK2-MDR1 cells at 10 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1871763	Inhibition of TXK (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1425165	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1591653	Antiproliferative activity against human Maver1 cells assessed as reduction in viability after 72 hrs by CellTiter-Glo luminescent assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.
AID1425124	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425144	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1155533	Plasma concentration in CB17 SCID mouse xenografted with human DOHH2 cells at 10 mg/kg, iv qd administered for 14 days measured at 2 hrs post last dose	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1418290	Inhibition of CYP3A4 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1470409	Induction of apoptosis in human Pfeiffer cells assessed as induction of caspase-3 cleavage at 10 uM after 48 hrs by immunoblot
AID1499274	Antiproliferative activity against primary CLL cells derived from p15 patient after 72 hrs by CellTiter-Glo assay
AID1714877	Inhibition of SYK (unknown origin)
AID1425177	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1458976	Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1417607	Inhibition of BTK in human PBMC	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1870001	Induction of cell cycle arrest in human SU-DHL-6 cells assessed as accumulation of cells at S phase at 0.5 uM incubated for 24 hrs by PI staining based FACScan flow cytometry analysis (Rvb = 24.18 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1656257	Inhibition of HER4 (unknown origin)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1772878	Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1375518	Antiproliferative activity against human TMD8 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1871761	Inhibition of TEC (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1155511	Inhibition of Btk phosphorylation at Tyr551 in human Ramos cells after 1 hr by Western blot analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1425208	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425073	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1475908	Inhibition of 4EBP1 phosphorylation at Thr 37/46 residues in human Mino cells at 10 to 25 uM after 48 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.
AID1524886	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation incubated for 72 hrs by Cell-titer-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1425143	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1650554	Metabolic stability in human liver microsomes assessed as half life at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1375524	Inhibition of recombinant human ErbB4 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425164	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499267	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay
AID1425133	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401320	Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98.7%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1549551	Antiproliferative activity against human JeKo1 cells	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1530075	Inhibition of BTK (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
AID1878123	Selectivity index, ratio of Kd for BMX (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1527032	Growth inhibition of human OCI-LY19 cells at 42 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1324663	Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 56.19%)	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1638800	Apparent permeability across apical to basolateral side in human Caco2 cells at 5 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1738573	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation at 10 uM measured upto 60 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1499258	Antiproliferative activity against human MOLM16 cells after 72 hrs by CellTiter-Glo assay
AID1673812	In vivo protein occupancy at BTK in Wistar Han rat spleen assessed as BTK level in plasma at 10 mg/kg, po measured after 2 hrs	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1425053	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615345	Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1615363	Inhibition of human BTK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1499263	Antiproliferative activity against human CMK cells after 72 hrs by CellTiter-Glo assay
AID1720524	Inhibition of recombinant full length human GST-tagged ITK expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1472049	Growth inhibition of human SUDHL2 cells at 0.001 uM after 3 days by AlamarBlue assay (Rvb = - 1 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1638798	Kinetic solubility of the compound in Hepes buffer at pH 7.4 after 90 mins	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1425028	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1571246	Antiproliferative activity against human Raji cells after 48 hrs by MTT assay
AID1488737	Inhibition of EGFR (unknown origin)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1425030	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425095	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1397236	Antiproliferative activity against human Raji cells after 72 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1425051	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1560833	Selectivity ratio of Kd for DNA-tagged recombinant EGFR (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1869075	Inhibition of BTK C481S mutant (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
AID1499246	Antiproliferative activity against human RV1 cells after 72 hrs by CellTiter-Glo assay
AID1418296	Intrinsic clearance in rat microsomes	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1615369	Inhibition of human BRK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1615362	Antiproliferative activity against human OCI-LY10 cells after 6 days by Celltiter-glo luminescent cell viability assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1880539	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1425087	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424919	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425045	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424980	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425100	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425204	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425103	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1574155	Antiproliferative activity against human DOHH2 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1875918	Inhibition of BTK (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1499236	Inhibition of TEL-fused JAK2 (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1425150	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563056	Induction of apoptosis in human Raji cells assessed as necrotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 1.87 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1725071	Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using TK1 as substrate incubated for 60 mins by HTRF assay	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1870006	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation of cells at G0/G1 phase at 1 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 23.47 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1469914	Effect on BTK transphosphorylation at PLCgamma1 Y783 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID1469905	Growth inhibition of human M07e cells
AID1469893	Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate additi
AID1425125	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425205	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1894186	Antiproliferative activity against anti-IgM-stimulated human KB cells assessed as cell growth inhibition pretreated for 30 mins followed by anti-IgM stimulation for 72 hrs by celltiter-glo reagent based assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1419869	Antitumor activity against human OCI-LY10 cells harboring MyD88 L256P/CD79MUT double mutant xenografted in SCID CB.17 mouse assessed as tumor growth inhibition at 12 mg/kg, po qd after 43 days relative to control	2018	Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
AID1880140	Inhibition of EGFR phosphorylation in human A-431 cells	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1155508	Inhibition of EGFR (unknown origin) at 5 nM after 1 hr by HTRF assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1889498	Inhibition of TEC (unknown origin) by lanthascreen Tb kinase activity assay	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID1399801	Half life in rat at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1880139	Inhibition of BTK in human whole blood	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1587027	Cytotoxicity against human THLE cells	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1425122	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1623552	Antiproliferative activity against human Raji cells after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1155535	Antitumor activity against human DOHH2 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 10 mg/kg, iv qd administered for 14 days measured over 14 days of compound treatment relative to vehicle-treated control	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1615383	Selectivity ratio of IC50 for human FGR to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1426156	Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 56.19%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1591649	Antiproliferative activity against human Mino cells assessed as reduction in viability after 72 hrs by CellTiter-Glo luminescent assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.
AID1425003	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1560830	Selectivity ratio of Kd for DNA-tagged recombinant BMX (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1880135	Inhibition of BTK (unknown origin)	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1425006	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499256	Antiproliferative activity against human MOLM13 cells after 72 hrs by CellTiter-Glo assay
AID1878102	Binding affinity to ERBB2 (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1782002	Selectivity index, ratio of IC50 for inhibition of EGFR (unknown origin) to IC50 for inhibition of BTK (unknown origin)	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1587023	Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1424940	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1334900	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry (Rvb = 0.2 %)	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1418285	Inhibition of CYP2C9 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1673923	Inhibition of BTK C481S (unknown origin)	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID1499261	Antiproliferative activity against human NB4 cells after 72 hrs by CellTiter-Glo assay
AID1424956	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425161	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1880136	Inhibition of TEC (unknown origin)	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	The Ascension of Targeted Covalent Inhibitors.
AID1425155	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1656330	Inhibition of BTK in human whole blood cells after 30 mins by ELISA	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1772873	Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1425117	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425097	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425174	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469916	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human Pfeiffer cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID1469887	Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay
AID1425075	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1472007	Inhibition of IRAK4 in human OCI-LY10 cells harboring MYD88 mutation assessed as reduction in IKBalpha phosphorylation at 3 nM after 14 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1155512	Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1424939	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1738572	Inhibition of BTK in human TMD8 cells assessed as reduction in cell proliferation incubated for 24 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1571248	Inhibition of human recombinant full-length BTK at 100 nM using poly (4:1 Glu, Tyr) peptide substrate after 60 mins by ADP-Glo assay relative to control
AID1822771	Selectivity ratio of IC50 for inhibition of EGFR phosphorylation in human A549 cells to IC50 for inhibition of BTK phosphorylation in human U-937 cells
AID1563037	Induction of apoptosis in human Ramos cells assessed as viable cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 96.5 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID671741	Inhibition of human BTK by enzymatic assay	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID1425102	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425158	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1426157	Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 42.23%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1782037	Antitumor activity against human TMD8 cells xenografted in CB-17 SCID nude mouse assessed as tumor growth inhibition at 7.5 mg/kg, po bid administered for 21 days	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1424971	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425209	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375537	Inhibition of BTK in human TMD8 cells assessed as decrease in PLCgamma2 phosphorylation at Y759 at 1 uM after 4 hrs by Western blot method	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1499259	Antiproliferative activity against human HEL cells after 72 hrs by CellTiter-Glo assay
AID1465442	Inhibition of TEC (unknown origin) after 2 hrs by LanthaScreen assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1425049	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424964	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424908	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1476269	Antiproliferative activity against mouse BAF3 cells harboring FLT3-ITD mutation after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
AID1571245	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay
AID1499245	Antiproliferative activity against human DU145 cells after 72 hrs by CellTiter-Glo assay
AID1591630	Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1553436	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1424900	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401311	Antiproliferative activity against human NAMALWA cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1424947	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1481309	Inhibition of EGFR exon 19 deletion mutant in human PC9 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1399802	Oral bioavailability in rat at 0.5 mg/kg	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1781999	Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1656244	Inhibition of His-tagged BTK (unknown origin) after 1.5 hrs by HTRF analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1460483	Antiviral activity against Dengue virus serotype 2 strain New Guinea C infected in HuH7 cells at 2.5 to 10 uM measured at 24 hrs post infection by focus forming assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.
AID1553407	Antiproliferative activity against human Ramos cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1499250	Antiproliferative activity against human Pfeiffer cells after 72 hrs by CellTiter-Glo assay
AID1880543	Antiproliferative activity against CRBN knockout human JeKo-1 cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1469922	Cell cycle arrest in human U2932 cells assessed as increase in accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide/RNase staining based flow cytometric method
AID1468809	Inhibition of recombinant human cytoplasmic GST-tagged ERBB4 expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1469899	Growth inhibition of human Ramos cells
AID1571259	Cell cycle arrest in human Ramos cells assessed as apoptotic cells at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.03%)
AID1738570	Inhibition of BLK (unknown origin) by ADP-Glo assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1725090	Half life in BALB/c mouse at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1656238	Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1851528	Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1424893	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425192	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425054	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424969	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424981	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1738563	Induction of cell cycle arrest in human Ramos cells assessed as subG1 phase accumulation at 5 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 2.53 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1424946	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424972	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425080	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424894	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424941	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1772884	Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1425108	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401319	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.0%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1425068	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425211	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1458987	Apparent permeability across basolateral to apical side in human Caco2 cells at 5 uM incubated for 2 hrs	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1738571	Inhibition of SRC (unknown origin) by ADP-Glo assay	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1401330	Induction of apoptosis in human Ramos cells assessed as total apoptosis rate at 10 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1418281	Volume of distribution at steady state in mouse at 0.5 mg/kg, po	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1465439	Inhibition of human TEC using poly[Glu:Tyr] as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition by filter binding method	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.
AID1822773	Induction of cell cycle arrest in human U-937 cells assessed a accumulation of cells at G1 phase at 5 uM measured after 48 hrs by PI staining based flow cytometry analysis relative to control (Rvb = 51.40 %)
AID1397250	Inhibition of BTK phosphorylation in human NAMALWA cells at 10 uM after 48 hrs by Western blot method	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1615366	Inhibition of HER2 (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1499241	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay
AID1499237	Inhibition of TEL-fused JAK3 (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1553435	Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residue at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
AID1425107	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425190	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1484554	Antiproliferative activity against human Ramos cells over expressing BTK after 48 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1425076	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425091	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425210	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714773	Inhibition of BTK (unknown origin) at 0.1 uM by caliper mobility shift assay relative to control
AID1725082	Inhibition of human ERG expressed in CHO cells at holding potential of -80 mV by patch clamp method	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1425069	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1334898	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1571254	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 0.98%)
AID1424948	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399789	Inhibition of BTK in whole blood (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1155519	Cytotoxicity against human DOHH2 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1245614	Inhibition of BTK (unknown origin) after 1 hr by TR-FRET assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1469888	Inhibition of full length recombinant human N-terminal GST-tagged BMX expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay
AID1425000	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375519	Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1897142	Inhibition of recombinant wild-type BTK (unknown origin) assessed as inhibition of substrate phosphorylation using peptide substrate in presence of ATP by microplate reader assay	2022	RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11	Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
AID1563053	Induction of apoptosis in human Raji cells assessed as viable cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 97.5 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1714835	Inhibition of ITK (unknown origin)
AID1424927	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1398715	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
AID1563055	Induction of apoptosis in human Raji cells assessed as late apoptotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 0.57 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1426147	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1%)	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
AID1468808	Inhibition of recombinant human cytoplasmic GST-tagged LTK expressed in baculovirus at 1 uM by Z'-LYTE assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1475899	Antiproliferative activity against human Mino cells at 25 uM preincubated for 48 hrs followed by thymidine addition measure after 16 hrs by Thymidine incorporation assay	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.
AID1772875	Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1469895	Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells
AID1499233	Inhibition of TEL-fused EGFR T790M/L858R mutant (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1304229	Irreversible inhibition of recombinant BTK (unknown origin) incubated for 1 hr by FRET assay	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
AID1375539	Irreversible inhibition of BTK autophosphorylation at Y223 in human TMD8 cells at 1 uM preincubated for 2 hrs followed by compound wash out measured after 2 to 24 hrs by Western blot method	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1424905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1398717	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 200 nM using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay relative to control	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
AID1398718	Inhibition of recombinant full length human N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells using poly (4:1 Glu, Tyr) as substrate after 60 mins by ADP-Glo assay	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
AID1424965	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1334879	Antiproliferative activity against human Raji cells measured after 48 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1425182	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424907	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1560827	Binding affinity to DNA-tagged recombinant ERBB2 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425059	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1267792	Inhibition of FLT3 ITD mutant (unknown origin) expressed in BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by CelltiterGlo assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
AID1424944	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499229	Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1401340	Inhibition of JAK3 in human NAMALWA cells assessed as reduction in STAT3 phosphorylation at 10 uM after 48 hrs by immunoblot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1418295	Intrinsic clearance in mouse microsomes	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1337177	Inhibition of PF-06658607 binding to recombinant C-terminal FLAG-tagged FAM213A (unknown origin) expressed in HEK293T cells after 1 hr by gel-based ABPP assay	2017	Nature reviews. Drug discovery, Jun, Volume: 16, Issue:6	Non-kinase targets of protein kinase inhibitors.
AID1468849	Inhibition of BTK C481S mutant (unknown origin) autophosphorylation at Y223 expressed in HEK293 cells at 1 uM by Western blot analysis	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
AID1476268	Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
AID1399790	Fraction unbound in human plasma	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1375489	Tmax in rat at 3 mg/kg, po	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1425181	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1549566	Inhibition of HER4 (unknown origin)	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1563038	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 0.14 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1571258	Cell cycle arrest in human Ramos cells assessed as accumulation of cells at G2/M phase at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 4.26%)
AID1623569	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residues after 4 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1880544	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1267791	Antiproliferative activity against human MV4-11 cells after 72 hrs by CelltiterGlo assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
AID1527027	Growth inhibition of human OCI-LY10 cells at 42 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1324665	Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 1.58%)	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1878121	Binding affinity to TEC (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1424955	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615375	Selectivity ratio of IC50 for ITK (unknown origin) to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1725074	Protein binding in human plasma at 2 uM incubated for 4 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1484562	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1822805	Inhibition of ITK in human Jurkat cells assessed as reduction in PLCgamma1 phosphorylation at 1000 nM incubated for 4 hrs by Western blot analysis
AID1725093	AUC (0 to last) in BALB/c mouse at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1560826	Binding affinity to DNA-tagged recombinant EGFR (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1563075	Inhibition of BTK in human Ramos cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1878130	Selectivity index, ratio of Kd for TXK (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1714855	Inhibition of MEK2 (unknown origin)
AID1375491	Oral bioavailability in rat at 3 mg/kg	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1563076	Inhibition of BTK in human Raji cells assessed as reduction in PLCgamma-2 phosphorylation at Y1217 residue at 0.1 to 5 uM after 48 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1878128	Selectivity index, ratio of Kd for JAK3 (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1324655	Antiproliferative activity against human Ramos cells after 48 hrs by CCK-8 assay	2016	ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12	Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
AID1458989	Metabolic stability in human plasma at 5 uM incubated for 1 hr by LC-MS method	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1424914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1401310	Antiproliferative activity against human Raji cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1872689	Cytotoxicity against human DOHH-2 cells expressing BTK and PI3kdelta assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo assay	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Recent development of BTK-based dual inhibitors in the treatment of cancers.
AID1424975	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375559	Antitumor activity against human TMD8 cells xenografted in CB17 SCID nude mouse assessed as effect on tumor volume at 25 mg/kg, po qd administered for 13 consecutive days measured on day 17 relative to control	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1638808	Intrinsic clearance in human liver microsomes at 3 uM measured up to 60 mins by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1375530	Inhibition of recombinant human ErbB2 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1481353	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1424982	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425056	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469910	Effect on BTK transphosphorylation at PLCgamma2 Y759 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID631101	Inhibition of LYN-A expressed in Sf9 cells after 60 mins by TR-FRET Assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
AID1772874	Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
AID1425067	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469921	Cell cycle arrest in human Pfeiffer cells assessed as increase in accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide/RNase staining based flow cytometric method
AID1869999	Induction of cell cycle arrest in human SU-DHL-6 cells assessed as accumulation of cells at G0/G1 phase at 0.5 uM incubated for 24 hrs by PI staining based FACScan flow cytometry analysis (Rvb = 55.61 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1714819	Antiarthritic activity in DBA/1J mouse model of collagen-induced arthritis at 20 mg/kg, po administered for 30 days and measured on day 30
AID1560825	Binding affinity to DNA-tagged recombinant ITK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1880540	Antiproliferative activity against human OCILY10 cells assessed as inhibition of cell growth incubated for 3 to 7 days by MTS assay	2022	Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.
AID1822769	Inhibition of EGFR phosphorylation in human A549 cells incubated for 4 hrs by Western blot assay
AID1412710	Inhibition of human ErbB2 using using poly (4:1 Glu, Tyr) as substrate measured after 1 hr in presence of [gamma-33P]ATP	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
AID1673830	Inhibition of BMX (unknown origin)	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1638787	Inhibition of wild type EGFR (unknown origin) by HTRF assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1673924	Inhibition of wild type BTK (unknown origin)	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID1615386	Selectivity ratio of IC50 for human TXK to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1164542	Inhibition of cell proliferation of human Rec1 cells at 5 uM after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
AID1425183	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425016	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714870	Inhibition of recombinant human FYN using biotinyl-beta Abeta-Abeta AYQAEENTYDEYEN as substrate incubate for 60 mins by LANCE assay
AID1870023	Induction of apoptosis in human DOHH-2 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 2.09 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1375531	Inhibition of recombinant human FLT3 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1472050	Growth inhibition of human SUDHL2 cells at 0.003 uM after 3 days by AlamarBlue assay (Rvb = - 1 %)	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
AID1418289	Inhibition of CYP2C8 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1425106	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714850	Inhibition of CSK (unknown origin)
AID1656236	Inhibition of BTK in human whole blood cells after 1 hr by ELISA	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1720538	Inhibition of recombinant full length human His-tagged BLK cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1830231	Inhibition of BTK in human Ramos cells assessed as reduction in BTK phosphorylation at Tyr223 residue incubated for 24 hrs by Western blot analysis	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
AID1623559	Antiproliferative activity against human Raji cells at 5 uM after 24 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1574157	Antiproliferative activity against human SU-DHL6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1425127	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615368	Inhibition of human BMX using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1458991	Fraction unbound in mouse 100% plasma at 5 uM incubated for 6 hrs by LC-MS method	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1725080	Inhibition of human liver microsome CYP2C9 using diclofenac as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1424979	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499253	Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo assay
AID1499271	Antiproliferative activity against primary CLL cells derived from p12 patient after 72 hrs by CellTiter-Glo assay
AID1425057	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1571252	Induction of apoptosis in human Ramos cells assessed as viable cells at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 96.83%)
AID1469911	Inhibition of BTK transphosphorylation at PLCgamma2 Y1217 in human U2932 cells up to 1 uM measured after 4 hrs by chemiluminescent assay
AID1714868	Inhibition of HCK (unknown origin)
AID1638801	Apparent permeability across basolateral to apical side in human Caco2 cells at 5 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1425042	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425104	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425196	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615372	Inhibition of human FRK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1164541	Inhibition of BTK phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
AID1571255	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 5 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 1.11%)
AID1425063	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1399782	Inhibition of human full length BTK using FITC-AHA-EEPLYWSFPAKKK-NH2 as substrate after 90 mins by microfluid mobility shift assay	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1397247	Induction of apoptosis in human NAMALWA cells assessed as late apoptotic cells at 5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0%)	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1870013	Induction of cell cycle arrest in human DOHH-2 cells assessed as accumulation of cells at G2/M phase at 1 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 21.42 %)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1725075	Protein binding in rat plasma at 2 uM incubated for 4 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1484553	Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1638788	Inhibition of EGFR L858R/T790M double mutant (unknown origin) by HTRF assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1424889	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1725089	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1878117	Binding affinity to BTK (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1720522	Inhibition of His-tagged recombinant human TEC expressed in baculovirus expression system preincubated for 1 hr by Z'lyte assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1475902	Inhibition of eIF4E in human Mino cells assessed as down regulation of c-Myc protein expression at 10 to 25 uM after 48 hrs by Western blot analysis	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.
AID1560882	Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and mea	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1397234	Antiproliferative activity against human NAMALWA cells after 72 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.
AID1425099	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714881	Inhibition of recombinant human PI3K using PIP2 as substrate incubate for 15 mins by LANCE assay
AID1870017	Induction of apoptosis in human SU-DHL-6 cells assessed as necrotic cells at 1.5 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 0.32%)	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1563025	Inhibition of human recombinant full length N-terminal His tagged BTK C481S mutant expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1563022	Antiproliferative activity against human Ramos cells measured after 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1623573	Cell cycle arrest in human Ramos cells assessed as accumulation at apoptotic phase at 5 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 5.03%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1458993	Intrinsic clearance in human liver microsomes at 3 uM after 50 mins by LC-MS method	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1499231	Inhibition of TEL-fused EGFR T790M mutant (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1399788	Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced CD69 expression incubated for 1 hr by flow cytometric analysis	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
AID1164540	Inhibition of Lyn phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
AID1615365	Inhibition of TEC (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1458984	Selectivity ratio of EC50 for human A431 cells expressing wild type EGFR to EC50 for human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1714856	Inhibition of RET (unknown origin)
AID1878129	Selectivity index, ratio of Kd for TEC (unknown origin) to Kd for BTK (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1425033	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1469904	Growth inhibition of human SKM1 cells
AID1375525	Inhibition of recombinant human EGFR using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1638803	Apparent permeability across basolateral to apical side in MDCK2-MDR1 cells at 10 uM after 2 hrs by transwell membrane based assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1425004	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425061	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425213	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615391	Selectivity ratio of IC50 for ITK in human Jurkat cells to IC50 for BTK in human Ramos cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425089	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1673835	Irreversible inhibition of full length human unphosphorylated BTK at 5.7 uM using peptide substrate preincubated for 2 hrs followed by compound dilution and measured after substrate addition for 1 hr in presence of ATP at Km concentration	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1650930	Inhibition of BTK (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3	Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
AID1458990	Metabolic stability in mouse plasma at 5 uM incubated for 1 hr by LC-MS method	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1375527	Inhibition of recombinant human TXK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1650544	Inhibition of recombinant human N-terminal His-tagged JAK3 (795 to 1124 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1401308	Inhibition of recombinant N-terminal GST-tagged human JAK3 (781 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
AID1851526	Antiproliferative activity against human OCILY3 cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1417598	Efflux ratio of permeability in human Caco2 cells	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
AID1424954	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1481308	Inhibition of EGFR L858R mutant in human H3255 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1563060	Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 37.66 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1425151	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425008	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1375533	Inhibition of recombinant human PDGFR-beta using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1458985	Permeability of the compound at 500 uM incubated for 20 hrs by PAMPA	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1650555	Metabolic stability in human liver microsomes assessed as intrinsic clearance at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1878116	Binding affinity to BMX (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1524892	Stability in human liver microsomes assessed as compound remaining incubated of 60 mins in presence of NADPH regenerating system by LC/MS analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
AID1155521	Cytotoxicity against human SU-DHL6 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
AID1424926	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424991	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425066	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499242	Antiproliferative activity against human NCI-H358 cells after 72 hrs by CellTiter-Glo assay
AID1418287	Inhibition of CYP2B6 (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1623562	Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 5 uM after 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 1.08%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1894185	Inhibition of ERK phosphorylation in anti-IgG stimulated human DOHH-2 cells preincubated for 1 hr followed by compound washout and anti-IgG stimulation for 2 mins by chemiluminescence based Western blotting analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1871762	Inhibition of ITK (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1560822	Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1878115	Binding affinity to BLK (unknown origin) assessed as dissociation constant by KINOMEscan analysis	2022	Bioorganic & medicinal chemistry letters, 03-15, Volume: 60	Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
AID1725084	Clearance in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1574158	Antiproliferative activity against human WSU-DLCL2 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1894182	Inhibition of BTK in human DOHH-2 cells preincubated for 1 hr followed by compound washout and anti-IgG stimulation for 2 mins by chemiluminescence based Western blotting analysis	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1425166	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424931	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424901	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615374	Inhibition of human TXK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1424976	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425074	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876107	Cytotoxicity against human PC-3 cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1615385	Selectivity ratio of IC50 for human LCK to IC50 for N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425096	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1738560	Induction of cell cycle arrest in human Ramos cells assessed as G0/G1 phase accumulation at 5 uM incubated for 24 hrs by PI staining based flow cytometry analysis (Rvb = 39.13 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1889496	Inhibition of BTK (unknown origin) by lanthascreen Tb kinase activity assay	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID1484563	Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.2%)	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
AID1656245	Inhibition of His-tagged BTK (unknown origin) assessed as ratio of Kinact to Ki(app) after 1.5 hrs by HTRF analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
AID1375485	Clearance in rat at 1 mg/kg, iv	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1488735	Aqueous solubility of the compound at 1 mg	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1425060	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615445	Oral bioavailability in human in fed state at 560 mg administered daily	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1488740	Antitumor activity against human NCI-H1975 cells xenografted in nude mouse assessed as tumor growth inhibition at 25 mg/kg administered via oral gavage qd measured every 2 days up to 18 days relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
AID1425111	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1499232	Inhibition of TEL-fused EGFR L858R mutant (unknown origin) expressed in mouse BA/F3 cells after 72 hrs by CellTiter-Glo assay
AID1309835	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 3 days by presto blue dye based plate reader method	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.
AID1424918	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1574152	Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay	2019	Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
AID1424985	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714772	Inhibition of BTK (unknown origin) at 1 uM by caliper mobility shift assay relative to control
AID1714839	Inhibition of ErBB2 (unknown origin)
AID1725092	Volume of distribution at steady state in BALB/c mouse at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1673819	Terminal plasma concentration in ovalbumin-immunized C57Bl6 mouse at 30 mg/kg, po administered 2 h prior to OVA immunization and measured after 5 hrs	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1638786	Inhibition of N-terminal His-tagged MKK7 beta1 S273D/T275D double mutant (unknown origin) expressed in insect cells using JNK1 K55M mutant as substrate by ADP-Glo assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1549595	Antiarthritic activity in DBA1/J mouse model of collagen-induced arthritis assessed as reduction in cartilage damage at 12.5 mg/kg, po qd by H and E staining based assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1425136	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425120	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1527030	Growth inhibition of human OCI-LY19 cells at 4.2 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1549565	Inhibition of human recombinant HER2 using biotinyl-beta amyloid beta amyloid beta AAEEEEYFELVAKKK measured after 10 mins in the presence of ATP by HTRF assay	2019	European journal of medicinal chemistry, May-01, Volume: 169	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
AID1709139	Inhibition of BTK (unknown origin) One-hour enzymatic assay without pre-incubation	2021	Bioorganic & medicinal chemistry letters, 04-15, Volume: 38	Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.
AID1423320	Glutathione reactivity assessed as formation of glutathione adduct formation in presence of pH 7.4 at 25 degC by NMR based method	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester.
AID1425131	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1650551	Antiproliferative activity against human HEL cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1870041	Antitumor activity against human SU-DHL-6 cells xenografted in NOD/SCID mouse assessed as tumor volume suppression at 10 mg/kg, po qd measured every 2 days	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1375480	Inhibition of recombinant full-length N-terminal His-tagged human BTK C481S mutant expressed in baculovirus infected Sf9 insect cells using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	2018	Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
AID1650542	Inhibition of recombinant human N-terminal GST-tagged JAK1 (850 to 1154 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
AID1418284	Inhibition of human ERG	2018	Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21	Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
AID1720509	Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 peptide as substrate preincubated for 1 hr by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1720528	Inhibition of recombinant human GST-tagged JAK3 catalytic domain (781 to 1124 residues) expressed in baculovirus expression system using tyrosine-6 peptide as substrate preincubated for 1 hr in presence of ATP by Z'-LYTE assay	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Discovery of quinoline-based irreversible BTK inhibitors.
AID1458981	Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1425141	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1563039	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 5 uM measured after 15 mins by Annexin-V-APC staining-based flow cytometric analysis (Rvb = 1.85 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1527031	Growth inhibition of human OCI-LY19 cells at 10 nM incubated for 3 days by Alamar blue dye based fluorescence assay (Rvb = 3%)
AID1623570	Inhibition of BTK in anti-human IgM-stimulated human Ramos cells assessed as reduction in PLCgamma2 phosphorylation at Tyr1217 residues after 4 hrs by Western blot analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1458977	Inhibition of human recombinant GST-tagged EGFR L858R mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 15 mins by HTRF assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1241390	Inhibition of BTK (unknown origin)	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1725085	Volume of distribution at steady state in Sprague-Dawley rat at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1458982	Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1623549	Inhibition of BTK (unknown origin) by ADP-gloassay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.
AID1587020	Inhibition of full-length recombinant human C-terminal His-tagged SRC cytoplasmic domain expressed in baculovirus expression system using FAM-Srctide peptide as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-F	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
AID1738558	Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 5 uM incubated for 24 hrs by annexin V-FITC and PI staining based flow cytometry analysis (Rvb = 2.2 %)	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
AID1638812	Covalent binding affinity to MKK7 (unknown origin) assessed as formation of covalent bond with Cys218 residues by MS/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1425157	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1615341	Inhibition of JAK3 (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1638809	Intrinsic clearance in mouse liver microsomes at 3 uM measured up to 60 mins by LC/MS analysis	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
AID1458986	Apparent permeability across apical to basolateral side in human Caco2 cells at 5 uM incubated for 2 hrs	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1673834	Inhibition of EGFR (unknown origin)	2019	ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10	Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
AID1334886	Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 39.95 %)	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
AID1615373	Inhibition of human LCK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425055	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425078	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1782000	Selectivity index, ratio of IC50 for inhibition of BMX (unknown origin) to IC50 for inhibition of BTK (unknown origin)	2021	Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21	Discovery of 1-Amino-1
AID1560834	Selectivity ratio of Kd for DNA-tagged recombinant ERBB2 (unknown origin) to Kd for DNA-tagged recombinant BTK (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1425138	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424912	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1851525	Antiproliferative activity against human Pfeiffer cells incubated for 72 hrs by CellTiter-Glo assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
AID1563071	Cell cycle arrest in human Raji cells assessed as accumulation at G2/M phase at 1 uM measured after 48 hrs by propidium iodide/RNase staining based flow cytometric analysis (Rvb = 18.14 %)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1871767	Inhibition of ERBB4 (unknown origin)	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
AID1615371	Inhibition of human FGR using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by filter binding method	2019	Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
AID1563019	Inhibition of human recombinant full length N-terminal His tagged BTK expressed in baculovirus infected Sf9 cells at 10 uM using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
AID1869073	Inhibition of BTK T474M mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
AID1469897	Growth inhibition of human MV411 cells
AID1424967	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714834	Inhibition of Tec (unknown origin)
AID1725095	Antiarthritic activity in collagen-induced arthritis mouse model assessed as clinical score at 10 mg/kg, po administered for 14 days and measured for 21 days after dosing	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery and Evaluation of Pyrazolo[3,4-
AID1425110	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424952	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1822786	Toxicity in human U-937 cells xenografted in BALB/c nude mouse assessed as increase in body weight at 25 mg/kg, po administered once daily 14 days
AID1412327	Glutathione reactivity of the compound assessed as pseudo first order reaction rate constant for GSH adduct formation at 37 degC by LC analysis
AID1425093	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1714873	Inhibition of recombinant human SRC using Ulight-Poly GAT[EAY(1:1:1)]n as substrate incubate for 10 mins by LANCE assay
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (0.05)	29.6817
2010's	1125 (59.06)	24.3611
2020's	779 (40.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	243 (12.62%)	5.53%
Reviews	291 (15.11%)	6.00%
Case Studies	273 (14.17%)	4.05%
Observational	30 (1.56%)	0.25%
Other	1,089 (56.54%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.25	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
adenine [no description available]	28.04	1,757	291	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.21	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	4.55	1	1	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.1	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycine [no description available]	2.31	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
histamine [no description available]	2.21	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	2.25	1	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.86	3	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	3.01	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.41	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.08	1	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
pd 173074 [no description available]	2.08	1	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
abt 702 [no description available]	2.08	1	0	bipyridines
ethacridine Ethacridine: A topically applied anti-infective agent.	2.13	1	0	acridines
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.85	3	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
acetovanillone apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.	2.25	1	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	3.66	2	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.08	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bisindolylmaleimide iv [no description available]	2.41	1	0	indoles; maleimides
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.51	2	0	aromatic ether; nitrile; polyether; tertiary amino compound
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	2.25	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.51	1	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
celecoxib [no description available]	2.08	1	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.08	1	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	13.75	28	15	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
cl 387785 CL 387785: structure in first source. N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.	3.17	1	0	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	3.17	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.21	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
e 4031 E 4031: class III anti-arrhythmia agent; structure given in UD	2.31	1	0	sulfonamide
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	4.15	2	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.08	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.08	1	0
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.52	2	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.41	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.76	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.15	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	5.55	2	2	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.25	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.15	1	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline WHI P131: a quinazoline derivative, inhibitor of glioblastoma cell adhesion and migration	2.15	1	0
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	4.02	2	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.57	2	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.08	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lg 100268 LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source	2.08	1	0
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.82	2	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
ly 303511 LY 303511: inhibitor of phosphatidylinositol 3-kinase	3.25	1	0	N-arylpiperazine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	3.97	3	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.58	2	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.25	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.15	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	5.07	2	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	2.15	1	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.08	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
entinostat [no description available]	2.08	1	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.41	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
olprinone olprinone: RN refers to HCl; structure given in first source	2.08	1	0	bipyridines
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	3.77	3	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
pd168393 PD 168393 : A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.	3.17	1	0	acrylamides; bromobenzenes; quinazolines; secondary carboxamide; substituted aniline	epidermal growth factor receptor antagonist
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.08	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.21	1	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.08	1	0	indoles
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.08	1	0	benzothiazoles
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.21	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
sb 206553 SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source	2.08	1	0	pyrroloindole
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.08	1	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	3.61	2	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.08	1	0	imidazoles
stearic acid octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.	2.21	1	0	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
imatinib [no description available]	4.67	4	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.8	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfanilamide [no description available]	2.6	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.08	1	0
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.25	1	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.08	1	0	stilbenoid
temozolomide [no description available]	2.93	3	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	12.69	21	4	phthalimides; piperidones
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.11	1	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.08	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tyrphostin a9 [no description available]	2.41	1	0	alkylbenzene	geroprotector
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	3.51	1	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
corticosterone [no description available]	2.41	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	4.69	4	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	13.06	38	8	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.1	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2.6	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	3.04	3	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	4.55	1	1	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.53	2	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.11	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
mepazine mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.	2.11	1	0	phenothiazines
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.11	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.13	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.1	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
cytarabine [no description available]	8.01	7	2	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	3.06	4	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
acrylamide [no description available]	3.41	1	0	acrylamides; N-acylammonia; primary carboxamide	alkylating agent; carcinogenic agent; Maillard reaction product; mutagen; neurotoxin
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.11	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.63	2	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
bromobenzene [no description available]	2.31	1	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.39	6	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.27	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
carbitol carbitol: used as lubricating oil & in braking fluid, structure. diethylene glycol monoethyl ether : A primary alcohol that is ethanol substituted by a 2-ethoxyethoxy group at position 2.	2.13	1	0	diether; glycol ether; hydroxypolyether; primary alcohol	protic solvent
cinnoline cinnoline: structure in first source. cinnoline : An azaarene that is the 1,2-diaza analogue of naphthalene. The parent of the class of cinnolines.	2.17	1	0	azaarene; cinnolines; mancude organic heterobicyclic parent; ortho-fused heteroarene
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	7.04	8	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.66	2	0	indazole
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.13	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.06	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	15.56	71	7	diazine; pyrazines	Daphnia magna metabolite
hydrazine diamine : Any polyamine that contains two amino groups.	5.6	5	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.92	2	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.15	1	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	9.18	12	1
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.15	1	0	thiazolidine
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.08	1	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
myristic acid Myristic Acid: A saturated 14-carbon fatty acid occurring in most animal and vegetable fats, particularly butterfat and coconut, palm, and nutmeg oils. It is used to synthesize flavor and as an ingredient in soaps and cosmetics. (From Dorland, 28th ed). tetradecanoic acid : A straight-chain, fourteen-carbon, long-chain saturated fatty acid mostly found in milk fat.. tetradecanoate : A long-chain fatty acid anion that is the conjugate base of myristic acid; major species at pH 7.3.	3.17	1	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite
formestane [no description available]	2.08	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.21	1	0	flavonols; monohydroxyflavone
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	2.31	1	0	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.56	1	1	cyclic ketone; erythromycin
hydroxychloroquine sulfate [no description available]	2.08	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	4.55	1	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
deoxycytidine [no description available]	2.69	2	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2,3,7,8-tetrachlorodibenzodioxine Tetrachlorodibenzodioxin: A mixture of isomers.	2.06	1	0	polychlorinated dibenzodioxine
amiloride hydrochloride, anhydrous amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride	diuretic; sodium channel blocker
acadesine [no description available]	2.52	2	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
cladribine [no description available]	7.23	5	3	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	12.73	33	6	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.6	1	0	f-block element atom; lanthanoid atom
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	2.21	1	0	calcium phosphate
silver nitrate Silver Nitrate: A silver salt with powerful germicidal activity. It has been used topically to prevent OPHTHALMIA NEONATORUM.	2.31	1	0	inorganic nitrate salt; silver salt	astringent
deuterium oxide Deuterium Oxide: The isotopic compound of hydrogen of mass 2 (deuterium) with oxygen. (From Grant & Hackh's Chemical Dictionary, 5th ed) It is used to study mechanisms and rates of chemical or nuclear reactions, as well as biological processes.	3.06	1	0	deuterated compound; water	NMR solvent
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.31	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.52	2	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	2.31	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	3.27	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.08	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.61	2	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	6.88	4	3	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ribavirin Rebetron: Rebetron is tradename	2.21	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
bezafibrate [no description available]	2.6	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.08	1	0	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
pirfenidone pirfenidone : A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.	2.25	1	0	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).	3.19	1	0	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
triciribine phosphate [no description available]	2.15	1	0
staurosporine [no description available]	2.69	2	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.08	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	5.19	3	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
pravadoline [no description available]	2.08	1	0
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.66	2	0	imidazoquinoline	antineoplastic agent; interferon inducer
zileuton [no description available]	2.08	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
niguldipine [no description available]	2.08	1	0	diarylmethane
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.08	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.	2.08	1	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	4.52	4	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.25	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.25	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.08	1	0
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.89	2	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.41	1	0	D-glucopyranose	epitope; mouse metabolite
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.11	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
bendamustine [no description available]	2.08	1	0	benzimidazoles
caroverine caroverine: structure	2.08	1	0	quinoxaline derivative
lercanidipine [no description available]	2.13	1	0	diarylmethane
cgs 9343b [no description available]	2.08	1	0	benzimidazoles
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.54	2	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	6.18	10	1	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	3.68	2	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.21	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
biphenyl-2-carboxylic acid biphenyl-2-carboxylic acid: structure in first source	2.25	1	0
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	4.52	4	1	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
alacepril [no description available]	2.08	1	0	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ubenimex ubenimex: growth inhibitor	2.08	1	0
honokiol [no description available]	2.25	1	0	biphenyls
picropodophyllin picropodophyllin: isolated from American May apple (Podophyllum); inhibits IGF-I autophosphorylation without interfering with tyrosine kinase activity. picropodophyllotoxin : An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.	2.15	1	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antineoplastic agent; insulin-like growth factor receptor 1 antagonist; plant metabolite; tyrosine kinase inhibitor
bendamustine hydrochloride [no description available]	15.95	62	18
cholest-5-ene-3,4-diol cholest-5-ene-3,4-diol: RN given refers to (3beta,4beta)-isomer	2.6	1	0
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	2.11	1	0	iditol	fungal metabolite
sr141716 [no description available]	3.51	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
vinpocetine [no description available]	2.08	1	0
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.08	1	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
triptolide [no description available]	2.08	1	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
parthenolide [no description available]	2.13	1	0	germacranolide
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.31	1	0
trans-1,2-dihydro-1,2-naphthalenediol trans-1,2-dihydro-1,2-naphthalenediol: structure in first source. (1S,2S)-1,2-dihydronaphthalene-1,2-diol : The (1S,2S)-isomer of trans-1,2-dihydronaphthalene-1,2-diol.	4.26	5	0	trans-1,2-dihydronaphthalene-1,2-diol
clofarabine [no description available]	3.41	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
sr 48692 SR 48692: structure in first source; a neurotensin receptor-1 antagonist	2.08	1	0	N-acyl-amino acid
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.08	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	3.41	5	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	5.3	8	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
bay x 1005 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;	2.08	1	0
lestaurtinib [no description available]	2.63	2	0	indolocarbazole
gyki 53655 GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist	2.08	1	0
methotrexate [no description available]	6.47	4	2	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
ml-3000 [no description available]	2.08	1	0
pixantrone pixantrone: an immunosuppressant; structure given in first source	3.71	2	0	isoquinolines
pomalidomide 3-aminophthalimidoglutarimide: structure in first source	3.69	2	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
cd 437 CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.13	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	3.82	2	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.08	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
perifosine [no description available]	2.52	2	0	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
mk 767 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source	2.08	1	0
vatalanib [no description available]	2.15	1	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2.15	1	0
bazedoxifene acetate [no description available]	2.08	1	0
canertinib [no description available]	4.14	4	0	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
birb 796 [no description available]	2.08	1	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
olmesartan olmesartan: an active metabolite of CS 866	2.25	1	0	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
tipifarnib [no description available]	2.08	1	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	3.08	4	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
frenolicin b frenolicin B: produced by Streptomyces roseofulvus strain AM 3867; structure	3.17	1	0	benzoisochromanequinone; p-quinones	metabolite
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	2.31	1	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
sb 203580 [no description available]	3.95	3	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
enzastaurin [no description available]	2.83	3	0	indoles; maleimides
erlotinib [no description available]	4.2	4	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
erlotinib hydrochloride [no description available]	2.53	2	0	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
piboserod Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.	2.08	1	0
l 163191 [no description available]	2.08	1	0
bd 1047 N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity	2.08	1	0	primary amine
lapatinib [no description available]	4.36	5	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
dabigatran Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.. dabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.	2.93	3	0	aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines	anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor
sorafenib [no description available]	3.44	6	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	15.35	40	11	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	aminoquinoline
sr 142806 [no description available]	2.08	1	0
vincaleukoblastine [no description available]	3.51	1	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.4	2	0
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	2.15	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
elesclomol [no description available]	2.08	1	0	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer
wortmannin [no description available]	3.61	2	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
nsc 663284 NSC 663284: structure in first source	2.08	1	0	quinolone
taurochenodeoxycholic acid Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.. taurochenodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. taurochenodeoxycholic acid : A bile acid taurine conjugate of chenodeoxycholic acid.	2.17	1	0	bile acid taurine conjugate	human metabolite; mouse metabolite
bortezomib [no description available]	12.68	33	4	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.08	1	0	cyclohexenones
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.13	1	0
nsc 23766 [no description available]	2.08	1	0	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
carboplatin [no description available]	5.55	2	2
n-acetylneuraminic acid N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.	2.72	2	0	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
naringenin (S)-naringenin : The (S)-enantiomer of naringenin.	2.21	1	0	(2S)-flavan-4-one; naringenin	expectorant; plant metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.31	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.25	1	0	cyclodextrin
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.41	1	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.7	1	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
lycopene [no description available]	2.25	1	0	acyclic carotene	antioxidant; plant metabolite
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.51	1	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
pd 166326 PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor	2.41	1	0
gw 3965 GW 3965: a liver X receptor ligand	2.54	2	0	diarylmethane
t0901317 T0901317: an LXRalpha and LXRbeta agonist	2.25	1	0
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.08	1	0	aromatic amide
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
purvalanol b purvalanol B: protein kinase inhibitor; structure in first source	2.08	1	0	purvalanol	protein kinase inhibitor
y-700 [no description available]	2.08	1	0
repsox RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect	2.08	1	0	pyrazolopyridine
decitabine [no description available]	3.64	1	1	2'-deoxyribonucleoside
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.72	2	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.41	1	0	purvalanol
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.08	1	0	tropane alkaloid
s 1033 [no description available]	4.69	7	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
fludarabine [no description available]	12.46	32	6	purine nucleoside
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.08	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
rg108 RG108: DNA methyltransferase inhibitor; structure in first source	2.08	1	0	indolyl carboxylic acid
stf 083010 [no description available]	2.08	1	0
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.41	1	0	substituted aniline
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	2.08	1	0	naphthalenecarboxamide
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.08	1	0	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
secinh3 SecinH3: a small molecule antagonist of cytohesins; structure in first source	2.08	1	0	triazoles
jk184 JK184: structure in first source	2.08	1	0
xl147 [no description available]	2.15	1	0	aromatic amine; benzothiadiazole; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.41	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
tamoxifen citrate [no description available]	2.08	1	0	citrate salt	angiogenesis inhibitor; anticoronaviral agent
tamoxifen [no description available]	2.17	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
hc-067047 HC-067047: a TRPA1 antagonist; structure in first source	2.08	1	0
bi-78d3 [no description available]	2.08	1	0	aryl sulfide
stattic [no description available]	3.25	1	0	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor
gsk 3787 [no description available]	2.08	1	0
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	3.61	2	0	organonitrogen compound; organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester [no description available]	2.08	1	0	monocarboxylic acid
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide [no description available]	2.08	1	0	sulfonamide
LSM-1318 [no description available]	2.08	1	0	oxa-steroid
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.41	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rwj 67657 RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source	2.08	1	0
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.41	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
6-methyl-2-(phenylethynyl)pyridine 6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.08	1	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.52	2	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sf 2370 SF 2370: indolocarbazole isolated from Actinomadura sp. SF-2370; structure given in first source. K-252a : A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a	2.15	1	0	bridged compound; gamma-lactam; methyl ester; organic heterooctacyclic compound	antimicrobial agent; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; tropomyosin-related kinase B receptor antagonist
tandutinib [no description available]	2.52	2	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	2.08	1	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.	2.08	1	0	hydrochloride	cardiotonic drug
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	6.05	12	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
ha 1100 HA 1100: intracellular calcium antagonist	2.15	1	0
7-epi-hydroxystaurosporine [no description available]	2.15	1	0
zd 6474 CH 331: structure in first source	3.94	3	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
compound 968 compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.	2.08	1	0	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor
sb-224289 SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.	2.08	1	0	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.08	1	0	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.08	1	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine [no description available]	2.08	1	0	imidazoles
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine [no description available]	2.08	1	0	aromatic amine; tertiary amino compound
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester [no description available]	2.08	1	0	isoquinolines
sch 79797 [no description available]	2.08	1	0	quinazolines
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.08	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one [no description available]	2.08	1	0	monobactam
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.41	1	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.52	2	0	benzamides
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.08	1	0	carbazoles; monocarboxylic acid amide; organochlorine compound
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.11	1	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	2.08	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
genistein [no description available]	2.57	2	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.27	1	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
fisetin [no description available]	2.21	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.41	1	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	2.11	1	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.41	1	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	3.27	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	10.43	14	6	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	3.97	3	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.08	1	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
ic 261 IC 261: a caseine kinase-1 inhibitor; structure in first source	3.25	1	0
ter 199 [no description available]	2.08	1	0
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	2.08	1	0
ly 320135 LY 320135: cannabinoid receptor antagonist; structure in first source	2.08	1	0	benzofurans
pd 166285 [no description available]	2.08	1	0
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	2.41	1	0	pyrimidines
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	2.08	1	0	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.08	1	0
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	3.51	1	1	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	2.52	2	0
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	3.46	6	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.08	1	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.15	1	0
su 11248 [no description available]	3.06	4	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	8.1	8	2	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	2.08	1	0	sulfonamide
cisplatin [no description available]	2.08	1	0	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	2.13	1	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	3.68	8	0	cysteinium	fundamental metabolite
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	2.25	1	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
vx680 [no description available]	2.52	2	0	N-arylpiperazine
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.41	1	0	cyanine dye; organic iodide salt	fluorochrome
viroxime [no description available]	2.41	1	0
d 4476 [no description available]	2.08	1	0	imidazoles
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.52	2	0
bay 19-8004 BAY 19-8004: a PDE4 inhibitor; structure in first source	2.08	1	0
everolimus [no description available]	5.7	9	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ekb 569 EKB 569: an EGF receptor kinase inhibitor	3.69	2	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
axitinib [no description available]	2.52	2	0	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
pai 039 tiplaxtinin: inhibitor of plasminogen activator inhibitor-1	2.08	1	0	indole-3-acetic acids
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	2.08	1	0	pyridopyrimidine
ispinesib [no description available]	2.08	1	0	benzamides
fk 866 N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source	2.13	1	0	benzamides; N-acylpiperidine
temsirolimus [no description available]	2.52	2	0	macrolide lactam
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.57	2	0	aminobenzoic acid
isavuconazole isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.	2.63	2	0	1,3-thiazoles; conazole antifungal drug; difluorobenzene; nitrile; tertiary alcohol; triazole antifungal drug	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; ergosterol biosynthesis inhibitor; orphan drug
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.57	2	0	substituted aniline
on 01910 ON 01910: a Plk1 inhibitor with antineoplastic activity; structure in first source. N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine : A glycine derivative that is glycine in which one of the hydrogens of the amino group is substituted by a 2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl group.. rigosertib : An N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties.	2.15	1	0	N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine	antineoplastic agent; apoptosis inducer; EC 2.7.11.21 (polo kinase) inhibitor; microtubule-destabilising agent
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	2.15	1	0	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42 HDAC-42: structure in first source	2.08	1	0	amidobenzoic acid
9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)- 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-: an epichaperome (purine-scaffold) inhibitor; structure in first source	2.54	2	0
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone [no description available]	2.08	1	0	benzamides; N-acylpiperidine
vacuolin-1 vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis	2.41	1	0
iniparib [no description available]	2.08	1	0	carbonyl compound; organohalogen compound
exp-3179 [no description available]	2.25	1	0
mk 0752 [no description available]	2.08	1	0
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	2.08	1	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
av 412 [no description available]	2.52	2	0
ag-041r AG-041R: structure in first source	2.08	1	0
telatinib [no description available]	2.52	2	0
y-39983 Y-39983: SNJ-1656 is an ophthalmic solution of Y-39983; ROCK (rho kinase) inhibitor, promotes regeneration of crushed axons of retinal ganglion cells; structure in first source	2.15	1	0	pyrrolopyridine
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.52	2	0
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	2.08	1	0
abiraterone acetate Abiraterone Acetate: An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.. abiraterone acetate : A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.	2.21	1	0	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.52	2	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
andarine [no description available]	2.08	1	0	acetamides; anilide
gw843682x [no description available]	2.08	1	0	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.85	3	0	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.85	3	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
ag 14361 [no description available]	2.08	1	0	benzimidazoles
sb 265610 [no description available]	2.08	1	0
ursodoxicoltaurine tauroursodeoxycholate : An organosulfonate oxoanion that is the conjugate base of tauroursodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.. tauroursodeoxycholic acid : A bile acid taurine conjugate derived from ursoodeoxycholic acid.	2.17	1	0	bile acid taurine conjugate	anti-inflammatory agent; apoptosis inhibitor; bone density conservation agent; cardioprotective agent; human metabolite; neuroprotective agent
px-866 PX-866: inhibitor of phosphoinositide-3-kinase signaling with antitumor activity; structure in first source. PX-866 : An organic heterotetracyclic compound that is obtained from wortmanin via aminolysis of its furan ring by diallyl amine.	2.15	1	0	acetate ester; delta-lactone; organic heterotetracyclic compound; tertiary amino compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cangrelor cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.	2.11	1	0	adenosine 5'-phosphate; aryl sulfide; nucleoside triphosphate analogue; organochlorine compound; organofluorine compound; secondary amino compound	P2Y12 receptor antagonist; platelet aggregation inhibitor
ripasudil [no description available]	2.15	1	0	isoquinolines
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	3.58	2	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.54	2	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	2.52	2	0	aromatic amide
ki 20227 [no description available]	2.08	1	0
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	2.52	2	0	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ssr 69071 SSR 69071: structure in first source	2.08	1	0	pyridopyrimidine
cp 724714 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide: CP-724714 is the ((2E)-isomer, 1:1.5 succinate); structure in first source	2.15	1	0	2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; hepatotoxic agent
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.41	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.08	1	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
sb 210313 [no description available]	2.08	1	0
hmn-214 (E)-4-(2-(2-(N-acetyl-N-(4-methoxybenzenesulfonyl)amino)stilbazole)) 1-oxide: an antineoplastic agent; structure in first source	2.15	1	0
gw 4064 [no description available]	2.08	1	0	stilbenoid
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide: an IKK-2 kinase inhibitor; structure in first source	2.13	1	0	aromatic amide; thiophenes
sa 4503 [no description available]	2.08	1	0
ic 87114 IC 87114: structure in first source	2.08	1	0	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation	2.08	1	0	phenylpyridine
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	2.52	2	0	aromatic ether
hki 272 [no description available]	5.27	8	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	3.4	6	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532 [no description available]	2.08	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.52	2	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.08	1	0	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	2.52	2	0	aromatic ether
gw0742 GW 610742: structure in first source	2.08	1	0	monocarboxylic acid
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- [no description available]	2.53	2	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
eht 1864 [no description available]	2.13	1	0
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.08	1	0	beta-carbolines
bay 41-8543 BAY 41-8543: structure in first source	2.08	1	0	pyrazolopyridine
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.08	1	0	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	2.08	1	0	quinoxaline derivative
palmarumycin cp2 palmarumycin CP2: a type of spirobisnaphthalene, which contain two naphthalene-derived c10 units bridged through a spiroketal linkage with two oxygen bridges; structure in first source	2.15	1	0
way-362450 [no description available]	2.08	1	0	indoles
osu 03012 OSU 03012: a PDK-1 inhibitor; structure in first source	2.41	1	0	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
masitinib [no description available]	2.52	2	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
bx795 BX795: structure in first source	2.57	2	0	ureas
ly-2157299 LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.	2.15	1	0	aromatic amide; methylpyridines; monocarboxylic acid amide; pyrrolopyrazole; quinolines	antineoplastic agent; TGFbeta receptor antagonist
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.52	2	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.08	1	0	organic cation
azd 6244 AZD 6244: a MEK inhibitor	2.85	3	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
su 14813 5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide: has both antineoplastic and antiangiogenic activities; structure in first source	2.15	1	0
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	2.08	1	0
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.41	1	0	indoles
apilimod [no description available]	2.41	1	0
bibw 2992 [no description available]	6.36	11	0	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.	2.08	1	0	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ar c155858 AR C155858: an MCT1 inhibitor; structure in first source	2.08	1	0
pik 75 PIK 75: structure in first source	2.41	1	0
binimetinib binimetinib : A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.	2.15	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monofluorobenzenes; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sotrastaurin sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.	2.81	3	0	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent
aee 788 AEE 788: structure in first source	2.52	2	0	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
saracatinib [no description available]	2.85	3	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
sd-208 [no description available]	2.08	1	0
vx 702 VX 702: a p38 MAP kinase inhibitor	2.52	2	0	phenylpyridine
crenolanib [no description available]	2.15	1	0	aminopiperidine; aromatic ether; benzimidazoles; oxetanes; quinolines; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tg100-115 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source	2.15	1	0	pteridines
cc 401 CC 401: an anthrapyrazolone	2.15	1	0	pyrazoles; ring assembly
bms 599626 [no description available]	2.15	1	0
(S)-Isosclerone [no description available]	2.15	1	0	tetralins
exel-7647 tesevatinib : A member of the class of quinazolines that is quinazoline substituted by (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups at positions 4, 6 and 7, respectively. It is a multi-target tyrosine kinase inhibitor of EGFR, ErbB2, KDR, Flt4 and EphB4 and exhibits anti-cancer properties.	2.15	1	0
volasertib BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source	3.91	3	0
glaucocalyxin a glaucocalyxin A: chemical constituent of Rabdosia japonica var. glaucocalyx	2.25	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.08	1	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.15	1	0
azd 7762 [no description available]	2.52	2	0	aromatic amide; thiophenes
krp-203 [no description available]	2.08	1	0
mk 0354 [no description available]	2.08	1	0
regorafenib [no description available]	2.85	3	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	2.08	1	0	pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.8	3	0	methoxybenzenes; substituted aniline
abt-737 [no description available]	2.11	1	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
brivanib [no description available]	2.52	2	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
brimonidine tartrate Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	3.27	1	0
icg 001 [no description available]	2.08	1	0	peptide
mp470 [no description available]	2.52	2	0	N-arylpiperazine
rgb 286638 [no description available]	2.15	1	0
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.15	1	0	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	3.61	2	0	dibenzothiophenes
at 7519 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.	2.82	3	0	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
bms-690514 [no description available]	2.15	1	0
bi 2536 [no description available]	4.17	4	0
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide [no description available]	3.25	1	0	biphenyls
inno-406 [no description available]	2.53	2	0	biaryl
kw 2449 KW 2449: has both multikinase inhibitory activity and antineoplastic activity; structure in first source	2.15	1	0
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.13	1	0	stilbenoid
danusertib [no description available]	2.52	2	0	piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide [no description available]	2.08	1	0	benzamides
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide [no description available]	2.08	1	0	benzamides
abt 869 [no description available]	2.52	2	0	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
azd 8931 sapitinib : A member of the class of quinazolines that is 4-amino-7-methoxyquinazoline in which the amino group has been substituted by a 3-chloro-2-fluorophenyl group and in which position 6 of the quinoline ring has been substituted by a {1-[2-(methylamino)-2-oxoethyl]piperidin-4-yl}oxy group. Sapitinib is a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptors (EGFR) HER2 and HER3.	2.15	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
arq 197 [no description available]	3.65	2	0	indoles
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	2.15	1	0	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
pf 00299804 dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.	5.65	6	0	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
ridaforolimus [no description available]	2.15	1	0	macrolide lactam
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.08	1	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066 [no description available]	2.08	1	0
ch 4987655 [no description available]	2.15	1	0
6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide [no description available]	2.15	1	0	phenylpyridine
carfilzomib [no description available]	6.25	11	3	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
gw9508 GW9508: structure in first source	2.08	1	0	aromatic amine
cc-930 [no description available]	2.15	1	0
N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide [no description available]	3.25	1	0	sulfonamide
jnj 26854165 [no description available]	2.08	1	0
pf 573228 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source	2.08	1	0	quinolines
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.08	1	0
tak 285 N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide: also inhibits HER2; structure in first source	2.15	1	0
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	14.95	100	3	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	5.62	8	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile [no description available]	2.08	1	0	benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Vx-11e: ERK1-2 inhibitor	2.08	1	0	aromatic amide; heteroarene
osi 906 [no description available]	2.52	2	0	cyclobutanes; quinolines
ly2109761 [no description available]	2.08	1	0
chir-265 [no description available]	2.52	2	0	aromatic ether
motesanib [no description available]	2.52	2	0	pyridinecarboxamide
fostamatinib fostamatinib: a spleen tyrosine kinase (Syk) inhibitor, metabolized to R406	5.8	8	0
az-628 AZ-628: a multikinase inhibitor; structure in first source	2.08	1	0	benzamides
4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine PF-670462 free base : A member of the class of imidazoles that is 1H-imidazole which is substituted at positions 1, 4, and 5 by cyclohexyl, p-fluorophenyl, and 2-aminopyrimidin-4-yl groups, respectively. It is a selective inhibitor of the delta- and epsilon-isoforms of casein kinase 1 (CK1delta and CK1epsilon).	3.25	1	0	aminopyrimidine; imidazoles; monofluorobenzenes	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
trametinib [no description available]	3.08	4	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
mln8054 [no description available]	2.15	1	0	benzazepine
pf-562,271 [no description available]	2.52	2	0	indoles
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.41	1	0	pyrrolopyridine
abexinostat abexinostat: structure in first source	2.13	1	0	benzofurans
jnj-26483327 JNJ-26483327: an orally active macrocyclic tyrosine kinase inhibitor for treatment of patients with advanced solid tumours; in Phase I trial, 9/2010	2.15	1	0
at 13387 (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone: structure in first source. onalespib : A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.	2.21	1	0	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor
ly2603618 [no description available]	2.15	1	0	ureas
veliparib [no description available]	2.08	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
ku-0060648 [no description available]	2.08	1	0	dibenzothiophenes
tg100801 [no description available]	2.15	1	0
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	3.4	6	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
bgt226 BGT226 free base : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor.. BGT226 : The maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor.	2.57	2	0	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine: a spleen tyrosine kinase (Syk) inhibitor; structure in first source	2.83	3	0
palomid 529 [no description available]	2.08	1	0
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	2.15	1	0
tosedostat [no description available]	2.08	1	0	carboxylic ester; hydroxamic acid; secondary carboxamide
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide [no description available]	2.41	1	0	organochlorine compound
mdv 3100 [no description available]	2.08	1	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
ku 60019 [no description available]	2.08	1	0
gsk 461364 GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1	2.52	2	0	(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source	2.08	1	0
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	2.15	1	0	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
nvp-tae684 [no description available]	2.08	1	0	piperidines
enmd 2076 ENMD 2076: an antiangiogenic agent with aurora kinase inhibitory and antineoplastic activities	2.15	1	0
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source	2.08	1	0
gsk 269962a [no description available]	2.08	1	0
e 7050 [no description available]	2.15	1	0	aromatic ether
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone [no description available]	2.15	1	0	pyrazolopyridine
tak-901 [no description available]	2.15	1	0
oligonucleotides [no description available]	2.07	1	0
ristocetin Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.	2.57	2	0	glycopeptide; heterodetic cyclic peptide; macrocycle; tetrasaccharide derivative	antibacterial drug; antimicrobial agent; bacterial metabolite; platelet-activating factor receptor agonist
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	2.25	1	0	glycoside
a-83-01 A-83-01: an ALK-5 inhibitor; structure in first source	2.08	1	0
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.08	1	0	indoles
vx-770 ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.	2.08	1	0	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug
gdc-0973 cobimetinib: has antineoplastic activity; structure in first source. cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma.	2.15	1	0	aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	6.48	4	1	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480 [no description available]	2.52	2	0
azd8330 [no description available]	2.63	2	0	pyridinecarboxamide
pha 848125 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide: a cyclin dependent kinase inhibitor	2.15	1	0
ro5126766 RO5126766: a dual MEK/RAF kinase inhibitor. CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3.	2.15	1	0	aryloxypyrimidine; coumarins; organofluorine compound; pyridines; sulfamides	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
tg101209 [no description available]	3.25	1	0	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	4.17	4	0	sulfonamide
gsk690693 [no description available]	2.52	2	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024 [no description available]	2.08	1	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
ku 0063794 Ku 0063794: an mTOR inhibitor; structure in first source	2.08	1	0	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.94	3	0
azd 7545 AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).	2.08	1	0	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
azd5438 [no description available]	2.15	1	0	sulfonamide
nutlin-3b [no description available]	2.08	1	0	Nutlin; piperazinone	anticoronaviral agent
pf 04217903 [no description available]	2.52	2	0	quinolines
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.52	2	0	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164 SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source	2.08	1	0	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent
chitosan [no description available]	2.25	1	0
icotinib [no description available]	2.15	1	0
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	2.52	2	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408 PHA 408: an IKK-2 antagonist; structure in first source	2.08	1	0
gsk 1016790a GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.	2.08	1	0	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist
kx-01 [no description available]	2.15	1	0
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	2.21	1	0
olaparib [no description available]	2.84	3	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
srt1720 [no description available]	2.08	1	0
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.08	1	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
mk 5108 [no description available]	2.15	1	0	aromatic ether
cx 4945 [no description available]	3.03	4	0
cudc 101 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source	2.52	2	0
arry-614 pexmetinib: inhibits both p38 mitogen-activated protein kinase and Tie2 protein	2.15	1	0
tak 593 TAK 593: structure in first source	2.15	1	0
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.52	2	0	benzazepine
lde225 sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.	2.08	1	0	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	2.08	1	0	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
sgx 523 [no description available]	2.52	2	0	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.15	1	0	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	2.52	2	0	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	2.52	2	0	imidazoles
ponatinib [no description available]	3.93	3	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
amg 900 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source	2.52	2	0
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.52	2	0	piperazines
cgi 1746 CGI 1746: inhibits Bruton's protein kinase (Btk); structure in first source	4.67	4	0
AMG-208 [no description available]	2.15	1	0	aromatic ether; quinolines; triazolopyridazine	antineoplastic agent; c-Met tyrosine kinase inhibitor
bag956 BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies	2.08	1	0
quizartinib [no description available]	3.08	4	0	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
at13148 [no description available]	2.15	1	0
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.08	1	0	carbamate ester
tak 733 [no description available]	2.52	2	0
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	3.24	5	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	3.6	2	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.52	2	0	ureas
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.08	1	0	benzodioxoles
lucitanib E-3810: a multi-kinase inhibitor with antineoplastic activity; structure in first source. E-3810 : A hydrochloride salt obtained by reaction of 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-N-methyl-1-naphthamide with one equivalent of hydrochloric acid. E-3810 is a dual VEGFR and FGFR inhibitor. E-3810 free base : A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.	2.15	1	0	aromatic ether; cyclopropanes; naphthalenecarboxamide; primary amino compound; quinolines	antineoplastic agent; fibroblast growth factor receptor antagonist; vascular endothelial growth factor receptor antagonist
pf-04691502 [no description available]	2.15	1	0
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.1	1	0	BODIPY compound
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	3.08	4	0	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.52	2	0	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	2.82	3	0	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
defactinib [no description available]	2.15	1	0
ly2584702 [no description available]	2.15	1	0
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide [no description available]	2.08	1	0	benzamides
incb-018424 [no description available]	9.23	15	1	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
poziotinib HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer	2.15	1	0	acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline	antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist
asp3026 ASP3026: an anaplastic lymphoma receptor tyrosine kinase inhibitor; structure in first source. ASP-3026 : A member of the class of diamino-1,3,5-triazines that is 1,3,5-triazine-2,4-diamine in which the amino groups at positions 2 and 4 are respectively carrying 2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl and 2-(propan-2-ylsulfonyl)phenyl substituents. It is a potent inhibitor of anaplastic lymphoma kinase (ALK), Ack and ROS1 activity (IC50 values are 3.5, 5.8 and 8.9 nM respectively) and exhibits anti-cancer properties.	2.15	1	0	aromatic amine; diamino-1,3,5-triazine; monomethoxybenzene; N-methylpiperazine; piperidines; secondary amino compound; sulfone	antimalarial; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
entrectinib entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.	2.15	1	0	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bix 01294 [no description available]	2.08	1	0	piperidines
pexidartinib pexidartinib: inhibits both CSF1R and c-kit receptor tyrosine kinase; structure in first source. pexidartinib : A pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT).	2.15	1	0	aminopyridine; organochlorine compound; organofluorine compound; pyrrolopyridine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
cobicistat [no description available]	2.31	1	0	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor
pf 3845 PF 3845: inhibits fatty acid amide hydrolase	2.08	1	0	piperidines
TAK-580 MLN 2480: brain-penetrant RAF dimer antagonist. TAK-580 : A 1,3-thiazolecarboxamide that is 2-[(1R)-1-aminoethyl]-1,3-thiazole-5-carboxylic acid in which the carboxy group undergoes formal condensation with the amino group of 5-chloro-4-(trifluoromethyl)pyridin-2-amine and in which the amino group undergoes formal condensation with the carboxy group of 6-amino-5-chloropyrimidine-4-carboxylic acid. It is a pan-RAF kinase inhibitor which is currently in clinical development for the treatment of radiographically recurrent or progressive low-grade glioma in children and young adults.	2.15	1	0	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.52	2	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
emd1214063 tepotinib: MET inhibitor	2.15	1	0
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.08	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
fit-039 FIT-039: CDK9 inhibitor; structure in first source	2.41	1	0
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.08	1	0	pyrimidines
pf 3758309 PF 3758309: a PAK4 p21-activated kinase inhibitor; structure in first source	2.15	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
gdc 0980 [no description available]	2.15	1	0
azd2014 vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source	2.86	3	0
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source	2.15	1	0	benzyl alcohols; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; apoptosis inducer; mTOR inhibitor
plx4032 [no description available]	4.85	5	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol [no description available]	2.08	1	0	biphenyls
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	2.52	2	0	aromatic ether
arry-334543 ARRY-334543: an antagonist of ATP-binding cassette subfamily G member 2 (ABCG2); structure in first source	2.15	1	0
kin-193 [no description available]	3.93	3	0	pyridopyrimidine
mk 2461 [no description available]	2.15	1	0
bay 869766 [no description available]	2.85	3	0
as 703026 [no description available]	2.15	1	0	pyridinecarboxamide
pf 04929113 [no description available]	2.31	1	0
ddd 85646 DDD 85646: a trypanocidal agent for treating African sleeping sickness; structure in first source	3.17	1	0
baricitinib [no description available]	4.25	4	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester WYE-354: an mTOR inhibitor; structure in first source	2.08	1	0	carbamate ester
piperidines Piperidines: A family of hexahydropyridines.	28.08	1,787	296
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	2.08	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.31	1	0
dabrafenib [no description available]	2.58	2	0	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor
anagliptin anagliptin: anagliptin hydrochloride salt is the active compound	3.51	1	0	amino acid amide
pki 587 gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source	2.15	1	0
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.08	1	0	benzenes; sulfonamide
cp 466722 [no description available]	2.08	1	0	quinazolines
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source	2.63	2	0
CAY10626 [no description available]	2.08	1	0	ureas
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide merestinib: in phase I clinical trials (2013); structure in first source	2.15	1	0
thiopental sodium [no description available]	5.12	7	0	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
pf 3644022 [no description available]	3.25	1	0
ribociclib ribociclib: inhibits both CDK4 and CDK6	3.71	2	0
mk-8033 1-(3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide: inhibits both Ron and c-Met kinases; structure in first source	2.15	1	0
pha 793887 [no description available]	2.52	2	0	piperidinecarboxamide
ly2784544 [no description available]	2.41	1	0	pyridazines
sb 1518 [no description available]	2.63	2	0
abemaciclib [no description available]	2.15	1	0
mk-8776 [no description available]	2.15	1	0
nvp-bsk805 [no description available]	2.08	1	0
afuresertib [no description available]	2.15	1	0	amphetamines
xmd 8-92 XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.	2.08	1	0	pyrimidobenzodiazepine	protein kinase inhibitor
gsk 1070916 GSK 1070916: an antineoplastic agent with aurora B/C kinase inhibitory activity	2.15	1	0	pyrazoles; ring assembly
jq1 compound [no description available]	2.08	1	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
rn486 RN486: a selective Bruton's tyrosine kinase inhibitor	4.12	2	0
jnj38877605 [no description available]	2.52	2	0	quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide [no description available]	2.08	1	0	benzothiazoles
dinaciclib [no description available]	4.88	5	0	pyrazolopyrimidine
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	2.63	2	0	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alectinib [no description available]	2.15	1	0	aromatic ketone; morpholines; nitrile; organic heterotetracyclic compound; piperidines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634 [no description available]	4.04	3	0
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	0	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
evacetrapib [no description available]	2.13	1	0	benzazepine
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	18.45	140	25	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ly2940680 [no description available]	2.08	1	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	2.08	1	0	ureas
ro 4929097 [no description available]	2.08	1	0	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor
LSM-6732 [no description available]	3.25	1	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound; tert-butyl ester
gsk4112 GSK4112: a Rev-erbalpha agonist; structure in first source	2.08	1	0
ipi-145 [no description available]	7.93	12	2	isoquinolines
delgocitinib delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.	2.41	1	0	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
encorafenib encorafenib: a BRAF inhibitor	2.15	1	0
bms-911543 N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide: has antineoplastic activity; structure in first source	2.15	1	0
gsk2141795 GSK2141795: an Akt inhibitor with antineoplastic activity; structure in first source	2.15	1	0
pf-670462 PF-670462: inhibitor of casein kinase I epsilon; structure in first source. PF-670462 : A hydrochloride salt resulting from the formal reaction of 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine with 2 mol eq. of hydrogen chloride. It is a selective inhibitor of the delta- and epsilon-isoforms of casein kinase 1 (CK1delta and CK1epsilon).	2.17	1	0	hydrochloride	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
torin 2 torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	3.96	3	0	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor
pf-4708671 [no description available]	2.08	1	0
azd8186 [no description available]	2.15	1	0
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	2.21	1	0	pyrimidinecarboxylic acid
incb039110 INCB039110: a JAK1 inhibitor; structure in first source	2.41	1	0
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.08	1	0	benzamides; N-acylpiperidine
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.	2.08	1	0	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
belinostat [no description available]	2.08	1	0	olefinic compound
pf 4800567 PF-4800567 : A pyrazolopyrimidine that is 1H-pyrazolo[3,4-d]pyrimidin-4-amine which is substituted at positions 1 and 3 by tetrahydro-2H-pyran-4-yl and (m-chlorophenoxy)methyl groups, respectively. It is a selective inhibitor of the epsilon isoform of casein kinase 1 (CK1epsilon).	3.25	1	0	aromatic ether; monochlorobenzenes; oxanes; pyrazolopyrimidine	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cudc-907 [no description available]	2.21	1	0
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	3.63	2	0	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source	2.08	1	0	carboxylic acid; pyrroline
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.98	3	0	benzenes; hydroxycoumarin; methyl ketone
lfm a13 LFM A13: inhibits Bruton's tyrosine kinase; structure in first source	3.74	3	0
a 769662 [no description available]	2.08	1	0	biphenyls
byl719 [no description available]	2.57	2	0	proline derivative
ent-crizotinib ent-crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that is the (S)-enantiomer of crizotinib.	3.25	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.13	1	0
cep-32496 agerafenib: inhibitor of RAF family kinases; structure in first source	2.15	1	0
LimKi 3 LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.	2.08	1	0	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone [no description available]	2.08	1	0	pyrroles
rociletinib rociletinib: inhibits epidermal growth factor receptor tyrosine kinase activity; structure in first source	2.84	3	0
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole [no description available]	2.08	1	0	dipyrrins
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	3.69	2	0	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide [no description available]	2.08	1	0	tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione [no description available]	2.08	1	0	pyrazines
gsk837149a GSK837149A: structure in first source	2.08	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide [no description available]	2.08	1	0	quinazolines
wnt-c59 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source	2.08	1	0
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime [no description available]	2.08	1	0	indanes
azd1208 [no description available]	2.15	1	0
cc-292 spebrutinib: inhibits Bruton's tyrosine kinase; structure in first source	5.24	13	0
vx-509 [no description available]	2.53	2	0
vx-970 berzosertib: an ATR kinase inhibitor	2.41	1	0	sulfonamide
gs-9973 [no description available]	2.25	1	0
debio 1347 CH5183284: a fibroblast growth factor receptor antagonist; structure in first source	2.15	1	0
gsk-2816126 GSK-2816126: inhibits EZH2 methyltransferase; structure in first source	2.21	1	0	piperazines; pyridines
volitinib [no description available]	2.15	1	0
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	16.17	78	10	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	2.21	1	0	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
selinexor selinexor: inhibits karyopherin XPO1	5.6	5	1
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	5.97	11	0	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
bmx-in-1 BMX-IN-1: a BMX tyrosine kinase inhibitor; structure in first source	2.15	1	0
cb-839 [no description available]	2.21	1	0
pf-06463922 lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein. lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.	3.35	1	0	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
9-(1-methyl-4-pyrazolyl)-1-[1-(1-oxoprop-2-enyl)-2,3-dihydroindol-6-yl]-2-benzo[h][1,6]naphthyridinone [no description available]	3.95	3	0	naphthyridine derivative
glutaminase [no description available]	2.72	2	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	3.04	4	0
onc201 TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source	2.21	1	0
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.41	1	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.11	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.63	2	0
at 9283 [no description available]	2.63	2	0
otssp167 OTS167: inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity	2.15	1	0
chir 258 [no description available]	2.52	2	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.21	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
osi 027 OSI 027: inhibits both mTORC1 and mTORC2; structure in first source	2.52	2	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.51	1	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.51	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.11	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
hli 373 [no description available]	2.08	1	0
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.65	2	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.08	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
da 8159 udenafil: a pyrazolo-pyrimidinone similar to sildenafil; phosphodiesterase type 5 inhibitor;	3.51	1	0	sulfonamide
xav939 XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.	2.08	1	0	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor
ag-879 AG-879: structure given in first source	2.41	1	0
2-carboxyarabinitol 1-phosphate [no description available]	2.08	1	0
hesperadin [no description available]	2.41	1	0
trypan blue Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).	2.1	1	0
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	3.07	4	0
amg531 [no description available]	2.41	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.08	1	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
sb-590885 N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.	2.08	1	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
pf-477736 PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).	2.08	1	0
bay 80-6946 copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.	6.29	3	1
pp242 torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	3.25	1	0	aromatic amine; biaryl; hydroxyindoles; phenols; primary amino compound; pyrazolopyrimidine	antineoplastic agent; mTOR inhibitor
fenobam fenobam: in USAN fenobam refers to monohydrate	2.08	1	0	ureas
cyanine dye 3 cyanine dye 3: structures of Cy3 derivatives given in first source	2.41	1	0
lipoteichoic acid lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.	2.21	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.21	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Rheumatoid Arthritis [description not available]	0	4.63	9	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	14.8	75	26
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	4.63	9	0
Innate Inflammatory Response [description not available]	0	7.55	14	1
B-Cell Leukemia [description not available]	0	6.91	10	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.55	14	1
B-Cell Lymphoma [description not available]	0	16.01	80	11
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	16.01	80	11
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	12.75	33	5
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	1	14.75	33	5
Acute Myelogenous Leukemia [description not available]	0	10.95	26	11
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1	12.95	26	11
Recrudescence [description not available]	0	20.65	192	114
Bilateral Headache [description not available]	0	7.55	4	4
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	27.28	1,189	348
Chromosome Deletion Actual loss of portion of a chromosome.	0	13.83	35	9
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	19.34	115	107
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	7.55	4	4
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	1	29.28	1,189	348
Leucocythaemia [description not available]	0	11.82	17	9
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1	13.82	17	9
Acute Lymphoid Leukemia [description not available]	0	6.65	6	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	1	8.65	6	1
Carcinoma, Non-Small Cell Lung [description not available]	0	4.85	11	0
Cancer of Lung [description not available]	0	6.72	18	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	1	6.85	11	0
Lung Neoplasms Tumors or cancer of the LUNG.	1	8.72	18	1
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	21.41	283	77
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	1	23.41	283	77
Benign Neoplasms [description not available]	0	10.67	33	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	15.1	66	4
Experimental Neoplasms [description not available]	0	5.51	8	0
Diffuse Large B-Cell Lymphoma [description not available]	0	18.51	145	34
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	1	20.51	145	34
Adjuvant Arthritis [description not available]	0	5.46	8	0
Libman-Sacks Disease [description not available]	0	4.14	5	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	4.14	5	0
Koch's Disease [description not available]	0	2.61	2	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	2.61	2	0
Cancer of Pancreas [description not available]	0	7.71	11	5
Carcinoma, Ductal, Pancreatic [description not available]	0	4.07	2	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	7.71	11	5
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	0	4.07	2	1
Germinoblastoma [description not available]	0	11.87	31	3
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1	13.87	31	3
Cryptogenic Fibrosing Alveolitis [description not available]	0	2.61	2	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	0	2.61	2	0
Blood Clot [description not available]	0	5.11	8	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	5.11	8	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
2019 Novel Coronavirus Disease [description not available]	0	8.95	21	2
Viral Diseases [description not available]	0	3.04	3	0
Virus Diseases A general term for diseases caused by viruses.	0	3.04	3	0
Autoimmune Disease [description not available]	0	10.23	15	3
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	10.23	15	3
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	9.93	12	5
Graft-Versus-Host Disease [description not available]	0	14.12	34	15
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	1	16.12	34	15
Familial Waldenstrom's Macroglobulinaemia [description not available]	0	17.88	131	20
Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.	1	22.62	262	40
Acquired Autoimmune Hemolytic Anemia [description not available]	0	8.62	21	0
Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.	1	10.62	21	0
Infection [description not available]	0	16.57	46	32
Lymphocytopenia [description not available]	0	5.48	4	1
Duncan Disease [description not available]	0	5.91	14	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	16.57	46	32
Lymphopenia Reduction in the number of lymphocytes.	0	5.48	4	1
Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified.	0	5.91	14	0
Abnormalities, Autosome [description not available]	0	5.52	7	2
Cerebral Ischemia [description not available]	0	2.76	2	0
Alloxan Diabetes [description not available]	0	2.31	1	0
Injury, Ischemia-Reperfusion [description not available]	0	2.69	2	0
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	2.76	2	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	2.69	2	0
Allergic Rhinitis [description not available]	0	2.41	1	0
Nasal Catarrh [description not available]	0	2.41	1	0
Rhinitis Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.	0	2.41	1	0
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	0	2.41	1	0
Ambulation Disorders, Neurologic [description not available]	0	3.23	1	0
Autoimmune Disease Models, Nervous System [description not available]	0	3.23	1	0
Gammapathy, Monoclonal [description not available]	0	3.23	1	0
Autoimmune Demyelinating Disease, Peripheral [description not available]	0	3.23	1	0
Autoimmune Demyelinating Diseases, Central Nervous System [description not available]	0	3.23	1	0
Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.	0	3.23	1	0
Cancer of Mediastinum [description not available]	0	2.41	1	0
Central Nervous System Neoplasm [description not available]	0	10.37	30	3
Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM.	0	2.41	1	0
Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.	0	10.37	30	3
Minimal Disease, Residual [description not available]	0	13.71	38	19
Local Neoplasm Recurrence [description not available]	0	18.7	143	56
Dysplastic Nevus Syndrome, Hereditary [description not available]	0	5.02	2	1
Malignant Melanoma [description not available]	0	5.6	4	1
Cancer of Skin [description not available]	0	6.13	9	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1	9.22	8	2
Skin Neoplasms Tumors or cancer of the SKIN.	0	6.13	9	1
Lung Injury, Acute [description not available]	0	4.25	12	0
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	0	2.41	1	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	0	4.25	12	0
Arrhythmia [description not available]	0	5.13	5	0
Auricular Fibrillation [description not available]	0	18.41	92	36
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	0	5.13	5	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	18.41	92	36
Dermatitis Medicamentosa [description not available]	0	6.62	9	1
Disease Exacerbation [description not available]	0	15.84	89	19
Brill-Symmers Disease [description not available]	0	12.03	20	10
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	1	16.59	40	20
Congenital Immunodeficiency Disease [description not available]	0	4.07	2	1
Primary Immunodeficiency Diseases Genetic immunologic deficiency diseases and syndromes due to mutations in genes involved in IMMUNITY generally characterized by an increased susceptibility to infectious diseases. They are often associated with AUTOIMMUNE DISEASE manifestations.	0	4.07	2	1
Bleb [description not available]	0	2.41	1	0
Bleeding [description not available]	0	17.45	73	29
Petechiae Pinhead size (3 mm) skin discolorization due to hemorrhage.	0	2.41	1	0
Infections, Staphylococcal [description not available]	0	2.41	1	0
Hemorrhage Bleeding or escape of blood from a vessel.	0	17.45	73	29
Purpura Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is	0	2.41	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	2.41	1	0
Disseminated Fungal Infection [description not available]	0	5.36	17	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	0	2.31	1	0
Chylopericardium [description not available]	0	2.41	1	0
Cardiac Tamponade Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.	0	2.76	2	0
Pericardial Effusion Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.	0	2.41	1	0
Thrombocytopathy [description not available]	0	2.31	1	0
Blood Platelet Disorders Disorders caused by abnormalities in platelet count or function.	0	2.31	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.31	1	0
Injuries, Spinal Cord [description not available]	0	2.31	1	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	0	2.31	1	0
Cardiac Failure [description not available]	0	4.06	4	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	0	4.06	4	0
Encephalitis, JC Polyomavirus [description not available]	0	4.4	6	0
Leukoencephalopathy, Progressive Multifocal An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7)	0	4.4	6	0
Kahler Disease [description not available]	0	10.28	18	4
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	1	12.28	18	4
Thrombopenia [description not available]	0	9.72	14	4
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	9.72	14	4
C gattii Infection [description not available]	0	4.73	9	0
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	0	4.73	9	0
Aplasia Pure Red Cell [description not available]	0	3.58	6	0
Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.	0	3.58	6	0
Chronic Hepatitis B [description not available]	0	2.41	1	0
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	0	2.41	1	0
Joint Pain [description not available]	0	6.25	4	1
Muscle Pain [description not available]	0	5.25	3	1
Arthralgia Pain in the joint.	0	6.25	4	1
Musculoskeletal Pain Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.	0	3.8	1	1
Myalgia Painful sensation in the muscles.	0	5.25	3	1
Constriction, Pathological [description not available]	0	2.41	1	0
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	0	2.41	1	0
Aspergillus Infection [description not available]	0	7.64	17	1
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	0	7.64	17	1
Campylobacter Infection [description not available]	0	2.41	1	0
Granuloma, Hodgkin [description not available]	0	5.2	9	1
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	1	8.4	18	2
Apoplexy [description not available]	0	6.05	8	1
Acute Ischemic Stroke [description not available]	0	2.41	1	0
Brain Hemorrhage, Cerebral [description not available]	0	2.41	1	0
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	0	2.41	1	0
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	0	2.41	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	6.05	8	1
Cardiac Toxicity [description not available]	0	5.77	8	0
Blood Pressure, High [description not available]	0	16.53	52	33
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	16.53	52	33
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	5.77	8	0
Cancer of Esophagus [description not available]	0	2.76	2	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	1	4.76	2	0
Breast Cancer [description not available]	0	4.98	7	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1	6.98	7	0
Cerebral Nocardiosis [description not available]	0	2.41	1	0
Exanthem [description not available]	0	5.54	9	0
Hives [description not available]	0	2.41	1	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	5.54	9	0
Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.	0	2.41	1	0
Schnitzler Syndrome An extremely rare condition manifested as monoclonal IMMUNOGLOBULIN M dysproteinemia without features of lymphoproliferative disease, but with chronic urticaria, fever of unknown origin, disabling bone pain, hyperostosis, and increased erythrocyte sedimentation rate.	0	3.2	4	0
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	0	3.33	1	0
Lymphoma of Mucosa-Associated Lymphoid Tissue [description not available]	0	9.36	10	4
Lymphoma, B-Cell, Marginal Zone Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.	1	11.36	10	4
DDD MPGNII [description not available]	0	2.41	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	2.66	2	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	0	2.76	2	0
Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.	0	2.41	1	0
Tumour Lysis Syndrome [description not available]	0	4.35	6	0
Tumor Lysis Syndrome A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.	0	4.35	6	0
Cancer of Rectum [description not available]	0	2.41	1	0
Colorectal Cancer [description not available]	0	5.67	4	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	0	2.41	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1	7.67	4	1
Acute Symptom Flare [description not available]	0	2.72	2	0
Hematologic Malignancies [description not available]	0	13.72	34	14
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	1	15.72	34	14
Blood Diseases [description not available]	0	11.47	18	10
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	11.47	18	10
Lassitude [description not available]	0	17.82	108	102
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	0	17.82	108	102
Adenopathy [description not available]	0	2.66	2	0
Lymphocytosis Excess of normal lymphocytes in the blood or in any effusion.	0	9.63	17	2
Leishmania Infection [description not available]	0	2.41	1	0
Black Fever [description not available]	0	2.69	2	0
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	0	2.41	1	0
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	0	2.69	2	0
Anaphylactic Reaction [description not available]	0	2.6	1	0
Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.	1	4.6	1	0
Cardiac Arrest, Sudden [description not available]	0	4.76	3	0
Atrioventricular Nodal Re-Entrant Tachycardia [description not available]	0	4.68	5	0
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	0	4.76	3	0
Tachycardia, Ventricular An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).	0	4.68	5	0
Blood Poisoning [description not available]	0	4.3	13	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	4.3	13	0
Primary Peritonitis [description not available]	0	4.02	9	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	0	4.02	9	0
Glial Cell Tumors [description not available]	0	4.27	13	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	4.27	13	0
Benign Neoplasms, Brain [description not available]	0	6.69	16	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	6.69	16	0
Autoimmune Thrombocytopenia [description not available]	0	6.97	10	0
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	0	6.97	10	0
Cardiac Diseases [description not available]	0	8.5	7	5
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	8.5	7	5
Congestive Ophthalmopathy [description not available]	0	3.33	4	0
Graves Ophthalmopathy An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.	0	3.33	4	0
Angiohemophilia [description not available]	0	3.33	4	0
von Willebrand Diseases Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.	0	3.33	4	0
Complication, Postoperative [description not available]	0	3.53	2	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	3.53	2	0
Adenocarcinoma, Basal Cell [description not available]	0	6.18	5	2
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	6.18	5	2
Cirrhosis [description not available]	0	2.93	3	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	2.93	3	0
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	0	2.6	1	0
Phlegmon [description not available]	0	3.68	2	0
Infections, Helicobacter [description not available]	0	2.6	1	0
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	0	3.68	2	0
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	0	2.6	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	0	2.6	1	0
Chronic Illness [description not available]	0	13.46	26	13
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	13.46	26	13
Hepatitis INFLAMMATION of the LIVER.	0	2.6	1	0
Cancer of the Retina [description not available]	0	5.31	3	1
Extravascular Hemolysis [description not available]	0	2.6	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.6	1	0
Mucorales Infection [description not available]	0	4.08	4	0
Mucormycosis Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION.	0	4.08	4	0
Hepatitis B Virus Infection [description not available]	0	5.07	8	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	0	5.07	8	1
Great Pox [description not available]	0	2.6	1	0
HIV Coinfection [description not available]	0	2.89	3	0
Syphilis A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.	0	2.6	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	0	2.89	3	0
Adenocarcinoma Of Kidney [description not available]	0	3.99	1	1
Cancer of Kidney [description not available]	0	3.99	1	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	1	5.99	1	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	3.99	1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	14.55	37	31
Pneumonia Infection of the lung often accompanied by inflammation.	0	14.55	37	31
Erythrophagocytic Lymphohistiocytosis, Familial [description not available]	0	3.5	2	0
Lymphohistiocytosis, Hemophagocytic A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.	0	3.5	2	0
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	0	3.12	1	0
Emesis [description not available]	0	3.12	1	0
Colicky Pain [description not available]	0	3.12	1	0
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	0	3.12	1	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	3.12	1	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	0	3.12	1	0
Abnormal Karyotype A variation from the normal set of chromosomes characteristic of a species.	0	3.11	4	0
Symptom Cluster [description not available]	0	6.03	16	0
Syndrome A characteristic symptom complex.	0	6.03	16	0
Angiitis [description not available]	0	2.63	2	0
Cryoglobulinemia A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas.	0	2.61	2	0
Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.	0	2.63	2	0
Cancer of Eye [description not available]	0	2.66	2	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	15.59	71	63
Hepatocellular Carcinoma [description not available]	0	2.61	2	0
Cancer of Liver [description not available]	0	2.61	2	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.61	2	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.61	2	0
Adverse Drug Event [description not available]	0	9.35	12	2
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	9.35	12	2
Cardiomyopathies, Primary [description not available]	0	2.63	2	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	0	2.63	2	0
Thyroid Nodule A small circumscribed mass in the THYROID GLAND that can be of neoplastic growth or non-neoplastic abnormality. It lacks a well-defined capsule or glandular architecture. Thyroid nodules are often benign but can be malignant. The growth of nodules can lead to a multinodular goiter (GOITER, NODULAR).	0	2.21	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	0	2.25	1	0
Mouth Ulcer [description not available]	0	2.25	1	0
Oral Ulcer A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)	0	2.25	1	0
Diabetic Feet [description not available]	0	2.21	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	0	2.21	1	0
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	0	2.21	1	0
Arteriosclerosis, Coronary [description not available]	0	2.21	1	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	0	2.21	1	0
Discitis Inflammation of an INTERVERTEBRAL DISC or disk space which may lead to disk erosion. Until recently, discitis has been defined as a nonbacterial inflammation and has been attributed to aseptic processes (e.g., chemical reaction to an injected substance). However, recent studies provide evidence that infection may be the initial cause, but perhaps not the promoter, of most cases of discitis. Discitis has been diagnosed in patients following discography, myelography, lumbar puncture, paravertebral injection, and obstetrical epidural anesthesia. Discitis following chemonucleolysis (especially with chymopapain) is attributed to chemical reaction by some and to introduction of microorganisms by others.	0	2.25	1	0
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	0	2.21	1	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	0	2.21	1	0
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	0	2.21	1	0
Carcinomatous Meningitis [description not available]	0	3.55	2	0
Meningeal Carcinomatosis Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.	0	3.55	2	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	7.02	15	1
Hepatic Failure [description not available]	0	2.25	1	0
Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)	0	2.25	1	0
B-Cell Prolymphocytic Leukemia [description not available]	0	3.32	5	0
Leukemia, Prolymphocytic, B-Cell A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.	0	3.32	5	0
Palmoplantaris Pustulosis [description not available]	0	2.66	2	0
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	0	2.66	2	0
Fungal Lung Diseases [description not available]	0	3.51	2	0
Metastase [description not available]	0	4.99	2	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	4.99	2	1
Polyneuropathy, Acquired [description not available]	0	2.66	2	0
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	0	2.66	2	0
Leukemia, Pre-B-Cell [description not available]	0	2.59	2	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	2.59	2	0
Central Nervous System Infection [description not available]	0	2.25	1	0
17p11.2 Monosomy [description not available]	0	7.79	11	1
Smith-Magenis Syndrome Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.	0	7.79	11	1
Carcinoma, Squamous Cell of Head and Neck [description not available]	0	2.25	1	0
Cancer of Head [description not available]	0	2.25	1	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	0	2.25	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	2.25	1	0
Leukemia, Lymphocytic [description not available]	0	2.83	3	0
Bacterial Infections, Gram-Negative [description not available]	0	2.25	1	0
Bacterial Meningitides [description not available]	0	2.59	2	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	1	4.83	3	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	2.25	1	0
Meningitis, Bacterial Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.	0	2.59	2	0
Dermatosclerosis [description not available]	0	2.31	1	0
Scleroderma, Localized A term used to describe a variety of localized asymmetrical SKIN thickening that is similar to those of SYSTEMIC SCLERODERMA but without the disease features in the multiple internal organs and BLOOD VESSELS. Lesions may be characterized as patches or plaques (morphea), bands (linear), or nodules.	0	2.31	1	0
Sclerosis, Systemic [description not available]	0	2.25	1	0
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	0	2.25	1	0
Leukokeratosis Leukoplakic lesions related to abnormal keratin fiber formation.	0	2.25	1	0
Leukoplakia A white patch lesion found on a MUCOUS MEMBRANE that cannot be scraped off. Leukoplakia is generally considered a precancerous condition, however its appearance may also result from a variety of HEREDITARY DISEASES.	0	2.25	1	0
Autoimmune Diseases of the Nervous System Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME).	0	2.25	1	0
Infections, Coronavirus [description not available]	0	6.06	8	1
Chronic Lung Injury [description not available]	0	2.25	1	0
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	0	6.06	8	1
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	0	6.06	8	1
Granulocytic Leukemia [description not available]	0	2.25	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	2.25	1	0
EBV Infections [description not available]	0	5.39	4	1
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	5.39	4	1
Fungal Diseases [description not available]	0	5.02	7	0
Mycoses Diseases caused by FUNGI.	0	5.02	7	0
Disseminated Fusariosis [description not available]	0	3.51	2	0
Fusariosis OPPORTUNISTIC INFECTIONS with the soil fungus FUSARIUM. Typically the infection is limited to the nail plate (ONYCHOMYCOSIS). The infection can however become systemic especially in an IMMUNOCOMPROMISED HOST (e.g., NEUTROPENIA) and results in cutaneous and subcutaneous lesions, fever, KERATITIS, and pulmonary infections.	0	3.51	2	0
Diathesis [description not available]	0	5.91	5	0
Sarcoma, Epithelioid [description not available]	0	2.25	1	0
Cancer, Second Primary [description not available]	0	4.22	5	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	2.25	1	0
Female Genital Neoplasms [description not available]	0	3.17	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	0	3.17	1	0
Cerebral Cryptococcosis [description not available]	0	2.25	1	0
Meningitis, Cryptococcal Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)	0	2.25	1	0
Ecchymosis Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.	0	3.17	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	3.6	2	0
Leukemia, Lymphocytic, Chronic, T Cell [description not available]	0	2.57	2	0
Leukemia, Prolymphocytic, T-Cell A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.	1	4.57	2	0
Acute Kidney Failure [description not available]	0	4.3	5	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	4.3	5	0
Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.	0	2.85	3	0
Chromosomal Translocation [description not available]	0	3.06	4	0
Skin Diseases, Vascular Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.	0	2.25	1	0
Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)	0	4.55	1	1
Angiogranuloma [description not available]	0	2.25	1	0
Enterovirus Infections Diseases caused by ENTEROVIRUS.	0	2.25	1	0
Dysmyelopoietic Syndromes [description not available]	0	3.64	1	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	1	5.64	1	1
Orphan Diseases Rare diseases that have not been well studied.	0	3.17	1	0
Hairy Cell Leukemia [description not available]	0	7.24	7	1
Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.	1	9.24	7	1
Plasmablastic Diffuse Large B-cell Lymphoma [description not available]	0	2.69	2	0
Histiocytosis General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: HISTIOCYTOSIS, LANGERHANS CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; and HISTIOCYTIC DISORDERS, MALIGNANT.	0	2.31	1	0
Infections, Pseudomonas [description not available]	0	2.72	2	0
Infections, Staphylococcal Skin [description not available]	0	2.31	1	0
Ecthyma An ulcerative pyoderma usually caused by group A beta-hemolytic streptococcal infection at the site of minor trauma. (Dorland, 27th ed)	0	4.13	4	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	2.72	2	0
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	0	2.31	1	0
Bacterial Disease [description not available]	0	2.9	3	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	0	6.21	10	1
Bacterial Infections Infections by bacteria, general or unspecified.	0	2.9	3	0
Enterobiasis Infection with nematodes of the genus ENTEROBIUS; E. vermicularis, the pinworm of man, causes a crawling sensation and pruritus. This condition results in scratching the area, occasionally causing scarification.	0	2.25	1	0
Dysphagia [description not available]	0	2.31	1	0
Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.	0	2.31	1	0
Diabetic Glomerulosclerosis [description not available]	0	2.63	2	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	0	2.63	2	0
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	0	2.31	1	0
Combined Immunodeficiency, X-Linked [description not available]	0	2.25	1	0
MODS [description not available]	0	2.63	2	0
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	0	2.63	2	0
X-Linked Combined Immunodeficiency Diseases Forms of combined immunodeficiency caused by mutations in the gene for INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT. Both severe and non-severe subtypes of the disease have been identified.	0	2.25	1	0
Depression, Involutional Form of depression in those MIDDLE AGE with feelings of ANXIETY.	0	2.31	1	0
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.31	1	0
Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)	0	2.31	1	0
Antibody Deficiency Syndrome [description not available]	0	2.25	1	0
Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.	0	2.25	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.88	3	0
Health Care Associated Infection [description not available]	0	2.31	1	0
Cross Infection Any infection which a patient contracts in a health-care institution.	0	2.31	1	0
Cholera Infantum [description not available]	0	6.91	4	2
Central Nervous System Disease [description not available]	0	4	4	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	0	4	4	0
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	0	3.17	1	0
Brain Hemorrhage [description not available]	0	2.41	1	0
Intracranial Hemorrhages Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.	0	2.41	1	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	2.31	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.31	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	2.31	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.31	1	0
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	0	3.07	3	0
Paronychia An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)	0	2.31	1	0
Interstitial Nephritis [description not available]	0	2.31	1	0
Prolymphocytic Leukemia [description not available]	0	2.9	3	0
Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.	0	2.31	1	0
Leukemia, Prolymphocytic A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.	1	4.9	3	0
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	0	2.31	1	0
Congenital Familial Lymphedema [description not available]	0	2.31	1	0
Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes.	0	2.31	1	0
Hypogammaglobulinemia [description not available]	0	4.8	6	0
Agammaglobulinemia An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.	0	4.8	6	0
Eye Disorders [description not available]	0	2.31	1	0
Ache [description not available]	0	2.31	1	0
Day Blindness [description not available]	0	2.76	2	0
Eye Diseases Diseases affecting the eye.	0	2.31	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	2.31	1	0
Eye Pain A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.	0	2.31	1	0
Splenic Rupture Rupture of the SPLEEN due to trauma or disease.	0	2.89	3	0
Amyloid Deposits [description not available]	0	2.31	1	0
Acute Confusional Senile Dementia [description not available]	0	2.66	2	0
Astrocytosis [description not available]	0	2.31	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.66	2	0
Hyphema Bleeding in the anterior chamber of the eye.	0	2.41	1	0
Uveitis, Anterior Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.	0	2.41	1	0
Brain Disorders [description not available]	0	3.32	5	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	3.32	5	0
Invasiveness, Neoplasm [description not available]	0	2.61	2	0
Allergy, Drug [description not available]	0	2.31	1	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	2.31	1	0
Peripheral Nerve Diseases [description not available]	0	2.31	1	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	2.31	1	0
HbS Disease [description not available]	0	2.31	1	0
Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.	0	2.31	1	0
Skin Ulcer An ULCER of the skin and underlying tissues.	0	2.31	1	0
Idiopathic Inflammatory Myopathies [description not available]	0	3.64	2	0
Myositis Inflammation of a muscle or muscle tissue.	0	3.64	2	0
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	0	2.31	1	0
Bradyarrhythmia [description not available]	0	2.31	1	0
Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.	0	2.31	1	0
Dermatoses [description not available]	0	2.31	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.31	1	0
Panuveitis Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.	0	2.31	1	0
Rhabdomyolysis Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.	0	2.31	1	0
Lung Adenocarcinoma [description not available]	0	2.59	2	0
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	0	2.59	2	0
Atopic Hypersensitivity [description not available]	0	2.31	1	0
Cyanosis A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.	0	2.31	1	0
Chylothorax The presence of chyle in the thoracic cavity. (Dorland, 27th ed)	0	2.63	2	0
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	0	2.41	1	0
Cytomegalic Inclusion Disease [description not available]	0	2.31	1	0
Viremia The presence of viruses in the blood.	0	2.31	1	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	0	2.31	1	0
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	0	2.31	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	6.23	2	1
African Lymphoma [description not available]	0	3.77	3	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	1	5.77	3	0
Condition, Preneoplastic [description not available]	0	2.15	1	0
Cancer of Spleen [description not available]	0	4.39	2	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	0	2.15	1	0
Leukemia, Acute Monocytic [description not available]	0	2.15	1	0
T-Cell Lymphoma [description not available]	0	6.3	4	1
Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.	0	2.15	1	0
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	0	6.3	4	1
Chronic Kidney Failure [description not available]	0	2.15	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	2.15	1	0
Cerebromeningitis [description not available]	0	2.15	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	2.57	2	0
Experimental Hepatoma [description not available]	0	2.15	1	0
Tachyarrhythmia [description not available]	0	2.15	1	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	0	2.15	1	0
Acute Hepatic Failure [description not available]	0	2.17	1	0
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	0	2.17	1	0
Infectious Diseases [description not available]	0	3.5	2	0
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	0	3.5	2	0
Blood Loss, Postoperative [description not available]	0	2.15	1	0
Astrocytoma, Grade IV [description not available]	0	3.77	3	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1	5.77	3	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	2.17	1	0
Drug Withdrawal Symptoms [description not available]	0	2.58	2	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	0	2.58	2	0
P carinii Pneumonia [description not available]	0	7.9	6	4
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	0	7.9	6	4
Ritter Disease [description not available]	0	2.17	1	0
Coin Lesion, Pulmonary [description not available]	0	2.15	1	0
Flank Pain Pain emanating from below the RIBS and above the ILIUM.	0	2.17	1	0
Inflammation, Perinephrium [description not available]	0	2.17	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.17	1	0
Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.	0	2.17	1	0
Cold Panniculitis [description not available]	0	2.54	2	0
Sinus Infections [description not available]	0	2.87	3	0
Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.	0	2.87	3	0
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	1	4.17	1	0
Autoimmune Diabetes [description not available]	0	3.5	2	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	0	3.5	2	0
Allergy, Peanut [description not available]	0	3.09	1	0
Allergy, Nut [description not available]	0	3.09	1	0
Peanut Hypersensitivity Allergic reaction to peanuts that is triggered by the immune system.	0	3.09	1	0
Nut Hypersensitivity Allergic reaction to tree nuts that is triggered by the immune system.	0	3.09	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	14.05	30	28
Aspergillosis, Nervous System Invasive [description not available]	0	2.89	3	0
Neuroaspergillosis Infections of the nervous system caused by fungi of the genus ASPERGILLUS, most commonly ASPERGILLUS FUMIGATUS. Aspergillus infections may occur in immunocompetent hosts, but are more prevalent in individuals with IMMUNOLOGIC DEFICIENCY SYNDROMES. The organism may spread to the nervous system from focal infections in the lung, mastoid region, sinuses, inner ear, bones, eyes, gastrointestinal tract, and heart. Sinus infections may be locally invasive and enter the intracranial compartment, producing MENINGITIS, FUNGAL; cranial neuropathies; and abscesses in the frontal lobes of the brain. (From Joynt, Clinical Neurology, 1998, Ch 27, pp62-3)	0	2.89	3	0
Allergic Bronchopulmonary Mycosis [description not available]	0	2.17	1	0
Central Nervous System Fungal Infections MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME).	0	2.17	1	0
Acute Febrile Neutrophilic Dermatosis [description not available]	0	2.17	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	0	3.79	3	0
Genetic Predisposition [description not available]	0	4.15	5	0
Infections, Orthomyxoviridae [description not available]	0	2.17	1	0
Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE.	0	2.17	1	0
Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.	0	2.57	2	0
Pemphigus Foliaceus [description not available]	0	2.57	2	0
Pemphigus Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.	0	2.57	2	0
Alveolitis, Fibrosing [description not available]	0	2.17	1	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	0	2.17	1	0
Atheroma [description not available]	0	2.17	1	0
Bacterial Skin Diseases [description not available]	0	2.17	1	0
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	2.17	1	0
Cutaneous T-Cell Lymphoma [description not available]	0	4.48	1	1
Lymphoma, T Cell, Peripheral [description not available]	0	4.9	2	1
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	0	4.48	1	1
Lymphoma, T-Cell, Peripheral A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.	0	4.9	2	1
Polyarthritis [description not available]	0	2.21	1	0
Arthritis Acute or chronic inflammation of JOINTS.	0	2.21	1	0
Infectious Myelitis [description not available]	0	2.21	1	0
Genome Instability [description not available]	0	2.87	3	0
Lymph Node Metastasis [description not available]	0	2.17	1	0
Neutrophilic Leukemia, Chronic [description not available]	0	2.21	1	0
Leukemia, Neutrophilic, Chronic A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).	0	2.21	1	0
Eosinophilia, Tropical [description not available]	0	2.17	1	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	0	2.17	1	0
Androgen-Independent Prostatic Cancer [description not available]	0	2.17	1	0
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	1	4.17	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.17	1	0
Empyema, Thoracic [description not available]	0	3.09	1	0
Empyema, Pleural Suppurative inflammation of the pleural space.	0	3.09	1	0
Genetic Diseases, X-Chromosome Linked [description not available]	0	4.22	3	0
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	0	14.64	50	49
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	0	2.21	1	0
Neoplasms, Plasma Cell Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.	0	3.09	1	0
Central Retinal Edema, Cystoid [description not available]	0	2.21	1	0
Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)	0	2.21	1	0
Superior Vena Cava Obstruction [description not available]	0	2.21	1	0
Central Venous Catheter Thrombosis [description not available]	0	2.21	1	0
Mucositis, Oral [description not available]	0	2.21	1	0
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	0	2.21	1	0
Intraocular Pressure The pressure of the fluids in the eye.	0	3.09	1	0
Iris Neoplasms Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.	0	2.17	1	0
Hemorrhagic Proctocolitis [description not available]	0	2.21	1	0
Colonic Polyps Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.	0	2.21	1	0
Proctocolitis Inflammation of the RECTUM and the distal portion of the COLON.	0	2.21	1	0
Retinal Pigment Epithelial Detachment [description not available]	0	2.31	1	0
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	0	2.31	1	0
Enterically-Transmitted Non-A, Non-B Hepatitis [description not available]	0	2.21	1	0
Hepatitis E Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.	0	2.21	1	0
Hyperplasia, Reactive Lymphoid [description not available]	0	2.21	1	0
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	0	2.21	1	0
Serositis Inflammation of a serous membrane.	0	2.21	1	0
Pyoderma Gangrenosum An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.	0	2.58	2	0
Chicken Pox [description not available]	0	2.21	1	0
Pyrexia [description not available]	0	2.58	2	0
Chickenpox A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)	0	2.21	1	0
Dermatitis Any inflammation of the skin.	0	2.21	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	0	2.58	2	0
Bronchiolitis, Exudative [description not available]	0	2.21	1	0
Bronchiolitis Obliterans Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.	0	2.21	1	0
Cytokine Release Syndrome A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.	0	4.51	1	1
Atrial Remodeling Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.	0	2.21	1	0
Hand Dermatosis [description not available]	0	2.21	1	0
Foot Dermatoses Skin diseases of the foot, general or unspecified.	0	2.21	1	0
Hand Dermatoses Skin diseases involving the HANDS.	0	2.21	1	0
Late Onset Diseases [description not available]	0	2.25	1	0
Left Ventricular Dysfunction [description not available]	0	2.25	1	0
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	0	2.25	1	0
Cancer of Gastrointestinal Tract [description not available]	0	4.94	2	1
Auricular Flutter [description not available]	0	2.21	1	0
Atrial Flutter Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).	0	2.21	1	0
Degenerative Diseases, Central Nervous System [description not available]	0	2.21	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	0	2.21	1	0
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	0	2.21	1	0
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	0	2.21	1	0
Benign Mastocytoma [description not available]	0	2.21	1	0
Canine Diseases [description not available]	0	2.21	1	0
Multiple Primary Neoplasms [description not available]	0	2.21	1	0
Argentaffinoma [description not available]	0	3.64	1	1
Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)	1	5.64	1	1
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	0	3.64	1	1
Itching [description not available]	0	2.21	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	0	2.21	1	0
Infections, Listeria [description not available]	0	9.7	9	9
Leishmaniasis, American [description not available]	0	9.7	9	9
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	0	9.7	9	9
Bone Loss, Osteoclastic [description not available]	0	2.1	1	0
Age-Related Osteoporosis [description not available]	0	2.1	1	0
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	0	2.1	1	0
Cells, Neoplasm Circulating [description not available]	0	4.81	2	1
Chromosomal Triplication [description not available]	0	2.11	1	0
Tuberculosis, Miliary An acute form of TUBERCULOSIS in which minute tubercles are formed in a number of organs of the body due to dissemination of the bacilli through the blood stream.	0	2.11	1	0
Cancer of Ovary [description not available]	0	2.11	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.11	1	0
Blast Phase [description not available]	0	2.11	1	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	0	2.11	1	0
Coccidioides immitis Infection [description not available]	0	3.03	1	0
Coccidioidomycosis Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN.	0	3.03	1	0
Cancer of Prostate [description not available]	0	2.11	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.11	1	0
Choked Disk [description not available]	0	2.13	1	0
Papilledema Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronic papilledema may cause OPTIC ATROPHY and visual loss. (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p175)	0	2.13	1	0
Liver Dysfunction [description not available]	0	4.84	2	1
Liver Diseases Pathological processes of the LIVER.	1	6.84	2	1
ATLL [description not available]	0	3.03	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	0	3.03	1	0
Nasal Bleeding [description not available]	0	4.43	1	1
Epistaxis Bleeding from the nose.	0	4.43	1	1
Diffuse Parenchymal Lung Disease [description not available]	0	2.13	1	0
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	0	2.13	1	0
Cystic Angiomatosis Of Bone, Diffuse [description not available]	0	2.13	1	0
Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.	0	3.04	1	0
Enlarged Spleen [description not available]	0	3.42	2	0
Hair Diseases Diseases affecting the orderly growth and persistence of hair.	0	4.43	1	1
Nail Diseases Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.	0	4.43	1	1
Nervous System Disorders [description not available]	0	2.13	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	0	2.13	1	0
Hospital-Acquired Condition [description not available]	0	2.13	1	0
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	0	3.72	3	0
Histiocytic Sarcoma Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.	0	2.13	1	0
Immune Reconstitution Disease [description not available]	0	2.15	1	0
Grippe [description not available]	0	3.51	1	1
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	0	3.51	1	1
Granulocytic Leukemia, Chronic [description not available]	0	2.57	2	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.57	2	0
Malacoplakia The formation of soft patches on the mucous membrane of a hollow organ, such as the urogenital tract or digestive tract.	0	2.13	1	0
Benign Meningeal Neoplasms [description not available]	0	3.04	1	0
Angioblastic Meningioma [description not available]	0	3.04	1	0
Neoplasms, Skull [description not available]	0	3.04	1	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	0	3.04	1	0
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	0	3.04	1	0
Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.	0	6.46	10	0
Drop Attack [description not available]	0	2.15	1	0
Torsade de Pointes [description not available]	0	2.15	1	0
Syncope A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)	0	2.15	1	0
Christmas Disease [description not available]	0	2.15	1	0
Congenital Thrombotic Thrombocytopenic Purpura [description not available]	0	2.15	1	0
Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)	0	2.15	1	0
Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.	0	2.15	1	0
Hematoma, Subdural Accumulation of blood in the SUBDURAL SPACE between the DURA MATER and the arachnoidal layer of the MENINGES. This condition primarily occurs over the surface of a CEREBRAL HEMISPHERE, but may develop in the spinal canal (HEMATOMA, SUBDURAL, SPINAL). Subdural hematoma can be classified as the acute or the chronic form, with immediate or delayed symptom onset, respectively. Symptoms may include loss of consciousness, severe HEADACHE, and deteriorating mental status.	0	2.15	1	0
Coagulation, Disseminated Intravascular [description not available]	0	2.15	1	0
Endotoxin Shock [description not available]	0	2.15	1	0
Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.	0	2.15	1	0
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	0	2.15	1	0
Hypersensitivity, Type III [description not available]	0	2.06	1	0
Adenoma, beta-Cell [description not available]	0	2.98	1	0
Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.	0	2.98	1	0
Glomerulonephritis, Lupus [description not available]	0	2.07	1	0
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	0	2.07	1	0

pci 32765

Description

Cross-References

Synonyms (77)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (6)

Pathways (1)

Protein Targets (326)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (2582)

Molecular Functions (529)

Ceullar Components (400)

Bioassays (1205)

Research

Studies (1,905)

Study Types

pci 32765

Description

Cross-References

Synonyms (77)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (6)

Pathways (1)

Protein Targets (326)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (2582)

Molecular Functions (529)

Ceullar Components (400)

Bioassays (1205)

Research

Studies (1,905)

Study Types

Related Drugs (758)

Related Conditions (653)